US20060003334A1 - Protein (poly)peptides libraries - Google Patents

Protein (poly)peptides libraries Download PDF

Info

Publication number
US20060003334A1
US20060003334A1 US10/834,397 US83439704A US2006003334A1 US 20060003334 A1 US20060003334 A1 US 20060003334A1 US 83439704 A US83439704 A US 83439704A US 2006003334 A1 US2006003334 A1 US 2006003334A1
Authority
US
United States
Prior art keywords
sequences
amino acid
group
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/834,397
Inventor
Knappik Achim
Peter Pack
Ge Liming
Moroney Simon
Pluckthun Andreas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/490,324 external-priority patent/US6828422B1/en
Application filed by Morphosys AG filed Critical Morphosys AG
Priority to US10/834,397 priority Critical patent/US20060003334A1/en
Publication of US20060003334A1 publication Critical patent/US20060003334A1/en
Priority to US11/642,593 priority patent/US8513164B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • C07K16/242Lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Definitions

  • the present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins/(poly)peptides, and methods for generating and applying libraries of these DNA sequences.
  • the invention relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences which cover the structural repertoire of antibodies encoded in the human genome.
  • the invention relates to the use of a single consensus antibody gene as a universal framework for highly diverse antibody libraries.
  • the Winter invention does not provide a method for optimizing the binding affinities of antibody fragments further on, a process which would be functionally equivalent to the naturally occurring phenomenon of “affinity maturation”, which is provided by the present invention. Furthermore, the Winter invention does not provide for artificial variable region genes, which represent a whole family of structurally similar natural genes, and which can be assembled from synthetic DNA oligonucleotides. Additionally, Winter does not enable the combinatorial assembly of portions of antibody variable regions, a feature which is provided by the present invention. Furthermore, this approach has the disadvantage that the genes of all antibodies obtained in the screening procedure have to be completely sequenced, since, except for the PCR priming regions, no additional sequence information about the library members is available. This is time and labor intensive and potentially leads to sequencing errors.
  • the expressibility of the genes is important for the library quality as well, since the screening procedure relies in most cases on the display of the gene product on a phage surface, and efficient display relies on at least moderate expression of the gene.
  • each gene is built up from modules which represent structural sub-elements on the protein/(poly)peptide level.
  • the modules consist of “framework” and “CDR” modules.
  • DNA cassettes encoding libraries of genetic sub-elements can be (i), pre-built, stored and reused and (ii), inserted in any of these sequences at the right position without knowing the actual sequence or having to determine the sequence of the individual library member.
  • the limited number of consensus sequences used for creating the library allows to speed up the identification of binding antibodies after screening. After having identified the underlying consensus gene sequence, which could be done by sequencing or by using fingerprint restriction sites, just those part(s) comprising the random sequence(s) have to be determined. This reduces the probability of sequencing errors and of false-positive results.
  • cleavage sites can be used only if they are unique in the vector system where the artificial genes have been inserted. As a result, the vector has to be modified to contain none of these cleavage sites.
  • the construction of a vector consisting of basic elements like resistance gene and origin of replication, where cleavage sites have been removed, is of general interest for many cloning attempts. Additionally, these vector(s) could be part of a kit comprising the above mentioned artificial genes and pre-built libraries.
  • the collection of artificial genes can be used for a rapid humanization procedure of non-human antibodies, preferably of rodent antibodies.
  • the amino acid sequence of the non-human, preferably rodent antibody is compared with the amino acid sequences encoded by the collection of artificial genes to determine the most homologous light and heavy framework regions. These genes are then used for insertion of the genetic sub-elements encoding the CDRs of the non-human, preferably rodent antibody.
  • one aspect of the present invention is the use of a single consensus sequence as a universal framework for the creation of useful (poly)peptide libraries and antibody consensus sequences useful therefor.
  • the present invention enables the creation of useful libraries of (poly)peptides.
  • the invention provides for a method of setting up nucleic acid sequences suitable for the creation of said libraries.
  • a collection of at least three homologous proteins is identified and then analyzed. Therefore, a database of the protein sequences is established where the protein sequences are aligned to each other. The database is used to define subgroups of protein sequences which show a high degree of similarity in both the sequence and, if information is available, in the structural arrangement.
  • a (poly)peptide sequence comprising at least one consensus sequence which represents the members of this subgroup; the complete collection of (poly)peptide sequences represent therefore the complete structural repertoire of the collection of homologous proteins.
  • These artificial (poly)peptide sequences are then analyzed, if possible, according to their structural properties to identify unfavorable interactions between amino acids within said (poly)peptide sequences or between said or other (poly)peptide sequences, for example, in multimeric proteins. Such interactions are then removed by changing the consensus sequence accordingly.
  • the (poly)peptide sequences are then analyzed to identify sub-elements such as domains, loops, helices or CDRs.
  • the amino acid sequence is backtranslated into a corresponding coding nucleic acid sequence which is adapted to the codon usage of the host planned for expressing said nucleic acid sequences.
  • a set of cleavage sites is set up in a way that each of the sub-sequences encoding the sub-elements identified as described above, is flanked by two sites which do not occur a second time within the nucleic acid sequence. This can be achieved by either identifying a cleavage site already flanking a sub-sequence of by changing one or more nucleotides to create the cleavage site, and by removing that site from the remaining part of the gene.
  • the cleavage sites should be common to all corresponding sub-elements or sub-sequences, thus creating a fully modular arrangement of the sub-sequences in the nucleic acid sequence and of the sub-elements in the corresponding (poly)peptide.
  • the invention provides for a method which sets up two or more sets of (poly)peptides, where for each set the method as described above is performed, and where the cleavage sites are not only unique within each set but also between any two sets.
  • This method can be applied for the creation of (poly)peptide libraries comprising for example two ⁇ -helical domains from two different proteins, where said library is screened for novel hetero-association domains.
  • At least two of the sets as described above are derived from the same collection of proteins or at least a part of it.
  • nucleic acid sequences set up as described above are synthesized. This can be achieved by any one of several methods well known to the practitioner skilled in the art, for example, by total gene synthesis or by PCR-based approaches.
  • the nucleic acid sequences are cloned into a vector.
  • the vector could be a sequencing vector, an expression vector or a display (e.g. phage display) vector, which are well known to those skilled in the art.
  • Any vector could comprise one nucleic acid sequence, or two or more nucleic sequences, either in different or the same operon. In the last case, they could either be cloned separately or as contiguous sequences.
  • the removal of unfavorable interactions as described above leads to enhanced expression of the modified (poly)peptides.
  • one or more sub-sequences of the nucleic acid sequences are replaced by different sequences. This can be achieved by excising the sub-sequences using the conditions suitable for cleaving the cleavage sites adjacent to or at the end of the sub-sequence, for example, by using a restriction enzyme at the corresponding restriction site under the conditions well known to those skilled in the art, and replacing the sub-sequence by a different sequence compatible with the cleaved nucleic acid sequence.
  • the different sequences replacing the initial sub-sequence(s) are genomic or rearranged genomic sequences, for example in grafting CDRs from non-human antibodies onto consensus antibody sequences for rapid humanization of non-human antibodies.
  • the different sequences are random sequences, thus replacing the sub-sequence by a collection of sequences to introduce variability and to create a library.
  • the random sequences can be assembled in various ways, for example by using a mixture of mononucleotides or preferably a mixture of trinucleotides (Virnelas et al., 1994) during automated oligonucleotide synthesis, by error-prone PCR or by other methods well known to the practitioner in the art.
  • the random sequences may be completely randomized or biased towards or against certain codons according to the amino acid distribution at certain positions in known protein sequences. Additionally, the collection of random sub-sequences may comprise different numbers of codons, giving rise to a collection of sub-elements having different lengths.
  • the invention provides for the expression of the nucleic acid sequences from a suitable vector and under suitable conditions well known to those skilled in the art.
  • the (poly)peptides expressed from said nucleic acid sequences are screened and, optionally, optimized. Screening may be performed by using one of the methods well known to the practitioner in the art, such as phage-display, selectively infective phage, polysome technology to screen for binding, assay systems for enzymatic activity or protein stability.
  • (Poly)peptides having the desired property can be identified by sequencing of the corresponding nucleic acid sequence or by amino acid sequencing or mass spectrometry.
  • the nucleic acid sequences encoding the initially selected (poly)peptides can optionally be used without sequencing. Optimization is performed by repeating the replacement of sub-sequences by different sequences, preferably by random sequences, and the screening step one or more times.
  • the desired property the (poly)peptides are screened for is preferably, but not exclusively, selected from the group of optimized affinity or specificity for a target molecule, optimized enzymatic activity, optimized expression yields, optimized stability and optimized solubility.
  • the cleavage sites flanking the sub-sequences are sites recognized and cleaved by restriction enzymes, with recognition and cleavage sequences being either identical or different, the restricted sites either having blunt or sticky ends.
  • the length of the sub-elements is preferably, but not exclusively ranging between 1 amino acid, such as one residue in the active site of an enzyme or a structure-determining residue, and 150 amino acids, as for whole protein domains. Most preferably, the length ranges between 3 and 25 amino acids, such as most commonly found in CDR loops of antibodies.
  • the nucleic acid sequences could be RNA or, preferably, DNA.
  • the (poly)peptides have an amino acid pattern characteristic of a particular species. This can for example be achieved by deducing the consensus sequences from a collection of homologous proteins of just one species, most preferably from a collection of human proteins. Since the (poly)peptides comprising consensus sequences are artificial, they have to be compared to the protein sequence(s) having the closest similarity to ensure the presence of said characteristic amino acid pattern.
  • the invention provides for the creation of libraries of (poly)peptides comprising at least part of members or derivatives of the immunoglobulin superfamily, preferably of member or derivatives of the immunoglobulins.
  • the invention provides for the creation of libraries of human antibodies, wherein said (poly)peptides are or are derived from heavy or light chain variable regions wherein said structural sub-elements are framework regions (FR) 1, 2, 3, or 4 or complementary determining regions (CDR) 1, 2, or 3.
  • FR framework regions
  • CDR complementary determining regions
  • the database is used to define subgroups of antibody sequences which show a high degree of similarity in both the sequence and the canonical fold of CDR loops (as determined by analysis of antibody structures). For each of the subgroups a consensus sequence is deduced which represents the members of this subgroup; the complete collection of consensus sequences represent therefore the complete structural repertoire of human antibodies.
  • genes are then constructed e.g. by total gene synthesis or by the use of synthetic genetic subunits.
  • These genetic subunits correspond to structural sub-elements on the (poly)peptide level.
  • On the DNA level these genetic subunits are defined by cleavage sites at the start and the end of each of the sub-elements, which are unique in the vector system. All genes which are members of the collection of consensus sequences are constructed such that they contain a similar pattern of corresponding genetic sub-sequences.
  • said (poly)peptides are or are derived from the HuCAL consensus genes: V ⁇ 1, V ⁇ 2, V ⁇ 3, V ⁇ 4, V ⁇ 1, V ⁇ 2, V ⁇ 3, VH1A, VH1B, VH2, VH3, VH4, VH5, VH6, C ⁇ , C ⁇ , CH1 or any combination of said HuCAL consensus genes.
  • the invention provides a method for identifying one or more genes encoding one or more antibody fragments which binds to a target, comprising the steps of expressing the antibody fragments, and then screening them to isolate one or more antibody fragments which bind to a given target molecule.
  • an scFv fragment library comprising the combination of HuCAL VH3 and HuCAL V ⁇ 2 consensus genes and at least a random sub-sequence encoding the heavy chain CDR3 sub-element is screened for binding antibodies.
  • the modular design of the genes can then be used to excise from the genes encoding the antibody fragments one or more genetic sub-sequences encoding structural sub-elements, and replacing them by one or more second sub-sequences encoding structural sub-elements.
  • the expression and screening steps can then be repeated until an antibody having the desired affinity is generated.
  • Particularly preferred is a method in which one or more of the genetic subunits (e.g. the CDRs) are replaced by a random collection of sequences (the library) using the said cleavage sites. Since these cleavage sites are (i) unique in the vector system and (ii) common to all consensus genes, the same (pre-built) library can be inserted into all artificial antibody genes. The resulting library is then screened against any chosen antigen. Binding antibodies are selected, collected and used as starting material for the next library. Here, one or more of the remaining genetic subunits are randomized as described above.
  • a further embodiment of the present invention relates to fusion proteins by providing for a DNA sequence which encodes both the (poly)peptide, as described above, as well as an additional moiety.
  • Particularly preferred are moieties which have a useful therapeutic function.
  • the additional moiety may be a toxin molecule which is able to kill cells (Vitetta et al., 1993).
  • toxins well known to the one skilled in the art, such as the bacterial toxins Pseudomonas exotoxin A, and diphtheria toxin, as well as the plant toxins ricin, abrin, modeccin, saporin, and gelonin.
  • the toxin can be targeted to, for example, diseased cells, and thereby have a beneficial therapeutic effect.
  • the additional moiety may be a cytokine, such as IL-2 (Rosenberg & Lotze, 1986), which has a particular effect (in this case a T-cell proliferative effect) on a family of cells.
  • the additional moiety may confer on its (poly)peptide partner a means of detection and/or purification.
  • the fusion protein could comprise the modified antibody fragment and an enzyme commonly used for detection purposes, such as alkaline phosphatase (Blake et al., 1984).
  • moieties which can be used as detection or purification tags, which are well known to the practitioner skilled in the art. Particularly preferred are peptides comprising at least five histidine residues (Hochuli et al., 1988), which are able to bind to metal ions, and can therefore be used for the purification of the protein to which they are fused (Lindner et al., 1992). Also provided for by the invention are additional moieties such as the commonly used C-myc and FLAG tags (Hopp et al., 1988; Knappik & Plückthun, 1994).
  • mini-antibodies are dimers comprising two antibody fragments, each fused to a self-associating dimerization domain.
  • Dimerization domains which are particularly preferred include those derived from a leucine zipper (Pack & Plückthun, 1992) or helix-turn-helix motif (Pack et al., 1993).
  • the random collection of sub-sequences (the library) is inserted into a singular nucleic acid sequence encoding one (poly)peptide, thus creating a (poly)peptide library based on one universal framework.
  • a random collection of CDR sub-sequences is inserted into a universal antibody framework, for example into the HuCAL H3 ⁇ 2 single-chain Fv fragment described above.
  • the invention provides for nucleic acid sequence(s), vector(s) containing the nucleic acid sequence(s), host cell(s) containing the vector(s), and (poly)peptides, obtainable according to the methods described above.
  • the invention provides for modular vector systems being compatible with the modular nucleic acid sequences encoding the (poly)peptides.
  • the modules of the vectors are flanked by restriction sites unique within the vector system and essentially unique with respect to the restriction sites incorporated into the nucleic acid sequences encoding the (poly)peptides, except for example the restriction sites necessary for cloning the nucleic acid sequences into the vector.
  • the list of vector modules comprises origins of single-stranded replication, origins of double-stranded replication for high- and low copy number plasmids, promotor/operator, repressor or terminator elements, resistance genes, potential recombination sites, gene III for display on filamentous phages, signal sequences, purification and detection tags, and sequences of additional moieties.
  • the vectors are preferably, but not exclusively, expression vectors or vectors suitable for expression and screening of libraries.
  • the invention provides for a kit, comprising one or more of the list of nucleic acid sequence(s), recombinant vector(s), (poly)peptide(s), and vector(s) according to the methods described above, and suitable host cell(s) for producing the (poly)peptide(s).
  • the invention provides for the creation of libraries of human antibodies.
  • a database of published antibody sequences of human origin is established: The database is used to define subgroups of antibody sequences which show a high degree of similarity in both the sequence and the canonical fold (as determined by analysis of antibody structures).
  • a consensus sequence is deduced which represents the members of this subgroup; the complete collection of consensus sequences represent therefore the complete structural repertoire of human antibodies.
  • genes are then constructed by the use of synthetic genetic subunits.
  • These genetic subunits correspond to structural sub-elements on the protein level. On the DNA level, these genetic subunits are defined by cleavage sites at the start and the end of each of the subelements, which are unique in the vector system. All genes which are members of the collection of consensus sequences are constructed such that they contain a similar pattern of said genetic subunits.
  • the invention provides a method for identifying one or more genes encoding one or more antibody fragments which binds to a target, comprising the steps of expressing the antibody fragments, and then screening them to isolate one or more antibody fragments which bind to a given target molecule.
  • the modular design of the genes can then be used to excise from the genes encoding the antibody fragments one or more genetic sub-sequences encoding structural sub-elements, and replacing them by one or more second sub-sequences encoding structural sub-elements.
  • the expression and screening steps can then be repeated until an antibody having the desired affinity is generated.
  • Particularly preferred is a method in which one or more or the genetic subunits (e.g. the CDR's) are replaced by a random collection of sequences (the library) using the said cleavage sites. Since these cleavage sites are (i) unique in the vector system and (ii) common to all consensus genes, the same (pre-built) library can be inserted into all artificial antibody genes. The resulting library is then screened against any chosen antigen. Binding antibodies are eluted, collected and used as starting material for the next library. Here, one or more of the remaining genetic subunits are randomised as described above.
  • protein comprises monomeric polypeptide chains as well as homo- or heteromultimeric complexes of two or more polypeptide chains connected either by covalent interactions (such as disulphide bonds) or by non-covalent interactions (such as hydrophobic or electrostatic interactions).
  • the amino acid sequences of three or more proteins are aligned to each other (allowing for introduction of gaps) in a way which maximizes the correspondence between identical or similar amino acid residues at all positions.
  • These aligned sequences are termed homologous if the percentage of the sum of identical and/or similar residues exceeds a defined threshold. This threshold is commonly regarded by those skilled in the art as being exceeded when at least 15% of the amino acids in the aligned genes are identical, and at least 30% are similar.
  • families of homologous proteins are: immunoglobulin superfamily, scavenger receptor superfamily, fibronectin superfamilies (e.g. type II and III), complement control protein superfamily, cytokine receptor superfamily, cystine knot proteins, tyrosine kinases, and numerous other examples well known to one of ordinary skill in the art.
  • the consensus sequence is that sequence which comprises the amino acids which are most frequently represented at each position. In the event that two or more amino acids are equally represented at a single position, the consensus sequence includes both or all of those amino acids.
  • the consensus sequence is per se in most cases artificial and has to be analyzed in order to change amino acid residues which, for example, would prevent the resulting molecule to adapt a functional tertiary structure or which would block the interaction with other (poly)peptide chains in multimeric complexes.
  • This can be done either by (i) building a three-dimensional model of the consensus sequence using known related structures as a template, and identifying amino acid residues within the model which may interact unfavorably with each other, or (ii) analyzing the matrix of aligned amino acid sequences in order to detect combinations of amino acid residues within the sequences which frequently occur together in one sequence and are therefore likely to interact with each other. These probable interaction-pairs are then tabulated and the consensus is compared with these “interaction maps”. Missing or wrong interactions in the consensus are repaired accordingly by introducing appropriate changes in amino acids which minimize unfavorable interactions.
  • Structural sub-elements are stretches of amino acid residues within a protein/(poly)peptide which correspond to a defined structural or functional part of the molecule. These can be loops (e.g. CDR loops of an antibody) or any other secondary or functional structure within the protein/(poly)peptide (domains, ⁇ -helices, ⁇ -sheets, framework regions of antibodies, etc.).
  • a structural sub-element can be identified using known structures of similar or homologous (poly)peptides, or by using the above mentioned matrices of aligned amino acid sequences. Here the variability at each position is the basis for determining stretches of amino acid residues which belong to a structural sub-element (e.g. hypervariable regions of an antibody).
  • a sub-sequence is defined as a genetic module which is flanked by unique cleavage sites and encodes at least one structural sub-element. It is not necessarily identical to a structural sub-element.
  • a short DNA sequence which is used as a specific target for a reagent which cleaves DNA in a sequence-specific manner e.g. restriction endonucleases.
  • Cleavage sites are compatible with each other, if they can be efficiently ligated without modification and, preferably, also without adding an adapter molecule.
  • a cleavage site is defined as unique if it occurs only once in a vector containing at least one of the genes of interest, or if a vector containing at least one of the genes of interest could be treated in a way that only one of the cleavage sites could be used by the cleaving agent.
  • a cleavage site in at least two corresponding sequences, which occurs at the same functional position (i.e. which flanks a defined sub-sequence), which can be hydrolyzed by the same cleavage tool and which yields identical compatible ends is termed a common cleavage site.
  • a method which uses the unique cleavage sites and the corresponding cleavage reagents to cleave the target DNA at the specified positions in order to isolate, remove or replace the genetic sub-sequence flanked by these unique cleavage sites.
  • the term expression refers to in vivo or in vitro processes, by which the information of a gene is transcribed into mRNA and then translated into a protein/(poly)peptide.
  • the term expression refers to a process which occurs inside cells, by which the information of a gene is transcribed into mRNA and then into a protein.
  • the term expression also includes all events of post-translational modification and transport, which are necessary for the (poly)peptide to be functional.
  • a (poly)peptide sequence is assumed to exhibit an amino acid pattern characteristic for a species if it is deduced from a collection of homologous proteins from just this species.
  • Immunoglobulin Superfamily (IgSF):
  • the IgSF is a family of proteins comprising domains being characterized by the immunoglobulin fold.
  • the IgSF comprises for example T-cell receptors and the immunoglobulins (antibodies).
  • a framework of an antibody variable domain is defined by Kabat et al. (1991) as the part of the variable domain which serves as a scaffold for the antigen binding loops of this variable domain.
  • the CDRs (complementarity determining regions) of an antibody consist of the antigen binding loops, as defined by Kabat et al. (1991). Each of the two variable domains of an antibody Fv fragment contain three CDRs.
  • antibody fragments are smaller than whole antibodies. Examples are Fv, disulphide-linked Fv, single-chain Fv (scFv), or Fab fragments. Additionally, antibody fragments are often engineered to include new functions or properties.
  • binding A molecule or ligand or any part of a molecukle or ligand which is recognized by an antibody is called the target.
  • the corresponding amino acid sequences of two or more genes are aligned to each other in a way which maximizes the correspondence between identical or similar amino acid residues at all positions. These aligned sequences are termed homologous if the percentage of the Sum of identical and/or similar residues exceeds a defined threshold. This threshold is commonly regarded by those skilled in the art as being exceeded when at least 15 percent of the amino acids in the aligned genes are identical, and at least 30 percent are similar.
  • FIG. 1 Flow chart outlining the process of construction of a synthetic human antibody library based on consensus sequences.
  • FIG. 2 Alignment of consensus sequences designed for each subgroup (amino acid residues are shown with their standard one-letter abbreviation).
  • A kappa sequences
  • B lambda sequences
  • C heavy chain sequences. The positions are numbered according to Kabat (1991). In order to maximize homology in the alignment, gaps ( ⁇ ) have been introduced in the sequence at certain positions.
  • FIG. 3 Gene sequences of the synthetic V kappa consensus genes. The corresponding amino acid sequences (see FIG. 2 ) as well as the unique cleavage sites are also shown.
  • FIG. 4 Gene sequences of the synthetic V lambda consensus genes. The corresponding amino acid sequences (see FIG. 2 ) as well as the unique cleavage sites are also shown.
  • FIG. 5 Gene sequences of the synthetic V heavy chain consensus genes. The corresponding amino acid sequences (see FIG. 2 ) as well as the unique cleavage sites are also shown.
  • FIG. 6 Oligonucleotides used for construction of the consensus genes.
  • the oligos are named according to the corresponding consensus gene, e.g. the gene V ⁇ 1 was constructed using the six oligonucleotides O1K1 to O1K6.
  • the oligonucleotides used for synthesizing the genes encoding the constant domains C ⁇ (OCLK1 to 8) and CH1 (OCH1 to 8) are also shown.
  • FIG. 7A /B Sequences of the synthetic genes encoding the constant domains C ⁇ (A) and CH1 (B). The corresponding amino acid sequences as well as unique cleavage sites introduced in these genes are also shown.
  • FIG. 7C Functional map and sequence of module M24 comprising the synthetic C ⁇ gene segment (huCL lambda).
  • FIG. 7D Oligonucleotides used for synthesis of module M24.
  • FIG. 8 Sequence and restriction map of the synthetic gene encoding the consensus single-chain fragment VH3-V ⁇ 2.
  • the signal sequence (amino acids 1 to 21) was derived from the E. coli phoA gene (Skerra & Plückthun, 1988). Between the phoA signal sequence and the VH3 domain, a short sequence stretch encoding 4 amino acid residues (amino acid 22 to 25) has been inserted in order to allow detection of the single-chain fragment in Western blot or ELISA using the monoclonal antibody M1 (Knappik & Plückthun, 1994). The last 6 basepairs of the sequence were introduced for cloning purposes (EcoRI site).
  • FIG. 9 Plasmid map of the vector pIG10.3 used for phage display of the H3 ⁇ 2 scFv fragment.
  • the vector is derived from pIG10 and contains the gene for the lac operon repressor, lacI, the artificial operon encoding the H3 ⁇ 2-gene3ss fusion under control of the lac promoter, the lpp terminator of transcription, the single-strand replication origin of the E. coli phage f1 (F1_ORI), a gene encoding ⁇ -lactamase (bla) and the ColEI derived origin of replication.
  • FIG. 10 Sequencing results of independent clones from the initial library, translated into the corresponding amino acid sequences.
  • A Amino acid sequence of the VH3 consensus heavy chain CDR3 (position 93 to 102, Kabat numbering).
  • B Amino acid sequences of 12 clones of the 10-mer library.
  • C Amino acid sequences of 11 clones of the 15-mer library, single base deletion.
  • FIG. 11 Expression test of individual library members.
  • A Expression of 9 independent clones of the 10-mer library.
  • B Expression of 9 independent clones of the 15-mer library.
  • the lane designated with M contains the size marker. Both the gp3-scFv fusion and the scFv monomer are indicated.
  • FIG. 12 Enrichment of specific phage antibodies during the panning against FITC-BSA.
  • the initial as well as the subsequent fluorescein-specific sub-libraries were panned against the blocking buffer and the ratio of the phage eluted from the FITC-BSA coated well vs. that from the powder milk coated well from each panning round is presented as the “specificity factor”.
  • FIG. 13 Phage ELISA of 24 independent clones after the third round of panning tested for binding on FITC-BSA.
  • FIG. 14 Competition ELISA of selected FITC-BSA binding clones.
  • the ELISA signals (OD 405 nm ) of scFv binding without inhibition are taken as 100%.
  • FIG. 15 Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against FITC-BSA, translated into the corresponding amino acid sequences (position 93 to 102. Kabat numbering).
  • FIG. 16 Coomassie-Blue stained SDS-PAGE of the purified anti-fluorescein scFv fragments: M: molecular weight marker, A: total soluble cell extract after induction, B: fraction of the flow-through, C, D and E: purified scFv fragments 1HA-3E4, 1HA-3E5 and 1HA-3E10, respectively.
  • FIG. 17 Enrichment of specific phage antibodies during the panning against ⁇ -estradiol-BSA, testosterone-BSA, BSA, ESL-1, interleukin-2, lymphotoxin- ⁇ , and LeY-BSA after three rounds of panning.
  • FIG. 18 ELISA of selected ESL-1 and ⁇ -estradiol binding clones.
  • FIG. 19 Selectivity and cross-reactivity of HuCAL antibodies: in the diagonal specific binding of HuCAL antibodies can be seen, off-diagonal signals show non-specific cross-reactivity.
  • FIG. 20 Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against ⁇ -estradiol-BSA, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering). One clone is derived from the 10mer library.
  • FIG. 21 Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against testosterone-BSA, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering).
  • FIG. 22 Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against lymphotoxin- ⁇ , translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering).
  • One clone comprises a 14mer CDR, presumably introduced by incomplete coupling of the trinucleotide mixture during oligonucleotide synthesis.
  • FIG. 23 Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against ESL-1, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering). Two clones are derived from the 10mer library. One clone comprises a 16mer CDR, presumably introduced by chain elongation during oligonucleotide synthesis using trinucleotides.
  • FIG. 24 Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against BSA, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering).
  • FIG. 25 Schematic representation of the modular pCAL vector system.
  • FIG. 25 a List of restriction sites already used in or suitable for the modular HuCAL genes and pCAL vector system.
  • FIG. 26 List of the modular vector elements for the pCAL vector series: shown are only those restriction sites which are part of the modular system.
  • FIG. 27 Functional map and sequence of the multi-cloning site module (MCS).
  • FIG. 28 Functional map and sequence of the pMCS cloning vector series.
  • FIG. 29 Functional map and sequence of the pCAL module M1 (see FIG. 26 ).
  • FIG. 30 Functional map and sequence of the pCAL module M7-III (see FIG. 26 ).
  • FIG. 31 Functional map and sequence of the pCAL module M9-II (see FIG. 26 ).
  • FIG. 32 Functional map and sequence of the pCAL module M11-II (see FIG. 26 ).
  • FIG. 33 Functional map and sequence of the pCAL module M14-Ext2 (see FIG. 26 ).
  • FIG. 34 Functional map and sequence of the PCAL module M17 (see FIG. 26 ).
  • FIG. 35 Functional map and sequence of the modular vector pCAL4.
  • FIG. 35 a Functional maps and sequences of additional pCAL modules (M2, M3, M7I, M7II, M8, M10II, M11II, M12, M13, M19, M20, M21, M41) and of low-copy number plasmid vectors (pCALO1 to pCALO3).
  • FIG. 35 b List of oligonucleotides and primers used for synthesis of pCAL vector modules.
  • FIG. 36 Functional map and sequence of the ⁇ -lactamase cassette for replacement of CDRs for CDR library cloning.
  • FIG. 37 Oligo and primer design for V ⁇ CDR3 libraries
  • FIG. 38 Oligo and primer design for V ⁇ CDR3 libraries.
  • FIG. 39 Functional map of the pBS13 expression vector series.
  • FIG. 40 Expression of all 49 HuCAL scFvs obtained by combining each of the 7 VH genes with each of the 7 VL genes (pBS13, 30° C.); Values are given for the percentage of soluble vs. insoluble material, the total and the soluble amount compared to the combination H3 ⁇ 2, which was set to 100%. In addition, the corresponding values for the McPC603 scFv are given.
  • Table 1 Summary of human immunoglobulin germline sequences used for computing the germline membership of rearranged sequences.
  • A kappa sequences
  • B lambda sequences
  • C heavy chain sequences.
  • Table 2 Rearranged human sequences used for the calculation of consensus sequences.
  • A kappa sequences
  • B lambda sequences
  • C heavy chain sequences.
  • the table summarized the name of the sequence (1), the length of the sequence in amino acids (2), the germline family (3) as well as the computed germline counterpart (4).
  • the number of amino acid exchanges between the rearranged sequence and the germline sequence is tabulated in (5), and the percentage of different amino acids is given in (6).
  • Column (7) gives the references number for the corresponding sequence (see appendix for sequence related citations).
  • Table 3 Assignment of rearranged V sequences to their germline counterparts.
  • A kappa sequences
  • B lambda sequences
  • C heavy chain sequences.
  • the germline genes are tabulated according to their family (1), and the number of rearranged genes found for every germline gene is given in (2).
  • Table 4 Computation of the consensus sequence of the rearranged V kappa sequences.
  • A V kappa subgroup 1,
  • B V kappa subgroup 2,
  • C V kappa subgroup 3
  • D V kappa subgroup 4.
  • Amino acids are given with their standard one-letter abbreviations (and B means D or N, Z means E or Q and X means any amino acid).
  • the statistical analysis summarizes the number of sequences found at each position (2), the number of occurrences of the most common amino acid (3), the amino acid residue which is most common at this position (4), the relative frequency of the occurrence of the most common amino acid (5) and the number of different amino acids found at each position (6).
  • Table 5 Computation of the consensus sequence of the rearranged V lambda sequences. (A), V lambda subgroup 1, (B), V lambda subgroup 2, and (C), V lambda subgroup 3. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. Abbreviations are the same as in Table 4.
  • Table 6 Computation of the consensus sequence of the rearranged V heavy chain sequences.
  • A V heavy chain subgroup 1A, (B), V heavy chain subgroup 1B, (C), V heavy chain subgroup 2, (D), V heavy chain subgroup 3, (E), V heavy chain subgroup 4, (F), V heavy chain subgroup 5, and (G), V heavy chain subgroup 6.
  • the number of each amino acid found at each position is tabulated together with the statistical analysis of the data. Abbreviations are the same as in Table 4.
  • the following example describes the design of a fully synthetic human combinatorial antibody library (HuCAL), based on consensus sequences of the human immunoglobulin repertoire, and the synthesis of the consensus genes.
  • the general procedure is outlined in FIG. 1 .
  • VH V heavy chain
  • V ⁇ V kappa
  • V ⁇ V lambda
  • the gene sequence was then translated into the corresponding amino acid sequence.
  • all amino acid sequences were aligned according to Kabat et al. (1991).
  • the numbering system of Chuchana et al. (1990) was used.
  • the first sub base contained all sequences derived from rearranged V genes, where more than 70 positions of the sequence were known.
  • the second sub base contained all germline gene segments (without the D- and J-minigenes; pseudogenes with internal stop codons were also removed). In all cases, where germline sequences with identical amino acid sequence but different names were found, only one sequence was used (see Table 1).
  • the final databases of rearranged sequences contained 386, 149 and 674 entries for V ⁇ , V ⁇ and VH, respectively.
  • the final databases of germline sequences contained 48, 26 and 141 entries for V ⁇ , V ⁇ and VH, respectively.
  • V ⁇ was divided into 8 families and VH into 6 families.
  • the VH germline genes of the VH7 family (Van Dijk et al., 1993) were grouped into the VH1 family, since the genes of the two families are highly homologous.
  • Each family contained different numbers of germline genes, varying from 1 (for example VH6) to 47 (VH3).
  • the nearest germline counterpart i.e. the germline sequence with the smallest number of amino acid differences was then calculated.
  • the number of somatic mutations which occurred in the rearranged gene and which led to amino acid exchanges could be tabulated.
  • the germline counterpart could not be calculated exactly, because more than one germline gene was found with an identical number of amino acid exchanges.
  • These rearranged sequences were removed from the database.
  • the number of amino acid exchanges was found to be unusually large (>20 for VL and >25 for VH), indicating either heavily mutated rearranged genes or derivation from germline genes not present in the database.
  • every rearranged gene could be arranged in one of the families established for the germline genes.
  • the usage of each germline gene i.e. the number of rearranged genes which originate from each germline gene, could be calculated (see Table 2). It was found that the usage was strongly biased towards a subset of germline genes, whereas most of the germline genes were not present as rearranged genes in the database and therefore apparently not used in the immune system (Table 3). This observation had already been reported in the case of V ⁇ (Cox, et al., 1994). All germline gene families, where no or only very few rearranged counterparts could be assigned, were removed from the database, leaving 4 V ⁇ , 3 V ⁇ , and 6 VH families.
  • the conformation of the antigen binding loops of antibody molecules, the CDRs, is strongly dependent on both the length of the CDRs and the amino acid residues located at the so-called canonical positions (Chothia & Lesk, 1987). It has been found that only a few canonical structures exist, which determine the structural repertoire of the immunoglobulin variable domains (Chothia et al., 1989). The canonical amino acid positions can be found in CDR as well as framework regions. The 13 used germline families defined above (7 VL and 6 VH) were now analyzed for their canonical structures in order to define the structural repertoire encoded in these families.
  • V ⁇ 1, 2 and 4 In 3 of the 4 V ⁇ families (V ⁇ 1, 2 and 4), one different type of CDR1 conformation could be defined for every family.
  • the family V ⁇ 3 showed two types of CDR1 conformation: one type which was identical to V ⁇ 1 and one type only found in V ⁇ 3. All V ⁇ CDR2s used the same type of canonical structure.
  • the CDR3 conformation is not encoded in the germline gene segments. Therefore, the 4 V ⁇ families defined by sequence homology and usage corresponded also to 4 types of canonical structures found in V ⁇ germline genes.
  • the 3 V ⁇ families defined above showed 3 types of CDR1 conformation, each family with one unique type.
  • the V ⁇ 1 family contained 2 different CDR1 lengths (13 and 14 amino acids), but identical canonical residues, and it is thought that both lengths adopt the same canonical conformation (Chothia & Lesk, 1987).
  • CDR2 of the used V ⁇ germlines only one canonical conformation exists, and the CDR3 conformation is not encoded in the germline gene segments. Therefore, the 3 V ⁇ families defined by sequence homology and usage corresponded also to 3 types of canonical structures.
  • VH1 family All the members of the VH1 family defined above contained the CDR1 conformation H1-1, but differed in their CDR2 conformation: the H2-2 conformation was found in 6 germline genes, whereas the conformation H2-3 was found in 8 germline genes. Since the two types of CDR2 conformations are defined by different types of amino acid at the framework position 72, the VH1 family was divided into two subfamilies: VH1A with CDR2 conformation H2-2 and VH1B with the conformation H2-3 The members of the VH2 family all had the conformations H1-3 and H2-1 in CDR1 and CDR2, respectively.
  • the CDR1 conformation of the VH3 members was found in all cases to be H1-1, but 4 different types were found in CDR2 (H2-1, H2-3, H2-4 and H2-x).
  • the canonical framework residue 71 is always defined by an arginine. Therefore, it was not necessary to divide the VH3 family into subfamilies, since the 4 types of CDR2 conformations were defined solely by the CDR2 itself. The same was true for the VH4 family.
  • all 3 types of CDR1 conformations were found, but since the CDR1 conformation was defined by the CDR itself (the canonical framework residue 26 was found to be glycine in all cases), no subdivisions were necessary.
  • the CDR2 conformation of the VH4 members was found to be H2-1 in all cases. All members of the VH5 family were found to have the conformation H1-1 and H2-2, respectively.
  • the single germline gene of the VH6 family had the conformations H1-3 and H2-5 in CDR1 and CDR2, respectively.
  • the 14 databases of rearranged sequences (4 V ⁇ , 3 V ⁇ , and 7 VH) were used to compute the HuCAL consensus sequences of each subgroup (4 HuCAL-V ⁇ , 3 HuCAL-V ⁇ , 7 HuCAL-VH, see Table 4, 5 and 6). This was done by counting the number of amino acid residues used at each position (position variability) and subsequently identifying the amino acid residue most frequently used at each position.
  • the consensus was weighted according to the frequency of usage. Additionally, frequently mutated and highly conserved positions could be identified.
  • the process described above provided the complete consensus sequences derived solely from the databases of rearranged sequences. It was rationalized that the CDR1 and CDR2 regions should be taken from the databases of used germline sequences, since the CDRs of rearranged and mutated sequences are biased towards their particular antigens. Moreover, the germline CDR sequences are known to allow binding to a variety of antigens in the primary immune response, where only CDR3 is varied. Therefore, the consensus CDRs obtained from the calculations described above were replaced by germline CDRs in the case of VH and V ⁇ . In the case of V ⁇ , a few amino acid exchanges were introduced in some of the chosen germline CDRs in order to avoid possible protease cleavage sites as well as possible structural constraints.
  • any sequence could be chosen since these CDRs were planned to be the first to be replaced by oligonucleotide libraries.
  • the dummy sequences QQHYTTPP and ARWGGDGFYAMDY were selected for the VL chains (kappa and lambda) and for the VH chains, respectively. These sequences are known to be compatible with antibody folding in E. coli (Carter et al., 1992).
  • the final outcome of the process described above was a collection of 14 HuCAL amino acid sequences, which represent the frequently used structural antibody repertoire of the human immune system (see FIG. 2 ). These sequences were back-translated into DNA sequences. In a first step, the back-translation was done using only codons which are known to be frequently used in E. coli . These gene sequences were then used for creating a database of all possible restriction endonuclease sites, which could be introduced without changing the corresponding amino acid sequences. Using this database, cleavage sites were selected which were located at the flanking regions of all sub-elements of the genes (CDRs and framework regions) and which could be introduced in all HuCAL VH, V ⁇ or V ⁇ genes simultaneously at the same position.
  • restriction endonuclease sites were identified, which were not located at the flanking regions of the sub-elements but which could be introduced in every gene of a given group without changing the amino acid sequence. These cleavage sites were also introduced in order to make the system more flexible for further improvements. Finally, all but one remaining restriction endonuclease sites were removed in every gene sequence. The single cleavage site, which was not removed was different in all genes of a subgroup and could be therefore used as a “fingerprint” site to ease the identification of the different genes by restriction digest.
  • the designed genes, together with the corresponding amino acid sequences and the group-specific restriction endonuclease sites are shown in FIGS. 3, 4 and 5 , respectively.
  • the consensus genes were synthesized using the method described by Prodromou & Pearl, 1992, using the oligonucleotides shown in FIG. 6 .
  • Gene segments encoding the human constant domains C ⁇ , C ⁇ and CH1 were also synthesized, based on sequence information given by Kabat et al., 1991 (see FIG. 6 and FIG. 7 ). Since for both the CDR3 and the framework 4 gene segments identical sequences were chosen in all HuCAL V ⁇ , V ⁇ and VH genes, respectively, this part was constructed only once, together with the corresponding gene segments encoding the constant domains.
  • the PCR products were cloned into pCR-Script KS(+) (Stratagene, Inc.) or pZErO-1 (Invitrogen, Inc.) and verified by sequencing.
  • a combination of two of the synthetic consensus genes was chosen after construction to test whether binding antibody fragments can be isolated from a library based on these two consensus frameworks.
  • the two genes were clones as a single-chain Fv (scFv) fragment, and a VH-CDR3 library was inserted.
  • scFv single-chain Fv
  • VH-CDR3 library was inserted.
  • FITC-BSA small hapten fluorescein bound to BSA
  • one randomly chosen combination of synthetic light and heavy gene (HuCAL-V ⁇ 2 and HuCAL-VH3) was used for the construction of a single-chain antibody (scFv) fragment.
  • the gene segments encoding the VH3 consensus gene and the CH1 gene segment including the CDR3-framework 4 region, as well as the V ⁇ 2 consensus gene and the C ⁇ gene segment including the CDR3-framework 4 region were assembled yielding the gene for the VH3-CH1 Fd fragment and the gene encoding the V ⁇ 2-C ⁇ light chain, respectively.
  • the CH1 gene segment was then replaced by an oligonucleotide cassette encoding a 20-mer peptide linker with the sequence AGGGSGGGGSGGGGSGGGGS.
  • the two oligonucleotides encoding this linker were 5′-TCAGCGGGTGGCGGTTCTGGCGGCGGTGGGAGCGGTGGCGGTGGTTCTGGCGGTGGTGGTTCCGATATCGGTCCACGTACGG-3′ and 5′-AATTCCGTACGTGGACCGATATCGGAACCACCACCACCGCCAGAACCACCGCCACCGCTCCCACCGC CGCCAGAACCGCCACCCGC-3′, respectively.
  • the HuCAL-V ⁇ 2 gene was inserted via EcoRV and BsiWI into the plasmid encoding the HuCAL-VH3-linker fusion, leading to the final gene HuCAL-VH3-V ⁇ 2, which encoded the two consensus sequences in the single-chain format VH-linker-VL.
  • the complete coding sequence is shown in FIG. 8 .
  • Phagemid pIG10.3 ( FIG. 9 ) was constructed in order to create a phage-display system (Winter et al., 1994) for the H3 ⁇ 2 scFv gene. Briefly, the EcoRI/HindIII restriction fragment in the phagemid vector pIG10 (Ge et al., 1995) was replaced by the c-myc followed by an amber codon (which encodes an glutamate in the amber-suppresser strain XL1 Blue and a stop codon in the non-suppresser strain JM83) and a truncated version of the gene III (fusion junction at codon 249, see Lowman et al., 1991) through PCR mutagenesis.
  • Heavy chain CDR3 libraries of two lengths (10 and 15 amino acids) were constructed using trinucleotide codon containing oligonucleotides (Virnelas et al., 1994) as templates and the oligonucleotides complementing the flanking regions as primers.
  • both phenylalanine and methionine were introduced at position 100 since these two residues were found to occur quite often in human CDR3s of this length (not shown).
  • valine and tyrosine were introduced at position 102. All other randomized positions contained codons for all amino acids except cystein, which was not used in the trinucleotide mixture.
  • the CDR3 libraries of lengths 10 and 15 were generated from the PCR fragments using oligonucleotide templates O3HCDR103T.
  • 5′-GATACGGCCGTGTATTATTGCGCGCGT (TRI) 6 GATTATTGGGGCCMGGCACCCTG-3′) and O3HCDR153T 5′-GATACGGCCGT GTATTATTGCGCGCGT(TRI) 10 (TTT/ATG)GAT(GTT/TAT)TGGGGCCAAGGCACCCTG-3′), and primers O3HCDR35 (5′-GATACGGCCGTGTATTATTGC-3′) and O3HCDR33 (5′-CAGGGTGCCTTGGCCCC-3′), where TRI are trinucleotide mixtures representing all amino acids without cystein, (TTT/ATG) and (GTT/TAT) are trinucleotide mixtures encoding the amino acids phenylalanine/methionine and valine/tyrosine, respectively.
  • the potential diversity of these libraries was 4.7 ⁇ 10 7 and 3.4 ⁇ 10 10 for 10-mer and 15-mer library, respectively.
  • the library cassettes were first synthesized from PCR amplification of the oligo templates in the presence of both primers: 25 pmol of the oligo template O3HCDR103T or O3HCDR153T, 50 pmol each of the primers O3HCDR35 and O3HCDR33, 20 nmol of dNTP, 10 ⁇ buffer and 2.5 units of Pfu DNA polymerase (Stratagene) in a total volume of 100 ⁇ l for 30 cycles (1 minute at 92° C., 1 minute at 62° C. and 1 minute at 72° C.). A hot-start procedure was used.
  • the resulting mixtures were phenol-extracted, ethanol-precipitated and digested overnight with EagI and StyI.
  • the vector pIG10.3-sCH3 ⁇ 2cat where the EagI-StyI fragment in the vector pIG10.3-sCH3 ⁇ 2 encoding the H-CDR3 was replaced by the chloramphenicol acetyltransferase gene (cat) flanked with these two sites, was similarly digested.
  • the digested vector 35 ⁇ g was gel-purified, and ligated with 100 ⁇ g of the library cassette overnight at 16° C.
  • the ligation mixtures were isopropanol precipitated, air-dried and the pellets were redissolved in 100 ⁇ l of ddH2O.
  • the ligation was mixed with 1 ml of freshly prepared electrocompetent XL1 Blue on ice. 20 rounds of electroporation were performed and the transformants were diluted in SOC medium, shaken at 37° C. for 30 minutes and plated out on large LB plates (Amp/Tet/Glucose) at 37° C. for 6-9 hrs.
  • the number of transformants (library size) was 3.2 ⁇ 10 7 and 2.3 ⁇ 10 7 for the 10-mer and the 15-mer library, respectively.
  • the colonies were suspended in 2 ⁇ YT medium (Amp/Tet/Glucose) and stored as glycerol culture.
  • phagemids from 24 independent colonies (12 from the 10-mer and 12 from the 15-mer library, respectively) were isolated and analyzed by restriction digestion and sequencing.
  • the restriction analysis of the 24 phagemids indicated the presence of intact vector in all cases.
  • Sequence analysis of these clones indicated that 22 out of 24 contained a functional sequence in their heavy chain CDR3 regions.
  • 1 out of 12 clones of the 10-mer library had a CDR3 of length 9 instead of 10
  • 2 out of 12 clones of the 15-mer library had no open reading frame, thereby leading to a non-functional scFv; one of these two clones contained two consecutive inserts, but out of frame (data not shown). All codons introduced were presented in an even distribution.
  • Phages displaying the antibody libraries were prepared using standard protocols. Phages derived from the 10-mer library were mixed with phages from the 15-mer library in a ratio of 20:1 (1 ⁇ 10 10 cfu/well of the 10-mer and 5 ⁇ 10 8 cfu/well of the 15-mer phages, respectively). Subsequently, the phage solution was used for panning in ELISA plates (Maxisorp, Nunc) coated with FITC-BSA (Sigma) at concentration of 100 ⁇ g/ml in PBS at 4° C. overnight. The antigen-coated wells were blocked with 3% powder milk in PBS and the phage solutions in 1% powder milk were added to each well and the plate was shaken at RT for 1 hr.
  • the wells were then washed with PBST and PBS (4 times each with shaking at RT for 5 minutes).
  • the bound phages were eluted with 0.1 M triethylamine (TEA) at RT for 10 minutes.
  • the eluted phage solutions were immediately neutralized with 1 ⁇ 2 the volume of 1 M Tris Cl, pH 7.6.
  • Eluted phage solutions (ca. 450 ⁇ l) were used to infect 5 ml of XL1 Blue cells at 37° C. for 30 min.
  • the infected cultures were then plated out on large LB plates (Amp/Tet/Glucose) and allowed to grow at 37° C. until the colonies were visible.
  • the colonies were suspended in 2 ⁇ YT medium and the glycerol cultures were made as above described. This panning round was repeated twice, and in the third round elution was carried out with addition of fluorescein in a concentration of 100 ⁇ g/ml in PBS. The enrichment of specific phage antibodies was monitored by panning the initial as well as the subsequent fluorescein-specific sub-libraries against the blocking buffer ( FIG. 12 ). Antibodies with specificity against fluorescein were isolated after 3 rounds of panning.
  • One of the criteria for the successful biopanning is the isolation of individual phage clones that bind to the targeted antigen or hapten.
  • 24 phagemid containing clones were used to inoculate 100 ⁇ l of 2 ⁇ YT medium (Amp/Tet/Glucose) in an ELISA plate (Nunc), which was subsequently shaken at 37° C. for 5 hrs. 100 ⁇ l of 2 ⁇ YT medium (Amp/Tet/1 mM IPTG) were added and shaking was continued for 30 minutes.
  • the heavy chain CDR3 region of 20 clones were sequenced in order to estimate the sequence diversity of fluorescein binding antibodies in the library ( FIG. 15 ). In total, 16 of 20 sequences (80%) were different, showing that the constructed library contained a highly diverse repertoire of fluorescein binders.
  • the CDR3s showed no particular sequence homology, but contained on average 4 arginine residues. This bias towards arginine in fluorescein binding antibodies had already been described by Barbas et al., 1992.
  • BioLogic system Bio-Rad
  • the ion-exchange column was one of the POROS®HS, CM or HQ or PI 20 (PerSeptive Biosystems, Inc.) depended on the theoretical pI of the scFv being purified.
  • the pH of all the buffers was adjusted to one unit lower or higher than the pI of the scFv being purified throughout.
  • the sample was loaded onto the first IMAC column, washed with 7 column volumes of 20 mM sodium phosphate, 1 M NaCl and 10 mM imidazole. This washing was followed by 7 column volumes of 20 mM sodium phosphate and 10 mM imidazole.
  • Example 2 In order to test the library used in Example 2 further, a new selection procedure was carried out using a variety of antigens comprising ⁇ -estradiol, testosterone, Lewis-Y epitope (LeY), interleukin-2 (IL-2), lymphotoxin- ⁇ (LT- ⁇ ), E-selectin ligand-1 (ESL-1), and BSA.
  • Antigens comprising ⁇ -estradiol, testosterone, Lewis-Y epitope (LeY), interleukin-2 (IL-2), lymphotoxin- ⁇ (LT- ⁇ ), E-selectin ligand-1 (ESL-1), and BSA.
  • the library and all procedures were identical to those described in Example 2.
  • the ELISA plates were coated with ⁇ -estradiol-BSA (100 ⁇ g/ml), testosterone-BSA (100 ⁇ g/ml), LeY-BSA (20 ⁇ g/ml) IL-2 (20 ⁇ g/ml), ESL-1 (20 ⁇ g/ml) and BSA (100 ⁇ g/ml), LT- ⁇ (denatured protein, 20 ⁇ g/ml).
  • bound phages were eluted with 0.1 M triethylamine (TEA) at RT for 10 minutes.
  • TAA triethylamine
  • FIG. 18 shows ELISA data for anti- ⁇ -estradiol and anti-ESL-1 antibodies.
  • selectivity and cross-reactivity of binding scFv fragments were tested.
  • an ELISA plate was coated with FITC, testosterone, ⁇ -estradiol, BSA, and ESL-1, with 5 wells for each antigen arranged in 5 rows, and 5 antibodies, one against each of the antigens, were screened against each of the antigens.
  • FIG. 19 shows the specific binding of the antibodies to the antigen it was selected for, and the low cross-reactivity with the other four antigens.
  • FIG. 25 shows a schematic representation of the pCAL vector system and the arrangement of vector modules and restriction sites therein.
  • FIG. 25 a shows a list of all restriction sites which are already incorporated into the consensus genes or the vector elements as part of the modular system or which are not yet present in the whole system. The latter could be used in a later stage for the introduction of or within new modules.
  • a series of vector modules was constructed where the restriction sites flanking the gene sub-elements of the HuCAL genes were removed, the vector modules themselves being flanked by unique restriction sites. These modules were constructed either by gene synthesis or by mutagenesis of templates. Mutagenesis was done by add-on PCR, by site-directed mutagenesis (Kunkel et al., 1991) or multisite oligonucleotide-mediated mutagenesis (Sutherland et al., 1995; Perlak, 1990) using a PCR-based assembly method.
  • FIG. 26 contains a list of the modules constructed. Instead of the terminator module M9 (HindIII-Ipp-PacI), a larger cassette M9II was prepared to introduce FseI as additional restriction site. M9II can be cloned via HindIII/BsrGI.
  • module M11-II All vector modules were characterized by restriction analysis and sequencing.
  • sequencing of the module revealed a two-base difference in positions 164/65 compared to the sequence database of the template. These two different bases (CA ⁇ GC) created an additional BanII site. Since the same two-base difference occurs in the f1 origin of other bacteriophages, it can be assumed that the two-base difference was present in the template and not created by mutagenesis during cloning. This BanII site was removed by site-directed mutagenesis, leading to module M11-II.
  • FIGS. 29 to 34 are showing the functional maps and sequences of the modules used for assembly of the modular vector pCAL4 (see below).
  • the functional maps and sequences of additional modules can be found in FIG. 35 a .
  • FIG. 35 b contains a list of oligonucleotides and primers used for the synthesis of the modules.
  • a cloning vector pMCS containing a specific multi-cloning site was constructed.
  • an MCS cassette FIG. 27
  • This cassette contains all those restriction sites in the order necessary for the sequential introduction of all vector modules and can be cloned via the 5′-HindIII site and a four base overhang at the 3′-end compatible with an AatII site.
  • the vector pMCS FIG. 28
  • the vector pMCS ( FIG. 28 ) was constructed by digesting pUC19 with AatII and HindIII, isolating the 2174 base pair fragment containing the bla gene and the ColE1 origin, and ligating the MCS cassette.
  • FIG. 35 is showing the functional map and the sequence of pCAL4.
  • FIG. 35 a is showing the functional maps and sequences of the vectors pCALO1 to pCALO3.
  • a universal ⁇ -lactamase cloning cassette was constructed having a multi-cloning site at the 5′-end as well as at the 3′-end.
  • the 5′-multi-cloning site comprises all restriction sites adjacent to the 5′-end of the HuCAL VH and VL CDRs
  • the 3′-multi-cloning site comprises all restriction sites adjacent to the 3′ end of the HuCAL VH and VL CDRs.
  • Both 5′- and 3′-multi-cloning site were prepared as cassettes via add-on PCR using synthetic oligonucleotides as 5′- and 3′-primers using wild type ⁇ -lactamase gene as template.
  • FIG. 36 shows the functional map and the sequence of the cassette bla-MCS.
  • VL-CDR3 libraries comprising 7 random positions were generated from the PCR fragments using oligonucleotide templates V ⁇ 1&V ⁇ 3, V ⁇ 2 and V ⁇ 4 and primers O_K3L — 5 and O_K3L — 3 ( FIG. 37 ) for the V ⁇ genes, and V ⁇ and primers O_L3L — 5 (5′-GCAGAAGGCGAACGTCC-3′) and O_L3LA — 3 ( FIG. 38 ) for the V ⁇ genes. Construction of the cassettes was performed as described in Example 2.3.
  • Each of the 49 single-chains was subcloned into pCAL4 via XbaI/EcoRI and the VL-CDR3 replaced by the ⁇ -lactamase cloning cassette via BbsI/MscI, which was then replaced by the corresponding VL-CDR3 library cassette synthesized as described above.
  • This CDR replacement is described in detail in Example 2.3 where the cat gene was used.
  • VH-CDR3 libraries were designed and synthesized as described in Example 2.3.
  • Each of the 49 single-chain VL-CDR3 libraries was digested with BssHII/StyI to replace VH-CDR3.
  • the “dummy” cassette digested with BssHII/StyI was inserted, and was then replaced by a corresponding VH-CDR3 library cassette synthesized as described above.
  • E. coli JM83 was transformed 49 times with each of the vectors and stored as glycerol stock. Between 4 and 6 clones were tested simultaneously, always including the clone H3 ⁇ 2, which was used as internal control throughout. As additional control, the McPC603 scFv fragment (Knappik & Plückthun, 1995) in pBS13 was expressed under identical conditions. Two days before the expression test was performed, the clones were cultivated on LB plates containing 30 ⁇ g/ml chloramphenicol and 60 mM glucose. Using this plates an 3 ml culture (LB medium containing 90 ⁇ g chloramphenicol and 60 mM glucose) was inoculated overnight at 37° C.
  • the overnight culture was used to inoculate 30 ml LB medium containing chloramphenicol (30 ⁇ g/ml).
  • the starting OD 600 nm was adjusted to 0.2 and a growth temperature of 30° C. was used.
  • the physiology of the cells was monitored by measuring every 30 minutes for 8 to 9 hours the optical density at 600 nm.
  • After the culture reached an OD 600 nm of 0.5 antibody expression was induced by adding IPTG to a final concentration of 1 mM.
  • a 5 ml aliquot of the culture was removed after 2 h of induction in order to analyze the antibody expression.
  • the cells were lysed and the soluble and insoluble fractions of the crude extract were separated as described in Knappik & Plückthun, 1995.
  • the fractions were assayed by reducing SDS-PAGE with the samples normalized to identical optical densities.
  • the lanes were scanned and the intensities of the bands of the expected size (appr. 30 kDa) were quantified densitometrically and tabulated relative to the control antibody (see FIG. 40 ).
  • a L-CDR3 library cassette was prepared from the oligonucleotide template CDR3L (5′-TGGAAGCTGAAGACGTGGGCGTGTATTATTGCCAGCAG(TR5)(TRI) 4 CCG (TRI)-TTTGGCCAGGGTACGAAAGTT-3′) and primer 5′-AACTTTCGTACCCTGGCC-3′ for synthesis of the complementary strand, where (TRI) was a trinucleotide mixture representing all amino acids except Cys, (TR5) comprised a trinucleotide mixture representing the 5 codons for Ala, Arg, His, Ser, and Tyr.
  • a H-CDR2 library cassette was prepared from the oligonucleotide template CDRsH (5′-AGGGTCTCGAGTGGGTGAGC(TRI)ATT(TRI) 2-3 (6) 2 (TRI)ACC(TRI)TATGCGGATAGCGTGAAAGGCCGTTTTACCATTTCACGTGATAATTCGAAAAACACCA-3′), and primer 5′-TGGTGTTTTTCGAATTATCA-3′ for synthesis of the complementary strand, where (TRI) was a trinucleotide mixture representing all amino acids except Cys, (6) comprised the incorporation of (A/G) (A/C/G) T, resulting in the formation of 6 codons for Ala, Asn, Asp, Gly, Ser, and Thr, and the length distribution being obtained by performing one substoichiometric coupling of the (TRI) mixture during synthesis, omitting the capping step normally used in DNA synthesis.
  • DNA was prepared from the collection of FITC binding clones obtained in Example 2 (approx. 10 4 to clones).
  • the collection of scFv fragments was isolated via XbaI/EcoRI digest.
  • the vector pCAL4 (100 fmole, 10 ⁇ g) described in Example 4.3 was similarly digested with XbaI/EcoRI, gel-purified and ligated with 300 fmole of the scFv fragment collection over night at 16° C.
  • the ligation mixture was isopropanol precipitated, air-dried, and the pellets were redissolved in 100 ⁇ l of dd H 2 O.
  • the ligation mixture was mixed with 1 ml of freshly prepared electrocompetent SCS 101 cells (for optimization of L-CDR3), or XL1 Blue cells (for optimization of H-CDR2) on ice.
  • One round of electroporation was performed and the transformants were eluted in SOC medium, shaken at 37° C. for 30 minutes, and an aliquot plated out on LB plates (Amp/Tet/Glucose) at 37° C. for 6-9 hrs.
  • the number of transformants was 5 ⁇ 10 4 .
  • Vector DNA 100 ⁇ g was isolated and digested (sequence and restriction map of sCH3 ⁇ 2 see FIG. 8 ) with BbsI/MscI for optimization of L-CDR3, or XhoI/NspV for optimization of H-CDR2.
  • 10 ⁇ g of purified vector fragments (5 pmole) were ligated with 15 pmole of the L-CDR3 or H-CDR2 library cassettes over night at 16° C.
  • the ligation mixtures were isopropanol precipitated, air-dried, and the pellets were redissolved in 100 ⁇ l of dd H 2 O.
  • the ligation mixtures were mixed with 1 ml of freshly prepared electrocompetent XL1 Blue cells on ice.
  • Electroporation was performed and the transformants were eluted in SOC medium and shaken at 37° C. for 30 minutes. An aliquot was plated out on LB plates (Amp/Tet/Glucose) at 37° C. for 6-9 hrs. The number of transformants (library size) was greater than 10 8 for both libraries. The libraries were stored as glycerol cultures.
  • Vk1-1 28 1 Vk1-2 0 1 Vk1-3 1 1 Vk1-4 0 1 Vk1-5 7 1 Vk1-6 0 1 Vk1-7 0 1 Vk1-8 2 1 Vk1-9 9 1 Vk1-10 0 1 Vk1-11 1 1 Vk1-12 7 1 Vk1-13 1 1 Vk1-14 7 1 Vk1-15 2 1 Vk1-16 2 1 Vk1-17 16 1 Vk1-18 1 1 Vk1-19 33 1 Vk1-20 1 1 Vk1-21 1 1 Vk1-22 0 1 Vk1-23 0 119 entries 2 Vk2-1 0 2 Vk2-2 1 2 Vk2-3 0 2 Vk2-4 0 2 Vk2-5 0 2 Vk2-6 16 2 Vk2-7 0 2 Vk2-8 0 2 Vk2-9 1 2 Vk2-10 0 2 Vk2-11 7 2 Vk2-12 0 25 entries 3 Vk
  • VH1-12-1 38 1 VH1-12-8 2 1 VH1-12-2 2 1 VH1-12-9 2 1 VH1-12-3 0 1 VH1-12-4 0 1 VH1-12-5 3 1 VH1-12-6 0 1 VH1-12-7 23 1 VH1-13-1 1 1 VH1-13-2 1 1 VH1-13-3 0 1 VH1-13-4 0 1 VH1-13-5 0 1 VH1-13-6 17 1 VH1-13-7 0 1 VH1-13-8 3 1 VH1-13-9 0 1 VH1-13-10 0 1 VH1-13-11 0 1 VH1-13-12 10 1 VH1-13-13 0 1 VH1-13-14 0 1 VH1-13-15 4 1 VH1-13-16 2 1 VH1-13-17 0 1 VH1-13-18 1 1 VH1-13-19 0 1 VH1-1X-1 1 110 entries 2 VH2-21-1 0
  • V lambda subgroup 2 Framework I amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 A 35 30 6 1 1 B C D E F G 42 H 2 I 1 K L 40 3 M N P 42 6 40 Q 22 4 41 R 6 1 S 41 40 42 42 T 42 1 V 1 2 36 W X Y Z 16 — 42 unknown (?) 1 not sequenced 3 1 1 3 1 1 1 1 1 1 1 1 sum of seq 2 40 42 42 40 42 42 42 42 42 42 42 43 43 43 oomcaa 3 22 41 35 40 42 41 42 30 40 42 36 42 42 42 40 mcaa 4 Q S A L T Q P A S — V S G S P rel.

Abstract

The present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins/(poly)peptides, and methods for generating and applying libraries of these DNA sequences. In particular, the invention relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences which cover the structural repertoire of antibodies encoded in the human genome. Furthermore, the invention relates to the use of a single consensus antibody gene as a universal framework for highly diverse antibody libraries.

Description

    FIELD OF THE INVENTION
  • The present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins/(poly)peptides, and methods for generating and applying libraries of these DNA sequences. In particular, the invention relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences which cover the structural repertoire of antibodies encoded in the human genome. Furthermore, the invention relates to the use of a single consensus antibody gene as a universal framework for highly diverse antibody libraries.
  • BACKGROUND TO THE INVENTION
  • All current recombinant methods which use libraries of proteins/(poly)peptides, e.g. antibodies, to screen for members with desired properties, e.g. binding a given ligand, do not provide the possibility to improve the desired properties of the members in an easy and rapid manner. Usually a library is created either by inserting a random oligonucleotide sequence into one or more DNA sequences cloned from an organism, or a family of DNA sequences is cloned and used as the library. The library is then screened, e.g. using phage display, for members which show the desired property. The sequences of one or more of these resulting molecules are then determined. There is no general procedure available to improve these molecules further on.
  • Winter (EP 0 368 684 B1) has provided a method for amplifying (by PCR), cloning, and expressing antibody variable region genes. Starting with these genes he was able to create libraries of functional antibody fragments by randomizing the CDR3 of the heavy and/or the light chain. This process is functionally equivalent to the natural process of VJ and VDJ recombination which occurs during the development of B-cells in the immune system.
  • However the Winter invention does not provide a method for optimizing the binding affinities of antibody fragments further on, a process which would be functionally equivalent to the naturally occurring phenomenon of “affinity maturation”, which is provided by the present invention. Furthermore, the Winter invention does not provide for artificial variable region genes, which represent a whole family of structurally similar natural genes, and which can be assembled from synthetic DNA oligonucleotides. Additionally, Winter does not enable the combinatorial assembly of portions of antibody variable regions, a feature which is provided by the present invention. Furthermore, this approach has the disadvantage that the genes of all antibodies obtained in the screening procedure have to be completely sequenced, since, except for the PCR priming regions, no additional sequence information about the library members is available. This is time and labor intensive and potentially leads to sequencing errors.
  • The teaching of Winter as well as other approaches have tried to create large antibody libraries having high diversity in the complementarity determining regions (CDRs) as well as in the frameworks to be able to find antibodies against as many different antigens as possible. It has been suggested that a single universal framework may be useful to build antibody libraries, but no approach has yet been successful.
  • Another problem lies in the production of reagents derived from antibodies. Small antibody fragments show exciting promise for use as therapeutic agents, diagnostic reagents, and for biochemical research. Thus, they are needed in large amounts, and the expression of antibody fragments, e.g. Fv, single-chain Fv (scFv), or Fab in the periplasm of E. coli (Skerra & Plückthun, 1988; Better et al., 1988) is now used routinely in many laboratories. Expression yields vary widely, however. While some fragments yield up to several mg of functional, soluble protein per liter and OD of culture broth in shake flask culture (Carter et al., 1992, Plückthun et al. 1996), other fragments may almost exclusively lead to insoluble material, often found in so-called inclusion bodies. Functional protein may be obtained from the latter in modest yields by a laborious and time-consuming refolding process. The factors influencing antibody expression levels are still only poorly understood. Folding efficiency and stability of the antibody fragments, protease lability and toxicity of the expressed proteins to the host cells often severely limit actual production levels, and several attempts have been tried to increase expression yields. For example, Knappik & Plückthun (1995) could show that expression yield depends on the antibody sequence. They identified key residues in the antibody framework which influence expression yields dramatically. Similarly, Ullrich et al. (1995) fount that point mutations in the CDRs can increase the yields in periplasmic antibody fragment expression. Nevertheless, these strategies are only applicable to a few antibodies. Since the Winter invention uses existing repertoires of antibodies, no influence on expressibility of the genes is possible.
  • Furthermore, the findings of Knappik & Plückthun ard Ullrich demonstrate that the knowledge about antibodies, especially about folding and expression is still increasing. The Winter invention does not allow to incorporate such improvements into the library design.
  • The expressibility of the genes is important for the library quality as well, since the screening procedure relies in most cases on the display of the gene product on a phage surface, and efficient display relies on at least moderate expression of the gene.
  • These disadvantages of the existing methodologies are overcome by the present invention, which is applicable for all collections of homologous proteins. It has the following novel and useful features illustrated in the following by antibodies as an example:
  • Artificial antibodies and fragments thereof can be constructed based on known antibody sequences, which reflect the structural properties of a whole group of homologous antibody genes. Therefore it is possible to reduce the number of different genes without any loss in the structural repertoire. This approach leads to a limited set of artificial genes, which can be synthesized de novo, thereby allowing introduction of cleavage sites and removing unwanted cleavages sites. Furthermore, this approach enables (i), adapting the codon usage of the genes to that of highly expressed genes in any desired host cell and (ii), analyzing all possible pairs of antibody light (L) and heavy (H) chains in terms of interaction preference, antigen preference or recombinant expression titer, which is virtually impossible using the complete collection of antibody genes of an organism and all combinations thereof.
  • The use of a limited set of completely synthetic genes makes it possible to create cleavage sites at the boundaries of encoded structural sub-elements. Therefore, each gene is built up from modules which represent structural sub-elements on the protein/(poly)peptide level. In the case of antibodies, the modules consist of “framework” and “CDR” modules. By creating separate framework and CDR modules, different combinatorial assembly possibilities are enabled. Moreover, if two or more artificial genes carry identical pairs of cleavage sites at the boundaries of each of the genetic sub-elements, pre-built libraries of sub-elements can be inserted in these genes simultaneously, without any additional information related to any particular gene sequence. This strategy enables rapid optimization of, for example, antibody affinity, since DNA cassettes encoding libraries of genetic sub-elements can be (i), pre-built, stored and reused and (ii), inserted in any of these sequences at the right position without knowing the actual sequence or having to determine the sequence of the individual library member.
  • Additionally, new information about amino acid residues important for binding, stability, or solubility and expression could be integrated into the library design by replacing existing modules with modules modified according to the new observations.
  • The limited number of consensus sequences used for creating the library allows to speed up the identification of binding antibodies after screening. After having identified the underlying consensus gene sequence, which could be done by sequencing or by using fingerprint restriction sites, just those part(s) comprising the random sequence(s) have to be determined. This reduces the probability of sequencing errors and of false-positive results.
  • The above mentioned cleavage sites can be used only if they are unique in the vector system where the artificial genes have been inserted. As a result, the vector has to be modified to contain none of these cleavage sites. The construction of a vector consisting of basic elements like resistance gene and origin of replication, where cleavage sites have been removed, is of general interest for many cloning attempts. Additionally, these vector(s) could be part of a kit comprising the above mentioned artificial genes and pre-built libraries.
  • The collection of artificial genes can be used for a rapid humanization procedure of non-human antibodies, preferably of rodent antibodies. First, the amino acid sequence of the non-human, preferably rodent antibody is compared with the amino acid sequences encoded by the collection of artificial genes to determine the most homologous light and heavy framework regions. These genes are then used for insertion of the genetic sub-elements encoding the CDRs of the non-human, preferably rodent antibody.
  • Surprisingly, it has been found that with a combination of only one consensus sequence for each of the light and heavy chains of a scFv fragment an antibody repertoire could be created yielding antibodies against virtually every antigen. Therefore, one aspect of the present invention is the use of a single consensus sequence as a universal framework for the creation of useful (poly)peptide libraries and antibody consensus sequences useful therefor.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention enables the creation of useful libraries of (poly)peptides. In a first embodiment, the invention provides for a method of setting up nucleic acid sequences suitable for the creation of said libraries. In a first step, a collection of at least three homologous proteins is identified and then analyzed. Therefore, a database of the protein sequences is established where the protein sequences are aligned to each other. The database is used to define subgroups of protein sequences which show a high degree of similarity in both the sequence and, if information is available, in the structural arrangement. For each of the subgroups a (poly)peptide sequence comprising at least one consensus sequence is deduced which represents the members of this subgroup; the complete collection of (poly)peptide sequences represent therefore the complete structural repertoire of the collection of homologous proteins. These artificial (poly)peptide sequences are then analyzed, if possible, according to their structural properties to identify unfavorable interactions between amino acids within said (poly)peptide sequences or between said or other (poly)peptide sequences, for example, in multimeric proteins. Such interactions are then removed by changing the consensus sequence accordingly. The (poly)peptide sequences are then analyzed to identify sub-elements such as domains, loops, helices or CDRs. The amino acid sequence is backtranslated into a corresponding coding nucleic acid sequence which is adapted to the codon usage of the host planned for expressing said nucleic acid sequences. A set of cleavage sites is set up in a way that each of the sub-sequences encoding the sub-elements identified as described above, is flanked by two sites which do not occur a second time within the nucleic acid sequence. This can be achieved by either identifying a cleavage site already flanking a sub-sequence of by changing one or more nucleotides to create the cleavage site, and by removing that site from the remaining part of the gene. The cleavage sites should be common to all corresponding sub-elements or sub-sequences, thus creating a fully modular arrangement of the sub-sequences in the nucleic acid sequence and of the sub-elements in the corresponding (poly)peptide.
  • In a further embodiment, the invention provides for a method which sets up two or more sets of (poly)peptides, where for each set the method as described above is performed, and where the cleavage sites are not only unique within each set but also between any two sets. This method can be applied for the creation of (poly)peptide libraries comprising for example two α-helical domains from two different proteins, where said library is screened for novel hetero-association domains.
  • In yet a further embodiment, at least two of the sets as described above, are derived from the same collection of proteins or at least a part of it. This describes libraries comprising for example, but not limited to, two domains from antibodies such as VH and VL, or two extracellular loops of transmembrane receptors.
  • In another embodiment, the nucleic acid sequences set up as described above, are synthesized. This can be achieved by any one of several methods well known to the practitioner skilled in the art, for example, by total gene synthesis or by PCR-based approaches.
  • In one embodiment, the nucleic acid sequences are cloned into a vector. The vector could be a sequencing vector, an expression vector or a display (e.g. phage display) vector, which are well known to those skilled in the art. Any vector could comprise one nucleic acid sequence, or two or more nucleic sequences, either in different or the same operon. In the last case, they could either be cloned separately or as contiguous sequences.
  • In one embodiment, the removal of unfavorable interactions as described above, leads to enhanced expression of the modified (poly)peptides.
  • In a preferred embodiment, one or more sub-sequences of the nucleic acid sequences are replaced by different sequences. This can be achieved by excising the sub-sequences using the conditions suitable for cleaving the cleavage sites adjacent to or at the end of the sub-sequence, for example, by using a restriction enzyme at the corresponding restriction site under the conditions well known to those skilled in the art, and replacing the sub-sequence by a different sequence compatible with the cleaved nucleic acid sequence. In a further preferred embodiment, the different sequences replacing the initial sub-sequence(s) are genomic or rearranged genomic sequences, for example in grafting CDRs from non-human antibodies onto consensus antibody sequences for rapid humanization of non-human antibodies. In the most preferred embodiment, the different sequences are random sequences, thus replacing the sub-sequence by a collection of sequences to introduce variability and to create a library. The random sequences can be assembled in various ways, for example by using a mixture of mononucleotides or preferably a mixture of trinucleotides (Virnekäs et al., 1994) during automated oligonucleotide synthesis, by error-prone PCR or by other methods well known to the practitioner in the art. The random sequences may be completely randomized or biased towards or against certain codons according to the amino acid distribution at certain positions in known protein sequences. Additionally, the collection of random sub-sequences may comprise different numbers of codons, giving rise to a collection of sub-elements having different lengths.
  • In another embodiment, the invention provides for the expression of the nucleic acid sequences from a suitable vector and under suitable conditions well known to those skilled in the art.
  • In a further preferred embodiment, the (poly)peptides expressed from said nucleic acid sequences are screened and, optionally, optimized. Screening may be performed by using one of the methods well known to the practitioner in the art, such as phage-display, selectively infective phage, polysome technology to screen for binding, assay systems for enzymatic activity or protein stability. (Poly)peptides having the desired property can be identified by sequencing of the corresponding nucleic acid sequence or by amino acid sequencing or mass spectrometry. In the case of subsequent optimization, the nucleic acid sequences encoding the initially selected (poly)peptides can optionally be used without sequencing. Optimization is performed by repeating the replacement of sub-sequences by different sequences, preferably by random sequences, and the screening step one or more times.
  • The desired property the (poly)peptides are screened for is preferably, but not exclusively, selected from the group of optimized affinity or specificity for a target molecule, optimized enzymatic activity, optimized expression yields, optimized stability and optimized solubility.
  • In one embodiment, the cleavage sites flanking the sub-sequences are sites recognized and cleaved by restriction enzymes, with recognition and cleavage sequences being either identical or different, the restricted sites either having blunt or sticky ends.
  • The length of the sub-elements is preferably, but not exclusively ranging between 1 amino acid, such as one residue in the active site of an enzyme or a structure-determining residue, and 150 amino acids, as for whole protein domains. Most preferably, the length ranges between 3 and 25 amino acids, such as most commonly found in CDR loops of antibodies.
  • The nucleic acid sequences could be RNA or, preferably, DNA.
  • In one embodiment, the (poly)peptides have an amino acid pattern characteristic of a particular species. This can for example be achieved by deducing the consensus sequences from a collection of homologous proteins of just one species, most preferably from a collection of human proteins. Since the (poly)peptides comprising consensus sequences are artificial, they have to be compared to the protein sequence(s) having the closest similarity to ensure the presence of said characteristic amino acid pattern.
  • In one embodiment, the invention provides for the creation of libraries of (poly)peptides comprising at least part of members or derivatives of the immunoglobulin superfamily, preferably of member or derivatives of the immunoglobulins. Most preferably, the invention provides for the creation of libraries of human antibodies, wherein said (poly)peptides are or are derived from heavy or light chain variable regions wherein said structural sub-elements are framework regions (FR) 1, 2, 3, or 4 or complementary determining regions (CDR) 1, 2, or 3. In a first step, a database of published antibody sequences of human origin is established where the antibody sequences are aligned to each other. The database is used to define subgroups of antibody sequences which show a high degree of similarity in both the sequence and the canonical fold of CDR loops (as determined by analysis of antibody structures). For each of the subgroups a consensus sequence is deduced which represents the members of this subgroup; the complete collection of consensus sequences represent therefore the complete structural repertoire of human antibodies.
  • These artificial genes are then constructed e.g. by total gene synthesis or by the use of synthetic genetic subunits. These genetic subunits correspond to structural sub-elements on the (poly)peptide level. On the DNA level, these genetic subunits are defined by cleavage sites at the start and the end of each of the sub-elements, which are unique in the vector system. All genes which are members of the collection of consensus sequences are constructed such that they contain a similar pattern of corresponding genetic sub-sequences. Most preferably, said (poly)peptides are or are derived from the HuCAL consensus genes: Vκ1, Vκ2, Vκ3, Vκ4, Vλ1, Vλ2, Vλ3, VH1A, VH1B, VH2, VH3, VH4, VH5, VH6, Cκ, Cπ, CH1 or any combination of said HuCAL consensus genes.
  • This collection of DNA molecules can then be used to create libraries of antibodies or antibody fragments, preferably Fv, disulphide-linked Fv, single-chain Fv (scFv), or Fab fragments, which may be used as sources of specificities against new target antigens. Moreover, the affinity of the antibodies can be optimized using pre-built library cassettes and a general procedure. The invention provides a method for identifying one or more genes encoding one or more antibody fragments which binds to a target, comprising the steps of expressing the antibody fragments, and then screening them to isolate one or more antibody fragments which bind to a given target molecule. Preferably, an scFv fragment library comprising the combination of HuCAL VH3 and HuCAL Vλ2 consensus genes and at least a random sub-sequence encoding the heavy chain CDR3 sub-element is screened for binding antibodies. If necessary, the modular design of the genes can then be used to excise from the genes encoding the antibody fragments one or more genetic sub-sequences encoding structural sub-elements, and replacing them by one or more second sub-sequences encoding structural sub-elements. The expression and screening steps can then be repeated until an antibody having the desired affinity is generated.
  • Particularly preferred is a method in which one or more of the genetic subunits (e.g. the CDRs) are replaced by a random collection of sequences (the library) using the said cleavage sites. Since these cleavage sites are (i) unique in the vector system and (ii) common to all consensus genes, the same (pre-built) library can be inserted into all artificial antibody genes. The resulting library is then screened against any chosen antigen. Binding antibodies are selected, collected and used as starting material for the next library. Here, one or more of the remaining genetic subunits are randomized as described above.
  • A further embodiment of the present invention relates to fusion proteins by providing for a DNA sequence which encodes both the (poly)peptide, as described above, as well as an additional moiety. Particularly preferred are moieties which have a useful therapeutic function. For example, the additional moiety may be a toxin molecule which is able to kill cells (Vitetta et al., 1993). There are numerous examples of such toxins, well known to the one skilled in the art, such as the bacterial toxins Pseudomonas exotoxin A, and diphtheria toxin, as well as the plant toxins ricin, abrin, modeccin, saporin, and gelonin. By fusing such a toxin for example to an antibody fragment, the toxin can be targeted to, for example, diseased cells, and thereby have a beneficial therapeutic effect. Alternatively, the additional moiety may be a cytokine, such as IL-2 (Rosenberg & Lotze, 1986), which has a particular effect (in this case a T-cell proliferative effect) on a family of cells. In a further embodiment, the additional moiety may confer on its (poly)peptide partner a means of detection and/or purification. For example, the fusion protein could comprise the modified antibody fragment and an enzyme commonly used for detection purposes, such as alkaline phosphatase (Blake et al., 1984). There are numerous other moieties which can be used as detection or purification tags, which are well known to the practitioner skilled in the art. Particularly preferred are peptides comprising at least five histidine residues (Hochuli et al., 1988), which are able to bind to metal ions, and can therefore be used for the purification of the protein to which they are fused (Lindner et al., 1992). Also provided for by the invention are additional moieties such as the commonly used C-myc and FLAG tags (Hopp et al., 1988; Knappik & Plückthun, 1994).
  • By engineering one or more fused additional domains, antibody fragments or any other (poly)peptide can be assembled into larger molecules which also fall under the scope of the present invention. For example, mini-antibodies (Pack, 1994) are dimers comprising two antibody fragments, each fused to a self-associating dimerization domain. Dimerization domains which are particularly preferred include those derived from a leucine zipper (Pack & Plückthun, 1992) or helix-turn-helix motif (Pack et al., 1993).
  • All of the above embodiments of the present invention can be effected using standard techniques of molecular biology known to anyone skilled in the art.
  • In a further embodiment, the random collection of sub-sequences (the library) is inserted into a singular nucleic acid sequence encoding one (poly)peptide, thus creating a (poly)peptide library based on one universal framework. Preferably a random collection of CDR sub-sequences is inserted into a universal antibody framework, for example into the HuCAL H3κ2 single-chain Fv fragment described above.
  • In further embodiments, the invention provides for nucleic acid sequence(s), vector(s) containing the nucleic acid sequence(s), host cell(s) containing the vector(s), and (poly)peptides, obtainable according to the methods described above.
  • In a further preferred embodiment, the invention provides for modular vector systems being compatible with the modular nucleic acid sequences encoding the (poly)peptides. The modules of the vectors are flanked by restriction sites unique within the vector system and essentially unique with respect to the restriction sites incorporated into the nucleic acid sequences encoding the (poly)peptides, except for example the restriction sites necessary for cloning the nucleic acid sequences into the vector. The list of vector modules comprises origins of single-stranded replication, origins of double-stranded replication for high- and low copy number plasmids, promotor/operator, repressor or terminator elements, resistance genes, potential recombination sites, gene III for display on filamentous phages, signal sequences, purification and detection tags, and sequences of additional moieties.
  • The vectors are preferably, but not exclusively, expression vectors or vectors suitable for expression and screening of libraries.
  • In another embodiment, the invention provides for a kit, comprising one or more of the list of nucleic acid sequence(s), recombinant vector(s), (poly)peptide(s), and vector(s) according to the methods described above, and suitable host cell(s) for producing the (poly)peptide(s).
  • In a preferred embodiment, the invention provides for the creation of libraries of human antibodies. In a first step, a database of published antibody sequences of human origin is established: The database is used to define subgroups of antibody sequences which show a high degree of similarity in both the sequence and the canonical fold (as determined by analysis of antibody structures). For each of the subgroups a consensus sequence is deduced which represents the members of this subgroup; the complete collection of consensus sequences represent therefore the complete structural repertoire of human antibodies.
  • These artificial genes are then constructed by the use of synthetic genetic subunits. These genetic subunits correspond to structural sub-elements on the protein level. On the DNA level, these genetic subunits are defined by cleavage sites at the start and the end of each of the subelements, which are unique in the vector system. All genes which are members of the collection of consensus sequences are constructed such that they contain a similar pattern of said genetic subunits.
  • This collection of DNA molecules can then be used to create libraries of antibodies which may be used as sources of specificities against new target antigens. Moreover, the affinity of the antibodies can be optimised using pre-built library cassettes and a general procedure. The invention provides a method for identifying one or more genes encoding one or more antibody fragments which binds to a target, comprising the steps of expressing the antibody fragments, and then screening them to isolate one or more antibody fragments which bind to a given target molecule. If necessary, the modular design of the genes can then be used to excise from the genes encoding the antibody fragments one or more genetic sub-sequences encoding structural sub-elements, and replacing them by one or more second sub-sequences encoding structural sub-elements. The expression and screening steps can then be repeated until an antibody having the desired affinity is generated.
  • Particularly preferred is a method in which one or more or the genetic subunits (e.g. the CDR's) are replaced by a random collection of sequences (the library) using the said cleavage sites. Since these cleavage sites are (i) unique in the vector system and (ii) common to all consensus genes, the same (pre-built) library can be inserted into all artificial antibody genes. The resulting library is then screened against any chosen antigen. Binding antibodies are eluted, collected and used as starting material for the next library. Here, one or more of the remaining genetic subunits are randomised as described above.
  • Definitions
  • Protein:
  • The term protein comprises monomeric polypeptide chains as well as homo- or heteromultimeric complexes of two or more polypeptide chains connected either by covalent interactions (such as disulphide bonds) or by non-covalent interactions (such as hydrophobic or electrostatic interactions).
  • Analysis of Homologous Proteins:
  • The amino acid sequences of three or more proteins are aligned to each other (allowing for introduction of gaps) in a way which maximizes the correspondence between identical or similar amino acid residues at all positions. These aligned sequences are termed homologous if the percentage of the sum of identical and/or similar residues exceeds a defined threshold. This threshold is commonly regarded by those skilled in the art as being exceeded when at least 15% of the amino acids in the aligned genes are identical, and at least 30% are similar. Examples for families of homologous proteins are: immunoglobulin superfamily, scavenger receptor superfamily, fibronectin superfamilies (e.g. type II and III), complement control protein superfamily, cytokine receptor superfamily, cystine knot proteins, tyrosine kinases, and numerous other examples well known to one of ordinary skill in the art.
  • Consensus Sequence:
  • Using a matrix of at least three aligned amino acid sequences, and allowing for gaps in the alignment, it is possible to determine the most frequent amino acid residue at each position. The consensus sequence is that sequence which comprises the amino acids which are most frequently represented at each position. In the event that two or more amino acids are equally represented at a single position, the consensus sequence includes both or all of those amino acids.
  • Removing Unfavorable Interactions:
  • The consensus sequence is per se in most cases artificial and has to be analyzed in order to change amino acid residues which, for example, would prevent the resulting molecule to adapt a functional tertiary structure or which would block the interaction with other (poly)peptide chains in multimeric complexes. This can be done either by (i) building a three-dimensional model of the consensus sequence using known related structures as a template, and identifying amino acid residues within the model which may interact unfavorably with each other, or (ii) analyzing the matrix of aligned amino acid sequences in order to detect combinations of amino acid residues within the sequences which frequently occur together in one sequence and are therefore likely to interact with each other. These probable interaction-pairs are then tabulated and the consensus is compared with these “interaction maps”. Missing or wrong interactions in the consensus are repaired accordingly by introducing appropriate changes in amino acids which minimize unfavorable interactions.
  • Identification of Structural Sub-Elements:
  • Structural sub-elements are stretches of amino acid residues within a protein/(poly)peptide which correspond to a defined structural or functional part of the molecule. These can be loops (e.g. CDR loops of an antibody) or any other secondary or functional structure within the protein/(poly)peptide (domains, α-helices, β-sheets, framework regions of antibodies, etc.). A structural sub-element can be identified using known structures of similar or homologous (poly)peptides, or by using the above mentioned matrices of aligned amino acid sequences. Here the variability at each position is the basis for determining stretches of amino acid residues which belong to a structural sub-element (e.g. hypervariable regions of an antibody).
  • Sub-Sequence:
  • A sub-sequence is defined as a genetic module which is flanked by unique cleavage sites and encodes at least one structural sub-element. It is not necessarily identical to a structural sub-element.
  • Cleavage Site:
  • A short DNA sequence which is used as a specific target for a reagent which cleaves DNA in a sequence-specific manner (e.g. restriction endonucleases).
  • Compatible Cleavage Sites:
  • Cleavage sites are compatible with each other, if they can be efficiently ligated without modification and, preferably, also without adding an adapter molecule.
  • Unique Cleavage Sites:
  • A cleavage site is defined as unique if it occurs only once in a vector containing at least one of the genes of interest, or if a vector containing at least one of the genes of interest could be treated in a way that only one of the cleavage sites could be used by the cleaving agent.
  • Corresponding (Poly)Peptide Sequences:
  • Sequences deduced from the same part of one group of homologous proteins are called corresponding (poly)peptide sequences.
  • Common Cleavage Sites:
  • A cleavage site in at least two corresponding sequences, which occurs at the same functional position (i.e. which flanks a defined sub-sequence), which can be hydrolyzed by the same cleavage tool and which yields identical compatible ends is termed a common cleavage site.
  • Excising Genetic Sub-Sequences:
  • A method which uses the unique cleavage sites and the corresponding cleavage reagents to cleave the target DNA at the specified positions in order to isolate, remove or replace the genetic sub-sequence flanked by these unique cleavage sites.
  • Exchanging Genetic Sub-Sequences:
  • A method by which an existing sub-sequence is removed using the flanking cleavage sites of this sub-sequence, and a new sub-sequence or a collection of sub-sequences, which contain ends compatible with the cleavage sites thus created, is inserted.
  • Expression of Genes:
  • The term expression refers to in vivo or in vitro processes, by which the information of a gene is transcribed into mRNA and then translated into a protein/(poly)peptide. Thus, the term expression refers to a process which occurs inside cells, by which the information of a gene is transcribed into mRNA and then into a protein. The term expression also includes all events of post-translational modification and transport, which are necessary for the (poly)peptide to be functional.
  • Screening of Protein/(Poly)Peptide Libraries:
  • Any method which allows isolation of one or more proteins/(poly)peptides having a desired property from other proteins/(poly)peptides within a library.
  • Amino Acid Pattern Characteristic for a Species:
  • A (poly)peptide sequence is assumed to exhibit an amino acid pattern characteristic for a species if it is deduced from a collection of homologous proteins from just this species.
  • Immunoglobulin Superfamily (IgSF):
  • The IgSF is a family of proteins comprising domains being characterized by the immunoglobulin fold. The IgSF comprises for example T-cell receptors and the immunoglobulins (antibodies).
  • Antibody Framework:
  • A framework of an antibody variable domain is defined by Kabat et al. (1991) as the part of the variable domain which serves as a scaffold for the antigen binding loops of this variable domain.
  • Antibody CDR:
  • The CDRs (complementarity determining regions) of an antibody consist of the antigen binding loops, as defined by Kabat et al. (1991). Each of the two variable domains of an antibody Fv fragment contain three CDRs.
  • HuCAL:
  • Acronym for Human Combinatorial Antibody Library. Antibody Library based on modular consensus genes according to the invention (see Example 1).
  • Antibody Fragment:
  • Any portion of an antibody which has a particular function, e.g. binding of antigen. Usually, antibody fragments are smaller than whole antibodies. Examples are Fv, disulphide-linked Fv, single-chain Fv (scFv), or Fab fragments. Additionally, antibody fragments are often engineered to include new functions or properties.
  • Universal Framework:
  • One single framework which can be used to create the full variability of functions, specificities or properties which is originally sustained by a large collection of different frameworks, is called universal framework.
  • Binding of an Antibody to its Target:
  • The process which leads to a tight and specific association between an antibody and a corresponding molecule or ligand is called binding. A molecule or ligand or any part of a molecukle or ligand which is recognized by an antibody is called the target.
  • Replacing Genetic Sub-Sequences
  • A method by which an existing sub-sequence is removed using the flanking cleavage sites of this sub-sequence, and a new sub-sequence or collection of sub-sequences, which contains ends compatible with the cleavage sites thus created, is inserted.
  • Assembling of Genetic Sequences:
  • Any process which is used to combine synthetic or natural genetic sequences in a specific manner in order to get longer genetic sequences which contain at least parts of the used synthetic or natural genetic sequences.
  • Analysis of Homologous Genes:
  • The corresponding amino acid sequences of two or more genes are aligned to each other in a way which maximizes the correspondence between identical or similar amino acid residues at all positions. These aligned sequences are termed homologous if the percentage of the Sum of identical and/or similar residues exceeds a defined threshold. This threshold is commonly regarded by those skilled in the art as being exceeded when at least 15 percent of the amino acids in the aligned genes are identical, and at least 30 percent are similar.
  • LEGENDS TO FIGURES AND TABLES
  • FIG. 1: Flow chart outlining the process of construction of a synthetic human antibody library based on consensus sequences.
  • FIG. 2: Alignment of consensus sequences designed for each subgroup (amino acid residues are shown with their standard one-letter abbreviation). (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. The positions are numbered according to Kabat (1991). In order to maximize homology in the alignment, gaps (−) have been introduced in the sequence at certain positions.
  • FIG. 3: Gene sequences of the synthetic V kappa consensus genes. The corresponding amino acid sequences (see FIG. 2) as well as the unique cleavage sites are also shown.
  • FIG. 4: Gene sequences of the synthetic V lambda consensus genes. The corresponding amino acid sequences (see FIG. 2) as well as the unique cleavage sites are also shown.
  • FIG. 5: Gene sequences of the synthetic V heavy chain consensus genes. The corresponding amino acid sequences (see FIG. 2) as well as the unique cleavage sites are also shown.
  • FIG. 6: Oligonucleotides used for construction of the consensus genes. The oligos are named according to the corresponding consensus gene, e.g. the gene Vκ1 was constructed using the six oligonucleotides O1K1 to O1K6. The oligonucleotides used for synthesizing the genes encoding the constant domains Cκ (OCLK1 to 8) and CH1 (OCH1 to 8) are also shown.
  • FIG. 7A/B: Sequences of the synthetic genes encoding the constant domains Cκ (A) and CH1 (B). The corresponding amino acid sequences as well as unique cleavage sites introduced in these genes are also shown.
  • FIG. 7C: Functional map and sequence of module M24 comprising the synthetic Cλ gene segment (huCL lambda).
  • FIG. 7D: Oligonucleotides used for synthesis of module M24.
  • FIG. 8: Sequence and restriction map of the synthetic gene encoding the consensus single-chain fragment VH3-Vκ2. The signal sequence (amino acids 1 to 21) was derived from the E. coli phoA gene (Skerra & Plückthun, 1988). Between the phoA signal sequence and the VH3 domain, a short sequence stretch encoding 4 amino acid residues (amino acid 22 to 25) has been inserted in order to allow detection of the single-chain fragment in Western blot or ELISA using the monoclonal antibody M1 (Knappik & Plückthun, 1994). The last 6 basepairs of the sequence were introduced for cloning purposes (EcoRI site).
  • FIG. 9: Plasmid map of the vector pIG10.3 used for phage display of the H3κ2 scFv fragment. The vector is derived from pIG10 and contains the gene for the lac operon repressor, lacI, the artificial operon encoding the H3κ2-gene3ss fusion under control of the lac promoter, the lpp terminator of transcription, the single-strand replication origin of the E. coli phage f1 (F1_ORI), a gene encoding β-lactamase (bla) and the ColEI derived origin of replication.
  • FIG. 10: Sequencing results of independent clones from the initial library, translated into the corresponding amino acid sequences. (A) Amino acid sequence of the VH3 consensus heavy chain CDR3 (position 93 to 102, Kabat numbering). (B) Amino acid sequences of 12 clones of the 10-mer library. (C) Amino acid sequences of 11 clones of the 15-mer library, single base deletion.
  • FIG. 11: Expression test of individual library members. (A) Expression of 9 independent clones of the 10-mer library. (B) Expression of 9 independent clones of the 15-mer library. The lane designated with M contains the size marker. Both the gp3-scFv fusion and the scFv monomer are indicated.
  • FIG. 12: Enrichment of specific phage antibodies during the panning against FITC-BSA. The initial as well as the subsequent fluorescein-specific sub-libraries were panned against the blocking buffer and the ratio of the phage eluted from the FITC-BSA coated well vs. that from the powder milk coated well from each panning round is presented as the “specificity factor”.
  • FIG. 13: Phage ELISA of 24 independent clones after the third round of panning tested for binding on FITC-BSA.
  • FIG. 14: Competition ELISA of selected FITC-BSA binding clones. The ELISA signals (OD405 nm) of scFv binding without inhibition are taken as 100%.
  • FIG. 15: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against FITC-BSA, translated into the corresponding amino acid sequences (position 93 to 102. Kabat numbering).
  • FIG. 16: Coomassie-Blue stained SDS-PAGE of the purified anti-fluorescein scFv fragments: M: molecular weight marker, A: total soluble cell extract after induction, B: fraction of the flow-through, C, D and E: purified scFv fragments 1HA-3E4, 1HA-3E5 and 1HA-3E10, respectively.
  • FIG. 17: Enrichment of specific phage antibodies during the panning against β-estradiol-BSA, testosterone-BSA, BSA, ESL-1, interleukin-2, lymphotoxin-β, and LeY-BSA after three rounds of panning.
  • FIG. 18: ELISA of selected ESL-1 and β-estradiol binding clones.
  • FIG. 19: Selectivity and cross-reactivity of HuCAL antibodies: in the diagonal specific binding of HuCAL antibodies can be seen, off-diagonal signals show non-specific cross-reactivity.
  • FIG. 20: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against β-estradiol-BSA, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering). One clone is derived from the 10mer library.
  • FIG. 21: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against testosterone-BSA, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering).
  • FIG. 22: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against lymphotoxin-β, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering). One clone comprises a 14mer CDR, presumably introduced by incomplete coupling of the trinucleotide mixture during oligonucleotide synthesis.
  • FIG. 23: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against ESL-1, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering). Two clones are derived from the 10mer library. One clone comprises a 16mer CDR, presumably introduced by chain elongation during oligonucleotide synthesis using trinucleotides.
  • FIG. 24: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against BSA, translated into the corresponding amino acid sequences (position 93 to 102, Kabat numbering).
  • FIG. 25: Schematic representation of the modular pCAL vector system.
  • FIG. 25 a: List of restriction sites already used in or suitable for the modular HuCAL genes and pCAL vector system.
  • FIG. 26: List of the modular vector elements for the pCAL vector series: shown are only those restriction sites which are part of the modular system.
  • FIG. 27: Functional map and sequence of the multi-cloning site module (MCS).
  • FIG. 28: Functional map and sequence of the pMCS cloning vector series.
  • FIG. 29: Functional map and sequence of the pCAL module M1 (see FIG. 26).
  • FIG. 30: Functional map and sequence of the pCAL module M7-III (see FIG. 26).
  • FIG. 31: Functional map and sequence of the pCAL module M9-II (see FIG. 26).
  • FIG. 32: Functional map and sequence of the pCAL module M11-II (see FIG. 26).
  • FIG. 33: Functional map and sequence of the pCAL module M14-Ext2 (see FIG. 26).
  • FIG. 34: Functional map and sequence of the PCAL module M17 (see FIG. 26).
  • FIG. 35: Functional map and sequence of the modular vector pCAL4.
  • FIG. 35 a: Functional maps and sequences of additional pCAL modules (M2, M3, M7I, M7II, M8, M10II, M11II, M12, M13, M19, M20, M21, M41) and of low-copy number plasmid vectors (pCALO1 to pCALO3).
  • FIG. 35 b: List of oligonucleotides and primers used for synthesis of pCAL vector modules.
  • FIG. 36: Functional map and sequence of the β-lactamase cassette for replacement of CDRs for CDR library cloning.
  • FIG. 37: Oligo and primer design for Vκ CDR3 libraries FIG. 38: Oligo and primer design for Vλ CDR3 libraries.
  • FIG. 39: Functional map of the pBS13 expression vector series.
  • FIG. 40: Expression of all 49 HuCAL scFvs obtained by combining each of the 7 VH genes with each of the 7 VL genes (pBS13, 30° C.); Values are given for the percentage of soluble vs. insoluble material, the total and the soluble amount compared to the combination H3κ2, which was set to 100%. In addition, the corresponding values for the McPC603 scFv are given.
  • Table 1: Summary of human immunoglobulin germline sequences used for computing the germline membership of rearranged sequences. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. (1) The germline name used in the various calculations, (2) the references number for the corresponding sequence (see appendix for sequence related citations), (3) the family where each sequence belongs to and (4), the various names found in literature for germline genes with identical amino acid sequences.
  • Table 2: Rearranged human sequences used for the calculation of consensus sequences. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. The table summarized the name of the sequence (1), the length of the sequence in amino acids (2), the germline family (3) as well as the computed germline counterpart (4). The number of amino acid exchanges between the rearranged sequence and the germline sequence is tabulated in (5), and the percentage of different amino acids is given in (6). Column (7) gives the references number for the corresponding sequence (see appendix for sequence related citations).
  • Table 3: Assignment of rearranged V sequences to their germline counterparts. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. The germline genes are tabulated according to their family (1), and the number of rearranged genes found for every germline gene is given in (2).
  • Table 4: Computation of the consensus sequence of the rearranged V kappa sequences. (A), V kappa subgroup 1, (B), V kappa subgroup 2, (C), V kappa subgroup 3 and (D), V kappa subgroup 4. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. (1) Amino acids are given with their standard one-letter abbreviations (and B means D or N, Z means E or Q and X means any amino acid). The statistical analysis summarizes the number of sequences found at each position (2), the number of occurrences of the most common amino acid (3), the amino acid residue which is most common at this position (4), the relative frequency of the occurrence of the most common amino acid (5) and the number of different amino acids found at each position (6).
  • Table 5: Computation of the consensus sequence of the rearranged V lambda sequences. (A), V lambda subgroup 1, (B), V lambda subgroup 2, and (C), V lambda subgroup 3. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. Abbreviations are the same as in Table 4.
  • Table 6: Computation of the consensus sequence of the rearranged V heavy chain sequences. (A), V heavy chain subgroup 1A, (B), V heavy chain subgroup 1B, (C), V heavy chain subgroup 2, (D), V heavy chain subgroup 3, (E), V heavy chain subgroup 4, (F), V heavy chain subgroup 5, and (G), V heavy chain subgroup 6. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. Abbreviations are the same as in Table 4.
  • EXAMPLES Example 1 Design of a Synthetic Human Combinatorial Antibody Library (HuCAL)
  • The following example describes the design of a fully synthetic human combinatorial antibody library (HuCAL), based on consensus sequences of the human immunoglobulin repertoire, and the synthesis of the consensus genes. The general procedure is outlined in FIG. 1.
  • 1.1 Sequence Database
  • 1.1.1 Collection and Alignment of Human Immunoglobulin Sequences
  • In a first step, sequences of variable domains of human immunoglobulins have been collected and divided into three sub bases: V heavy chain (VH), V kappa (Vκ) and V lambda (Vλ). For each sequence, the gene sequence was then translated into the corresponding amino acid sequence. Subsequently, all amino acid sequences were aligned according to Kabat et al. (1991). In the case of Vλ sequences, the numbering system of Chuchana et al. (1990) was used. Each of the three main databases was then divided into two further sub bases: the first sub base contained all sequences derived from rearranged V genes, where more than 70 positions of the sequence were known. The second sub base contained all germline gene segments (without the D- and J-minigenes; pseudogenes with internal stop codons were also removed). In all cases, where germline sequences with identical amino acid sequence but different names were found, only one sequence was used (see Table 1). The final databases of rearranged sequences contained 386, 149 and 674 entries for Vκ, Vλ and VH, respectively. The final databases of germline sequences contained 48, 26 and 141 entries for Vκ, Vλ and VH, respectively.
  • 1.1.2 Assignment of Sequences to Subgroups
  • The sequences in the three germline databases where then grouped according to sequence homology (see also Tomlinson et al., 1992, Williams & Winter, 1993, and Cox et al., 1994). In the case of Vκ, 7 families could be established. Vλ was divided into 8 families and VH into 6 families. The VH germline genes of the VH7 family (Van Dijk et al., 1993) were grouped into the VH1 family, since the genes of the two families are highly homologous. Each family contained different numbers of germline genes, varying from 1 (for example VH6) to 47 (VH3).
  • 1.2 Analysis of Sequences
  • 1.2.1 Computation of Germline Membership
  • For each of the 1209 amino acid sequences in the databases of rearranged genes, the nearest germline counterpart, i.e. the germline sequence with the smallest number of amino acid differences was then calculated. After the germline counterpart was found, the number of somatic mutations which occurred in the rearranged gene and which led to amino acid exchanges could be tabulated. In 140 cases, the germline counterpart could not be calculated exactly, because more than one germline gene was found with an identical number of amino acid exchanges. These rearranged sequences were removed from the database. In a few cases, the number of amino acid exchanges was found to be unusually large (>20 for VL and >25 for VH), indicating either heavily mutated rearranged genes or derivation from germline genes not present in the database. Since it was not possible to distinguish between these two possibilities, these sequences were also removed from the database. Finally, 12 rearranged sequences were removed from the database because they were found to have very unusual CDR lengths and composition or unusual amino acids at canonical positions (see below). In summary, 1023 rearranged sequences out of 1209 (85%) could be clearly assigned to their germline counterparts (see Table 2).
  • After this calculation, every rearranged gene could be arranged in one of the families established for the germline genes. Now the usage of each germline gene, i.e. the number of rearranged genes which originate from each germline gene, could be calculated (see Table 2). It was found that the usage was strongly biased towards a subset of germline genes, whereas most of the germline genes were not present as rearranged genes in the database and therefore apparently not used in the immune system (Table 3). This observation had already been reported in the case of Vκ (Cox, et al., 1994). All germline gene families, where no or only very few rearranged counterparts could be assigned, were removed from the database, leaving 4 Vκ, 3 Vλ, and 6 VH families.
  • 1.2.2 Analysis of CDR Conformations
  • The conformation of the antigen binding loops of antibody molecules, the CDRs, is strongly dependent on both the length of the CDRs and the amino acid residues located at the so-called canonical positions (Chothia & Lesk, 1987). It has been found that only a few canonical structures exist, which determine the structural repertoire of the immunoglobulin variable domains (Chothia et al., 1989). The canonical amino acid positions can be found in CDR as well as framework regions. The 13 used germline families defined above (7 VL and 6 VH) were now analyzed for their canonical structures in order to define the structural repertoire encoded in these families.
  • In 3 of the 4 Vκ families (Vκ1, 2 and 4), one different type of CDR1 conformation could be defined for every family. The family Vκ3 showed two types of CDR1 conformation: one type which was identical to Vκ1 and one type only found in Vκ3. All Vκ CDR2s used the same type of canonical structure. The CDR3 conformation is not encoded in the germline gene segments. Therefore, the 4 Vκ families defined by sequence homology and usage corresponded also to 4 types of canonical structures found in Vκ germline genes.
  • The 3 Vλ families defined above showed 3 types of CDR1 conformation, each family with one unique type. The Vλ1 family contained 2 different CDR1 lengths (13 and 14 amino acids), but identical canonical residues, and it is thought that both lengths adopt the same canonical conformation (Chothia & Lesk, 1987). In the CDR2 of the used Vλ germlines, only one canonical conformation exists, and the CDR3 conformation is not encoded in the germline gene segments. Therefore, the 3 Vλ families defined by sequence homology and usage corresponded also to 3 types of canonical structures.
  • The structural repertoire of the human VH sequences was analyzed in detail by Chothia et al., 1992. In total, 3 conformations of CDR1 (H1-1, H1-2 and H1-3) and 6 conformations of CDR2 (H2-1, H2-2, H2-3, H2-4, H2-5 and H2-x) could be defined. Since the CDR3 is encoded in the D- and J-minigene segments, no particular canonical residues are defined for this CDR.
  • All the members of the VH1 family defined above contained the CDR1 conformation H1-1, but differed in their CDR2 conformation: the H2-2 conformation was found in 6 germline genes, whereas the conformation H2-3 was found in 8 germline genes. Since the two types of CDR2 conformations are defined by different types of amino acid at the framework position 72, the VH1 family was divided into two subfamilies: VH1A with CDR2 conformation H2-2 and VH1B with the conformation H2-3 The members of the VH2 family all had the conformations H1-3 and H2-1 in CDR1 and CDR2, respectively. The CDR1 conformation of the VH3 members was found in all cases to be H1-1, but 4 different types were found in CDR2 (H2-1, H2-3, H2-4 and H2-x). In these CDR2 conformations, the canonical framework residue 71 is always defined by an arginine. Therefore, it was not necessary to divide the VH3 family into subfamilies, since the 4 types of CDR2 conformations were defined solely by the CDR2 itself. The same was true for the VH4 family. Here, all 3 types of CDR1 conformations were found, but since the CDR1 conformation was defined by the CDR itself (the canonical framework residue 26 was found to be glycine in all cases), no subdivisions were necessary. The CDR2 conformation of the VH4 members was found to be H2-1 in all cases. All members of the VH5 family were found to have the conformation H1-1 and H2-2, respectively. The single germline gene of the VH6 family had the conformations H1-3 and H2-5 in CDR1 and CDR2, respectively.
  • In summary, all possible CDR conformations of the Vκ and Vλ genes were present in the 7 families defined by sequence comparison. From the 12 different CDR conformations found in the used VH germline genes, 7 could be covered by dividing the family VH1 into two subfamilies, thereby creating 7 VH families. The remaining 5 CDR conformations (3 in the VH3 and 2 in the VH4 family) were defined by the CDRs themselves and could be created during the construction of CDR libraries. Therefore, the structural repertoire of the used human V genes could be covered by 49 (7×7) different frameworks.
  • 1.2.3 Computation of Consensus Sequences
  • The 14 databases of rearranged sequences (4 Vκ, 3 Vλ, and 7 VH) were used to compute the HuCAL consensus sequences of each subgroup (4 HuCAL-Vκ, 3 HuCAL-Vλ, 7 HuCAL-VH, see Table 4, 5 and 6). This was done by counting the number of amino acid residues used at each position (position variability) and subsequently identifying the amino acid residue most frequently used at each position. By using the rearranged sequences instead of the used germline sequences for the calculation of the consensus, the consensus was weighted according to the frequency of usage. Additionally, frequently mutated and highly conserved positions could be identified. The consensus sequences were cross-checked with the consensus of the germline families to see whether the rearranged sequences were biased at certain positions towards amino acid residues which do not occur in the collected germline sequences, but this was found not to be the case. Subsequently, the number of differences of each of the 14 consensus sequences to each of the germline sequences found in each specific family was calculated. The overall deviation from the most homologous germline sequence was found to be 2.4 amino acid residues (s.d.=2.7), ensuring that the “artificial” consensus sequences can still be considered as truly human sequences as far as immunogenicity is concerned.
  • 1.3 Structural Analysis
  • So far, only sequence information was used to design the consensus sequences. Since it was possible that during the calculation certain artificial combinations of amino acid residues have been created, which are located far away in the sequence but have contacts to each other in the three dimensional structure, leading to destabilized or even misfolded frameworks, the 14 consensus sequences were analyzed according to their structural properties.
  • It was rationalized that all rearranged sequences present in the database correspond to functional and therefore correctly folded antibody molecules. Hence, the most homologous rearranged sequence was calculated for each consensus sequence. The positions where the consensus differed from the rearranged sequence were identified as potential “artificial residues” and inspected.
  • The inspection itself was done in two directions. First, the local sequence stretch around each potentially “artificial residue” was compared with the corresponding stretch of all the rearranged sequences. If this stretch was found to be truly artificial, i.e. never occurred in any of the rearranged sequences, the critical residue was converted into the second most common amino acid found at this position and analyzed again. Second, the potentially “artificial residues” were analyzed for their long range interactions. This was done by collecting all available structures of human antibody variable domains from the corresponding PDB files and calculating for every structure the number and type of interactions each amino acid residue established to each side-chain. These “interaction maps” were used to analyze the probable side-chain/side-chain interactions of the potentially “artificial residues”. As a result of this analysis, the following residues were exchanged (given is the name of the gene, the position according to Kabat's numbering scheme, the amino acid found at this position as the most abundant one and the amino acid which was used instead):
    • VH2: S65T
    • Vκ1: N34A,
    • Vκ3: G9A, D60A, R77S
    • Vλ3: V78T
      1.4 Design of CDR Sequences
  • The process described above provided the complete consensus sequences derived solely from the databases of rearranged sequences. It was rationalized that the CDR1 and CDR2 regions should be taken from the databases of used germline sequences, since the CDRs of rearranged and mutated sequences are biased towards their particular antigens. Moreover, the germline CDR sequences are known to allow binding to a variety of antigens in the primary immune response, where only CDR3 is varied. Therefore, the consensus CDRs obtained from the calculations described above were replaced by germline CDRs in the case of VH and Vκ. In the case of Vλ, a few amino acid exchanges were introduced in some of the chosen germline CDRs in order to avoid possible protease cleavage sites as well as possible structural constraints.
  • The CDRs of following germline genes have been chosen:
    HuCAL gene CDR1 CDR2
    HuCAL-VH1A VH1-12-1 VH1-12-1
    HuCAL-VH1B VH1-13-16 VH1-13-6, -7, -8, -9
    HuCAL-VH2 VH2-31-10, -11, VH2-31-3, -4
    -12, -13
    HuCAL-VH3 VH3-13-8, -9, -10 VH3-13-8, -9, -10
    HuCAL-VH4 VH4-11-7 to -14 VH4-11-8, -9, -11, -12, -14, -16
    VH4-31-17, -18, -19, -20
    HuCAL-VH5 VH5-12-1, -2 VH5-12-1, -2
    HuCAL-VH6 VH6-35-1 VH6-35-1
    HuCAL-Vκ1 Vκ1-14, -15 Vκ1-2, -3, -4, -5, -7,
    -8, -12, -13, -18, -19
    HuCAL-Vκ2 Vκ2-6 Vκ2-6
    HuCAL-Vκ3 Vκ3-1, -4 Vκ3-4
    HuCAL-Vκ4 Vκ4-1 Vκ4-1
    HuCAL-Vλ1 HUMLV117, DPL5 DPL5
    HuCAL-Vλ2 DPL11, DPL12 DPL12
    HuCAL-Vλ3 DPL23 HUMLV318
  • In the case of the CDR3s, any sequence could be chosen since these CDRs were planned to be the first to be replaced by oligonucleotide libraries. In order to study the expression and folding behavior of the consensus sequences in E. coli, it would be useful to have all sequences with the same CDR3, since the influence of the CDR3s on the folding behavior would then be identical in all cases. The dummy sequences QQHYTTPP and ARWGGDGFYAMDY were selected for the VL chains (kappa and lambda) and for the VH chains, respectively. These sequences are known to be compatible with antibody folding in E. coli (Carter et al., 1992).
  • 1.5 Gene Design
  • The final outcome of the process described above was a collection of 14 HuCAL amino acid sequences, which represent the frequently used structural antibody repertoire of the human immune system (see FIG. 2). These sequences were back-translated into DNA sequences. In a first step, the back-translation was done using only codons which are known to be frequently used in E. coli. These gene sequences were then used for creating a database of all possible restriction endonuclease sites, which could be introduced without changing the corresponding amino acid sequences. Using this database, cleavage sites were selected which were located at the flanking regions of all sub-elements of the genes (CDRs and framework regions) and which could be introduced in all HuCAL VH, Vκ or Vλ genes simultaneously at the same position. In a few cases it was not possible to find cleavage sites for all genes of a subgroup. When this happened, the amino acid sequence was changed, if this was possible according to the available sequence and structural information. This exchange was then analyzed again as described above. In total, the following 6 amino acid residues were exchanged during this design (given is the name of the gene, the position according to Kabat's numbering scheme, the amino acid found at this position as the most abundant one and the amino acid which was used instead):
    • VH2: T3Q
    • VH6: S42G
    • Vκ3: E1D, I58V
    • Vκ4: K24R
    • Vλ3: T22S
  • In one case (5′-end of VH framework 3) it was not possible to identify a single cleavage site for all 7 VH genes. Two different type of cleavage sites were used instead: BstEII for HuCAL VH1A, VH1B, VH4 and VH5, and NspV for HuCAL VH2, VH3, VH4 and VH6.
  • Several restriction endonuclease sites were identified, which were not located at the flanking regions of the sub-elements but which could be introduced in every gene of a given group without changing the amino acid sequence. These cleavage sites were also introduced in order to make the system more flexible for further improvements. Finally, all but one remaining restriction endonuclease sites were removed in every gene sequence. The single cleavage site, which was not removed was different in all genes of a subgroup and could be therefore used as a “fingerprint” site to ease the identification of the different genes by restriction digest. The designed genes, together with the corresponding amino acid sequences and the group-specific restriction endonuclease sites are shown in FIGS. 3, 4 and 5, respectively.
  • 1.6 Gene Synthesis and Cloning
  • The consensus genes were synthesized using the method described by Prodromou & Pearl, 1992, using the oligonucleotides shown in FIG. 6. Gene segments encoding the human constant domains Cκ, Cλ and CH1 were also synthesized, based on sequence information given by Kabat et al., 1991 (see FIG. 6 and FIG. 7). Since for both the CDR3 and the framework 4 gene segments identical sequences were chosen in all HuCAL Vκ, Vλ and VH genes, respectively, this part was constructed only once, together with the corresponding gene segments encoding the constant domains. The PCR products were cloned into pCR-Script KS(+) (Stratagene, Inc.) or pZErO-1 (Invitrogen, Inc.) and verified by sequencing.
  • Example 2 Cloning and Testing of a HuCAL-Based Antibody Library
  • A combination of two of the synthetic consensus genes was chosen after construction to test whether binding antibody fragments can be isolated from a library based on these two consensus frameworks. The two genes were clones as a single-chain Fv (scFv) fragment, and a VH-CDR3 library was inserted. In order to test the library for the presence of functional antibody molecules, a selection procedure was carried out using the small hapten fluorescein bound to BSA (FITC-BSA) as antigen.
  • 2.1 Cloning of the HuCAL VH3-Vk2 scFv Fragment
  • In order to test the design of the consensus genes, one randomly chosen combination of synthetic light and heavy gene (HuCAL-Vκ2 and HuCAL-VH3) was used for the construction of a single-chain antibody (scFv) fragment. Briefly, the gene segments encoding the VH3 consensus gene and the CH1 gene segment including the CDR3-framework 4 region, as well as the Vκ2 consensus gene and the Cκ gene segment including the CDR3-framework 4 region were assembled yielding the gene for the VH3-CH1 Fd fragment and the gene encoding the Vκ2-Cκ light chain, respectively. The CH1 gene segment was then replaced by an oligonucleotide cassette encoding a 20-mer peptide linker with the sequence AGGGSGGGGSGGGGSGGGGS. The two oligonucleotides encoding this linker were 5′-TCAGCGGGTGGCGGTTCTGGCGGCGGTGGGAGCGGTGGCGGTGGTTCTGGCGGTGGTGGTTCCGATATCGGTCCACGTACGG-3′ and 5′-AATTCCGTACGTGGACCGATATCGGAACCACCACCGCCAGAACCACCGCCACCGCTCCCACCGC CGCCAGAACCGCCACCCGC-3′, respectively. Finally, the HuCAL-Vκ2 gene was inserted via EcoRV and BsiWI into the plasmid encoding the HuCAL-VH3-linker fusion, leading to the final gene HuCAL-VH3-Vκ2, which encoded the two consensus sequences in the single-chain format VH-linker-VL. The complete coding sequence is shown in FIG. 8.
  • 2.2 Construction of a Monovalent Phage-Display Phagemid Vector pIG10.3
  • Phagemid pIG10.3 (FIG. 9) was constructed in order to create a phage-display system (Winter et al., 1994) for the H3κ2 scFv gene. Briefly, the EcoRI/HindIII restriction fragment in the phagemid vector pIG10 (Ge et al., 1995) was replaced by the c-myc followed by an amber codon (which encodes an glutamate in the amber-suppresser strain XL1 Blue and a stop codon in the non-suppresser strain JM83) and a truncated version of the gene III (fusion junction at codon 249, see Lowman et al., 1991) through PCR mutagenesis.
  • 2.3 Construction of H-CDR3 Libraries
  • Heavy chain CDR3 libraries of two lengths (10 and 15 amino acids) were constructed using trinucleotide codon containing oligonucleotides (Virnekäs et al., 1994) as templates and the oligonucleotides complementing the flanking regions as primers. To concentrate only on the CDR3 structures that appear most often in functional antibodies, we kept the salt-bridge of RH94 and D H101 in the CDR3 loop. For the 15-mer library, both phenylalanine and methionine were introduced at position 100 since these two residues were found to occur quite often in human CDR3s of this length (not shown). For the same reason, valine and tyrosine were introduced at position 102. All other randomized positions contained codons for all amino acids except cystein, which was not used in the trinucleotide mixture.
  • The CDR3 libraries of lengths 10 and 15 were generated from the PCR fragments using oligonucleotide templates O3HCDR103T. (5′-GATACGGCCGTGTATTATTGCGCGCGT (TRI)6GATTATTGGGGCCMGGCACCCTG-3′) and O3HCDR153T (5′-GATACGGCCGT GTATTATTGCGCGCGT(TRI)10(TTT/ATG)GAT(GTT/TAT)TGGGGCCAAGGCACCCTG-3′), and primers O3HCDR35 (5′-GATACGGCCGTGTATTATTGC-3′) and O3HCDR33 (5′-CAGGGTGCCTTGGCCCC-3′), where TRI are trinucleotide mixtures representing all amino acids without cystein, (TTT/ATG) and (GTT/TAT) are trinucleotide mixtures encoding the amino acids phenylalanine/methionine and valine/tyrosine, respectively. The potential diversity of these libraries was 4.7×107 and 3.4×1010 for 10-mer and 15-mer library, respectively. The library cassettes were first synthesized from PCR amplification of the oligo templates in the presence of both primers: 25 pmol of the oligo template O3HCDR103T or O3HCDR153T, 50 pmol each of the primers O3HCDR35 and O3HCDR33, 20 nmol of dNTP, 10× buffer and 2.5 units of Pfu DNA polymerase (Stratagene) in a total volume of 100 μl for 30 cycles (1 minute at 92° C., 1 minute at 62° C. and 1 minute at 72° C.). A hot-start procedure was used. The resulting mixtures were phenol-extracted, ethanol-precipitated and digested overnight with EagI and StyI. The vector pIG10.3-sCH3κ2cat, where the EagI-StyI fragment in the vector pIG10.3-sCH3κ2 encoding the H-CDR3 was replaced by the chloramphenicol acetyltransferase gene (cat) flanked with these two sites, was similarly digested. The digested vector (35 μg) was gel-purified, and ligated with 100 μg of the library cassette overnight at 16° C. The ligation mixtures were isopropanol precipitated, air-dried and the pellets were redissolved in 100 μl of ddH2O. The ligation was mixed with 1 ml of freshly prepared electrocompetent XL1 Blue on ice. 20 rounds of electroporation were performed and the transformants were diluted in SOC medium, shaken at 37° C. for 30 minutes and plated out on large LB plates (Amp/Tet/Glucose) at 37° C. for 6-9 hrs. The number of transformants (library size) was 3.2×107 and 2.3×107 for the 10-mer and the 15-mer library, respectively. The colonies were suspended in 2×YT medium (Amp/Tet/Glucose) and stored as glycerol culture.
  • In order to test the quality of the initial library, phagemids from 24 independent colonies (12 from the 10-mer and 12 from the 15-mer library, respectively) were isolated and analyzed by restriction digestion and sequencing. The restriction analysis of the 24 phagemids indicated the presence of intact vector in all cases. Sequence analysis of these clones (see FIG. 10) indicated that 22 out of 24 contained a functional sequence in their heavy chain CDR3 regions. 1 out of 12 clones of the 10-mer library had a CDR3 of length 9 instead of 10, and 2 out of 12 clones of the 15-mer library had no open reading frame, thereby leading to a non-functional scFv; one of these two clones contained two consecutive inserts, but out of frame (data not shown). All codons introduced were presented in an even distribution.
  • Expression levels of individual library members were also measured. Briefly, 9 clones from each library were grown in 2×YT medium containing Amp/Tet/0.5% glucose at 37° C. overnight. Next day, the cultures were diluted into fresh medium with Amp/Tet. At an OD600 nm of 0.4, the cultures were induced with 1 mM of IPTG and shaken at RT overnight. Then the cell pellets were suspended in 1 ml of PBS buffer+1 mM of EDTA. The suspensions were sonicated and the supernatants were separated on an SDS-PAGE under reducing conditions, blotted on nylon membrane and detected with anti-FLAG M1 antibody (see FIG. 11). From the nine clones of the 10-mer library, all express the scFv fragments. Moreover, the gene III/scFv fusion proteins were present in all cases. Among the nine clones from the 15-mer library analyzed, 6/9 (67%) led to the expression of both scFv and the gene III/scFv fusion proteins. More importantly, all clones expressing the scFvs and gene III/scFv fusions gave rise to about the same level of expression.
  • 2.4 Biopanning
  • Phages displaying the antibody libraries were prepared using standard protocols. Phages derived from the 10-mer library were mixed with phages from the 15-mer library in a ratio of 20:1 (1×1010 cfu/well of the 10-mer and 5×108 cfu/well of the 15-mer phages, respectively). Subsequently, the phage solution was used for panning in ELISA plates (Maxisorp, Nunc) coated with FITC-BSA (Sigma) at concentration of 100 μg/ml in PBS at 4° C. overnight. The antigen-coated wells were blocked with 3% powder milk in PBS and the phage solutions in 1% powder milk were added to each well and the plate was shaken at RT for 1 hr. The wells were then washed with PBST and PBS (4 times each with shaking at RT for 5 minutes). The bound phages were eluted with 0.1 M triethylamine (TEA) at RT for 10 minutes. The eluted phage solutions were immediately neutralized with ½ the volume of 1 M Tris Cl, pH 7.6. Eluted phage solutions (ca. 450 μl) were used to infect 5 ml of XL1 Blue cells at 37° C. for 30 min. The infected cultures were then plated out on large LB plates (Amp/Tet/Glucose) and allowed to grow at 37° C. until the colonies were visible. The colonies were suspended in 2×YT medium and the glycerol cultures were made as above described. This panning round was repeated twice, and in the third round elution was carried out with addition of fluorescein in a concentration of 100 μg/ml in PBS. The enrichment of specific phage antibodies was monitored by panning the initial as well as the subsequent fluorescein-specific sub-libraries against the blocking buffer (FIG. 12). Antibodies with specificity against fluorescein were isolated after 3 rounds of panning.
  • 2.5 ELISA Measurements
  • One of the criteria for the successful biopanning is the isolation of individual phage clones that bind to the targeted antigen or hapten. We undertook the isolation of anti-FITC phage antibody clones and characterized them first in a phage ELISA format. After the 3rd round of biopanning (see above), 24 phagemid containing clones were used to inoculate 100 μl of 2×YT medium (Amp/Tet/Glucose) in an ELISA plate (Nunc), which was subsequently shaken at 37° C. for 5 hrs. 100 μl of 2×YT medium (Amp/Tet/1 mM IPTG) were added and shaking was continued for 30 minutes. A further 100 μl of 2×YT medium (Amp/Tet) containing the helper phage (1×109 cfu/well) was added and shaking was done at RT for 3 hrs. After addition of kanamycin to select for successful helper phage infection, the shaking was continued overnight. The plates were then centrifuged and the supernatants were pipetted directly into ELISA wells coated with 100 μl FITC-BSA (100 μg/ml) and blocked with milk powder. Washing was performed similarly as during the panning procedure and the bound phages were detected with anti-M13 antibody-POD conjugate (Pharmacia) using soluble POD substrate (Boehringer-Mannheim). Of the 24 clones screened against FITC-BSA, 22 were active in the ELISA (FIG. 13). The initial libraries of similar titer gave rise to no detectable signal.
  • Specificity for fluorescein was measured in a competitive ELISA. Periplasmic fractions of five FITC specific scFvs were prepared as described above. Western blotting indicated that all clones expressed about the same amount of scFv fragment (data not shown). ELISA was performed as described above, but additionally, the periplasmic fractions were incubated 30 min at RT either with buffer (no inhibition), with 10 mg/ml BSA (inhibition with BSA) or with 10 mg/ml fluorescein (inhibition with fluorescein) before adding to the well. Binding scFv fragment was detected using the anti-FLAG antibody M1. The ELISA signal could only be inhibited, when soluble fluorescein was added, indicating binding of the scFvs was specific for fluorescein (FIG. 14).
  • 2.6 Sequence Analysis
  • The heavy chain CDR3 region of 20 clones were sequenced in order to estimate the sequence diversity of fluorescein binding antibodies in the library (FIG. 15). In total, 16 of 20 sequences (80%) were different, showing that the constructed library contained a highly diverse repertoire of fluorescein binders. The CDR3s showed no particular sequence homology, but contained on average 4 arginine residues. This bias towards arginine in fluorescein binding antibodies had already been described by Barbas et al., 1992.
  • 2.7 Production
  • E. coli JM83 was transformed with phagemid DNA of 3 selected clones and cultured in 0.5 L 2×YT medium. Induction was carried out with 1 mM IPTG at OD600 nm=0.4 and growth was continued with vigorous shaking at RT overnight. The cells were harvested and pellets were suspended in PBS buffer and sonicated. The supernatants were separated from the cell debris via centrifugation and purified via the BioLogic system (Bio-Rad) by with a POROS®MC 20 column (IMAC, PerSeptive Biosystems, Inc.) coupled with an ion-exchange chromatography column. The ion-exchange column was one of the POROS®HS, CM or HQ or PI 20 (PerSeptive Biosystems, Inc.) depended on the theoretical pI of the scFv being purified. The pH of all the buffers was adjusted to one unit lower or higher than the pI of the scFv being purified throughout. The sample was loaded onto the first IMAC column, washed with 7 column volumes of 20 mM sodium phosphate, 1 M NaCl and 10 mM imidazole. This washing was followed by 7 column volumes of 20 mM sodium phosphate and 10 mM imidazole. Then 3 column volumes of an imidazole gradient (10 to 250 mM) were applied and the eluent was connected directly to the ion-exchanger. Nine column volumes of isocratic washing with 250 mM imidazole was followed by 15 column volumes of 250 mM to 100 mM and 7 column volumes of an imidazole/NaCl gradient (100 to 10 mM imidazole, 0 to 1 M NaCl). The flow rate was 5 ml/min. The purity of scFv fragments was checked by SDS-PAGE Coomassie staining (FIG. 16). The concentration of the fragments was determined from the absorbance at 280 nm using the theoretically determined extinction coefficient (Gill & von Hippel, 1989). The scFv fragments could be purified to homogeneity (see FIG. 16). The yield of purified fragments ranged from 5 to 10 mg/L/OD.
  • Example 3 HuCAL H3κ2 Library Against a Collection of Antigens
  • In order to test the library used in Example 2 further, a new selection procedure was carried out using a variety of antigens comprising β-estradiol, testosterone, Lewis-Y epitope (LeY), interleukin-2 (IL-2), lymphotoxin-β (LT-β), E-selectin ligand-1 (ESL-1), and BSA.
  • 3.1 Biopanning
  • The library and all procedures were identical to those described in Example 2. The ELISA plates were coated with β-estradiol-BSA (100 μg/ml), testosterone-BSA (100 μg/ml), LeY-BSA (20 μg/ml) IL-2 (20 μg/ml), ESL-1 (20 μg/ml) and BSA (100 μg/ml), LT-β (denatured protein, 20 μg/ml). In the first two rounds, bound phages were eluted with 0.1 M triethylamine (TEA) at RT for 10 minutes. In the case of BSA, elution after three rounds of panning was carried out with addition of BSA in a concentration of 100 μg/ml in PBS. In the case of the other antigens, third round elution was done with 0.1 M triethylamine. In all cases except LeY, enrichment of binding phages could be seen (FIG. 17). Moreover, a repetition of the biopanning experiment using only the 15-mer library resulted in the enrichment of LeY-binding phages as well (data not shown).
  • 3.2. ELISA Measurements
  • Clones binding to β-estradiol, testosterone, LeY, LT-β, ESL-1 and BSA were further analyzed and characterized as described in Example 2 for FITC. ELISA data for anti-β-estradiol and anti-ESL-1 antibodies are shown in FIG. 18. In one experiment, selectivity and cross-reactivity of binding scFv fragments were tested. For this purpose, an ELISA plate was coated with FITC, testosterone, β-estradiol, BSA, and ESL-1, with 5 wells for each antigen arranged in 5 rows, and 5 antibodies, one against each of the antigens, were screened against each of the antigens. FIG. 19 shows the specific binding of the antibodies to the antigen it was selected for, and the low cross-reactivity with the other four antigens.
  • 3.3 Sequence Analysis
  • The sequencing data of several clones against β-estradiol (34 clones), testosterone (12 clones), LT-β (23 clones), ESL-1 (34 clones), and BSA (10 clones) are given in FIGS. 20 to 24.
  • Example 4 Vector Construction
  • To be able to take advantage of the modularity of the consensus gene repertoire, a vector system had to be constructed which could be used in phage display screening of HuCAL libraries and subsequent optimization procedures. Therefore, all necessary vector elements such as origins of single-stranded or double-stranded replication, promotor/operator, repressor or terminator elements, resistance genes, potential recombination sites, gene III for display on filamentous phages, signal sequences, or detection tags had to be made compatible with the restriction site pattern of the modular consensus genes. FIG. 25 shows a schematic representation of the pCAL vector system and the arrangement of vector modules and restriction sites therein. FIG. 25 a shows a list of all restriction sites which are already incorporated into the consensus genes or the vector elements as part of the modular system or which are not yet present in the whole system. The latter could be used in a later stage for the introduction of or within new modules.
  • 4.1 Vector Modules
  • A series of vector modules was constructed where the restriction sites flanking the gene sub-elements of the HuCAL genes were removed, the vector modules themselves being flanked by unique restriction sites. These modules were constructed either by gene synthesis or by mutagenesis of templates. Mutagenesis was done by add-on PCR, by site-directed mutagenesis (Kunkel et al., 1991) or multisite oligonucleotide-mediated mutagenesis (Sutherland et al., 1995; Perlak, 1990) using a PCR-based assembly method.
  • FIG. 26 contains a list of the modules constructed. Instead of the terminator module M9 (HindIII-Ipp-PacI), a larger cassette M9II was prepared to introduce FseI as additional restriction site. M9II can be cloned via HindIII/BsrGI.
  • All vector modules were characterized by restriction analysis and sequencing. In the case of module M11-II, sequencing of the module revealed a two-base difference in positions 164/65 compared to the sequence database of the template. These two different bases (CA→GC) created an additional BanII site. Since the same two-base difference occurs in the f1 origin of other bacteriophages, it can be assumed that the two-base difference was present in the template and not created by mutagenesis during cloning. This BanII site was removed by site-directed mutagenesis, leading to module M11-II. The BssSI site of module M14 could initially not be removed without impact on the function of the ColE1 origin, therefore M14-Ext2 was used for cloning of the first pCAL vector series. FIGS. 29 to 34 are showing the functional maps and sequences of the modules used for assembly of the modular vector pCAL4 (see below). The functional maps and sequences of additional modules can be found in FIG. 35 a. FIG. 35 b contains a list of oligonucleotides and primers used for the synthesis of the modules.
  • 4.2 Cloning Vector pMCS
  • To be able to assemble the individual vector modules, a cloning vector pMCS containing a specific multi-cloning site (MCS) was constructed. First, an MCS cassette (FIG. 27) was made by gene synthesis. This cassette contains all those restriction sites in the order necessary for the sequential introduction of all vector modules and can be cloned via the 5′-HindIII site and a four base overhang at the 3′-end compatible with an AatII site. The vector pMCS (FIG. 28) was constructed by digesting pUC19 with AatII and HindIII, isolating the 2174 base pair fragment containing the bla gene and the ColE1 origin, and ligating the MCS cassette.
  • 4.3 Cloning of Modular Vector pCAL4
  • This was cloned step by step by restriction digest of pMCS and subsequent ligation of the modules M1 (via AatII/XbaI), M7III (via EcoRI/HindIII), and M9II (via HindIII/BsrGI), and M11-II (via BsrGI/NheI). Finally, the bla gene was replaced by the cat gene module M17 (via AatII/BglII), and the wild type ColE1 origin by module M14-Ext2 (via BglII/NheI). FIG. 35 is showing the functional map and the sequence of pCAL4.
  • 4.4 Cloning of Low-Copy Number Plasmid Vectors pCALO
  • A series of low-copy number plasmid vectors was constructed in a similar way using the p15A module M12 instead of the ColE1 module M14-Ext2. FIG. 35 a is showing the functional maps and sequences of the vectors pCALO1 to pCALO3.
  • Example 5 Construction of a HuCAL scFv Library
  • 5.1. Cloning of All 49 HuCAL scFv Fragments
  • All 49 combinations of the 7 HuCAL-VH and 7 HuCAL-VL consensus genes were assembled as described for the HuCAL VH3-Vκ2 scFv in Example 2 and inserted into the vector pBS12, a modified version of the pLisc series of antibody expression vectors (Skerra et al., 1991).
  • 5.2 Construction of a CDR Cloning Cassette
  • For replacement of CDRs, a universal β-lactamase cloning cassette was constructed having a multi-cloning site at the 5′-end as well as at the 3′-end. The 5′-multi-cloning site comprises all restriction sites adjacent to the 5′-end of the HuCAL VH and VL CDRs, the 3′-multi-cloning site comprises all restriction sites adjacent to the 3′ end of the HuCAL VH and VL CDRs. Both 5′- and 3′-multi-cloning site were prepared as cassettes via add-on PCR using synthetic oligonucleotides as 5′- and 3′-primers using wild type β-lactamase gene as template. FIG. 36 shows the functional map and the sequence of the cassette bla-MCS.
  • 5.3. Preparation of VL-CDR3 Library Cassettes
  • The VL-CDR3 libraries comprising 7 random positions were generated from the PCR fragments using oligonucleotide templates Vκ1&Vκ3, Vκ2 and Vκ4 and primers O_K3L5 and O_K3L3 (FIG. 37) for the Vκ genes, and Vλ and primers O_L3L5 (5′-GCAGAAGGCGAACGTCC-3′) and O_L3LA3 (FIG. 38) for the Vλ genes. Construction of the cassettes was performed as described in Example 2.3.
  • 5.4 Cloning of HuCAL scFv Genes With VL-CDR3 Libraries
  • Each of the 49 single-chains was subcloned into pCAL4 via XbaI/EcoRI and the VL-CDR3 replaced by the β-lactamase cloning cassette via BbsI/MscI, which was then replaced by the corresponding VL-CDR3 library cassette synthesized as described above. This CDR replacement is described in detail in Example 2.3 where the cat gene was used.
  • 5.5 Preparation of VH-CDR3 Library Cassette
  • The VH-CDR3 libraries were designed and synthesized as described in Example 2.3.
  • 5.6 Cloning of HuCAL scFv Genes With VL- and VH-CDR3 Libraries
  • Each of the 49 single-chain VL-CDR3 libraries was digested with BssHII/StyI to replace VH-CDR3. The “dummy” cassette digested with BssHII/StyI was inserted, and was then replaced by a corresponding VH-CDR3 library cassette synthesized as described above.
  • Example 6 Expression Tests
  • Expression and toxicity studies were performed using the scFv format VH-linker-VL. All 49 combinations of the 7 HuCAL-VH and 7 HuCAL-VL consensus genes assembled as described in Example 5 were inserted into the vector pBS13, a modified version of the pLisc series of antibody expression vectors (Skerra et al., 1991). A map of this vector is shown in FIG. 39.
  • E. coli JM83 was transformed 49 times with each of the vectors and stored as glycerol stock. Between 4 and 6 clones were tested simultaneously, always including the clone H3κ2, which was used as internal control throughout. As additional control, the McPC603 scFv fragment (Knappik & Plückthun, 1995) in pBS13 was expressed under identical conditions. Two days before the expression test was performed, the clones were cultivated on LB plates containing 30 μg/ml chloramphenicol and 60 mM glucose. Using this plates an 3 ml culture (LB medium containing 90 μg chloramphenicol and 60 mM glucose) was inoculated overnight at 37° C. Next day the overnight culture was used to inoculate 30 ml LB medium containing chloramphenicol (30 μg/ml). The starting OD600 nm was adjusted to 0.2 and a growth temperature of 30° C. was used. The physiology of the cells was monitored by measuring every 30 minutes for 8 to 9 hours the optical density at 600 nm. After the culture reached an OD600 nm of 0.5, antibody expression was induced by adding IPTG to a final concentration of 1 mM. A 5 ml aliquot of the culture was removed after 2 h of induction in order to analyze the antibody expression. The cells were lysed and the soluble and insoluble fractions of the crude extract were separated as described in Knappik & Plückthun, 1995. The fractions were assayed by reducing SDS-PAGE with the samples normalized to identical optical densities. After blotting and immunostaining using the α-FLAG antibody M1 as the first antibody (see Ge et al., 1994) and an Fc-specific anti-mouse antiserum conjugated to alkaline phosphatase as the second antibody, the lanes were scanned and the intensities of the bands of the expected size (appr. 30 kDa) were quantified densitometrically and tabulated relative to the control antibody (see FIG. 40).
  • Example 7 Optimization of Fluorescein Binders
  • 7.1. Construction of L-CDR3 and H-CDR2 Library Cassettes
  • A L-CDR3 library cassette was prepared from the oligonucleotide template CDR3L (5′-TGGAAGCTGAAGACGTGGGCGTGTATTATTGCCAGCAG(TR5)(TRI)4CCG (TRI)-TTTGGCCAGGGTACGAAAGTT-3′) and primer 5′-AACTTTCGTACCCTGGCC-3′ for synthesis of the complementary strand, where (TRI) was a trinucleotide mixture representing all amino acids except Cys, (TR5) comprised a trinucleotide mixture representing the 5 codons for Ala, Arg, His, Ser, and Tyr.
  • A H-CDR2 library cassette was prepared from the oligonucleotide template CDRsH (5′-AGGGTCTCGAGTGGGTGAGC(TRI)ATT(TRI)2-3(6)2(TRI)ACC(TRI)TATGCGGATAGCGTGAAAGGCCGTTTTACCATTTCACGTGATAATTCGAAAAACACCA-3′), and primer 5′-TGGTGTTTTTCGAATTATCA-3′ for synthesis of the complementary strand, where (TRI) was a trinucleotide mixture representing all amino acids except Cys, (6) comprised the incorporation of (A/G) (A/C/G) T, resulting in the formation of 6 codons for Ala, Asn, Asp, Gly, Ser, and Thr, and the length distribution being obtained by performing one substoichiometric coupling of the (TRI) mixture during synthesis, omitting the capping step normally used in DNA synthesis.
  • DNA synthesis was performed on a 40 nmole scale, oligos were dissolved in 1E buffer, purified via gel filtration using spin columns (S-200), and the DNA concentration determined by OD measurement at 260 nm (OD 1.0=40 μg/ml).
  • 10 nmole of the oligonucleotide templates and 12 nmole of the corresponding primers were mixed and annealed at 80° C. for 1 min, and slowly cooled down to 37° C. within 20 to 30 min. The fill-in reaction was performed for 2 h at 37° C. using Klenow polymerase (2.0 μl) and 250 nmole of each dNTP. The excess of dNTPs was removed by gel filtration using Nick-Spin columns (Pharmacia), and the double-stranded DNA digested with BbsI/MscI (L-CDR3), or XhoI/SfuI (H-CDR2) over night at 37° C. The cassettes were purified via Nick-Spin columns (Pharmacia), the concentration determined by OD measurement, and the cassettes aliquoted (15 pmole) for being stored at −80° C.
  • 7.2 Library Cloning:
  • DNA was prepared from the collection of FITC binding clones obtained in Example 2 (approx. 104 to clones). The collection of scFv fragments was isolated via XbaI/EcoRI digest. The vector pCAL4 (100 fmole, 10 μg) described in Example 4.3 was similarly digested with XbaI/EcoRI, gel-purified and ligated with 300 fmole of the scFv fragment collection over night at 16° C. The ligation mixture was isopropanol precipitated, air-dried, and the pellets were redissolved in 100 μl of dd H2O. The ligation mixture was mixed with 1 ml of freshly prepared electrocompetent SCS 101 cells (for optimization of L-CDR3), or XL1 Blue cells (for optimization of H-CDR2) on ice. One round of electroporation was performed and the transformants were eluted in SOC medium, shaken at 37° C. for 30 minutes, and an aliquot plated out on LB plates (Amp/Tet/Glucose) at 37° C. for 6-9 hrs. The number of transformants was 5×104.
  • Vector DNA (100 μg) was isolated and digested (sequence and restriction map of sCH3κ2 see FIG. 8) with BbsI/MscI for optimization of L-CDR3, or XhoI/NspV for optimization of H-CDR2. 10 μg of purified vector fragments (5 pmole) were ligated with 15 pmole of the L-CDR3 or H-CDR2 library cassettes over night at 16° C. The ligation mixtures were isopropanol precipitated, air-dried, and the pellets were redissolved in 100 μl of dd H2O. The ligation mixtures were mixed with 1 ml of freshly prepared electrocompetent XL1 Blue cells on ice. Electroporation was performed and the transformants were eluted in SOC medium and shaken at 37° C. for 30 minutes. An aliquot was plated out on LB plates (Amp/Tet/Glucose) at 37° C. for 6-9 hrs. The number of transformants (library size) was greater than 108 for both libraries. The libraries were stored as glycerol cultures.
  • 7.3. Biopanning
  • This was performed as described for the initial H3κ2H-CDR3 library in Example 2.1. Optimized scFvs binding to FITC could be characterized and analyzed as described in Example 2.2 and 2.3, and further rounds of optimization could be made if necessary.
  • REFERENCES
    • Barbas III, C. F., Bain, J. D., Hoekstra, D. M. & Lerner, R. A., PNAS 89, 4457-4461 (1992).
    • Better, M., Chang, P., Robinson, R. & Horwitz, A. H., Science 240, 1041-1043 (1988).
    • Blake, M. S., Johnston, K. H., Russel-Jones, G. J. & Gotschlich, E. C., Anal. Biochem. 136, 175-179 (1984).
    • Carter, P., Kelly, R. F., Rodrigues, M. L., Snedecor, B., Covrrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts, C. E., Carver, M. E., Yang, M., Bourell, J. H., Shepard, H. M. & Henner, D., Bio/Technology 10, 163-167 (1992).
    • Chothia, C. & Lesk, A. M., J. Biol. Chem. 196, 910-917 (1987).
    • Chothia, C., Lesk, A. M., Gherardi, E., Tomlinson, I. A., Walter, G., Marks, J. D., Llewelyn, M. B. & Winter, G., J. Mol. Biol. 227, 799-817 (1992).
    • Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M., Smith-Gill, S. J., Air, G., Sheriff, S., Padlan, E. A., Davies, D., Tulip, W. R., Colman, P. M., Spinelli, S., Alzari, P. M. & Poljak, R. J., Nature 342, 877-883 (1989).
    • Chuchana, P., Blancher, A., Brockly, F., Alexandre, D., Lefranc, G & Lefranc, M.-P., Eur. J. Immunol. 20, 1317-1325 (1990).
    • Cox, J. P. L., Tomlinson, I. M. & Winter, G., Eur. J. Immunol. 24, 827-836 (1994).
    • Ge, L., Knappik, A., Pack, P., Freund, C. & Plückthun, A., In: Antibody Engineering Borrebaeck, C. A. K. (Ed.). p. 229-266 (1995), Oxford University Press, New York, Oxford.)
    • Gill, S. C. & von Hippel, P. H., Anal. Biochem. 182, 319.326 (1989).
    • Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R. & Stüber, D., Bio/Technology 6, 1321-1325 (1988).
    • Hopp, T. P., Prickett, K. S., Price, V. L., Libby, R. T., March, C. J., Cerretti, D. P., Urdal, D. L. & Conlon, P. J. Bio/Technology 6, 1204-1210 (1988).
    • Kabat, E. A., Wu, T. T., Perry, H. M., Gottesmann, K. S. & Foeller, C., Sequences of proteins of immunological interest, NIH publication 91-3242 (1991).
    • Knappik, A. & Plückthun, A., Biotechniques 17, 754-761 (1994).
    • Knappik, A. & Plückthun, A., Protein Engineering 8, 81-89 (1995).
    • Kunkel, T. A., Bebenek, K. & McClary, J., Methods in Enzymol. 204, 125-39 (1991).
    • Lindner, P., Guth, B., Wülfing, C., Krebber, C., Steipe, B., Müller, F. & Plückthun, A., Methods: A Companion to Methods Enzymol. 4, 41-56 (1992).
    • Lowman, H. B., Bass, S. H., Simpson, N. and Wells, J. A., Biochemistry 30, 10832-10838 (1991).
    • Pack, P. & Plückthun, A., Biochemistry 31, 1579-1584 (1992).
    • Pack, P., Kujau. M., Schroeckh, V., Knüpfer, U., Wenderoth, R., Riesenberg D. & Plückthun, A., Bio/Technology 11, 1271-1277 (1993).
    • Pack, P., Ph.D. thesis, Ludwig-Maximilians-Universität München (1994).
    • Perlak, F. J., Nuc. Acids Res. 18, 7457-7458 (1990).
    • Plückthun, A., Krebber, A., Krebber, C., Horn, U., Knüpfer, U., Wenderoth, R., Nieba, L., Proba, K. & Riesenberg, D., A practical approach. Antibody Engineering (Ed. J. McCafferty). IRL Press, Oxford, pp. 203-252 (1996).
    • Prodromou, C. & Pearl, L. H., Protein Engineering 5, 827-829 (1992).
    • Rosenberg, S. A. & Lotze, M. T., Ann. Rev. Immunol. 4, 681-709 (1986).
    • Skerra, A. & Plückthun, A., Science 240, 1038-1041 (1988).
    • Skerra, A., Pfitzinger, I. & Plückthun, A., Bio/Technology 9, 273-278 (1991).
    • Sutherland, L., Davidson, J., Glass, L. L., & Jacobs, H. T., BioTechniques 18, 458-464, 1995.
    • Tomlinson, I. M., Walter, G., Marks, J. D., Llewelyn, M. B. & Winter, G., J. Mol. Biol. 227, 776-798 (1992).
    • Ullrich, H. D., Patten, P. A., Yang, P. L., Romesberg, F. E. & Schultz, P. G., Proc. Natl. Acad. Sci. USA 2, 11907-11911 (1995).
    • Van Dijk, K. W., Mortari, F., Kirkham, P. M., Schroeder Jr., H. W. & Milner, E. C. B., Eur. J. Immunol. 23, 832-839 (1993).
    • Virnekäs, B., Ge, L., Plückthun, A., Schneider, K. C., Wellnhofer, G. & Moroney, S. E., Nucleic Acids Research 22, 5600-5607 (1994).
    • Viletta, E. S., Thorpe, P. E. & Uhr, J., Immunol. Today 14, 253-259 (1993).
    • Williams, S. C. & Winter, G., Eur. J. Immunol. 23, 1456-1461 (1993).
  • Winter, G., Griffiths, A. D., Hawkins, R. E. & Hoogenboom, H. R., Ann. Rev. Immunol. 12, 433-455 (1994).
    TABLE 1A
    Human kappa germline gene segments
    Used Name1 Reference2 Family3 Germline genes4
    Vk1-1 9 1 O8; O18; DPK1
    Vk1-2 1 1 L14; DPK2
    Vk1-3 2 1 L15(1); HK101; HK146; HK189
    Vk1-4 9 1 L11
    Vk1-5 2 1 A30
    Vk1-6 1 1 LFVK5
    Vk1-7 1 1 LFVK431
    Vk1-8 1 1 L1; HK137
    Vk1-9 1 1 A20; DPK4
    Vk1-10 1 1 L18; Va″
    Vk1-11 1 1 L4; L18; Va′; V4a
    Vk1-12 2 1 L5; L19(1); Vb; Vb4; DPK5;
    L19(2); Vb″; DPK6
    Vk1-13 2 1 L15(2); HK134; HK166; DPK7
    Vk1-14 8 1 L8; Vd; DPK8
    Vk1-15 8 1 L9; Ve
    Vk1-16 1 1 L12(1); HK102; V1
    Vk1-17 2 1 L12(2)
    Vk1-18 1 1 O12a (V3b)
    Vk1-19 6 1 O2; O12; DPK9
    Vk1-20 2 1 L24; Ve″; V13; DPK10
    Vk1-21 1 1 O4; O14
    Vk1-22 2 1 L22
    Vk1-23 2 1 L23
    Vk2-1 1 2 A2; DPK12
    Vk2-2 6 2 O1; O11(1); DPK13
    Vk2-3 6 2 O12(2); V3a
    Vk2-4 2 2 L13
    Vk2-5 1 2 DPK14
    Vk2-6 4 2 A3; A19; DPK15
    Vk2-7 4 2 A29; DPK27
    Vk2-8 4 2 A13
    Vk2-9 1 2 A23
    Vk2-10 4 2 A7; DPK17
    Vk2-11 4 2 A17; DPK18
    Vk2-12 4 2 A1; DPK19
    Vk3-1 11 3 A11; humkv305; DPK20
    Vk3-2 1 3 L20; Vg″
    Vk3-3 2 3 L2; L16; humkv328; humkv328h2;
    humkv328h5; DPK21
    Vk3-4 11 3 A27; humkv325; VkRF; DPK22
    Vk3-5 2 3 L25; DPK23
    Vk3-6 2 3 L10(1)
    Vk3-7 7 3 L10(2)
    Vk3-8 7 3 L6; Vg
    Vk4-1 3 4 B3; VkIV; DPK24
    Vk5-1 10 5 B2; EV15
    Vk6-1 12 6 A14; DPK25
    Vk6-2 12 6 A10; A26; DPK26
    Vk7-1 5 7 B1
  • TABLE 1B
    Human lambda germline gene segments
    Used Name1 Reference2 Family3 Germline genes4
    DPL1 1 1
    DPL2 1 1 HUMLV1L1
    DPL3
    1 1 HUMLV122
    DPL4
    1 1 VLAMBDA 1.1
    HUMLV117 2 1
    DPL5 1 1 HUMLV117D
    DPL6
    1 1
    DPL7 1 1 IGLV1S2
    DPL8
    1 1 HUMLV1042
    DPL9
    1 1 HUMLV101
    DPL10
    1 2
    VLAMBDA 2.1 3 2
    DPL11 1 2
    DPL12 1 2
    DPL13 1 2
    DPL14 1 2
    DPL16 1 3 Humlv418; IGLV3S1
    DPL23
    1 3 VI III.1
    Humlv318 4 3
    DPL18 1 7 4A; HUMIGLVA
    DPL19
    1 7
    DPL21 1 8 VL8.1
    HUMLV801 5 8
    DPL22 1 9
    DPL24 1 unassigned VLAMBDA N.2
    gVLX-4.4 6 10
  • TABLE 1C
    Human heavy chain germline gene segments
    Used Name1 Reference2 Family3 Germline genes4
    VH1-12-1 19 1 DP10; DA-2; DA-6
    VH1-12-8 22 1 RR.VH1.2
    VH1-12-2 6 1 hv1263
    VH1-12-9 7 1 YAC-7; RR.VH1.1; 1-69
    VH1-12-3 19 1 DP3
    VH1-12-4 19 1 DP21; 4d275a; VH7a
    VH1-12-5 18 1 I-4.1b; V1-4.1b
    VH1-12-6 21 1 1D37; VH7b; 7-81; YAC-10
    VH1-12-7 19 1 DP14; VH1GRR; V1-18
    VH1-13-1 10 1 71-5; DP2
    VH1-13-2 10 1 E3-10
    VH1-13-3 19 1 DP1
    VH1-13-4 12 1 V35
    VH1-13-5 8 1 V1-2b
    VH1-13-6 18 1 I-2; DP75
    VH1-13-7 21 1 V1-2
    VH1-13-8 19 1 DP8
    VH1-13-9 3 1 1-1
    VH1-13-10 19 1 DP12
    VH1-13-11 15 1 V13C
    VH1-13-12 18 1 I-3b; DP25; V1-3b
    VH1-13-13 3 1 1-92
    VH1-13-14 18 1 I-3; V1-3
    VH1-13-15 19 1 DP15; V1-8
    VH1-13-16 3 1 21-2; 3-1; DP7; V1-46
    VH1-13-17 16 1 HG3
    VH1-13-18 19 1 DP4; 7-2; V1-45
    VH1-13-19 27 1 COS 5
    VH1-1X-1 19 1 DP5; 1-24P
    VH2-21-1 18 2 II-5b
    VH2-31-1 2 2 VH2S12-1
    VH2-31-2 2 2 VH2S12-7
    VH2-31-3 2 2 VH2S12-9; DP27
    VH2-31-4 2 2 VH2S12-10
    VH2-31-5 14 2 V2-26; DP26; 2-26
    VH2-31-6 15 2 VF2-26
    VH2-31-7 19 2 DP28; DA-7
    VH2-31-14 7 2 YAC-3; 2-70
    VH2-31-8 2 2 VH2S12-5
    VH2-31-9 2 2 VH2S12-12
    VH2-31-10 18 2 II-5; V2-5
    VH2-31-11 2 2 VH2S12-2; VH2S12-8
    VH2-31-12 2 2 VH2S12-4; VH2S12-6
    VH2-31-13 2 2 VH2S12-14
    VH3-11-1 13 3 v65-2; DP44
    VH3-11-2 19 3 DP45
    VH3-11-3 3 3 13-2; DP48
    VH3-11-4 19 3 DP52
    VH3-11-5 14 3 v3-13
    VH3-11-6 19 3 DP42
    VH3-11-7 3 3 8-1B; YAC-5; 3-66
    VH3-11-8 14 3 V3-53
    VH3-13-1 3 3 22-2B; DP35; V3-11
    VH3-13-5 19 3 DP59; VH19; V3-35
    VH3-13-6 25 3 f1-p1; DP61
    VH3-13-7 19 3 DP46; GL-SJ2; COS 8; hv3005;
    hv3005f3; 3d21b; 56p1
    VH3-13-8 24 3 VH26
    VH3-13-9 5 3 vh26c
    VH3-13-10 19 3 DP47; VH26; 3-23
    VH3-13-11 3 3 1-91
    VH3-13-12 19 3 DP58
    VH3-13-13 3 3 1-9III; DP49; 3-30; 3d28.1
    VH3-13-14 24 3 3019B9; DP50; 3-33; 3d277
    VH3-13-15 27 3 COS 3
    VH3-13-16 19 3 DP51
    VH3-13-17 16 3 H11
    VH3-13-18 19 3 DP53; COS 6; 3-74; DA-8
    VH3-13-19 19 3 DP54; VH3-11; V3-7
    VH3-13-20 14 3 V3-64; YAC-6
    VH3-13-21 14 3 V3-48
    VH3-13-22 14 3 V3-43; DP33
    VH3-13-23 14 3 V3-33
    VH3-13-24 14 3 V3-21; DP77
    VH3-13-25 14 3 V3-20; DP32
    VH3-13-26 14 3 V3-9; DP31
    VH3-14-1 3 3 12-2; DP29; 3-72; DA-3
    VH3-14-4 7 3 YAC-9; 3-73; MTGL
    VH3-14-2 4 3 VHD26
    VH3-14-3 19 3 DP30
    VH3-1X-1 1 3 LSG8.1; LSG9.1; LSG10.1;
    HUM12IGVH; HUM13IGVH
    VH3-1X-2 1 3 LSG11.1; HUM4IGVH
    VH3-1X-3 3 3 9-1; DP38; LSG7.1; RCG1.1;
    LSG1.1; LSG3.1; LSG5.1;
    HUM15IGVH; HUM2IGVH;
    HUM9IGVH
    VH3-1X-4 1 3 LSG4.1
    VH3-1X-5 1 3 LSG2.1
    VH3-1X-6 1 3 LSG6.1; HUM10IGVH
    VH3-1X-7 18 3 3-15; V3-15
    VH3-1X-8 1 3 LSG12.1; HUM5IGVH
    VH3-1X-9 14 3 V3-49
    VH4-11-1 22 4 Tou-VH4.21
    VH4-11-2 17 4 VH4.21; DP63; VH5;
    4d76; V4-34
    VH4-11-3 23 4 4.44
    VH4-11-4 23 4 4.44.3
    VH4-11-5 23 4 4.36
    VH4-11-6 23 4 4.37
    VH4-11-7 18 4 IV-4; 4.35; V4-4
    VH4-11-8 17 4 VH4.11; 3d197d;
    DP71; 58p2
    VH4-11-9 20 4 H7
    VH4-11-10 20 4 H8
    VH4-11-11 20 4 H9
    VH4-11-12 17 4 VH4.16
    VH4-11-13 23 4 4.38
    VH4-11-14 17 4 VH4.15
    VH4-11-15 11 4 58
    VH4-11-16 10 4 71-4; V4-59
    VH4-21-1 11 4 11
    VH4-21-2 17 4 VH4.17; VH4.23; 4d255;
    4.40; DP69
    VH4-21-3 17 4 VH4.19; 79; V4-4b
    VH4-21-4 19 4 DP70; 4d68; 4.41
    VH4-21-5 19 4 DP67; VH4-4B
    VH4-21-6 17 4 VH4.22; VHSP; VH-JA
    VH4-21-7 17 4 VH4.13; 1-9II; 12G-1;
    3d28d; 4.42; DP68; 4-28
    VH4-21-8 26 4 hv4005; 3d24d
    VH4-21-9 17 4 VH4.14
    VH4-31-1 23 4 4.34; 3d230d; DP78
    VH4-31-2 23 4 4.34.2
    VH4-31-3 19 4 DP64; 3d216d
    VH4-31-4 19 4 DP65; 4-31; 3d277d
    VH4-31-5 23 4 4.33; 3d75d
    VH4-31-6 20 4 H10
    VH4-31-7 20 4 H11
    VH4-31-8 23 4 4.31
    VH4-31-9 23 4 4.32
    VH4-31-10 20 4 3d277d
    VH4-31-11 20 4 3d216d
    VH4-31-12 20 4 3d279d
    VH4-31-13 17 4 VH4.18; 4d154; DP79
    VH4-31-14 8 4 V4-39
    VH4-31-15 11 4 2-1; DP79
    VH4-31-16 23 4 4.30
    VH4-31-17 17 4 VH4.12
    VH4-31-18 10 4 71-2; DP66
    VH4-31-19 23 4 4.39
    VH4-31-20 8 4 V4-61
    VH5-12-1 9 5 VH251; DP73; VHVCW; 51-R1;
    VHVLB; VHVCH; VHVTT;
    VHVAU; VHVBLK; VhAU;
    V5-51
    VH5-12-2 17 5 VHVJB
    VH5-12-3 3 5 1-v; DP80; 5-78
    VH5-12-4 9 5 VH32; VHVRG; VHVMW; 5-2R1
    VH6-35-1 4 6 VHVI; VH6; VHVIIS; VHVITE:
    VHVIJB; VHVICH; VHVICW;
    VHVIBLK; VHVIMW; DP74;
    6-1G1; V6-1
  • TABLE 2A
    rearranged human kappa sequences
    Computed Germline Diff. to % diff. to
    Name1 aa2 family3 gene4 germline5 germline6 Reference7
    III-3R 108 1 O8 1 1.1% 70
    No. 86 109 1 O8 3 3.2% 80
    AU 108 1 O8 6 6.3% 103
    ROY 108 1 O8 6 6.3% 43
    IC4 108 1 O8 6 6.3% 70
    HIV-B26 106 1 O8 3 3.2% 8
    GRI 108 1 O8 8 8.4% 30
    AG 106 1 O8 8 8.6% 116
    REI 108 1 O8 9 9.5% 86
    CLL PATIENT 16 88 1 O8 2 2.3% 122
    CLL PATIENT 14 87 1 O8 2 2.3% 122
    CLL PATIENT 15 88 1 O8 2 2.3% 122
    GM4672 108 1 O8 11 11.6% 24
    HUM. YFC51.1 108 1 O8 12 12.6% 110
    LAY 108 1 O8 12 12.6% 48
    HIV-b13 106 1 O8 9 9.7% 8
    MAL-NaCl 108 1 O8 13 13.7% 102
    STRAb SA-1A 108 1 O2 0 0.0% 120
    HuVHCAMP 108 1 O8 13 13.7% 100
    CRO 108 1 O2 10 10.5% 30
    Am 107 108 1 O2 12 12.6% 108
    WALKER 107 1 O2 4 4.2% 57
    III-2R 109 1 A20 0 0.0% 70
    FOG1-A4 107 1 A20 4 4.2% 41
    HK137 95 1 L1 0 0.0% 10
    CEA4-8A 107 1 O2 7 7.4% 41
    Va′ 95 1 L4 0 0.0% 90
    TR1.21 108 1 O2 4 4.2% 92
    HAU 108 1 O2 6 6.3% 123
    HK102 95 1 L12(1) 0 0.0% 9
    H20C3K 108 1 L12(2) 3 3.2% 125
    CHEB 108 1 O2 7 7.4% 5
    HK134 95 1 L15(2) 0 0.0% 10
    TEL9 108 1 O2 9 9.5% 73
    TR1.32 103 1 O2 3 3.2% 92
    RF-KES1 97 1 A20 4 4.2% 121
    WES 108 1 L5 10 10.5% 61
    DILp1 95 1 O4 1 1.1% 70
    SA-4B 107 1 L12(2) 8 8.4% 120
    HK101 95 1 L15(1) 0 0.0% 9
    TR1.23 108 1 O2 5 5.3% 92
    HF2-1/17 108 1 A30 0 0.0% 4
    2E7 108 1 A30 1 1.1% 62
    33.C9 107 1 L12(2) 7 7.4% 126
    3D6 105 1 L12(2) 2 2.1% 34
    I-2a 108 1 L8 8 8.4% 70
    RF-KL1 97 1 L8 4 4.2% 121
    TNF-E7 108 1 A30 9 9.5% 41
    TR1.22 108 1 O2 7 7.4% 92
    HIV-B35 106 1 O2 2 2.2% 8
    HIV-b22 106 1 O2 2 2.2% 8
    HIV-b27 106 1 O2 2 2.2% 8
    HIV-B8 107 1 O2 10 10.8% 8
    HIV-b3 107 1 O2 10 10.8% 8
    RF-SJ5 95 1 A30 5 5.3% 113
    GAL(I) 108 1 A30 6 6.3% 64
    R3.5H5G 108 1 O2 6 6.3% 70
    HIV-b14 106 1 A20 2 2.2% 8
    TNF-E1 105 1 L5 8 8.4% 41
    WEA 108 1 A30 8 8.4% 37
    EU 108 1 L12(2) 5 5.3% 40
    FOG1-G8 108 1 L8 11 11.6% 41
    1X7RG1 108 1 L1 8 8.4% 70
    BLI 108 1 L8 3 3.2% 72
    KUE 108 1 L12(2) 11 11.6% 32
    LUNm01 108 1 L12(2) 10 10.5% 6
    HIV-b1 106 1 A20 4 4.3% 8
    HIV-s4 103 1 O2 2 2.2% 8
    CAR 107 1 L12(2) 11 11.7% 79
    BR 107 1 L12(2) 11 11.6% 50
    CLL PATIENT 10 88 1 O2 0 0.0% 122
    CLL PATIENT 12 88 1 O2 0 0.0% 122
    KING 108 1 L12(2) 12 12.6% 30
    V13 95 1 L24 0 0.0% 46
    CLL PATIENT 11 87 1 O2 0 0.0% 122
    CLL PATIENT 13 87 1 O2 0 0.0% 122
    CLL PATIENT 9 88 1 O12 1 1.1% 122
    HIV-B2 106 1 A20 9 9.7% 8
    HIV-b2 106 1 A20 9 9.7% 8
    CLL PATIENT 5 88 1 A20 1 1.1% 122
    CLL PATIENT 1 88 1 L8 2 2.3% 122
    CLL PATIENT 2 88 1 L8 0 0.0% 122
    CLL PATIENT 7 88 1 L5 0 0.0% 122
    CLL PATIENT 8 88 1 L5 0 0.0% 122
    HIV-b5 105 1 L5 11 12.0% 8
    CLL PATIENT 3 87 1 L8 1 1.1% 122
    CLL PATIENT 4 88 1 L9 0 0.0% 122
    CLL PATIENT 18 85 1 L9 6 7.1% 122
    CLL PATIENT 17 86 1 L12(2) 7 8.1% 122
    HIV-b20 107 3 A27 11 11.7% 8
    2C12 108 1 L12(2) 20 21.1% 68
    1B11 108 1 L12(2) 20 21.1% 68
    1H1 108 1 L12(2) 21 22.1% 68
    2A12 108 1 L12(2) 21 22.1% 68
    CUR 109 3 A27 0 0.0% 66
    GLO 109 3 A27 0 0.0% 16
    RF-TS1 96 3 A27 0 0.0% 121
    GAR′ 109 3 A27 0 0.0% 67
    FLO 109 3 A27 0 0.0% 66
    PIE 109 3 A27 0 0.0% 91
    HAH 14.1 109 3 A27 1 1.0% 51
    HAH 14.2 109 3 A27 1 1.0% 51
    HAH 16.1 109 3 A27 1 1.0% 51
    NOV 109 3 A27 1 1.0% 52
    33.F12 108 3 A27 1 1.0% 126
    8E10 110 3 A27 1 1.0% 25
    TH3 109 3 A27 1 1.0% 25
    HIC (R) 108 3 A27 0 0.0% 51
    SON 110 3 A27 1 1.0% 67
    PAY 109 3 A27 1 1.0% 66
    GOT 109 3 A27 1 1.0% 67
    mAbA6H4C5 109 3 A27 1 1.0% 12
    BOR′ 109 3 A27 2 2.1% 84
    RF-SJ3 96 3 A27 2 2.1% 121
    SIE 109 3 A27 2 2.1% 15
    ESC 109 3 A27 2 2.1% 98
    HEW′ 110 3 A27 2 2.1% 98
    YES8c 109 3 A27 3 3.1% 33
    TI 109 3 A27 3 3.1% 114
    mAb113 109 3 A27 3 3.1% 71
    HEW 107 3 A27 0 0.0% 94
    BRO 106 3 A27 0 0.0% 94
    ROB 106 3 A27 0 0.0% 94
    NG9 96 3 A27 4 4.2% 11
    NEU 109 3 A27 4 4.2% 66
    WOL 109 3 A27 4 4.2% 2
    35G6 109 3 A27 4 4.2% 59
    RF-SJ4 109 3 A11 0 0.0% 88
    KAS 109 3 A27 4 4.2% 84
    BRA 106 3 A27 1 1.1% 94
    HAH 106 3 A27 1 1.1% 94
    HIC 105 3 A27 0 0.0% 94
    FS-2 109 3 A27 6 6.3% 87
    JH′ 107 3 A27 6 6.3% 38
    EV1-15 109 3 A27 6 6.3% 83
    SCA 108 3 A27 6 6.3% 65
    mAb112 109 3 A27 6 6.3% 71
    SIC 103 3 A27 3 3.3% 94
    SA-4A 109 3 A27 6 6.3% 120
    SER 108 3 A27 6 6.3% 98
    GOL′ 109 3 A27 7 7.3% 82
    B5G10K 105 3 A27 9 9.7% 125
    HG2B10K 110 3 A27 9 9.4% 125
    Taykv322 105 3 A27 5 5.4% 52
    CLL PATIENT 24 89 3 A27 1 1.1% 122
    HIV-b24 107 3 A27 7 7.4% 8
    HIV-b6 107 3 A27 7 7.4% 8
    Taykv310 99 3 A27 1 1.1% 52
    KA3D1 108 3 L6 0 0.0% 85
    19.E7 107 3 L6 0 0.0% 126
    rsv6L 109 3 A27 12 12.5% 7
    Taykv320 98 3 A27 1 1.2% 52
    Vh 96 3 L10(2) 0 0.0% 89
    LS8 108 3 L6 1 1.1% 109
    LS1 108 3 L6 1 1.1% 109
    LS2S3-3 107 3 L6 2 2.1% 99
    LS2 108 3 L6 1 1.1% 109
    LS7 108 3 L6 1 1.1% 109
    LS2S3-4d 107 3 L6 2 2.1% 99
    LS2S3-4a 107 3 L6 2 2.1% 99
    LS4 108 3 L6 1 1.1% 109
    LS6 108 3 L6 1 1.1% 109
    LS2S3-10a 107 3 L6 2 2.1% 99
    LS2S3-8c 107 3 L6 2 2.1% 99
    LS5 108 3 L6 1 1.1% 109
    LS2S3-5 107 3 L6 3 3.2% 99
    LUNm03 109 3 A27 13 13.5% 6
    IARC/BL41 108 3 A27 13 13.7% 55
    slkv22 99 3 A27 3 3.5% 13
    POP 108 3 L6 4 4.2% 111
    LS2S3-10b 107 3 L6 3 3.2% 99
    LS2S3-8f 107 3 L6 3 3.2% 99
    LS2S3-12 107 3 L6 3 3.2% 99
    HIV-B30 107 3 A27 11 11.7% 8
    HIV-B20 107 3 A27 11 11.7% 8
    HIV-b3 108 3 A27 11 11.7% 8
    HIV-s6 104 3 A27 9 9.9% 8
    YSE 107 3 L2/L16 1 1.1% 72
    POM 109 3 L2/L16 9 9.4% 53
    Humkv328 95 3 L2/L16 1 1.1% 19
    CLL 109 3 L2/L16 3 3.2% 47
    LES 96 3 L2/L16 3 3.2% 38
    HIV-s5 104 3 A27 11 12.1% 8
    HIV-s7 104 3 A27 11 12.1% 8
    slkv1 99 3 A27 7 8.1% 13
    Humka31es 95 3 L2/L16 4 4.2% 18
    slkv12 101 3 A27 8 9.2% 13
    RF-TS2 95 3 L2/L16 3 3.2% 121
    II-1 109 3 L2/L16 4 4.2% 70
    HIV-s3 105 3 A27 13 14.3% 8
    RF-TMC1 96 3 L6 10 10.5% 121
    GER 109 3 L2/L16 7 7.4% 75
    GF4/1.1 109 3 L2/L16 8 8.4% 36
    mAb114 109 3 L2/L16 6 6.3% 71
    HIV-loop13 109 3 L2/L16 7 7.4% 8
    bkv16 86 3 L6 1 1.2% 13
    CLL PATIENT 29 86 3 L6 1 1.2% 122
    slkv9 98 3 L6 3 3.5% 13
    bkv17 99 3 L6 1 1.2% 13
    slkv14 99 3 L6 1 1.2% 13
    slkv16 101 3 L6 2 2.3% 13
    bkv33 101 3 L6 4 4.7% 13
    slkv15 99 3 L6 2 2.3% 13
    bkv6 100 3 L6 3 3.5% 13
    R6B8K 108 3 L2/L16 12 12.6% 125
    AL 700 107 3 L2/L16 9 9.5% 117
    slkv11 100 3 L2/L16 3 3.5% 13
    slkv4 97 3 L6 4 4.8% 13
    CLL PATIENT 26 87 3 L2/L16 1 1.1% 122
    AL Se124 103 3 L2/L16 9 9.5% 117
    slkv13 100 3 L2/L16 6 7.0% 13
    bkv7 100 3 L2/L16 5 5.8% 13
    bkv22 100 3 L2/L16 6 7.0% 13
    CLL PATIENT 27 84 3 L2/L16 0 0.0% 122
    bkv35 100 3 L6 8 9.3% 13
    CLL PATIENT 25 87 3 L2/L16 4 4.6% 122
    slkv3 86 3 L2/L16 7 8.1% 13
    slkv7 99 1 O2 7 8.1% 13
    HuFd79 111 3 L2/L16 24 24.2% 21
    RAD 99 3 A27 9 10.3% 78
    CLL PATIENT 28 83 3 L2/L16 4 4.8% 122
    REE 104 3 L2/L16 25 27.2% 95
    FR4 99 3 A27 8 9.2% 77
    MD3.3 92 3 L6 1 1.3% 54
    MD3.1 92 3 L6 0 0.0% 54
    GA3.6 92 3 L6 2 2.6% 54
    M3.5N 92 3 L6 3 3.8% 54
    WEI′ 82 3 A27 0 0.0% 65
    MD3.4 92 3 L2/L16 1 1.3% 54
    MD3.2 91 3 L6 3 3.8% 54
    VER 97 3 A27 19 22.4% 20
    CLL PATIENT 30 78 3 L6 3 3.8% 122
    M3.1N 92 3 L2/L16 1 1.3% 54
    MD3.6 91 3 L2/L16 0 0.0% 54
    MD3.8 91 3 L2/L16 0 0.0% 54
    GA3.4 92 3 L6 7 9.0% 54
    M3.6N 92 3 A27 0 0.0% 54
    MD3.10 92 3 A27 0 0.0% 54
    MD3.13 91 3 A27 0 0.0% 54
    MD3.7 93 3 A27 0 0.0% 54
    MD3.9 93 3 A27 0 0.0% 54
    GA3.1 93 3 A27 6 7.6% 54
    bkv32 101 3 A27 5 5.7% 13
    GA3.5 93 3 A27 5 6.3% 54
    GA3.7 92 3 A27 7 8.9% 54
    MD3.12 92 3 A27 2 2.5% 54
    M3.2N 90 3 L6 6 7.8% 54
    MD3.5 92 3 A27 1 1.3% 54
    M3.4N 91 3 L2/L16 8 10.3% 54
    M3.8N 91 3 L2/L16 7 9.0% 54
    M3.7N 92 3 A27 3 3.8% 54
    GA3.2 92 3 A27 9 11.4% 54
    GA3.8 93 3 A27 4 5.1% 54
    GA3.3 92 3 A27 8 10.1% 54
    M3.3N 92 3 A27 5 6.3% 54
    B6 83 3 A27 8 11.3% 78
    E29.1 KAPPA 78 3 L2/L16 0 0.0% 22
    SCW 108 1 O8 12 12.6% 31
    REI-based CAMPATH-9 107 1 O8 14 14.7% 39
    RZ 107 1 O8 14 14.7% 50
    BI 108 1 O8 14 14.7% 14
    AND 107 1 O2 13 13.7% 69
    2A4 109 1 O2 12 12.6% 23
    KA 108 1 O8 19 20.0% 107
    MEV 109 1 O2 14 14.7% 29
    DEE 106 1 O2 13 14.0% 76
    OU(IOC) 108 1 O2 18 18.9% 60
    HuRSV19VK 111 1 O8 21 21.0% 115
    SP2 108 1 O2 17 17.9% 93
    BJ26 99 1 O8 21 24.1% 1
    NI 112 1 O8 24 24.2% 106
    BMA 0310EUCIV2 106 1 L12(1) 21 22.3% 105
    CLL PATIENT 6 71 1 A20 0 0.0% 122
    BJ19 85 1 O8 16 21.9% 1
    GM 607 113 2 A3 0 0.0% 58
    R5A3K 114 2 A3 1 1.0% 125
    R1C8K 114 2 A3 1 1.0% 125
    VK2.R149 113 2 A3 2 2.0% 118
    TR1.6 109 2 A3 4 4.0% 92
    TR1.37 104 2 A3 5 5.0% 92
    FS-1 113 2 A3 6 6.0% 87
    TR1.8 110 2 A3 6 6.0% 92
    NIM 113 2 A3 8 8.0% 28
    Inc 112 2 A3 11 11.0% 35
    TEW 107 2 A3 6 6.4% 96
    CUM 114 2 O1 7 6.9% 44
    HRF1 71 2 A3 4 5.6% 124
    CLL PATIENT 19 87 2 A3 0 0.0% 122
    CLL PATIENT 20 87 2 A3 0 0.0% 122
    MIL 112 2 A3 16 16.2% 26
    FR 113 2 A3 20 20.0% 101
    MAL-Urine 83 1 O2 6 8.6% 102
    Taykv306 73 3 A27 1 1.6% 52
    Taykv312 75 3 A27 1 1.6% 52
    HIV-b29 93 3 A27 14 17.5% 8
    1-185-37 110 3 A27 0 0.0% 119
    1-187-29 110 3 A27 0 0.0% 119
    TT117 110 3 A27 9 9.4% 63
    HIV-loop8 108 3 A27 16 16.8% 8
    rsv23L 108 3 A27 16 16.8% 7
    HIV-b7 107 3 A27 14 14.9% 8
    HIV-b11 107 3 A27 15 16.0% 8
    HIV-LC1 107 3 A27 19 20.2% 8
    HIV-LC7 107 3 A27 20 21.3% 8
    HIV-LC22 107 3 A27 21 22.3% 8
    HIV-LC13 107 3 A27 21 22.3% 8
    HIV-LC3 107 3 A27 21 22.3% 8
    HIV-LC5 107 3 A27 21 22.3% 8
    HIV-LC28 107 3 A27 21 22.3% 8
    HIV-b4 107 3 A27 22 23.4% 8
    CLL PATIENT 31 87 3 A27 15 17.2% 122
    HIV-loop2 108 3 L2/L16 17 17.9% 8
    HIV-loop35 108 3 L2/L16 17 17.9% 8
    HIV-LC11 107 3 A27 23 24.5% 8
    HIV-LC24 107 3 A27 23 24.5% 8
    HIV-b12 107 3 A27 24 25.5% 8
    HIV-LC25 107 3 A27 24 25.5% 8
    HIV-b21 107 3 A27 24 25.5% 8
    HIV-LC26 107 3 A27 26 27.7% 8
    G3D10K 108 1 L12(2) 12 12.6% 125
    TT125 108 1 L5 8 8.4% 63
    HIV-s2 103 3 A27 28 31.1% 8
    265-695 108 1 L5 7 7.4% 3
    2-115-19 108 1 A30 2 2.1% 119
    rsv13L 107 1 O2 20 21.1% 7
    HIV-b18 106 1 O2 14 15.1% 8
    RF-KL5 98 3 L6 36 36.7% 97
    ZM1-1 113 2 A17 7 7.0% 3
    HIV-s8 103 1 O8 16 17.8% 8
    K-EV15 95 5 B2 0 0.0% 112
    RF-TS3 100 2 A23 0 0.0% 121
    HF-21/28 111 2 A17 1 1.0% 17
    RPMI6410 113 2 A17 1 1.0% 42
    JC11 113 2 A17 1 1.0% 49
    O-81 114 2 A17 5 5.0% 45
    FK-001 113 4 B3 0 0.0% 81
    CD5+.28 101 4 83 1 1.0% 27
    LEN 114 4 B3 1 1.0% 104
    UC 114 4 B3 1 1.0% 111
    CD5+.5 101 4 B3 1 1.0% 27
    CD5+.26 101 4 B3 1 1.0% 27
    CD5+.12 101 4 B3 2 2.0% 27
    CD5+.23 101 4 B3 2 2.0% 27
    CD5+.7 101 4 B3 2 2.0% 27
    VJI 113 4 B3 3 3.0% 56
    LOC 113 4 B3 3 3.0% 72
    MAL 113 4 B3 3 3.0% 72
    CD5+.6 101 4 B3 3 3.0% 27
    H2F 113 4 B3 3 3.0% 70
    PB17IV 114 4 B3 4 4.0% 74
    CD5+.27 101 4 B3 4 4.0% 27
    CD5+.9 101 4 B3 4 4.0% 27
    CD5−.28 101 4 B3 5 5.0% 27
    CD5−.26 101 4 B3 6 5.9% 27
    CD5+.24 101 4 B3 6 5.9% 27
    CD5+.10 101 4 B3 6 5.9% 27
    CD5−.19 101 4 B3 6 5.9% 27
    CD5−.18 101 4 B3 7 6.9% 27
    CD5−.16 101 4 B3 8 7.9% 27
    CD5−.24 101 4 B3 8 7.9% 27
    CD5−.17 101 4 B3 10 9.9% 27
    MD4.1 92 4 B3 0 0.0% 54
    MD4.4 92 4 B3 0 0.0% 54
    MD4.5 92 4 B3 0 0.0% 54
    MD4.6 92 4 B3 0 0.0% 54
    MD4.7 92 4 B3 0 0.0% 54
    MD4.2 92 4 B3 1 1.3% 54
    MD4.3 92 4 B3 5 6.3% 54
    CLL PATIENT 22 87 2 A17 2 2.3% 122
    CLL PATIENT 23 84 2 A17 2 2.4% 122
  • TABLE 2B
    rearranged human lambda sequences
    Computed Germline Diff. to % diff. to
    Name1 aa2 family3 gene4 germline5 germline6 Reference7
    WAH 110 1 DPL3 7 7% 68
    1B9/F2 112 1 DPL3 7 7% 9
    DIA 112 1 DPL2 7 7% 36
    mAb67 89 1 DPL3 0 0% 29
    HiH2 110 1 DPL3 12 11% 3
    NIG-77 112 1 DPL2 9 9% 72
    OKA 112 1 DPL2 7 7% 84
    KOL 112 1 DPL2 12 11% 40
    T2:C5 111 1 DPL5 0 0% 6
    T2:C14 110 1 DPL5 0 0% 6
    PR-TS1 110 1 DPL5 0 0% 55
    4G12 111 1 DPL5 1 1% 35
    KIM46L 112 1 HUMLV117 0 0% 8
    Fog-B 111 1 DPL5 3 3% 31
    9F2L 111 1 DPL5 3 3% 79
    mAb111 110 1 DPL5 3 3% 48
    PHOX15 111 1 DPL5 4 4% 49
    BL2 111 1 DPL5 4 4% 74
    NIG-64 111 1 DPL5 4 4% 72
    RF-SJ2 100 1 DPL5 6 6% 78
    AL EZI 112 1 DPL5 7 7% 41
    ZIM 112 1 HUMLV117 7 7% 18
    RF-SJ1 100 1 DPL5 9 9% 78
    IGLV1.1 98 1 DPL4 0 0% 1
    NEW 112 1 HUMLV117 11 10% 42
    CB-201 87 1 DPL2 1 1% 62
    MEM 109 1 DPL2 6 6% 50
    H210 111 2 DPL10 4 4% 45
    NOV 110 2 DPL10 8 8% 25
    NEI 111 2 DPL10 8 8% 24
    AL MC 110 2 DPL11 6 6% 28
    MES 112 2 DPL11 8 8% 84
    FOG1-A3 111 2 DPL11 9 9% 27
    AL NOV 112 2 DPL11 7 7% 28
    HMST-1 110 2 DPL11 4 4% 82
    HBW4-1 108 2 DPL12 9 9% 52
    WH 110 2 OPL11 11 11% 34
    11-50 110 2 DPL11 7 7% 82
    HBp2 110 2 DPL12 8 8% 3
    NIG-84 113 2 DPL11 12 11% 73
    VIL 112 2 DPL11 9 9% 58
    TRO 111 2 DPL12 10 10% 61
    ES492 108 2 DPL11 15 15% 76
    mAb216 89 2 DPL12 1 1% 7
    BSA3 109 3 DPL16 0 0% 49
    THY-29 110 3 DPL16 0 0% 27
    PR-TS2 108 3 DPL16 0 0% 55
    E29.1 LAMBDA 107 3 DPL16 1 1% 13
    mAb63 109 3 DPL16 2 2% 29
    TEL14 110 3 DPL16 6 6% 49
    6H-3C4 108 3 DPL16 7 7% 39
    SH 109 3 DPL16 7 7% 70
    AL GIL 109 3 DPL16 8 8% 23
    H6-3C4 108 3 DPL16 8 8% 83
    V-lambda-2.DS 111 2 DPL11 3 3% 15
    8.12 ID 110 2 DPL11 3 3% 81
    DSC 111 2 DPL11 3 3% 56
    PV11 110 2 DPL11 1 1% 56
    33.H11 110 2 DPL11 4 4% 81
    AS17 111 2 DPL11 7 7% 56
    SD6 110 2 DPL11 7 7% 56
    KS3 110 2 DPL11 9 9% 56
    PV6 110 2 DPL12 5 5% 56
    NGD9 110 2 DPL11 7 7% 56
    MUC1-1 111 2 DPL11 11 10% 27
    A30c 111 2 DPL10 6 6% 56
    KS6 110 2 DPL12 6 6% 56
    TEL13 111 2 DPL11 11 10% 49
    AS7 110 2 DPL12 6 6% 56
    MCG 112 2 DPL12 12 11% 20
    U266L 110 2 DPL12 13 12% 77
    PR-SJ2 110 2 DPL12 14 13% 55
    BOH 112 2 DPL12 11 10% 37
    TOG 111 2 DPL11 19 18% 53
    TEL16 111 2 DPL11 19 18% 49
    No. 13 110 2 DPL10 14 13% 52
    BO 112 2 DPL12 18 17% 80
    WIN 112 2 DPL12 17 16% 11
    BUR 104 2 DPL12 15 15% 46
    NIG-58 110 2 DPL12 20 19% 69
    WEIR 112 2 DPL11 26 25% 21
    THY-32 111 1 DPL8 8 8% 27
    TNF-H9G1 111 1 DPL8 9 9% 27
    mAb61 111 1 DPL3 1 1% 29
    LV1L1 98 1 DPL2 0 0% 54
    HA 113 1 DPL3 14 13% 63
    LA1L1 111 1 DPL2 3 3% 54
    RHE 112 1 DPL1 17 16% 22
    K1B12L 113 1 DPL8 17 16% 79
    LOC 113 1 DPL2 15 14% 84
    NIG-51 112 1 DPL2 12 11% 67
    NEWM 104 1 DPL8 23 22% 10
    MD3-4 106 3 DPL23 14 13% 4
    COX 112 1 DPL2 13 12% 84
    HiH10 106 3 DPL23 13 12% 3
    VOR 112 1 DPL2 16 15% 16
    AL POL 113 1 DPL2 16 15% 57
    CD4-74 111 1 DPL2 19 18% 27
    AMYLOID MOL 102 3 DPL23 15 15% 30
    OST577 108 3 Humlv318 10 10% 4
    NIG-48 113 1 DPL3 42 40% 66
    CARR 108 3 DPL23 18 17% 19
    mAb60 108 3 DPL23 14 13% 29
    NIG-68 99 3 DPL23 25 26% 32
    KERN 107 3 DPL23 26 25% 59
    ANT 106 3 DPL23 17 16% 19
    LEE 110 3 DPL23 18 17% 85
    CLE 94 3 DPL23 17 17% 19
    VL8 98 8 DPL21 0 0% 81
    MOT 110 3 Humlv318 23 22% 38
    GAR 108 3 DPL23 26 25% 33
    32.B9 98 8 DPL21 5 5% 81
    PUG 108 3 Humlv318 24 23% 19
    T1 115 8 HUMLV801 52 50% 6
    RF-TS7 96 7 DPL18 4 4% 60
    YM-1 116 8 HUMLV801 51 49% 75
    K6H6 112 8 HUMLV801 20 19% 44
    K5C7 112 8 HUMLV801 20 19% 44
    K5B8 112 8 HUMLV801 20 19% 44
    K5G5 112 8 HUMLV801 20 19% 44
    K4B8 112 8 HUMLV801 19 18% 44
    K6F5 112 8 HUMLV801 17 16% 44
    HIL 108 3 DPL23 22 21% 47
    KIR 109 3 DPL23 20 19% 19
    CAP 109 3 DPL23 19 18% 84
    1B8 110 3 DPL23 22 21% 43
    SHO 108 3 DPL23 19 18% 19
    HAN 108 3 DPL23 20 19% 19
    cML23 96 3 DPL23 3 3% 12
    PR-SJ1 96 3 DPL23 7 7% 55
    BAU 107 3 DPL23 9 9% 5
    TEX 99 3 DPL23 8 8% 19
    X(PET) 107 3 DPL23 9 9% 51
    DOY 106 3 DPL23 9 9% 19
    COT 106 3 DPL23 13 12% 19
    Pag-1 111 3 Humlv318 5 50% 31
    DIS 107 3 Humlv318 2 2% 19
    WIT 108 3 Humlv318 7 7% 19
    I.RH 108 3 Humlv318 12 11% 19
    s1-1 108 3 Humlv318 12 11% 52
    DEL 108 3 Humlv318 14 13% 17
    TYR 108 3 Humlv318 11 10% 19
    J.RH 109 3 Humlv318 13 12% 19
    THO 112 2 DPL13 38 36% 26
    LBV 113 1 DPL3 38 36% 2
    WLT 112 1 DPL3 33 31% 14
    SUT 112 2 DPL12 37 35% 65
  • TABLE 2C
    rearranged human heavy chain sequences
    Computed Germline Diff. to % diff. to
    Name1 aa2 family3 gene4 germline5 germline6 Reference7
    21/28 119 1 VH1-13-12 0 0.0% 31
    8E10 123 1 VH1-13-12 0 0.0% 31
    MUC1-1 118 1 VH1-13-6 4 4.1% 42
    gF1 98 1 VH1-13-12 10 10.2% 75
    VHGL 1.2 98 1 VH1-13-6 2 2.0% 26
    HV1L1 98 1 VH1-13-6 0 0.0% 81
    RF-TS7 104 1 VH1-13-6 3 3.1% 96
    E55 1.A15 106 1 VH1-13-15 1 1.0% 26
    HA1L1 126 1 VH1-13-6 7 7.1% 81
    UC 123 1 VH1-13-6 5 5.1%
    Figure US20060003334A1-20060105-P00899
    5
    WIL2 123 1 VH1-13-6 6 6.1% 55
    R3.5H5G 122 1 VH1-13-6 10 10.2% 70
    N89P2 123 1 VH1-13-16 11 11.2% 77
    mAb113 126 1 VH1-13-6 10 10.2% 71
    LS2S3-3 125 1 VH1-12-7 5 5.1% 98
    LS2S3-12a 125 1 VH1-12-7 5 5.1% 98
    LS2S3-5 125 1 VH1-12-7 5 5.1% 98
    LS2S3-12e 125 1 VH1-12-7 5 5.1% 98
    LS2S3-4 125 1 VH1-12-7 5 5.1% 98
    LS2S3-10 125 1 VH1-12-7 5 5.1% 98
    LS2S3-12d 125 1 VH1-12-7 6 6.1% 98
    LS2S3-8 125 1 VH1-12-7 5 5.1% 98
    LS2 125 1 VH1-12-7 6 6.1% 113
    LS4 105 1 VH1-12-7 6 6.1% 113
    LS5 125 1 VH1-12-7 6 6.1% 113
    LS1 125 1 VH1-12-7 6 6.1% 113
    LS6 125 1 VH1-12-7 6 6.1% 113
    LS8 125 1 VH1-12-7 7 7.1% 113
    THY-29 122 1 VH1-12-7 0 0.0% 42
    1B9/F2 122 1 VH1-12-7 10 10.2% 21
    51P1 122 1 VH1-12-1 0 0.0% 105
    NEI 127 1 VH1-12-1 0 0.0% 55
    AND 127 1 VH1-12-1 0 0.0% 55
    L7 127 1 VH1-12-1 0 0.0% 54
    L22 124 1 VH1-12-1 0 0.0% 54
    L24 127 1 VH1-12-1 0 0.0% 54
    L26 116 1 VH1-12-1 0 0.0% 54
    L33 119 1 VH1-12-1 0 0.0% 54
    L34 117 1 VH1-12-1 0 0.0% 54
    L36 118 1 VH1-12-1 0 0.0% 54
    L39 120 1 VH1-12-1 0 0.0% 54
    L41 120 1 VH1-12-1 0 0.0% 54
    L42 125 1 VH1-12-1 0 0.0% 54
    VHGL 1.8 101 1 VH1-12-1 0 0.0% 26
    783c 127 1 VH1-12-1 0 0.0% 22
    X17115 127 1 VH1-12-1 0 0.0% 37
    L25 124 1 VH1-12-1 0 0.0% 54
    L17 120 1 VH1-12-1 1 1.0% 54
    L30 127 1 VH1-12-1 1 1.0% 54
    L37 120 1 VH1-12-1 1 1.0% 54
    TNF-E7 116 1 VH1-12-1 2 2.0% 42
    mAb111 122 1 VH1-12-1 7 7.1% 71
    III-2R 122 1 VH1-12-9 3 3.1% 70
    KAS 121 1 VH1-12-1 7 7.1% 79
    YES8c 122 1 VH1-12-1 8 8.2% 34
    RF-TS1 123 1 VH1-12-1 8 8.2% 82
    BOR′ 121 1 VH1-12-8 7 7.1% 79
    VHGL 1.9 101 1 VH1-12-1 8 8.2% 26
    mAb410.30F305 117 1 VH1-12-9 5 5.1% 52
    EV1-15 127 1 VH1-12-8 10 10.2% 78
    mAb112 122 1 VH1-12-1 11 11.2% 71
    EU 117 1 VH1-12-1 11 11.2% 28
    H210 127 1 VH1-12-1 12 12.2% 66
    TRANSGENE 104 1 VH1-12-1 0 0.0% 111
    CLL2-1 93 1 VH1-12-1 0 0.0% 30
    CLL10 13-3 97 1 VH1-12-1 0 0.0% 29
    LS7 99 1 VH1-12-7 4 4.1% 113
    ALL7-1 87 1 VH1-12-7 0 0.0% 30
    CLL3-1 91 1 VH1-12-7 1 1.0% 30
    ALL56-1 85 1 VH1-13-8 0 0.0% 30
    ALL1-1 87 1 VH1-13-6 1 1.0% 30
    ALL4-1 94 1 VH1-13-8 0 0.0% 30
    ALL56 15-4 85 1 VH1-13-8 5 5.1% 29
    CLL4-1 88 1 VH1-13-1 1 1.0% 30
    Au92.1 98 1 VH1-12-5 0 0.0% 49
    RF-TS3 120 1 VH1-12-5 1 1.0% 82
    Au4.1 98 1 VH1-12-5 1 1.0% 49
    HP1 121 1 VH1-13-6 13 13.3% 110
    BLI 127 1 VH1-13-15 5 5.1% 72
    No. 13 127 1 VH1-12-2 19 19.4% 76
    TR1.23 122 1 VH1-13-2 23 23.5% 88
    S1-1 125 1 VH1-12-2 18 18.4% 76
    TR1.10 119 1 VH1-13-12 14 14.3% 88
    E55 1.A2 102 1 VH1-13-15 3 3.1% 26
    SP2 119 1 VH1-13-6 15 15.3% 89
    TNF-H9G1 111 1 VH1-13-18 2 2.0% 42
    G3D10H 127 1 VH1-13-16 19 19.4% 127
    TR1.9 118 1 VH1-13-12 14 14.3% 88
    TR1.8 121 1 VH1-12-1 24 24.5% 88
    LUNm01 127 1 VH1-13-6 22 22.4% 9
    K1B12H 127 1 VH1-12-7 23 23.5% 127
    L3B2 99 1 VH1-13-6 2 2.0% 46
    ss2 100 1 VH1-13-6 2 2.0% 46
    No. 86 124 1 VH1-12-1 20 20.4% 76
    TR1.6 124 1 VH1-12-1 19 19.4% 88
    ss7 99 1 VH1-12-7 3 3.1% 46
    s5B7 102 1 VH1-12-1 0 0.0% 46
    s6A3 97 1 VH1-12-1 0 0.0% 46
    ss6 99 1 VH1-12-1 0 0.0% 46
    L2H7 103 1 VH1-13-12 0 0.0% 46
    s6BG8 93 1 VH1-13-12 0 0.0% 46
    s6C9 107 1 VH1-13-12 0 0.0% 46
    HIV-b4 124 1 VH1-13-12 21 21.4% 12
    HIV-b12 124 1 VH1-13-12 21 21.4% 12
    L3G5 98 1 VH1-13-6 1 1.0% 46
    22 115 1 VH1-13-6 11 11.2% 118
    L2A12 99 1 VH1-13-15 3 3.1% 46
    PHOX15 124 1 VH1-12-7 20 20.4% 73
    LUNm03 127 1 VH1-1X-1 18 18.4% 9
    CEA4-8A 129 1 VH1-12-7 1 1.0% 42
    M60 121 2 VH2-31-3 3 3.0% 103
    HiH10 127 2 VH2-31-5 9 9.0% 4
    COR 119 2 VH2-31-2 11 11.0% 91
    2-115-19 124 2 VH2-31-11 8 8.1% 124
    OU 125 2 VH2-31-14 20 25.6% 92
    HE 120 2 VH2-31-13 19 19.0% 27
    CLL33 40-1 78 2 VH2-31-5 2 2.0% 29
    E55 3.9 88 3 VH3-11-5 7 7.2% 26
    MTFC3 125 3 VH3-14-4 21 21.0% 131
    MTFC11 125 3 VH3-14-4 21 21.0% 131
    MTFJ1 114 3 VH3-14-4 21 21.0% 131
    MTFJ2 114 3 VH3-14-4 21 21.0% 131
    MTFUJ4 100 3 VH3-14-4 21 21.0% 131
    MTFUJ5 100 3 VH3-14-4 21 21.0% 131
    MTFUJ2 100 3 VH3-14-4 22 22.0% 131
    MTFC8 125 3 VH3-14-4 23 23.0% 131
    TD e Vq 113 3 VH3-14-4 0 0.0% 16
    rMTF 114 3 VH3-14-4 5 5.0% 131
    MTFUJ6 100 3 VH3-14-4 10 10.0% 131
    RF-KES 107 3 VH3-14-4 9 9.0% 85
    N51P8 126 3 VH3-14-1 9 9.0% 77
    TEI 119 3 VH3-13-8 21 21.4% 20
    33.H11 115 3 VH3-13-19 10 10.2% 129
    SB1/D8 101 3 VH3-IX-8 14 14.0% 2
    38P1 119 3 VH3-11-3 0 0.0% 104
    BRO'IGM 119 3 VH3-11-3 13 13.4% 19
    NIE 119 3 VH3-13-7 15 15.3% 87
    3D6 126 3 VH3-13-26 5 5.1% 35
    ZM1-1 112 3 VH3-11-3 8 8.2% S
    E55 3.15 110 3 VH3-13-26 0 0.0% 26
    gF9 108 3 VH3-13-8 15 15.3% 75
    THY-32 120 3 VH3-13-26 3 3.1% 42
    RF-KL5 100 3 VH3-13-26 5 5.1% 96
    OST577 122 3 VH3-13-13 6 6.1% 5
    BO 113 3 VH3-13-19 15 15.3% 10
    TT125 121 3 VH3-13-10 15 15.3% 64
    2-115-58 127 3 VH3-13-10 11 11.2% 124
    KOL 126 3 VH3-13-14 16 16.3% 102
    mAb60 118 3 VH3-13-17 14 14.3% 45
    RF-AN 106 3 VH3-13-26 8 8.2% 85
    BUT 115 3 VH3-11-6 13 13.4% 119
    KOL-based CAMPATH-9 118 3 VH3-13-13 16 16.3% 41
    B1 119 3 VH3-13-19 13 13.3% 53
    N98P1 127 3 VH3-13-1 13 13.3% 77
    TT117 107 3 VH3-13-10 12 12.2% 64
    WEA 114 3 VH3-13-12 15 15.3% 40
    HIL 120 3 VH3-13-14 14 14.3% 23
    s5A10 97 3 VH3-13-14 0 0.0% 46
    s5D11 98 3 VH3-13-7 0 0.0% 46
    s6C8 100 3 VH3-13-7 0 0.0% 46
    s6H12 98 3 VH3-13-7 0 0.0% 46
    VH10.7 119 3 VH3-13-14 16 16.3% 128
    HIV-loop2 126 3 VH3-13-7 16 16.3% 12
    HIV-loop35 126 3 VH3-13-7 16 16.3% 12
    TRO 122 3 VH3-13-1 13 13.3% 61
    SA-4B 123 3 VH3-13-1 15 15.3% 125
    L2B5 98 3 VH3-13-13 0 0.0% 46
    s6E11 95 3 VH3-13-13 0 0.0% 46
    s6H7 100 3 VH3-13-13 0 0.0% 46
    ss1 102 3 VH3-13-13 0 0.0% 46
    ss8 94 3 VH3-13-13 0 0.0% 46
    DOB 120 3 VH3-13-26 21 21.4% 116
    THY-33 115 3 VH3-13-15 20 20.4% 42
    NOV 118 3 VH3-13-19 14 14.3% 38
    rsv13H 120 3 VH3-13-24 20 20.4% 11
    L3G11 98 3 VH3-13-20 2 2.0% 46
    L2E8 99 3 VH3-13-19 0 0.0% 46
    L2D10 101 3 VH3-13-10 1 1.0% 46
    L2E7 98 3 VH3-13-10 1 1.0% 46
    L3A10 100 3 VH3-13-24 0 0.0% 46
    L2E5 97 3 VH3-13-2 1 1.0% 46
    BUR 119 3 VH3-13-7 21 21.4% 67
    s4D5 107 3 VH3-11-3 1 1.0% 46
    19 116 3 VH3-13-16 4 4.1% 118
    s5D4 99 3 VH3-13-1 0 0.0% 46
    s6A8 100 3 VH3-13-1 0 0.0% 46
    HIV-loop13 123 3 VH3-13-12 17 17.3% 12
    TR1.32 112 3 VH3-11-8 18 18.6% 88
    L2B10 97 3 VH3-11-3 1 1.0% 46
    TR1.5 114 3 VH3-11-8 21 21.6% 88
    s6H9 101 3 VH3-13-25 0 0.0% 46
    8 112 3 VH3-13-1 6 6.1% 118
    23 115 3 VH3-13-1 6 6.1% 118
    7 115 3 VH3-13-1 4 4.1% 118
    TR1.3 120 3 VH3-11-8 20 20.6% 88
    18/2 125 3 VH3-13-10 0 0.0% 32
    18/9 125 3 VH3-13-10 0 0.0% 31
    30P1 119 3 VH3-13-10 0 0.0% 106
    HF2-1/17 125 3 VH3-13-10 0 0.0% 8
    A77 109 3 VH3-13-10 0 0.0% 44
    B19.7 108 3 VH3-13-10 0 0.0% 44
    M43 119 3 VH3-13-10 0 0.0% 103
    1/17 125 3 VH3-13-10 0 0.0% 31
    18/17 125 3 VH3-13-10 0 0.0% 31
    E54 3.4 109 3 VH3-13-10 0 0.0% 26
    LAMBDA-VH26 98 3 VH3-13-10 1 1.0% 95
    E54 3.8 111 3 VH3-13-10 1 1.0% 26
    GL16 106 3 VH3-13-10 1 1.0% 44
    4G12 125 3 VH3-13-10 1 1.0% 56
    A73 106 3 VH3-13-10 2 2.0% 44
    AL1.3 111 3 VH3-13-10 3 3.1% 117
    3.A290 118 3 VH3-13-10 2 2.0% 108
    Ab18 127 3 VH3-13-8 2 2.0% 100
    E54 3.3 105 3 VH3-13-10 3 3.1% 26
    35G6 121 3 VH3-13-10 3 3.1% 57
    A95 107 3 VH3-13-10 5 5.1% 44
    Ab25 128 3 VH3-13-10 5 5.1% 100
    N87 126 3 VH3-13-10 4 4.1% 77
    ED8.4 99 3 VH3-13-10 6 6.1% 2
    RF-KL1 122 3 VH3-13-10 6 6.1% 82
    AL1.1 112 3 VH3-13-10 2 2.0% 117
    AL3.11 102 3 VH3-13-10 1 1.0% 117
    32.B9 127 3 VH3-13-8 6 6.1% 129
    TK1 109 3 VH3-13-10 2 2.0% 117
    POP 123 3 VH3-13-10 8 8.2% 115
    9F2H 127 3 VH3-13-10 9 9.2% 127
    VD 115 3 VH3-13-10 9 9.2% 10
    Vh38Cl.10 121 3 VH3-13-10 8 8.2% 74
    Vh38Cl.9 121 3 VH3-13-10 8 8.2% 74
    Vh38Cl.8 121 3 VH3-13-10 8 8.2% 74
    63P1 120 3 VH3-11-8 0 0.0% 104
    60P2 117 3 VH3-11-8 0 0.0% 104
    AL3.5 90 3 VH3-13-10 2 2.0% 117
    GF4/1.1 123 3 VH3-13-10 10 10.2% 39
    Ab21 126 3 VH3-13-10 12 12.2% 100
    TD d Vp 118 3 VH3-13-17 2 2.0% 16
    Vh38Cl.4 119 3 VH3-13-10 8 8.2% 74
    Vh38Cl.5 119 3 VH3-13-10 8 8.2% 74
    AL3.4 104 3 VH3-13-10 1 1.0% 117
    FOG1-A3 115 3 VH3-13-19 2 2.0% 42
    HA3D1 117 3 VH3-13-21 1 1.0% 81
    E54 3.2 112 3 VH3-13-24 0 0.0% 26
    mAb52 128 3 VH3-13-12 2 2.0% 51
    mAb53 128 3 VH3-13-12 2 2.0% 51
    mAb56 128 3 VH3-13-12 2 2.0% 51
    mAb57 128 3 VH3-13-12 2 2.0% 51
    mAb58 128 3 VH3-13-12 2 2.0% 51
    mAb59 128 3 VH3-13-12 2 2.0% 51
    mAb105 128 3 VH3-13-12 2 2.0% 51
    mAb107 128 3 VH3-13-12 2 2.0% 51
    E55 3.14 110 3 VH3-13-19 0 0.0% 26
    F13-28 106 3 VH3-13-19 1 1.0% 94
    mAb55 127 3 VH3-13-18 4 4.1% 51
    YSE 117 3 VH3-13-24 6 6.1% 72
    E55 3.23 106 3 VH3-13-19 2 2.0% 26
    RF-TS5 101 3 VH3-13-1 3 3.1% 85
    N42P5 124 3 VH3-13-2 7 7.1% 77
    FOG1-H6 110 3 VH3-13-16 7 7.1% 42
    O-81 115 3 VH3-13-19 11 11.2% 47
    HIV-s8 122 3 VH3-13-12 11 11.2% 12
    mAb114 125 3 VH3-13-19 12 12.2% 71
    33.F12 116 3 VH3-13-2 4 4.1% 129
    4B4 119 3 VH3-1X-3 0 0.0% 101
    M26 123 3 VH3-1X-3 0 0.0% 103
    VHGL 3.1 100 3 VH3-1X-3 0 0.0% 26
    E55 3.13 113 3 VH3-1X-3 1 1.0% 26
    SB5/D6 101 3 VH3-1X-6 3 3.0% 2
    RAY4 101 3 VH3-1X-6 3 3.0% 2
    82-D V-D 106 3 VH3-1X-3 5 5.0% 112
    MAL 129 3 VH3-1X-3 5 5.0% 72
    LOC 123 3 VH3-1X-6 5 5.0% 72
    LSF2 101 3 VH3-1X-6 11 11.0% 2
    HIB RC3 100 3 VH3-1X-6 11 11.0% 1
    56P1 119 3 VH3-13-7 0 0.0% 104
    M72 122 3 VH3-13-7 0 0.0% 103
    M74 121 3 VH3-13-7 0 0.0% 103
    E54 3.5 105 3 VH3-13-7 0 0.0% 26
    2E7 123 3 VH3-13-7 0 0.0% 63
    2P1 117 3 VH3-13-7 0 0.0% 104
    RF-SJ2 127 3 VH3-13-7 1 1.0% 83
    PR-TS1 114 3 VH3-13-7 1 1.0% 85
    KIM46H 127 3 VH3-13-13 0 0.0% 18
    E55 3.6 108 3 VH3-13-7 2 2.0% 26
    E55 3.10 107 3 VH3-13-13 1 1.0% 26
    3.B6 114 3 VH3-13-13 1 1.0% 108
    E54 3.6 110 3 VH3-13-13 1 1.0% 26
    FL2-2 114 3 VH3-13-13 1 1.0% 80
    RF-SJ3 112 3 VH3-13-7 2 2.0% 85
    E55 3.5 105 3 VH3-13-14 1 1.0% 26
    BSA3 121 3 VH3-13-13 1 1.0% 73
    HMST-1 119 3 VH3-13-7 3 3.1% 130
    RF-TS2 126 3 VH3-13-13 4 4.1% 82
    E55 3.12 109 3 VH3-13-15 0 0.0% 26
    19.E7 126 3 VH3-13-14 3 3.1% 129
    11-50 119 3 VH3-13-13 6 6.1% 130
    E29.1 120 3 VH3-13-15 2 2.0% 25
    E55 3.16 108 3 VH3-13-7 6 6.1% 26
    TNF-E1 117 3 VH3-13-7 7 7.1% 42
    RF-SJ1 127 3 VH3-13-13 6 6.1% 83
    FOG1-A4 116 3 VH3-13-7 8 8.2% 42
    TNF-A1 117 3 VH3-13-15 4 4.1% 42
    PR-SJ2 107 3 VH3-13-14 8 8.2% 85
    HN.14 124 3 VH3-13-13 10 10.2% 33
    CAM′ 121 3 VH3-13-7 12 12.2% 65
    HIV-B8 125 3 VH3-13-7 9 9.2% 12
    HIV-b27 125 3 VH3-13-7 9 9.2% 12
    HIV-b8 125 3 VH3-13-7 9 9.2% 12
    HIV-s4 125 3 VH3-13-7 9 9.2% 12
    HIV-B26 125 3 VH3-13-7 9 9.2% 12
    HIV-B35 125 3 VH3-13-7 10 10.2% 12
    HIV-b18 125 3 VH3-13-7 10 10.2% 12
    HIV-b22 125 3 VH3-13-7 11 11.2% 12
    HIV-b13 125 3 VH3-13-7 12 12.2% 12
    333 117 3 VH3-14-4 24 24.0% 24
    1H1 120 3 VH3-14-4 24 24.0% 24
    1B11 120 3 VH3-14-4 23 23.0% 24
    CLL3O 2-3 86 3 VH3-13-19 1 1.0% 29
    GA 110 3 VH3-13-7 19 19.4% 36
    JeB 99 3 VH3-13-14 3 3.1% 7
    GAL 110 3 VH3-13-19 10 10.2% 126
    K6H6 119 3 VH3-1X-6 18 18.0% 60
    K4B8 119 3 VH3-1X-6 18 18.0% 60
    K5B8 119 3 VH3-1X-6 18 18.0% 60
    K5C7 119 3 VH3-1X-6 19 19.0% 60
    K5G5 119 3 VH3-1X-6 19 19.0% 60
    K6F5 119 3 VH3-1X-6 19 19.0% 60
    AL3.16 98 3 VH3-13-10 1 1.0% 117
    N86P2 98 3 VH3-13-10 3 3.1% 77
    N54P6 95 3 VH3-13-16 7 7.1% 77
    LAMBDA HT112-1 126 4 VH4-11-2 0 0.0% 3
    HY18 121 4 VH4-11-2 0 0.0% 43
    mAb63 126 4 VH4-11-2 0 0.0% 45
    FS-3 105 4 VH4-11-2 0 0.0% 86
    FS-5 111 4 VH4-11-2 0 0.0% 86
    FS-7 107 4 VH4-11-2 0 0.0% 86
    FS-8 110 4 VH4-11-2 0 0.0% 86
    PR-TS2 105 4 VH4-11-2 0 0.0% 85
    RF-TMC 102 4 VH4-11-2 0 0.0% 85
    mAb216 122 4 VH4-11-2 1 1.0% 15
    mAb410.7.F91 122 4 VH4-11-2 1 1.0% 52
    mAbA6H4C5 124 4 VH4-11-2 1 1.0% 15
    Ab44 127 4 VH4-11-2 2 2.1% 100
    6H-3C4 124 4 VH4-11-2 3 3.1% 59
    FS-6 108 4 VH4-11-2 6 6.2% 86
    FS-2 114 4 VH4-11-2 6 6.2% 84
    HIG1 126 4 VH4-11.2 7 7.2% 62
    FS-4 105 4 VH4-11-2 8 8.2% 86
    SA-4A 123 4 VH4-11-2 9 9.3% 125
    LES-C 119 4 VH4-11-2 10 10.3% 99
    DI 78 4 VH4-11-9 16 16.5% 58
    Ab26 126 4 VH4-31-4 8 8.1% 100
    TS2 124 4 VH4-31-12 15 15.2% 110
    265-695 115 4 VH4-11-7 16 16.5% 5
    WAH 129 4 VH4-31-13 19 19.2% 93
    268-D 122 4 VH4-11-8 22 22.7% 6
    58P2 118 4 VH4-11-8 0 0.0% 104
    mAb67 128 4 VH4-21-4 1 1.0% 45
    4.L39 115 4 VH4-11-8 2 2.1% 108
    mF7 111 4 VH4-31-13 3 3.0% 75
    33.C9 122 4 VH4-21-5 7 7.1% 129
    Pag-1 124 4 VH4-11-16 5 5.2% 50
    B3 123 4 VH4-21-3 8 8.2% 53
    IC4 120 4 VH4-11-8 6 6.2% 70
    C6B2 127 4 VH4-31-12 4 4.0% 48
    N78 118 4 VH4-11-9 11 11.3% 77
    B2 109 4 VH4-11-8 12 12.4% 53
    WRD2 123 4 VH4-11-12 6 6.2% 90
    mAb426.4.2F20 126 4 VH4-11-8 2 2.1% 52
    E54 4.58 115 4 VH4-11-8 1 1.0% 26
    WRD6 123 4 VH4-11-12 10 10.3% 90
    mAb426.12.3F1.4 122 4 VH4-11-9 4 4.1% 52
    E54 4.2 108 4 VH4-21-6 2 2.0% 26
    WIL 127 4 VH4-31-13 0 0.0% 90
    COF 126 4 VH4-31-13 0 0.0% 90
    LAR 122 4 VH4-31-13 2 2.0% 90
    WAT 125 4 VH4-31-13 4 4.0% 90
    mAb61 123 4 VH4-31-13 5 5.1% 45
    WAG 127 4 VH4-31-4 0 0.0% 90
    RF-SJ4 108 4 VH4-31-12 2 2.0% 85
    E54 4.4 110 4 VH4-11-7 0 0.0% 26
    E55 4.A1 108 4 VH4-11-7 0 0.0% 26
    PR-SJ1 103 4 VH4-11-7 1 1.0% 85
    E54 4.23 111 4 VH4-11-7 1 1.0% 26
    CLL7 7-2 97 4 VH4-11-12 0 0.0% 29
    37P1 95 4 VH4-11-12 0 0.0% 104
    ALL52 30-2 91 4 VH4-31-12 4 4.0% 29
    EBV-21 98 5 VH5-12-1 0 0.0% 13
    CB-4 98 5 VH5-12-1 0 0.0% 13
    CLL-12 98 5 VH5-12-1 0 0.0% 13
    L3-4 98 5 VH5-12-1 0 0.0% 13
    CLL11 98 5 VH5-12-1 0 0.0% 17
    CORD3 98 5 VH5-12-1 0 0.0% 17
    CORD4 98 5 VH5-12-1 0 0.0% 17
    CORD8 98 5 VH5-12-1 0 0.0% 17
    CORD9 98 5 VH5-12-1 0 0.0% 17
    CD+1 98 5 VH5-12-1 0 0.0% 17
    CD+3 98 5 VH5-12-1 0 0.0% 17
    CD+4 98 5 VH5-12-1 0 0.0% 17
    CD−1 98 5 VH5-12-1 0 0.0% 17
    CD−5 98 5 VH5-12-1 0 0.0% 17
    VERG14 98 5 VH5-12-1 0 0.0% 17
    PBL1 98 5 VH5-12-1 0 0.0% 17
    PBL10 98 5 VH5-12-1 0 0.0% 17
    STRAb SA-1A 127 5 VH5-12-1 0 0.0% 125
    DOB′ 122 5 VH5-12-1 0 0.0% 97
    VERG5 98 5 VH5-12-1 0 0.0% 17
    PBL2 98 5 VH5-12-1 1 1.0% 17
    Tu16 119 5 VH5-12-1 1 1.0% 49
    PBL12 98 5 VH5-12-1 1 1.0% 17
    CD+2 98 5 VH5-12-1 1 1.0% 17
    CORD10 98 5 VH5-12-1 1 1.0% 17
    PBL9 98 5 VH5-12-1 1 1.0% 17
    CORD2 98 5 VH5-12-1 2 2.0% 17
    PBL6 98 5 VH5-12-1 2 2.0% 17
    CORD5 98 5 VH5-12-1 2 2.0% 17
    CD−2 98 5 VH5-12-1 2 2.0% 17
    CORD1 98 5 VH5-12-1 2 2.0% 17
    CD−3 98 5 VH5-12-1 3 3.1% 17
    VERG4 98 5 VH5-12-1 3 3.1% 17
    PBL13 98 5 VH5-12-1 3 3.1% 17
    PBL7 98 5 VH5-12-1 3 3.1% 17
    HAN 119 5 VH5-12-1 3 3.1% 97
    VERG3 98 5 VH5-12-1 3 3.1% 17
    PBL3 98 5 VH5-12-1 3 3.1% 17
    VERG7 98 5 VH5-12-1 3 3.1% 17
    PBL5 94 5 VH5-12-1 0 0.0% 17
    CD−4 98 5 VH5-12-1 4 4.1% 17
    CLL10 98 5 VH5-12-1 4 4.1% 17
    PBL11 98 5 VH5-12-1 4 4.1% 17
    CORD6 98 5 VH5-12-1 4 4.1% 17
    VERG2 98 5 VH5-12-1 5 5.1% 17
    83P2 119 5 VH5-12-1 0 0.0% 103
    VERG9 98 5 VH5-12-1 6 6.1% 17
    CLL6 98 5 VH5-12-1 6 6.1% 17
    PBL8 98 5 VH5-12-1 7 7.1% 17
    Ab2022 120 5 VH5-12-1 3 3.1% 100
    CAV 127 5 VH5-12-4 0 0.0% 97
    HOW′ 120 5 VH5-12-4 0 0.0% 97
    PET 127 5 VH5-12-4 0 0.0% 97
    ANG 121 5 VH5-12-4 0 0.0% 97
    KER 121 5 VH5-12-4 0 0.0% 97
    5.M13 118 5 VH5-12-4 0 0.0% 107
    Au2.1 118 5 VH5-12-4 1 1.0% 49
    WS1 126 5 VH5-12-1 9 9.2% 110
    TD Vn 98 5 VH5-12-4 1 1.0% 16
    TEL13 116 5 VH5-12-1 9 9.2% 73
    E55 5.237 112 5 VH5-12-4 2 2.0% 26
    VERG1 98 5 VH5-12-1 10 10.2% 17
    CD4-74 117 5 VH5-12-1 10 10.2% 42
    257-D 125 5 VH5-12-1 11 11.2% 6
    CLL4 98 5 VH5-12-1 11 11.2% 17
    CLL8 98 5 VH5-12-1 11 11.2% 17
    Ab2 124 5 VH5-12-1 12 12.2% 120
    Vh383ex 98 5 VH5-12-1 12 12.2% 120
    CLL3 98 5 VH5-12-2 11 11.2% 17
    Au59.1 122 5 VH5-12-1 12 12.2% 49
    TEL16 117 5 VH5-12-1 12 12.2% 73
    M61 104 5 VH5-12-1 0 0.0% 103
    Tu0 99 5 VH5-12-1 5 5.1% 49
    P2-51 122 5 VH5-12-1 13 13.3% 121
    P2-54 122 5 VH5-12-1 11 11.2% 121
    P1-56 119 5 VH5-12-1 9 9.2% 121
    P2-53 122 5 VH5-12-1 10 10.2% 121
    P1-51 123 5 VH5-12-1 19 19.4% 121
    P1-54 123 5 VH5-12-1 3 3.1% 121
    P3-69 127 5 VH5-12-1 4 4.1% 121
    P3-9 119 5 VH5-12-1 4 4.1% 121
    1-185-37 125 5 VH5-12-4 0 0.0% 124
    1-187-29 125 5 VH5-12-4 0 0.0% 124
    P1-58 128 5 VH5-12-4 10 10.2% 121
    P2-57 118 5 VH5-12-4 3 3.1% 121
    P2-55 123 5 VH5-12-1 5 5.1% 121
    P2-56 123 5 VH5-12-1 20 20.4% 121
    P2-52 122 5 VH5-12-1 11 11.2% 121
    P3-60 122 5 VH5-12-1 8 8.2% 121
    P1-57 123 5 VH5-12-1 4 4.1% 121
    P1-55 122 5 VH5-12-1 14 14.3% 121
    MD3-4 128 5 VH5-12-4 12 12.2% 5
    P1-52 121 5 VH5-12-1 11 11.2% 121
    CLL5 98 5 VH5-12-1 13 13.3% 17
    CLL7 98 5 VH5-12-1 14 14.3% 17
    L2F10 100 5 VH5-12-1 1 1.0% 46
    L3B6 98 5 VH5-12-1 1 1.0% 46
    VH6.A12 119 6 VH6-35-1 13 12.9% 122
    s5A9 102 6 VH6-35-1 1 1.0% 46
    s6G4 99 6 VH6-35-1 1 1.0% 46
    ss3 99 6 VH6-35-1 1 1.0% 46
    6-1G1 101 6 VH6-35-1 0 0.0% 14
    F19L16 107 6 VH6-35-1 0 0.0% 68
    L16 120 6 VH6-35-1 0 0.0% 69
    M71 121 6 VH6-35-1 0 0.0% 103
    ML1 120 6 VH6-35-1 0 0.0% 69
    F19ML1 107 6 VH6-35-1 0 0.0% 68
    15P1 127 6 VH6-35-1 0 0.00% 104
    VH6.N1 121 6 VH6-35-1 0 0.0% 122
    VH6.N11 123 6 VH6-35-1 0 0.0% 122
    VH6.N12 123 6 VH6-35-1 0 0.0% 122
    VH6.N2 125 6 VH6-35-1 0 0.0% 122
    VH6.N5 125 6 VH6-35-1 0 0.0% 122
    VH6.N6 127 6 VH6-35-1 0 0.0% 122
    VH6.N7 126 6 VH6-35-1 0 0.0% 122
    VH6.N8 123 6 VH6-35-1 0 0.0% 122
    VH6.N9 123 6 VH6-35-1 0 0.0% 122
    VH6.N10 123 6 VH6-35-1 0 0.0% 122
    VH6.A3 123 6 VH6-35-1 0 0.0% 122
    VH6.A1 124 6 VH6-35-1 0 0.0% 122
    VH6.A4 120 6 VH6-35-1 0 0.0% 122
    E55 6.16 116 6 VH6-35-1 0 0.0% 26
    E55 6.17 120 6 VH6-35-1 0 0.0% 26
    E55 6.6 120 6 VH6-35-1 0 0.0% 26
    VHGL 6.3 102 6 VH6-35-1 0 0.0% 26
    CB-201 118 6 VH6-35-1 0 0.0% 109
    VH6.N4 122 6 VH6-35-1 0 0.0% 122
    E54 6.4 109 6 VH6-35-1 1 1.0% 26
    VH6.A6 126 6 VH6-35-1 1 1.0% 122
    E55 6.14 120 6 VH6-35-1 1 1.0% 26
    E54 6.6 107 6 VH6-35-1 1 1.0% 26
    E55 6.10 112 6 VH6-35-1 1 1.0% 26
    E54 6.1 107 6 VH6-35-1 2 2.0% 26
    E55 6.13 120 6 VH6-35-1 2 2.0% 26
    E55 6.3 120 6 VH6-35-1 2 2.0% 26
    E55 6.7 116 6 VH6-35-1 2 2.0% 26
    E55 6.2 120 6 VH6-35-1 2 2.0% 26
    E55 6.X 111 6 VH6-35-1 2 2.0% 26
    E55 6.11 111 6 VH6-35-1 3 3.0% 26
    VH6.A11 118 6 VH6-35-1 3 3.0% 122
    A10 107 6 VH6-35-1 3 3.0% 68
    E55 6.1 120 6 VH6-35-1 4 4.0% 26
    FK-001 124 6 VH6-35-1 4 4.0% 65
    VH6.A5 121 6 VH6-35-1 4 4.0% 122
    VH6.A7 123 6 VH6-35-1 4 4.0% 122
    HBp2 119 6 VH6-35-1 4 4.0% 4
    Au46.2 123 6 VH6-35-1 5 5.0% 49
    A431 106 6 VH6-35-1 5 5.0% 68
    VH6.A2 120 6 VH6-35-1 5 5.0% 122
    VH6.A9 125 6 VH6-35-1 8 7.9% 122
    VH6.A8 118 6 VH6-35-1 10 9.9% 122
    VH6-FF3 118 6 VH6-35-1 2 2.0% 123
    VH6.A10 126 6 VH6-35-1 12 11.9% 122
    VH6-EB10 117 6 VH6-35-1 3 3.0% 123
    VH6-E6 119 6 VH6-35-1 6 5.9% 123
    VH6-FE2 121 6 VH6-35-1 6 5.9% 123
    VH6-EE6 116 6 VH6-35-1 6 5.9% 123
    VH6-FD10 118 6 VH6-35-1 6 5.9% 123
    VH6-EX8 113 6 VH6-35-1 6 5.9% 123
    VH6-FG9 121 6 VH6-35-1 8 7.9% 123
    VH6-E5 116 6 VH6-35-1 9 8.9% 123
    VH6-EC8 122 6 VH6-35-1 9 8.9% 123
    VH6-E10 120 6 VH6-35-1 10 9.9% 123
    VH6-FF11 122 6 VH6-35-1 11 10.9% 123
    VH6-FD2 115 6 VH6-35-1 11 10.9% 123
    CLL10 17-2 88 6 VH6-35-1 4 4.0% 29
    VH6-BB11 94 6 VH6-35-1 4 4.0% 123
    VH6-B4I 93 6 VH6-35-1 7 6.9% 123
    JU17 102 6 VH6-35-1 3 3.0% 114
    VH6-BD9 96 6 VH6-35-1 11 10.9% 123
    VH6-BB9 94 6 VH6-35-1 12 11.9% 123
  • TABLE 3A
    assignment of rearranged V kappa sequences to their germline
    counterparts
    Family1 Name Rearranged2 Sum
    1 Vk1-1 28
    1 Vk1-2 0
    1 Vk1-3 1
    1 Vk1-4 0
    1 Vk1-5 7
    1 Vk1-6 0
    1 Vk1-7 0
    1 Vk1-8 2
    1 Vk1-9 9
    1 Vk1-10 0
    1 Vk1-11 1
    1 Vk1-12 7
    1 Vk1-13 1
    1 Vk1-14 7
    1 Vk1-15 2
    1 Vk1-16 2
    1 Vk1-17 16
    1 Vk1-18 1
    1 Vk1-19 33
    1 Vk1-20 1
    1 Vk1-21 1
    1 Vk1-22 0
    1 Vk1-23 0 119 entries
    2 Vk2-1 0
    2 Vk2-2 1
    2 Vk2-3 0
    2 Vk2-4 0
    2 Vk2-5 0
    2 Vk2-6 16
    2 Vk2-7 0
    2 Vk2-8 0
    2 Vk2-9 1
    2 Vk2-10 0
    2 Vk2-11 7
    2 Vk2-12 0  25 entries
    3 Vk3-1 1
    3 Vk3-2 0
    3 Vk3-3 35
    3 Vk3-4 115
    3 Vk3-5 0
    3 Vk3-6 0
    3 Vk3-7 1
    3 Vk3-8 40 192 entries
    4 Vk4-1 33  33 entries
    5 Vk5-1 1  1 entry
    6 Vk6-1 0
    6 Vk6-2 0  0 entries
    7 Vk7-1 0  0 entries
  • TABLE 3B
    assignment of rearranged V lambda sequences to their germline
    counterparts
    Family1 Name Rearranged2 Sum
    1 DPL1 1
    1 DPL2 14
    1 DPL3 6
    1 DPL4 1
    1 HUMLV117 4
    1 DPL5 13
    1 DPL6 0
    1 DPL7 0
    1 DPL8 3
    1 DPL9 0 42 entries
    2 DPL10 5
    2 VLAMBDA 2.1 0
    2 DPL11 23
    2 DPL12 15
    2 DPL13 0
    2 DPL14 0 43 entries
    3 DPL16 10
    3 DPL23 19
    3 Humlv318 9 38 entries
    7 DPL18 1
    7 DPL19 0  1 entries
    8 DPL21 2
    8 HUMLV801 6  8 entries
    9 DPL22 0  0 entries
    unassigned DPL24 0  0 entries
    10  gVLX-4.4 0  0 entries
  • TABLE 3C
    assignment of rearranged V heavy chain sequences to their germline
    counterparts
    Family1 Name Rearranged2 Sum
    1 VH1-12-1 38
    1 VH1-12-8 2
    1 VH1-12-2 2
    1 VH1-12-9 2
    1 VH1-12-3 0
    1 VH1-12-4 0
    1 VH1-12-5 3
    1 VH1-12-6 0
    1 VH1-12-7 23
    1 VH1-13-1 1
    1 VH1-13-2 1
    1 VH1-13-3 0
    1 VH1-13-4 0
    1 VH1-13-5 0
    1 VH1-13-6 17
    1 VH1-13-7 0
    1 VH1-13-8 3
    1 VH1-13-9 0
    1 VH1-13-10 0
    1 VH1-13-11 0
    1 VH1-13-12 10
    1 VH1-13-13 0
    1 VH1-13-14 0
    1 VH1-13-15 4
    1 VH1-13-16 2
    1 VH1-13-17 0
    1 VH1-13-18 1
    1 VH1-13-19 0
    1 VH1-1X-1 1 110 entries
    2 VH2-21-1 0
    2 VH2-31-1 0
    2 VH2-31-2 1
    2 VH2-31-3 1
    2 VH2-31-4 0
    2 VH2-31-5 2
    2 VH2-31-6 0
    2 VH2-31-7 0
    2 VH2-31-14 1
    2 VH2-31-8 0
    2 VH2-31-9 0
    2 VH2-31-10 0
    2 VH2-31-11 1
    2 VH2-31-12 0
    2 VH2-31-13 1  7 entries
    3 VH3-11-1 0
    3 VH3-11-2 0
    3 VH3-11-3 5
    3 VH3-11-4 0
    3 VH3-11-5 1
    3 VH3-11-6 1
    3 VH3-11-7 0
    3 VH3-11-8 5
    3 VH3-13-1 9
    3 VH3-13-2 3
    3 VH3-13-3 0
    3 VH3-13-4 0
    3 VH3-13-5 0
    3 VH3-13-6 0
    3 VH3-13-7 32
    3 VH3-13-8 4
    3 VH3-13-9 0
    3 VH3-13-10 46
    3 VH3-13-11 0
    3 VH3-13-12 11
    3 VH3-13-13 17
    3 VH3-13-14 8
    3 VH3-13-15 4
    3 VH3-13-16 3
    3 VH3-13-17 2
    3 VH3-13-18 1
    3 VH3-13-19 13
    3 VH3-13-20 1
    3 VH3-13-21 1
    3 VH3-13-22 0
    3 VH3-13-23 0
    3 VH3-13-24 4
    3 VH3-13-25 1
    3 VH3-13-26 6
    3 VH3-14-1 1
    3 VH3-14-4 15
    3 VH3-14-2 0
    3 VH3-14-3 0
    3 VH3-1X-1 0
    3 VH3-1X-2 0
    3 VH3-1X-3 6
    3 VH3-1X-4 0
    3 VH3-1X-5 0
    3 VH3-1X-6 11
    3 VH3-1X-7 0
    3 VH3-1X-8 1
    3 VH3-1X-9 0 212 entries
    4 VH4-11-1 0
    4 VH4-11-2 20
    4 VH4-11-3 0
    4 VH4-11-4 0
    4 VH4-11-5 0
    4 VH4-11-6 0
    4 VH4-11-7 5
    4 VH4-11-8 7
    4 VH4-11-9 3
    4 VH4-11-10 0
    4 VH4-11-11 0
    4 VH4-11-12 4
    4 VH4-11-13 0
    4 VH4-11-14 0
    4 VH4-11-15 0
    4 VH4-11-16 1
    4 VH4-21-1 0
    4 VH4-21-2 0
    4 VH4-21-3 1
    4 VH4-21-4 1
    4 VH4-21-5 1
    4 VH4-21-6 1
    4 VH4-21-7 0
    4 VH4-21-8 0
    4 VH4-21-9 0
    4 VH4-31-1 0
    4 VH4-31-2 0
    4 VH4-31-3 0
    4 VH4-31-4 2
    4 VH4-31-5 0
    4 VH4-31-6 0
    4 VH4-31-7 0
    4 VH4-31-8 0
    4 VH4-31-9 0
    4 VH4-31-10 0
    4 VH4-31-11 0
    4 VH4-31-12 4
    4 VH4-31-13 7
    4 VH4-31-14 0
    4 VH4-31-15 0
    4 VH4-31-16 0
    4 VH4-31-17 0
    4 VH4-31-18 0
    4 VH4-31-19 0
    4 VH4-31-20 0  57 entries
    5 VH5-12-1 82
    5 VH5-12-2 1
    5 VH5-12-3 0
    5 VH5-12-4 14  97 entries
    6 VH6-35-1 74  74 entries
  • TABLE 4A
    Analysis of V kappa subgroup 1
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
    A  1  1 102   1
    B  1  1
    C  1
    D 64
    E  8 14  1
    F  1  6  1
    G 105 
    H
    I
    65  4
    K  1
    L  6 21 96  1
    M  1 66
    N
    P
    103   1  2  1
    Q 62 88  1
    R
    S 89 102  80 103  103 
    T  1 88 18
    V  1  9  8  2 98
    W
    X  1
    Y
    unknown (?)
    not sequenced 31 31 18 18 17 16 16  2  1
    sum of seq 2 74 74 87 87 88 89 89 103  104  105  105  105  105  105  105  105 
    oomcaa 3 64 65 62 66 88 88 89 103  102  80 96 103  102  103  98 105 
    mcaa4 D I Q M T Q S P S S L S A S V G
    rel. oomcaa5 86% 88% 71% 76% 100% 99% 100% 100% 98% 76% 91% 98% 97% 98% 93% 100%
    pos occupied6  4  5  5  2  1  2  1  1  3  4  3  2  3  3  5  1
    Framework I CDR I
    amino acid 1 17 18 19 20 21 22 23 24 25 26 27 A B C D
    A  1  1  1 103 
    B  1
    C 105 
    D 101 
    E  2  1  1  2
    F  2
    G  1
    H  1
    I  6  4 101   1
    K  2  1
    L  1
    M
    N  1
    P
    Q
    20 100 
    R 94 81
    S  5  1 102 
    T  6 99 103   1  1
    V 98  2
    W
    X  1
    Y  1
    105  105  105  105 
    unknown (?)
    not sentenced
    sum of seq2 105  105  105  105  105  105  105  105  105  105  105  105  105  105  105 
    oomcaa 3 101  94 98 99 101  103  105  81 103  102  100  105  105  105  105 
    mcaa4 D R V T I T C R A S Q
    rel. oomcaa5 96% 90% 93% 94% 96% 98% 100% 77% 98% 97% 95% 100% 100% 100% 100%
    pos occupied6  4  3  3  4  3  3  1  5  3  4  5  1  1  1  1
    CDR I Framework II
    amino acid1 E F 28 29 30 31 32 33 34 35 36 37 38 39 40
    A  1  1  1 42
    B  1  1
    C  1
    D 25  1  5  7  1
    E  1  2
    F  1  1  7  6
    G 25  7  3  4
    H  1  2  2  1  2
    I 98  1  4  1
    K  7 95
    L  2  1 101 
    M
    N
     6 16 42 50
    P 102 
    Q 98 103   2
    R 16  3  2  3  1
    S 41  2 57 32  3  1  1  1
    T  7  4  4  1
    V  1  4  1  1
    W 21 104 
    X  1
    Y  1 60 98
    105  105 
    unknown (?)  3
    not sequenced  1  1  1  1  1  1  1  1  1  1
    sum of seq2 105  105  105  105  105  104  104  104  104  104  104  104  104  104  104 
    oomcaa3 105  105  41 98 57 42 60 101  50 104  98 98 103  95 102 
    mcaa4 S I S N Y L N W Y Q Q K P
    rel. oomcaa5 100% 100% 39% 93% 54% 40% 58% 97% 48% 100% 94% 94% 99% 91% 98%
    pos occupied6  1  1  6  4 12 11  9  4  8  1  2  5  2  4  3
    Framework II CDR II
    amino acid 1 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55
    A 94 50 95
    B
    C
    D
    21  1  1  1
    E  1  3  1  1  1  1 33
    F  1  3  1
    G 100   1  9  2
    H  2  1
    I  1  1 100   1
    K 95 86 16  2  5
    L  1 89 103  101 
    M  2
    N 10  2  1 25
    P 104   1  1
    Q  1  1 62
    R  3  3  1  1  2
    S  1  5  1  1 99 41  2
    T  3  1  1  4  1 31
    V  9  9  1  1
    W
    X
     1  1
    Y 92  1
    unknown (?)  3
    not sequenced  1  1  1  1  1  1  2  3  3  2  1  1  1  1  1
    sum of seq 2 104  104  104  104  104  104  103  102  102  103  104  104  104  104  104 
    oomcaa 3 100  95 94 104  86 89 103  100  92 50 95 99 41 101  62
    mcaa4 G K A P K L L I Y A A S S L Q
    rel. oomcaa5 96% 91% 90% 100% 83% 86% 100% 98% 90% 49% 91% 95% 39% 97% 60%
    pos occupied6  2  6  3  1  8  6  1  2  4 10  6  6  9  3  6
    CDR
    II Framework III
    amino acid 1 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
    A  3  2  1  1  1
    B  1
    C
    D
     1 67
    E  1 30
    F  1 103   3
    G  2 105  105   4 101  102 
    H  3
    I  3  4  1  3
    K  1  1  1
    L  1
    M  1
    N  6
    P  1 101   2
    Q  1
    R  1 103   1  1  1  2
    S 68  2 103  98 96 100 
    T 19  1  1  2  3 101 
    V 99  1  1
    W
    X
     1  1  1  2
    Y  1  1
    unknown (?)
    not sequenced
    sum of seq2 105  105  105  105  105  105  105  105  105  105  105  105  105  105  105 
    oomcaa 3 68 105  99 101  103  103  103  98 105  96 101  100  102  101  67
    mcaa4 S G V P S R F S G S G S G T D
    rel. oomcaa5 65% 100% 94% 96% 98% 98% 98% 93% 100% 91% 96% 95% 97% 96% 64%
    pos occupied6 10  1  4  4  2  3  3  5  1  5  4  4  4  4  7
    Framework III
    amino acid 1 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85
    A  3  1  2 101   1
    B  1  3  2
    C
    D
     1 16 101 
    E 83
    F 102   1 21 73
    G  4  1  2
    H
    I 99  5 17
    K
    L
    81 103   1  1
    M  1
    N  7  4  1
    P 97  1
    Q 97
    R  2  1  2
    S  2  1 86 94  4  1
    T 98 102   2  1 97
    V  1  2  4  1 11  1
    W
    X
     1  1  2
    Y  1
    unknown (?)
    not sequenced  1  1  1  1  1  1  1  1  2  2  2  2  2  2  3
    sum ofseq 2 104  104  104  104  104  104  104  104  103  103  103  103  103  103  102 
    oomcaa 3 102  98 81 102  99 86 94 103  97 97 83 101  73 101  97
    mcaa4 F T L T I S S L Q P E D F A T
    rel. oomcaa5 98% 94% 78% 98% 95% 83% 90% 99% 94% 94% 81% 98% 71% 98% 95%
    pos occupied6  3  4  3  3  3  7  5  2  4  3  5  2  5  2  6
    Framework III CDR III
    amino acid 1 86 87 88 89 90 91 92 93 94 95 A B C D E F
    A  1  7  1  5  1
    B  2  3
    C 102 
    D 23  5  1
    E  1  1  1  1
    F  7  3 13
    G  1  1  2  1  1
    H  1  4  6  7  3  1
    I  4  1  2  1
    K  1  7  1
    L  7  6  2 18  2
    M
    N
     6 31 19  1
    P  1 82  6
    Q 90 86  1  2
    R  1  2  2
    S  1 27  3 58  5 10
    T  3  1 15 25
    V  5
    W  1
    X
    Y
    101  93 42 32  1 23
     3 82 88 89 89 89 89
    unknown (?)  1
    not sequenced  2  3  3  2  2  1  1  1  1  4 16 16 16 16 16 16
    sum of seq 2 103  102  102  103  103  104  104  104  104  101  89 89 89 89 89 89
    oomcaa 3 101  93 102  90 86 42 32 58 25 82 82 88 89 89 89 89
    mcaa4 Y Y C Q Q Y Y S T P
    rel. oomcaa5 98% 91% 100% 87% 83% 40% 31% 56% 24% 81% 92% 99% 100% 100% 100% 100%
    pos occupied6  3  3  1  4  5 11 12 10 14  8  3  2  1  1  1  1
    CDR III Framework IV
    amino acid 1 96 97 98 99 100 101 102 103 104 105 106 A 107 108 sum
    A  1 627
    B  1  1 19
    C 209
    D  1 15 459
    E  2 65 258
    F  6 86  2 451
    G 87 29 87  2 894
    H  2  1 40
    I  5  1 72 606
    K  1  1 77 79 480
    L 18  1  1 22  4  2 793
    M  1  5 77
    N  1  1  2 232
    P  6  7  1 620
    Q  1 48  1 865
    R  6  6  2 70 413
    S  2  2 1636
    T  2 82 87  3  2 1021
    V  2  1 63  3 440
    W 15 141
    X 14
    Y 16 564
     4  1 85  1 1250
    unknown (?) 7
    not sequenced 16 16 18 18 18 18 18 18 19 19 20 20 20 31 589
    sum of seq 2 89 89 87 87 87 87 87 87 86 86 85 85 85 74
    oomcaa 3 18 82 86 87 48 87 87 77 63 65 72 85 79 70
    mcaa4 L T F G G G T K V E I K R
    rel. oomcaa5 20% 92% 99% 100% 55% 100% 100% 89% 73% 76% 85% 100% 93% 95%
    pos occupied6 17  7  2  1  5  1  1  4  3  5  6  1  4  4
  • TABLE 4B
    Analysis of V kappa subgroup 2
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
    A
    B
    C
    D 14
    E  3
    F  1  1
    G 22
    H
    I  8
    K
    L
     3  1 17 18  6
    M 15
    N
    P
    18 18 15
    Q 18
    R
    S
    18 17
    T 17 21
    V  6 17  1 18
    X
    Y
    unknown (?)  1
    not sequenced  5  5  5  5  4  4  4  4  4  4  4  4  4  1  1
    sum of seq 2 17 17 17 17 18 18 18 18 18 18 18 18 18 21 21 22
    oomcaa 3 14  8 17 15 17 18 18 18 17 17 18 18 18 21 15 22
    mcaa4 D I V M T Q S P L S L P V T P G
    rel. oomcaa5 82% 47% 100% 88% 94% 100% 100% 100% 94% 94% 100% 100% 100% 100% 71% 100%
    pos occupied6  2  3  1  3  1  1  1  1  2  2  1  1  1  1  2  1
    Framework I CDR I
    amino acid 1 17 18 19 20 21 22 23 24 25 26 27 A B C D E
    A 22
    B
    C 22
    D  1
    E 15
    F
    G  1
    H 16
    I 22
    K  1
    L  1 22 13
    M  1
    N
    P 22
    Q  7  1 21
    R 21  2
    S 22 21 22 22 22 19
    T
    V  8
    X  1
    Y
     4
    unknown (?)
    not sequenced
    sum of seq 2 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22
    oomcaa 3 15 22 22 22 22 21 22 21 22 22 21 22 22 13 16 19
    mcaa4 E P A S I S C R S S Q S L L H S
    rel. oomcaa5 68% 100% 100% 100% 100 95% 100% 95% 100% 100% 95% 100% 100% 59% 73% 86%
    pos occupied6  2  1  1  1  1  2  1  2  1  1  2  1  1  3  4  3
    CDR I Framework II
    amino acid1 F 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
    A
    B
    C
    D
     9  1  1 11
    E
    F  2  7
    G 22 22
    H  1  1
    I
    K  1 15
    L 22 16
    M
    N
    10  7 12  9
    P 22
    Q  6 22 22
    R  7
    S  1
    T  8
    V
    W 22
    X  1  1  1
    Y  1 11 21 15
    22
    unknown (?)
    not sequenced
    sum of seq 2 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22
    oomcaa 3 22 10 22 11 12 21 22 11 22 15 16 22 15 22 22 22
    mcaa4 N G Y N Y L D W Y L Q K P G Q
    rel. oomcaa5 100% 45% 100% 50% 55% 95% 100% 50% 100% 68% 73% 100% 68% 100% 100% 100%
    pos occupied6  1  5  1  5  4  2  1  4  1  2  2  1  2  1  1  1
    Framework
    Framework II CDR II III
    amino acid 1 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58
    A 14
    B
    C
    D  7
    E  1
    F
    G 12  1 22
    H
    I  1 22
    K  5
    L 14 21 14  1
    M
    N 18
    P 21
    Q 12  1
    R  8  7  1 22
    S 21  2 22  2 22
    T  1
    V  1  6 22
    W
    X
    Y
    21  1
    unknown (?)
    not sequenced 1  1  1  1  1  1
    sum of seq 2 21 21 21 22 22 22 21 21 21 22 22 22 22 22 22 22
    oomcaa 3 21 21 12 14 21 22 21 14 12 22 18 22 14 22 22 22
    mcaa4 S P Q L L I Y L G S N R A S G V
    rel. oomcaa5 100% 100% 57% 64% 95% 100% 100% 67% 57% 100% 82% 100% 64% 100% 100% 100%
    pos occupied6  1  1  3  3  2  1  1  4  4  1  4  1  3  1  1  1
    Framework III
    amino acid 1 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74
    A
    B
    C
    D
    22  1  1 22
    E
    F 21 22
    G 21 22 21
    H
    I  1
    K 19
    L 21  1
    M
    N
    P 22
    Q
    R 20  1
    S  1 22 21 22
    T  1 22 21
    V  1
    W
    X
    Y
    unknown (?)  1
    not sequenced  1  1
    sum of seq 2 22 22 22 22 22 22 22 22 22 22 22 22 22 22 21 21
    oomcaa 3 22 22 20 21 22 21 21 22 22 21 22 22 22 21 21 19
    mcaa4 P D R F S G S G S G T D F T L K
    rel. oomcaa5 100% 100% 91% 95% 100% 95% 95% 100% 100% 95% 100% 100% 100% 95% 100% 90%
    pos occupied6  1  1  3  2  1  2  2  1  1  2  1  1  1  1  1  3
    Framework III CDR III
    amino acid1 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
    A 20
    B  1
    C 21
    D  1 21
    E 19 20
    F
    G  1 21
    H
    I 21  1
    K
    L  1
    M 21
    N
    P  1
    Q  1 20
    R 20
    S 20  1
    T  1
    V 21 21 19
    W
    X
    Y
    21 21
    unknown (?)
    not sequenced  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1
    sum of seq 2 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21
    oomcaa 3 21 20 20 21 19 20 20 21 21 21 19 21 21 21 21 20
    mcaa4 I S R V E A E D V G V Y Y C M Q
    rel. oomcaa5 100% 95% 95% 100% 90% 95% 95% 100% 100% 100% 90% 100% 100% 100% 100% 95%
    pos occupied6  1  2  2  1  3  2  2  1  1  1  3  1  1  1  1  2
    CDR III Framework IV
    amino acid 1 91 92 93 94 95 A B C D E F 96 97 98 99 100
    A 14  1
    B  1
    C
    D
    E
    F  1 17
    G  6  1  2 17  2
    H  1  7
    I  1  3
    K
    L
    12  2  2
    M
    N
    P  2 16  1  1
    Q 13  1 14
    R  1
    S  3  2
    T  8  7 17
    V
    W
     6  2
    X
    Y
     7
    14 17 17 17 17 17
    unknown (?)
    not sequenced 1  1  1  1  2  5  5  5  5  5  5  5  5  5  5  6
    sum of seq 2 21 21 21 21 20 17 17 17 17 17 17 17 17 17 17 16
    oomcaa 3 14 12 13  7 16 14 17 17 17 17 17  7 17 17 17 14
    mcaa4 A L Q T P Y T F G Q
    rel. oomcaa5 67% 57% 62% 33% 80% 82% 100% 100% 100% 100% 100% 41% 100% 100% 100% 88%
    pos occupied6 3  3  3  7  3  3  1  1  1  1  1  7  1  1  1  2
    Framework IV
    amino acid 1 101 102 103 104 105 106 A 107 108 Sum
    A 71
    B  1 3
    C 43
    D 112
    E 13 71
    F 72
    G 16  1 233
    H 26
    I 14 94
    K 12 13 66
    L 11 219
    M 37
    N 56
    P 159
    Q 159
    R  4 12 126
    S 325
    T 16 140
    V  5 146
    W 31
    X 3
    Y 123
    13 134
    unknown (?) 2
    not sequenced 6  6  6  6  7  8  9  9 10 211
    sum of seq 2 16 16 16 16 15 14 13 13 12
    oomcaa 3 16 16 12 11 13 14 13 13 12
    mcaa4 G T K L E I K R
    rel. oomcaa5 100% 100% 75% 69% 87% 100% 100% 100% 100%
    pos occupied6 1  1  2  2  3  1  1  1  1
  • TABLE 4C
    Analysis of V kappa subgroup 3
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
    A  5  2 27  1
    B  1
    C  2
    D  2 14
    E 76 27
    F  1  1
    G  1 82  1 152 
    H  1
    I 75
    K  3
    L  4  1 104   1 150  129   1
    M  5 13
    N  5
    P 124  147 
    Q 123 
    R  1
    S 119   3  1 150   1 141 
    T  2 117  147   5  1
    V  1 89  1  1  1 22  1
    W
    X
    Y
    unknown (?)
    not sequenced
    sum of seq 2 88 88 117  118  118  123  123  124  126  149  151  152  152  152  152  152 
    oomcaa 3 76 75 89 104  117  123  119  124  82 147  150  150  129  141  147  152 
    mcaa4 E I V L T Q S P G T L S L S P G
    rel. oomcaa5 86% 85% 76% 88% 99% 100% 97% 100% 65% 99% 99% 99% 85% 93% 97% 100%
    pos occupied6  6  6  3  3  2  1  4  1  4  3  2  2  3  4  6  1
    Framework I CDR I
    amino acid 1 17 18 19 20 21 22 23 24 25 26 27 A B C D E
    A 178   2 166   1
    B
    C 181   1
    D  6
    E 146   1  1
    F  7  1
    G  1  1  1  1  1
    H 17
    I  1  5  2
    K  1  5
    L 173   1  1
    M
    N  9
    P
    Q 159 
    R 175  176   1  1 10
    S 180   7 175  87
    T  1 174   7  2  1
    V  1  4  1  1  1
    W  1
    X
    Y
     1  1
    72 182  182  182  182 
    unknown (?)  1
    not sequenced
    sum of seq2 153  181  182  182  182  182  181  182  182  181  181  182  182  182  182  182 
    oomcaa3 146  175  178  174  173  180  181  176  166  175  159  87 182  182  182  182 
    mcaa4 E R A T L S C R A S Q S
    rel. oomcaa5 95% 97% 98% 96% 95% 99% 100% 97% 91% 97% 88% 48% 100% 100% 100% 100%
    pos occupied6  3  7  2  4  3  3  1  3  5  6  6  8  1  1  1  1
    CDR I Framework II
    amino acid1 F 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
    A  1  1 181 
    B
    C
    D  1  1  2  1
    E  1  1  1
    F  1  7  1
    G  2  7  3  1  2  1 184 
    H  1  2  1 12  1  1
    I 24  4  1  1
    K  1  1 153 
    L  8  1  1 176   3  2
    M
    N
     3 12 25 32
    P  1 170 
    Q  1  1 183  167   1 181 
    R 10  3 18 16  1  1 27  5
    S 72 86 151  118   4  5
    T  1  1  3  8  1  1
    V 76 68  1  7  3  2
    W  5 185 
    X
    Y
     1  1 115  183 
    182 
    unknown (?)  1
    not sequenced
    sum of seq 2 182  182  182  181  181  182  183  184  185  185  185  185  184  184  184  184 
    oomcaa 3 182  76 86 151  118  115  176  181  185  183  183  167  153  170  184  181 
    mcaa4 V S S S Y L A W Y Q Q K P G Q
    rel. oomcaa5 100% 42% 47% 83% 65% 63% 96% 98% 100% 99% 99% 90% 83% 92% 100% 98%
    pos occupied6  1  6 11 10 13 12  2  3  1  3  2  4  6  6  1  3
    Framework
    Framework II CDR II III
    amino acid 1 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58
    A 176   4 147  176   1
    B
    C  1
    D 43  2  4
    E
    F  1  1  4
    G 125   2 10 179 
    H  9  1
    I 178   1 168 
    K  1  7  1
    L  1 179  174   1
    M  3  1
    N  1  1 53  2
    P  5 184   2  2  2
    Q  1
    R 182   1  4 180 
    S  3  6  4 179  74  1  5
    T  3 11  2 44 164   2
    V  3  9  3 19  3 15
    W  1  1
    X
    Y
    165   2
    unknown (?)  1
    not sequenced
    sum of seq2 184  185  185  183  183  183  183  183  183  183  183  183  185  185  185  185 
    oomcaa 3 176  184  182  179  174  178  165  125  147  179  74 180  176  164  179  168 
    mcaa4 A P R L L I Y G A S S R A T G I
    rel. oomcaa5 96% 99% 98% 98% 95% 97% 90% 68% 80% 98% 40% 98% 95% 89% 97% 91%
    pos occupied6  3  2  3  3  2  4  6  7  6  3  6  4  5  7  3  3
    Framework III
    amino acid 1 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74
    A 68  3  5  3  1  3
    B
    C
    D 112   1 152 
    E  1  1 30
    F 183  183   2
    G 184   3 178  177 
    H  1
    I  1  1  3
    K  1
    L  1 182 
    M  1
    N  1  1
    P 177 
    Q  1
    R 182   2  1  2
    S  7 180  179  185   3  7  2
    T  1  2  3  2 177  172  179 
    V  3  1  1
    W  1
    X
    Y
     1
    unknown (?)  1
    not sequenced
    sum of seq2 185  185  185  185  185  185  185  185  185  185  185  184  184  184  184  184 
    oomcaa 3 177  112  182  183  180  184  179  178  185  177  177  152  183  172  182  179 
    mcaa4 P D R F S G S G S G T D F T L T
    rel. oomcaa5 96% 61% 98% 99% 97% 99% 97% 96% 100% 96% 96% 83% 99% 93% 99% 97%
    pos occupied6  3  5  3  3  3  2  4  5  1  5  4  4  2  5  2  3
    Framework III CDR III
    amino acid1 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
    A  3 174 
    B  1
    C  2  1 182 
    D  1  3 182 
    E 149  175   2
    F  1 178   2  1  4
    G  3  1  2
    H  1  1  7
    I 178   1  1  9
    K  1
    L 178   1  1  7  1  1
    M  1  5
    N  1  5
    P 149 
    Q 34  1 181  155 
    R  1 111   3  1
    S 169  65 34  1  2
    T  8  4  1  8
    V  4  6  1  3 159   7
    W
    X
    Y
     1  1 183  176   1  2
    unknown (?)
    not sequenced
    sum of seq2 184  184  184  184  184  184  182  184  184  184  184  184  184  183  183  183 
    oomcaa 3 178  169  111  178  149  149  175  182  178  174  159  183  176  182  181  155 
    mcaa4 I S R L E P E D F A V Y Y C Q Q
    rel. oomcaa5 97% 92% 60% 97% 81% 81% 96% 99% 97% 95% 86% 99% 96% 99% 99% 85%
    pos occupied6  4  5  5  2  3  3  4  3  6  6  7  2  5  2  3  8
    CDR III Framework IV
    amino acid 1 91 92 93 94 95 A B C D E F 96 97 98 99 100
    A  1  8  3  3  1
    B
    C  2  1  2
    D  8  5  1
    E  2  1
    F  5  2  7 166 
    G  1 104  15  1  1  2  1 166  41
    H  4  1  2
    I  1  1  4
    K  2  1  1  1
    L  2  7  5 42
    M  1  1  2
    N 28 71  1
    P  1 139  24  7  2  9
    Q  1  1  3  1  3 114
    R 34  2  3  2  2 19
    S  2 33 58 102  15  2  1  8
    T  2 13  1  1  2  1 154 
    V  3  1  2
    W 69 24
    X
    Y 134   1  1 43
     3  3  7 127  167  169  169  169  169   8  1  1  1  1
    unknown (?)
    not sequenced 14 14 14 14 14 14 14 17 16 16 16
    sum of seq2 183  183  183  182  182  169  169  169  169  169  169  169  166  167  167  167 
    oomcaa3 134  104  71 102  139  127  167  169  169  169  169  43 154  166  166  114 
    mcaa4 Y G N S P Y T F G Q
    rel. oomcaa 5 73% 57% 39% 56% 76% 75% 99% 100% 100% 100% 100% 25% 93% 99% 99% 68%
    pos occupied6  8 11 13  8 11 12  2  1  1  1  1 18  5  2  2  6
    Framework IV
    amino acid 1 101 102 103 104 105 106 A 107 108 sum
    A 1345
    B  2
    C 375
    D 23 564
    E  3 141  759
    F  6 765
    G 166   1 1804
    H  1 64
    I 143  803
    K 152  157  489
    L 54  1  2 1596
    M  3 36
    N  1  3 255
    P  1  1 1147
    Q  1  1 1314
    R  9  2  4 134  1326
    S  2 2629
    T 162   1  1 1593
    V 111  11 646
    W 287
    X
    Y
     1 1014
     1  1  1  1  1  1 166  1  1 2151
    unknown (?)  4
    not sequenced 16 16 15 16 16 16 17 17 45 337
    sum of seq 2 167  167  168  167  167  167  166  166  138 
    oomcaa 3 166  162  152  111  141  143  166  157  134 
    mcaa4 G T K V E I K R
    rel. oomcaa5 99% 97% 90% 66% 84% 86% 100% 95% 97%
    pos occupied6  2  5  7  4  5  7  1  5  4
  • TABLE 4D
    Analysis of V kappa subgroup 4
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
    A 24  1
    B
    C
     1  1
    D 25 26
    E 25
    F
    G  1 24
    H
    I 26
    K  1
    L  1 26 26
    M 24
    N  1
    P 26  1
    Q  1 25
    R 26
    S 26 25 26  1
    T 26
    V 25  1 26
    W
    X
    Y
    unknown (?)
    not sequenced  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7
    sum of seq 2 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26
    oomcaa 3 25 26 25 24 26 25 26 26 26 25 26 24 26 26 26 24 25 26
    mcaa4 D I V M T Q S P D S L A V S L G E R
    rel. oomcaa5 96% 100% 96% 92% 100% 96% 100% 100% 100% 96% 100% 92% 100% 100% 100% 92% 96% 100%
    pos occupied6  2  1  2  3  1  2  1  1  1  2  1  3  1  1  1  3  2  1
    Framework I CDR I
    amino acid 1 19 20 21 22 23 24 25 26 27 A B C D E F 28 29 30
    A 26  1  1
    B
    C 33
    D  1  1  1
    E
    F
    G
    H
    I 26  1
    K 33  2 30
    L  2 31
    M
    N
    26 30 31  1
    P  1  1
    Q 32  1
    R  1  1  1
    S 31 33 33 32 32  1
    T 26  1
    V 28  2
    W
    X
    Y
    32
    unknown (?)
    not sequenced  7  7  7  7
    sum of seq 2 26 26 26 26 33 33 33 33 33 33 33 33 33 33 33 33 33 33
    oomcaa 3 26 26 26 26 33 33 31 33 32 33 28 31 32 32 32 30 31 30
    mcaa4 A T I N C K S S Q S V L Y S S N N K
    rel. oomcaa5 100% 100% 100% 100% 100% 100% 94% 100% 97% 100% 85% 94% 97% 97% 97% 91% 94% 91%
    pos occupied6  1  1  1  1  1  1  3  1  2  1  5  2  2  2  2  3  3  4
    CDR I Framework II
    amino acid1 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
    A 32  2
    B
    C
    D
    E  1
    F
    G 32
    H  2
    I 32
    K 33 32
    L 33 29 33
    M  1
    N 33
    P 31 31 33
    Q 32 33 32
    R  1  1  1
    S  2
    T  1
    V  4
    W 33
    X
    Y
    33 31
    unknown (?)
    not sequenced
    sum of seq 2 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33
    oomcaa 3 33 33 33 32 33 31 32 33 33 31 32 32 31 33 32 29 33 32
    mcaa4 N Y L A W Y Q Q K P G Q P P K L L I
    rel. oomcaa5 100% 100% 100% 97% 100% 94% 97% 100% 100% 94% 97% 97% 94% 100% 97% 88% 100% 97%
    pos occupied6  1  1  1  2  1  2  2  1  1  2  2  2  2  1  2  2  1  2
    Frame-
    work II CDR II Framework III
    amino acid 1 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66
    A 30
    B
    C
    D 33
    E 32
    F 33
    G 33  1 33 33
    H
    I  1
    K
    L
    M
    N  2
    P  1 33  1
    Q
    R
    33 32
    S  1 31  1 33 32 33
    T  2  1 29
    V  1 33
    W 33
    X
    Y
    33
    unknown (?)
    not sequenced
    sum of seq 2 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33
    oomcaa 3 33 33 30 31 29 33 32 33 33 33 33 33 32 33 32 33 33 33
    mcaa4 Y W A S T R E S G V P D R F S G S G
    rel. oomcaa5 100% 100% 91% 94% 88% 100% 97% 100% 100% 100% 100% 100% 97% 100% 97% 100% 100% 100%
    pos occupied6  1  1  3  3  4  1  2  1  1  1  1  1  2  1  2  1  1  1
    Framework III
    amino acid 1 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84
    A 33 32
    B
    C
    D
    32 33
    E 33
    F 32
    G 33  1  1
    H
    I 33
    K
    L
    33 32
    M  1
    N  2  1
    P
    Q 32
    R  1
    S 33 30 32
    T 33 33 33  1
    V  1 33
    W
    X
    Y
    unknown (?)
    not sequenced
    sum of seq 2 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33
    oomcaa 3 33 33 33 32 32 33 33 33 33 30 32 32 32 33 33 33 33 32
    mcaa4 S G T D F T L T I S S L Q A E D V A
    rel. oomcaa5 100% 100% 100% 97% 97% 100% 100% 100% 100% 91% 97% 97% 97% 100% 100% 100% 100% 97%
    pos occupied6  1  1  1  2  2  1  1  1  1  3  2  2  2  1  1  1  1  2
    Framework III CDR III
    amino acid 1 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96
    A  1
    B
    C 33
    D  1  1
    E
    F  1  1
    G  2
    H  1  3
    I  2
    K
    L
     1  2  1  3  1
    M
    N
     4  4
    P  1 29  1  4
    Q 30 32  1  1
    R  1  1  2
    S  2 23  2  1
    T  2 22
    V 33
    W  2
    X
    Y
    33 31 31 29  1
    13 15 15 15 15 15  3
    unknown (?)
    not sequenced 18 18 18 18 18 18 18
    sum of seq 2 33 33 33 33 33 33 33 33 33 33 33 15 15 15 15 15 15 15
    oomcaa 3 33 33 31 33 30 32 31 29 23 22 29 13 15 15 15 15 15  4
    mcaa4 V Y Y C Q Q Y Y S T P P
    rel. oomcaa5 100% 100% 94% 100% 91% 97% 94% 88% 70% 67% 88% 87% 100% 100% 100% 100% 100% 27%
    pos occupied6  1  1  3  1  2  2  2  4  6  7  3  3  1  1  1  1  1  8
    CDR III Framework IV
    amino acid 1 97 98 99 100 101 102 103 104 105 106 A 107 108 sum
    A 183
    B
    C 68
    D 154
    E 14 105
    F 15 82
    G 15  4 15 228
    H  6
    I 14 135
    K 14 13 158
    L  4 258
    M  1 27
    N  1 136
    P  1 195
    Q 11  1 264
    R  1  1  1 11 116
    S  2  1 499
    T 12 14 236
    V  9 196
    W  1 69
    X
    Y
    254
    15 106
    unknown (?)
    not sequenced 18 18 18 18 18 18 18 18 18 18 18 18 22 518
    sum of seq 2 15 15 15 15 15 15 15 15 15 15 15 15 11
    oomcaa 3 12 15 15 11 15 14 14  9 14 14 15 13 11
    mcaa4 T F G Q G T K V E I K R
    rel. oomcaa5 80% 100% 100% 73% 100% 93% 93% 60% 93% 93% 100% 87% 100%
    pos occupied6  3  1  1  2  1  2  2  4  2  2  1  3  1
  • TABLE 5A
    Analysis of V lambda subgroup 1
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A 19 18 20
    B
    C
    D
    E
    F
    G 22
    H  2
    I  1  1
    K
    L
     1 41  1
    M
    N
    P
    41 41  1 41
    Q 22  1 41
    R
    S 39 41 41  1
    T 41 19
    V  1 38 20  1  1
    W
    X
    Y
    Z
    16
    41
    unknown (?)
    not sequenced  2  2  1  1  1  1  1  1  1  1  1  1  1  1
    sum of seq 2 40 40 41 41 41 41 41 41 41 41 41 41 41 41 42
    oomcaa 3 22 39 38 41 41 41 41 41 41 41 20 41 22 20 41
    mcaa4 Q S V L T Q P P S V S G A P
    rel. oomcaa5 55% 98% 93% 100% 100% 100% 100% 100% 100% 100% 49% 100% 54% 49% 98%
    pos occupied6  3  2  4  1  1  1  1  1  1  1  4  1  3  4 2
    Framework I CDRI
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 D E 28
    A  2  1
    B
    C 42
    D  3
    E  1
    F  1  1
    G 42 42  3  1  2
    H
    I  1 41  1 37
    K 14  1
    L  1  1
    M  1
    N  2  1 37
    P
    Q 42
    R 25  1  1
    S  1  1 42 38 34 34 38
    T  1 38  3  4  3  2
    V 42  1
    W
    X
    Y
    Z
    unknown (?)
    not sequenced
    sum of seq 2 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42
    oomcaa 3 42 42 25 42 38 41 42 42 38 42 34 34 38 37 37
    mcaa4 G Q R V T I S C S G S S S N I
    rel. oomcaa5 100% 100% 60% 100% 90% 98% 100% 100% 90% 100% 81% 81% 90% 88% 88%
    pos occupied6  1  1  5  1  4  2  1  1  3  1  4  6  4  4  5
    CDRI Framework II
    amino acid 1 29 30 31 A 32 33 34 35 36 37 38 39 40 41 42
    A  2  2  1  4
    B
    C
    D
     3  1  3  1  1
    E  1
    F  1  1  1  4
    G 39  4  2 39
    H  2  2  2  1  1  6  1
    I  1
    K  1  1
    L  1 31
    M  1
    N 13 31  2  1  9
    P  1 42  1
    Q  1 39 34
    R  5  2  1  1
    S 13  1  1  3 19
    T  1  1  7  2 36
    V  2 40  1  5
    W 42
    X
    Y
     4  1 20  7 40
    Z
    36
    unknown (?)
    not sequenced  1  1  1  1
    sum of seq 2 42 42 42 41 41 41 41 42 42 42 42 42 42 42 42
    oomcaa 3 39 13 31 36 20 40 19 42 40 39 34 31 42 39 36
    mcaa4 G N N Y V S W Y Q Q L P G T
    rel. oomcaa5 93% 31% 74% 88% 49% 98% 46% 100% 95% 93% 81% 74% 100% 93% 86%
    pos occupied6  3  8  7  5 10  2  7  1  3  3  4  5  1  4  4
    Framework II CDR II
    amino acid 1 43 44 45 46 47 48 49 50 51 52 53 54 55 56 A
    A 40  1  1
    B
    C
    D
    13 10  8
    E  2  5  1
    F  1
    G  1
    H  1  1
    I 40  1
    K 35  1  1 18
    L 41 40  1  1  1
    M  1  1
    N  1  3 28 30  2
    P 42 38
    Q 15
    R  4  7  2 40
    S  1  9  2  3  1  2 40
    T  1  1
    V  1  2  1
    W  1
    X
    Y
    40  1  1
    Z
    41
    unknown (?)
    not sequenced  1  1
    sum of seq 2 42 42 42 42 42 42 42 42 42 42 42 42 41 41 41
    oomcaa 3 40 42 35 41 40 40 40 13 28 30 18 40 38 40 41
    mcaa4 A P K L L I Y D N N K R P S
    rel. oomcaa5 95% 100% 83% 98% 95% 95% 95% 31% 67% 71% 43% 95% 93% 98% 100%
    pos occupied6  3  1  4  2  2  3  3 10  5  4  9  3  3  2  1
    CDR II Framework III
    amino acid1 B C D E 57 58 59 60 61 62 63 64 65 66 A
    A  5
    B
    C
    D 38
    E
    F 38
    G 41  2 36
    H  1
    I 17  3
    K 38
    L  1
    M
    N
    P 38
    Q
    R 42  4
    S  2 42 42
    T  1
    V 24  1
    W
    X
    Y
    Z
    41 41 41 42 42
    unknown (?)
    not sequenced  1  1  1  1
    sum of seq 2 41 41 41 42 41 41 41 41 42 42 42 42 42 42 42
    oomcaa 3 41 41 41 42 41 24 38 38 42 38 42 36 42 38 42
    mcaa4 G V P D R F S G S K
    rel. oomcaa5 100% 100% 100% 100% 100% 59% 93% 93% 100% 90% 100% 86% 100% 90% 100%
    pos occupied6  1  1  1  1  1  2  3  3  1  3  1  3  1  2  1
    Framework III
    amino acid1 B 67 68 69 70 71 72 73 74 75 76 77 78 79 80
    A  1  3 41 24  2
    B
    C
    D  1
    E  1
    F
    G 40 17  1 42
    H  1
    I 41
    K
    L
    42 41
    M
    N
    P  2
    Q 31
    R  8
    S 42  1 42 24 20 20
    T 38 18 21 17
    V  1  1  1  1  1
    W  1
    X
    Y
    Z
    42
    unknown (?)
    not sequenced
    sum of seq 2 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42
    oomcaa 3 42 42 40 38 42 41 24 42 24 41 21 42 41 31 20
    mcaa4 S G T S A S L A I T G L Q S
    rel. oomcaa 5 100% 100% 95% 90% 100% 98% 57% 100% 57% 98% 50% 100% 98% 74% 48%
    pos occupicd6  1  1  3  3  1  2  2  1  3  2  3  1  2  5  5
    Framework III CDR III
    amino acid 1 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95
    A 38  1 22 15  1
    B
    C 42
    D  1 41 37 39 17
    E 24 42  1
    F  2  1
    G 15 14  1
    H  2  1
    I  1
    K
    L
     1 37
    M
    N
     1  2  2
    P  1
    Q  3
    R  5  1
    S  1  4 17 35
    T  3 22  1  1
    V  1  1  1
    W  2 38
    X
    Y
    42 39  3  1
    Z
    unknown (?)
    not sequenced  1  1  1  1  1  1  1
    sum of seq 2 42 42 42 42 42 42 42 42 41 41 41 41 41 41 41
    oomcaa 3 24 41 42 38 37 42 39 42 22 22 38 39 17 35 37
    mcaa4 E D E A D Y Y C A T W D D S L
    rel. oomcaa5 57% 98% 100% 90% 88% 100% 93% 100% 54% 54% 93% 95% 41% 85% 90%
    pos occupied6  4  2  1  3  5  1  3  1  5  3  2  2  8  3  5
    CDR III Framework IV
    amino acid1 A B C D E F 96 97 98 99 100 101 102 103 104
    A 16  4  1
    B
    C
    D  7
    E  1  1  1
    F 36
    G 17  1  5  1 36 31 36
    H  1
    I  1  1
    K  1 30
    L  1  1 25
    M  1
    N  9  1  1
    P  6
    Q  3
    R  2  2  1
    S 18  1  1  1
    T  1  3 36  1
    V  2  9 34 11
    W  7
    X
    Y  3
    Z
     2  4 35 39 38 38  1
    unknown (?)
    not sequenced  1  1  3  3  3  3  3  3  4  4  6  6  6  6  6
    sum of seq 2 41 41 39 39 38 38 39 39 36 36 36 36 36 36 36
    oomcaa 3 18 17 35 39 38 38  9 34 36 36 31 36 36 30 25
    mcaa4 S G V V F G G G T K L
    rel. oomcaa 5 44% 41% 90% 100% 100% 100% 23% 87% 100% 100% 86% 100% 100% 83% 69%
    pos occupied6  8  6  5  1  1  1 10  6  1  1  4  1  1  5  2
    Framework IV
    amino acid1 105 106 A 107 108 sum
    A 285
    B
    C 84
    D 224
    E 81
    F 87
    G 26 559
    H 25
    I 188
    K 141
    L 34 344
    M  5
    N 176
    P  1 296
    Q  1 18 251
    R  2 156
    S  2 720
    T 36 359
    V 36  1 282
    W  1 92
    X
    Y 202
    Z 16
    524
    unknown (?)
    not sequenced  6  6  6 10 22 141
    sum of seq 2 36 36 36 31 19
    oomcaa 3 36 36 34 26 18
    mcaa4 T V L G Q
    rel. oomcaa5 100% 100% 94% 84% 95%
    pos occupied6  1  1  3  4  2
  • TABLE 5B
    Analysis of V lambda subgroup 2
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A 35 30  6  1  1
    B
    C
    D
    E
    F
    G 42
    H  2
    I  1
    K
    L
    40  3
    M
    N
    P
    42  6 40
    Q 22  4 41
    R  6  1
    S 41 40 42 42
    T 42  1
    V  1  2 36
    W
    X
    Y
    Z
    16
    42
    unknown (?)  1
    not sequenced  3  1  1  3  1  1  1  1  1  1  1  1
    sum of seq 2 40 42 42 40 42 42 42 42 42 42 42 42 43 43 43
    oomcaa 3 22 41 35 40 42 41 42 30 40 42 36 42 42 42 40
    mcaa4 Q S A L T Q P A S V S G S P
    rel. oomcaa5 55% 98% 83% 100% 100% 98% 100% 71% 95% 100% 86% 100% 98% 98% 93%
    pos occupied6  3  2  4  1  1  1  1  3  3  1  2  1  2  2  2
    Framework I CDRI
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 D E 28
    A  3  1
    B
    C
    42  1
    D  1 39
    E
    F  1
    G 42 43  1
    H  1  1
    I 28 41  1  6
    K
    L
     1  1
    M
    N
     1  3  4
    P  1
    Q 42
    R  1
    S 43 42  3  3 35 38
    T 43 36 39  3
    V 14 37
    W
    X
    Y  1
    Z
    unknown (?)
    not sequenced  1  1
    sum of seq 2 43 43 43 43 43 43 42 42 43 43 43 43 43 43 43
    oomcaa 3 42 42 43 28 43 41 42 42 36 43 39 35 38 39 37
    mcaa4 G Q S I T I S C T G T S S D V
    rel. oomcaa5 98% 98% 100% 65% 100% 95% 100% 100% 84% 100% 91% 81% 88% 91% 86%
    pos occupied6  2  2  1  3  1  3  1  1  4  1  3  7  4  2  2
    CDRI Framework II
    amino acid 1 29 30 31 A 32 33 34 35 36 37 38 39 40 41 42
    A  1  1  1  4
    B
    C  1
    D  1  4  5  1  2
    E  1
    F  1  4  2
    G 39 26 36
    H  1  1  2 34
    I  1
    K  4 40
    L  4  1  1
    M
    N
     1  4  3 28  2
    P 41
    Q 41 39
    R  2  1  1
    S  5  1  2  4  1 42  1
    T  1  1  1
    V 41  1
    W 43
    X
    Y
     1 37 29 41  5
    Z
     1
    unknown (?)  1  1  1
    not sequenced  1  1
    sum of seq 2 43 43 43 43 43 42 42 43 43 43 43 43 43 43 43
    oomcaa 3 39 26 37 28 29 41 42 43 41 41 39 34 41 36 40
    mcaa4 G G Y N Y V S W Y Q Q H P G K
    rel. oomcaa5 91% 60% 86% 65% 67% 98% 100% 100% 95% 95% 91% 79% 95% 84% 93%
    pos occupied6  5  7  5  7  6  2  1  1  2  2  3  5  3  4  4
    Framework II CDR II
    amino acid 1 43 44 45 46 47 48 49 50 51 52 53 54 55 56 A
    A 40
    B
    C
    D
    20  1  2  1
    E 20  2
    F  7  1
    G  2  2  1
    H  1
    I  1  9 43  1
    K 41  1 21
    L 38  6
    M 26  1
    N  1  8 12
    P 43 43
    Q  2
    R  2 43
    S  2 21  3 43
    T  7
    V  3  4  2 39
    W
    X
    Y 34  2
    Z
    43
    unknown (?)
    not sequenced
    sum of seq 2 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43
    oomcaa 3 40 43 41 38 26 43 34 20 39 21 21 43 43 43 43
    mcaa4 A P K L M I Y D V S K R P S
    rel. oomcaa 5 93% 100% 95% 88% 60% 100% 79% 47% 91% 49% 49% 100% 100% 100% 100%
    pos occupied6  2  1  2  3  4  1  3  4  4  8  8  1  1  1  1
    CDR II Framework III
    amino acid1 B C D E 57 58 59 60 61 62 63 64 65 66 A
    A  2
    B
    C  1
    D 17
    E
    F 42
    G 43  1 41
    H  2
    I  3
    K 42
    L  1  1
    M
    N 19
    P 15
    Q
    R 43  1
    S 28  2 43 42
    T
    V 39
    W
    X
    Y  2
    Z
    43 43 43 43 43
    unknown (?)
    not sequenced
    sum of seq 2 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43
    oomcaa 3 43 43 43 43 43 39 28 19 43 42 43 41 42 42 43
    mcaa4 G V S N R F S G S K
    rel. oomcaa5 100% 100% 100% 100% 100% 91% 65% 44% 100% 98% 100% 95% 98% 98% 100%
    pos occupied6  1  1  1  1  1  3  2  6  1  2  1  2  2  2  1
    Framework III
    amino acid1 B 67 68 69 70 71 72 73 74 75 76 77 78 79 80
    A  3  1 43 36
    B
    C
    D
     1  2
    E  1
    F
    G 39 42
    H
    I 35
    K  1
    L 43 43
    M
    N 38
    P  2
    Q 41
    R  2
    S 42  1 43 42
    T  1 41 43  1  2
    V  8  3
    W
    X
    Y
    Z
    43
    unknown (?)  1
    not sequenced  1
    sum of seq 2 43 42 43 43 43 43 43 43 43 43 43 43 43 43 43
    oomcaa 3 43 42 39 38 41 43 43 43 43 35 42 42 43 41 36
    mcaa4 S G N T A S L T I S G L Q A
    rel. oomcaa5 100% 100% 91% 88% 95% 100% 100% 100% 100% 81% 98% 98% 100% 95% 84%
    pos occupied6  1  1  3  4  3  1  1  1  1  2  2  2  1  2  4
    Framework III CDR III
    amino acid 1 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95
    A 43  2  1 21  1
    B
    C
    43 11
    D  3 42 39  3  1  2
    E 38 43  1  1
    F  3  3  1
    G  1  1 21  3  4
    H  2  1
    I  1  1  1
    K  3
    L
    M
    N
     1  1  1  5  7
    P  1
    Q  1
    R  2  3
    S  1 30 41 12 23 14
    T 16  4  4  3
    V  1
    W
    X
    Y
    43 39 39  1  6
    Z
     1
    unknown (?)  1  2
    not sequenced  1
    sum of seq 2 43 43 43 43 43 43 43 43 43 42 43 43 43 43 43
    oomcaa 3 38 42 43 43 39 43 39 43 30 41 39 21 21 23 14
    mcaa4 E D E A D Y Y C S S Y A G S S
    rel. oomcaa5 88% 98% 100% 100% 91% 100% 91% 100% 70% 98% 91% 49% 49% 53% 33%
    pos occupied6  4  2  1  1  3  1  3  1  3  2  3  7  7  8 11
    CDR III Framework IV
    amino acid1 A B C D E F 96 97 98 99 100 101 102 103 104
    A  1  1  1
    B
    C
    D  1
    E
    F  1  5 42
    G  1 42 33 42
    H
    I  2  1  7
    K 36
    L  1  1  6  5 28
    M  1  1
    N  5  1  1
    P  4
    Q  2  1
    R  1  5  1  2
    S  9  1
    T 21  7 41
    V 11 28 14
    W  5
    X
    Y
     4  1
    Z
     3 36 42 43 43 43
    unknown (?)
    not sequenced  1  1  1  1  1  1  2  2  1
    sum of seq 2 42 43 43 43 43 43 43 42 42 42 42 42 41 41 42
    oomcaa 3 21 36 42 43 43 43 11 28 42 42 33 42 41 36 28
    mcaa4 T V V F G G G T K L
    rel. oomcaa 5 50% 84% 98% 100% 100% 100% 26% 67% 100% 100% 79% 100% 100% 88% 67%
    pos occupied6  6  5  2  1  1  1 13  5  1  1  4  1  1  5  2
    Framework IV
    amino acid1 105 106 A 107 108 sum
    A 280
    B
    C 99
    D 188
    E 107
    F 113
    G 19 567
    H 48
    I  1 184
    K 189
    L 40 264
    M 29
    N 146
    P 238
    Q 14 250
    R  4 121
    S  1  2 831
    T 40 398
    V 42  1 327
    W 48
    X
    Y 285
    Z 16
    555
    unknown (?)  8
    not sequenced  1  1  2 15 28 80
    sum of seq 2 42 42 41 25 14
    oomcaa 3 40 42 40 19 14
    mcaa4 T V L G Q
    rel. oomcaa5 95% 100% 98% 76% 100%
    pos occupied6  3  1  2  3  1
  • TABLE 5C
    Analysis of V lambda subgroup 3
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A  1  1  2  7 20  1
    B
    C
    D
     5 10
    E 20  1
    F  1  1  1  1
    G  1
    H
    I
    K
    L
    37  4  1  9
    M
    N
    P
    26 35  1 27
    Q  4  4 38
    R
    S
    13 14  1  1 28 37 18
    T 36  1
    V  8  1  2 34 36
    W
    X
    Y 23
    Z
    20 38
    unknown (?)
    not sequenced
    sum of seq 2 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38
    oomcaa 3 20 23 20 37 36 38 26 35 28 38 34 37 36 20 27
    mcaa4 Y E L T Q P P S V S V A P
    rel. oomcaa5 53% 61% 53% 97% 95% 100% 68% 92% 74% 100% 89% 97% 95% 53% 71%
    pos occupied6  4  3  5  2  3  1  4  3  4  1  2  2  3  2  4
    Framework I CDRI
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 D E 28
    A 27  1  5
    B
    C 38
    D 30  1
    E  1  2  2
    F
    G 37  9 38  1
    H  1
    I 38  9
    K  2  7
    L 28
    M  1
    N  2  4  9  1
    P  1  1
    Q 36 10
    R 25  2
    S  9  1 19 10
    T 38  3 33  1
    V 10
    W
    X
    Y  1
    Z
    38 38
    unknown (?)
    not sequenced
    sum of seq 2 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38
    oomcaa 3 37 36 38 27 25 38 33 38 19 38 30 10 38 38 28
    mcaa4 G Q T A R I T C S G D S L
    rel. oomcaa5 97% 95% 100% 71% 66% 100% 87% 100% 50% 100% 79% 26% 100% 100% 74%
    pos occupied6  2  2  1  3  4  1  5  1  3  1  5  9  1  1  3
    CDRI Framework II
    amino acid 1 29 30 31 A 32 33 34 35 36 37 38 39 40 41 42
    A  1  1 21  3
    B
    C  5
    D 10  3  1
    E  1  3  6  1
    F  1  2  3
    G 23  4 36
    H  2  9  1
    I  1
    K  2 13 32
    L  2
    M  1
    N  2  1  2
    P  3 36  1
    Q  4 37 35  1 36
    R 10  1  1  1  4  2
    S 11  2  8 14  1  2
    T  1  4
    V  1 15
    W 38
    X
    Y
     8 20  1  4 35
    Z
    37
    unknown (?)
    not sequenced  1  1
    sum of seq 2 38 38 37 37 37 38 38 38 38 38 38 38 38 38 38
    oomcaa 3 23 11 13 37 20 21 14 38 35 37 35 32 36 36 36
    mcaa4 G S K Y A S W Y Q Q K P G Q
    rel. oomcaa5 61% 29% 35% 100% 54% 55% 37% 100% 92% 97% 92% 84% 95% 95% 95%
    pos occupied6  5  9  9  1  7  4  7  1  2  2  3  4  2  2  3
    Framework II CDR II
    amino acid 1 43 44 45 46 47 48 49 50 51 52 53 54 55 56 A
    A 23  1  1  1
    B
    C
    D
     9 22  2  8
    E  5  3  3
    F  2  1
    G  9  2
    H  1  3  1
    I  1 28  1
    K  2  6  1 13
    L  6 33  1
    M  1  1
    N  1 19  9
    P 38 37  1
    Q  9  1
    R  1  1  1 38
    S 14 10  1  1 36
    T  2  4
    V  1 31  4 37  9
    W
    X
    Y 35
    Z
    38
    unknown (?)
    not sequenced
    sum of seq 2 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38
    oomcaa 3 23 38 31 33 37 28 35  9 22 19 13 38 37 36 38
    mcaa4 A P V L V I Y D D N K R P S
    rel. oomcaa 5 61% 100% 82% 87% 97% 74% 92% 24% 58% 50% 34% 100% 97% 95% 100%
    pos occupied6 3  1  3  3  2  3  3  7  8  7  9  1  2  3  1
    CDR II Framework III
    amino acid1 B C D E 57 58 59 60 61 62 63 64 65 66 A
    A
    B
    C
    D  9
    E 27
    F 38
    G 38 38
    H
    I 37
    K
    L
    M
    N 21
    P 36
    Q
    R 38
    S  1 38 38 12
    T  5
    V
    W
    X
    Y
    Z
    38 38 38 38 38
    unknown (?)  1
    not sequenced  1  1  1
    sum of seq 2 38 38 38 38 38 37 37 37 38 38 38 38 38 38 38
    oomcaa 3 38 38 38 38 38 37 36 27 38 38 38 38 38 21 38
    mcaa4 G I P E R F S G S N
    rel. oomcaa5 100% 100% 100% 100% 100% 100% 97% 73% 100% 100% 100% 100% 100% 55% 100%
    pos occupied6 1  1  1  1  1  1  2  2  1  1  1  1  1  3  1
    Framework III
    amino acid1 B 67 68 69 70 71 72 73 74 75 76 77 78 79 80
    A  1 36  1  1 11  1 34
    B
    C
    D
    E 10
    F
    G 37 28
    H  1
    I  1  1 37  1
    K  1
    L 38
    M
    N
    28  1
    P
    Q
     1 25
    R  1 10  1
    S 37  2 11 23  1
    T  1  6 37 25 36 12 13  2
    V  2  1 14  1  1
    W
    X
    Y
    Z
    38
    unknown (?)
    not sequenced
    sum of seq 2 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38
    oomcaa 3 38 37 37 28 37 36 25 38 36 37 23 28 14 25 34
    mcaa4 S G N T A T L T I S G V Q A
    rel. oomcaa5 100% 97% 97% 74% 97% 95% 66% 100% 95% 97% 61% 74% 37% 66% 89%
    pos occupied6  1  2  2  5  2  2  4  1  3  2  5  2  3  5  4
    framework III CDR III
    amino acid 1 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95
    A 38 13  3  2  1
    B
    C 38
    D 38 37 32  1  1
    E 14 38  1  1
    F  2  2
    G 10  3 14
    H
    I  1
    K
    L
     2  1  1  1
    M 10  1
    N 10  2  1  2
    P  1
    Q 25  1
    R 10  1  2
    S  1 14  1 28 26 13
    T  1  3  7
    V  1 11
    W 23
    X
    Y
    38 36  1  1
    Z
    unknown (?)
    not sequenced  1  1  1  1
    sum of seq 2 38 38 38 38 38 38 38 38 38 38 38 37 37 37 37
    oomcaa 3 14 38 38 38 37 38 36 38 25 14 23 32 28 26 14
    mcaa4 E D E A D Y Y C Q S W D S S G
    rel. oomcaa5 37% 100% 100% 100% 97% 100% 95% 100% 66% 37% 61% 86% 76% 70% 38%
    pos occupied6  6  1  1  1  2  1  2  1  5  3  5  4  7  8  6
    CDR III Framework IV
    amino acid1 A B C D E F 96 97 98 99 100 101 102 103 104
    A  2  4
    B
    C
    D  6
    E  2  2  2
    F 35
    G  3  1  3  1 35 31 35
    H 12  1
    I  4
    K  1 30
    L  1  1  4  2 28
    M  1  1
    N 10  1
    P  3  1
    Q  1
    R  2  2
    S  1  1
    T  2  4 35
    V 18 28  7
    W  1
    X
    Y
     1  3  1  3
    Z
    10 15 31 36 37 36  1
    unknown (?)
    not sequenced  2  1  1  1  1  1  1  1  3  3  3  3  3  4  3
    sum of seq 2 36 37 37 37 37 37 37 37 35 35 35 35 35 34 35
    oomcaa 3 10 15 31 36 37 36 18 28 35 35 31 35 35 30 28
    mcaa4 N V V F G G G T K L
    rel. oomcaa5 28% 41% 84% 97% 100% 97% 49% 76% 100% 100% 89% 100% 100% 88% 80%
    pos occupied6  9  8  5  2  1  2  9  6  1  1  2  1  1  3  2
    Framework IV
    amino acid1 105 106 A 107 108 sum
    A 265
    B
    C  1 82
    D 225
    E 145
    F 90
    G 24 461
    H 32
    I 160
    K 110
    L 33 233
    M 17
    N 126
    P  1 249
    Q  7 275
    R 154
    S  2 501
    T 35 347
    V 35 308
    W 62
    X
    Y 211
    Z
    603
    unknown (?)  1
    not sequenced  3  3  4 11 28 89
    sum of seq 2 35 35 34 27  7
    oomcaa 3 35 35 33 24  7
    mcaa4 T V L G Q
    rel. oomcaa5 100% 100% 97% 89% 100%
    pos occupied6 1  1  2  3  1
  • TABLE 6A
    Analysis of V heavy chain subgroup 1A
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A  1 14 60
    B
    C
    D
    E
     1  2  1  2 64
    F
    G
    58  1 64
    H  2
    I  2
    K  2 57 64
    L  2 59  3
    M  1
    N  6
    P 63
    Q 53 56  2 45
    R  1
    S 60  3  1
    T
    V
     2 55  1 55 61
    W
    X
    Y
    Z
     3
    unknown (?)
    not sequenced 11 10 10 10 10 10 10 10  6  6  6  6  6  6  6
    sum of seq 2 59 60 60 60 60 60 60 60 64 64 64 64 64 64 64
    oomcaa3 53 55 56 59 55 45 60 58 60 64 61 57 64 63 64
    mcaa4 Q V Q L V Q S G A E V K K P G
    rel. oomcaa5 90% 92% 93% 98% 92% 75% 100% 97% 94% 100% 95% 89% 100% 98% 100%
    pos occupied6  4  4  3  2  4  3  1  2  3  1  2  3  1  2 1
    Framework I
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
    A 24  1 62  1
    B
    C 63
    D  1
    E
    F 69
    G  1 69 41  1
    H  1
    I  1
    K 60 63  1
    L
    M
    N  2
    P
    Q
    R  3  1  1  1
    S 40 63 63 68  1 40
    T  1  1  2 68 25
    V 64 64
    W
    X
    Y 27
    Z
    unknown (?)
    not sequenced  6  6  6  6  6  6  6  6  5  2  1
    sum of seq 2 64 64 64 64 64 64 64 64 65 68 69 70 70 70 70
    oomcaa 3 40 63 64 60 64 63 63 63 62 68 69 41 68 69 40
    mcaa4 S S V K V S C K A S G G T F S
    rel. oomcaa5 63% 98% 100% 94% 100% 98% 98% 98% 95% 100% 100% 59% 97% 99% 57%
    pos occupied6  2  2  1  3  1  2  2  2  3  1  1  4  3  2 6
    CDR I Framework II
    amino acid1 31 A B 32 33 34 35 36 37 38 39 40 41 42 43
    A 41 70
    B
    C
    D
    E
    F  3  3
    G 23  1 68
    H  1  1  1
    I 61  1  1
    K  1
    L  1  2  1
    M  4
    N  5  4
    P  1 68
    Q 69 69
    R  1 70  1  1
    S 60  2 60  1
    T  3  3  4
    V  1 69
    W 70
    X
    Y 64
    Z
    70 70
    unknown (?)
    not sequenced
    sum of seq 2 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70
    oomcaa 3 60 70 70 64 41 61 60 70 69 70 69 70 68 68 69
    mcaa4 S Y A I S W V R Q A P G Q
    rel. oomcaa5 86% 100% 100% 91% 59% 87% 86% 100% 99% 100% 99% 100% 97% 97% 99%
    pos occupied6  5  1  1  4  6  4  5  1  2  1  2  1  3  3 2
    Framework II CDR II
    amino acid 1 44 45 46 47 48 49 50 51 52 A B C 53 54 55
    A  1  5
    B
    C
    D  1
    E 69
    F  2  3 39
    G 69  1 69 39  1 68
    H
    I 65 38 34
    K
    L
    68  1  1  2  4
    M 67  2  4
    N  4  3 22
    P  1 44
    Q  1  1  1
    R  1  4  1
    S  1  1 22  1  1
    T  1  2  4  1  3
    V  1  2  2 16  1
    W  1 67 26
    X
    Y
     1 20
    Z
    70 70
    unknown (?)
    not sequenced
    sum of seq 2 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70
    oomcaa 3 69 68 69 67 67 69 39 65 38 44 70 70 34 39 68
    mcaa4 G L E W M G G I I P I F G
    rel. oomcaa5 99% 97% 99% 96% 96% 99% 56% 93% 54% 63% 100% 100% 49% 56% 97%
    pos occupied6  2  3  2  4  4  2  4  4  6  5  1  1 10  6 3
    CDR II Framework III
    amino acid 1 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
    A  1 34 69
    B
    C
    D
    15  1  2
    E  1
    F  1 48  3  4
    G  1  3 67
    H  1
    I  4  1 44
    K  1  2  1 47  1  1
    L  1  1 22  2  1
    M 21
    N  9 59 18
    P  1  7
    Q  1  1 70 64
    R  2  2  1 69
    S  1  2  1  5
    T 34 26  4  3 66 65
    V  1 65  3
    W
    X
    Y
     1 68
    Z
    unknown (?)
    not sequenced
    sum of seq 2 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70
    oomcaa3 34 34 59 68 69 70 47 48 64 67 69 65 66 44 65
    mcaa4 T A N Y A Q K F Q G R V T I T
    rel. oomcaa5 49% 49% 84% 97% 99% 100% 67% 69% 91% 96% 99% 93% 94% 63% 93%
    pos occupied6 11  6  7  3  2  1  4  2  5  3  2  3  3  4 2
    Framework III
    amino acid 1 71 72 73 74 75 76 77 78 79 80 81 82 A B C
    A 43 64  1
    B
    C
    D
    70  2
    E 33 64
    F
    G  1
    H  1  1
    I  1  1  3  1  1
    K  8
    L  3  3 63 70
    M 67
    N  4  1 16
    P
    Q
     1  3
    R  1  3 23  1
    S 70 62  1 41 49
    T 24 27 67  1 69  2  3  2
    V  3  3  4
    W
    X
    Y 68
    Z
    unknown (?)
    not sequenced
    sum of seq 2 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70
    oomcaa 3 43 70 33 70 67 62 69 64 68 67 64 63 41 49 70
    mcaa4 A D E S T S T A Y M E L S S L
    rel. oomcaa5 61% 100% 47% 100% 96% 89% 99% 91% 97% 96% 91% 90% 59% 70% 100%
    pos occupied6  3  1  5  1  2  4  2  4  3  2  4  3  6  6 1
    Framework III CDR III
    amino acid 1 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
    A  3  1 70 66  2 16  1
    B
    C
    70  1
    D 26 70 16  5  3
    E 44  9
    F  1  1  2  1
    G  2 14 13 20
    H
    I  2  2  5
    K  3  5  2
    L  2  1  4  4  2
    M  1  1  1  2
    N  2  2
    P 20  3
    Q  1
    R 62 55  1  5  7
    S 67  1  1  1  5  5
    T  4 67  1  3  3  5  4
    V  1 64  3  3  2  4
    W  1  1
    X
    Y
    69 68  1  2  3
    Z
     1  2
    unknown (?)
    not sequenced  2  2  2
    sum of seq 2 70 70 70 70 70 70 70 70 70 70 70 70 68 68 68
    oomcaa3 62 67 44 70 67 70 64 69 68 70 66 55 16 20 20
    mcaa4 R S E D T A V Y Y C A R A P G
    rel. oomcaa5 89% 96% 63% 100% 96% 100% 91% 99% 97% 100% 94% 79% 24% 29% 29%
    pos occupied6  4  2  2  1  4  1  5  2  2  1  3  8 10 14 18
    CDR III
    amino acid 1 98 99 100 A B C D E F G H I J K 101
    A  1  1  4  1  2  2  1  1  1  1  1  2  1
    B
    C  1 16  2  1  1  7  2  1
    D  3  5  4  3  4  1  1 14 59
    E  2  1  1  1
    F  3  2  3  1  2  2  1 28  2
    G 10 14  5 20 15 16  3  3  4 15  1  1  7
    H  1  1  1  1
    I  2  2  2  2  1  1  1
    K  1  1
    L  5  2  1  1  4  2  1  1  1
    M  1  1  1  1 10
    N  1  2  1  2  2  2  2  1  1  4
    P  1  3  2  2  2  4  2  1  4  1  1  1
    Q  1  1  1  1
    R  8  1  4  2  1 16
    S  5  5 21  5 11  8  4  3  2  1  2  1
    T  1  3  4  2  5  2  1  1  1
    V  3  3  3  4  2  2  2  1  2  1
    W  3  1  1  2  3  1  5  1
    X
    Y
    20  5  4  9  1  2 11 20 10  6  9 10  7  1
    Z
     2  3  6 11 11 14 23 26 26 31 34 46 39 21  1
    unknown (?)  1  1  1  2  3
    not sequenced  4  4  4  4  5  5  5  5  5  5  5  5  5  5  5
    sum of seq 2 66 66 66 66 65 65 65 65 65 65 65 65 65 65 65
    oomcaa 3 20 16 21 20 15 16 23 26 26 31 34 46 39 28 59
    mcaa4 Y C S G F D
    rel. oomcaa5 30% 24% 32% 30% 23% 25% 35% 40% 40% 48% 52% 71% 60% 43% 91%
    pos occupied6 15 18 15 15 17 17 15 12 11 11 10  8  7  6 6
    Framework IV
    amino acid 1 102 103 104 105 106 107 108 109 110 111 112 113 sum
    A 670
    B
    C 165
    D  1  1 308
    E  1  1 297
    F  2 226
    G 58 59  1  1 928
    H  1 14
    I  3  4 286
    K  3  1 325
    L  3  1 40  1 386
    M  1  3 189
    N  1 176
    P  5  1 238
    Q 52 494
    R  1 351
    S 53 51 972
    T 54 11  1 51  1 736
    V 15  1  1 54 54  1 699
    W 59  1 243
    X
    Y 34  1 542
    Z  3
     1 578
    unknown (?)  8
    not sequenced  5  9  9 10 11 14 14 14 15 16 16 17 406
    sum of seq 2 65 61 61 60 59 56 56 56 55 54 54 53
    oomcaa3 34 59 58 52 59 54 40 54 51 54 53 51
    mcaa4 Y W G Q G T L V T V S S
    rel. oomcaa5 52% 97% 95% 87% 100% 96% 71% 96% 93% 100% 98% 96%
    pos occupied6  9  3  4  7  1  3  5  3  2  1  2  3
  • TABLE 6B
    Analysis of V heavy chain subgroup 1B
    Frame work I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A 32
    B
    C
    D
    E
    1 5 1 35
    F
    G
    27 35
    H 1 1
    I
    K
    3 1 34 33
    L 3 26 1
    M 1 1
    N
    P
    1 33
    Q 21 20 26
    R 1 1 2
    S 27
    T 1 1
    V 3 21 20 35
    W
    X
    Y
    Z
    unknown (?)
    not sequenced 15 15 15 13 13 13 13 13 6 5 5 5 5 5 5
    sum of seq 2 25 25 25 27 27 27 27 27 34 35 35 35 35 35 35
    oomcaa 3 21 21 20 26 20 26 27 27 32 35 35 34 33 33 35
    mcaa4 Q V Q L V Q S G A E V K K P G
    rel. oomcaa5 84% 84% 80% 96% 74% 96% 100% 100% 94% 100% 100% 97% 94% 94% 100%
    pos occupied6 3 3 4 2 4 2 1 1 3 1 1 2 2 3 1
    Frame work I
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
    A 34 30
    B
    C 35
    D
    E 3
    F 2 39
    G 1 40 1
    H
    I 1 1 1
    K 33 28
    L 1
    M
    N
    1 1
    P 1
    Q 2
    R 2 2
    S 1 34 35 40 5 2
    T 2 3 32 34
    V 35 34 1 1 1
    W
    X
    Y 36
    Z
    unknown (?)
    not sequenced 5 5 5 5 5 5 5 5 5
    sum of seq 2 35 35 35 35 35 35 35 35 35 40 40 40 40 40 40
    oomcaa3 34 34 35 33 34 35 35 28 30 40 40 36 32 39 34
    mcaa4 A S V K V S C K A S G Y T F T
    rel. oomcaa5 97% 97% 100% 94% 97% 100% 100% 80% 86% 100% 100% 90% 80% 98% 85%
    pos occupied6 2 2 1 2 2 1 1 4 4 1 1 4 4 2 6
    CDRI Frame work II
    amino acid1 31 A B 32 33 34 35 36 37 38 39 40 41 42 43
    A 2 6 39
    B
    C
    D
    1 5 1 1
    E 1 1
    F 2 2
    G 14 1 1 39
    H 3 1 34
    I 9
    K 1
    L 1 5 2 1
    M 23
    N 3 1 3
    P 1 1 34
    Q 1 1 1 1 39 39
    R 1 37 1
    S 15 2 1 1
    T 1 4
    V 1 2 2 38
    W 40
    X
    Y
    1 32 19 1
    Z
    40 40
    unknown (?)
    not sequenced
    sum of seq 2 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
    oomcaa 3 15 40 40 32 19 23 34 40 38 37 39 39 34 39 39
    mcaa4 S Y Y M H W V R Q A P G Q
    rel. oomcaa5 38% 100% 100% 80% 48% 58% 85% 100% 95% 93% 98% 98% 85% 98% 98%
    pos occupied6 10 1 1 5 11 5 5 1 2 4 2 2 4 2 2
    Frame work II CDR II
    amino acid 1 44 45 46 47 48 49 50 51 52 A B C 53 54 55
    A 1 1 7 1
    B
    C
    D
    1 1
    E 39 1 1
    F 2 1 1
    G 28 39 1 1 9 1 39
    H 2
    I 3 34
    K 1
    L 37 1
    M 37 2 4
    N 35 20 12 1
    P 1 31
    Q 1
    R 10 4 3 1
    S 1 2 1 20
    T 1 3
    V 1 1
    W 40 33
    X
    Y 2
    Z
    40 40
    unknown (?)
    not sequenced
    sum of seq 2 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
    oomcaa 3 28 37 39 40 37 39 33 34 35 31 40 40 20 20 39
    mcaa4 G L E W M G W I N P N S G
    rel. oomcaa5 70% 93% 98% 100% 93% 98% 83% 85% 88% 78% 100% 100% 50% 50% 98%
    pos occupied6 4 3 2 1 2 2 4 4 5 4 1 1 9 8 2
    CDR II Framework III
    amino acid 1 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
    A 1 2 27 2 1 1
    B
    C
    D
    1 4
    E 2 2 1 1
    F 4 39 3
    G 15 6 1 34
    H 1 1
    I 1 1 1 1 13
    K 2 2 8 36 1
    L 1 1 1
    M 23
    N 17 18 1
    P
    Q
    36 37
    R 2 1 2 37
    S 1 2 11 1
    T 35 2 1 1 39 40
    V 1 38
    W 3
    X
    Y 33
    Z
    unknown (?)
    not sequenced
    sum of seq 2 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
    oomcaa 3 17 35 18 33 27 36 36 39 37 34 37 38 39 23 40
    mcaa4 N T N Y A Q K F Q G R V T M T
    rel. oomcaa5 43% 88% 45% 83% 68% 90% 90% 98% 93% 85% 93% 95% 98% 58% 100%
    pos occupied6 8 4 8 4 4 4 5 2 3 4 2 3 2 4 1
    Framework III
    amino acid 1 71 72 73 74 75 76 77 78 79 80 81 82 A B C
    A 2 12 35
    B
    C
    D
    35 1 4
    E 1 35
    F 1
    G 1 1 2
    H 1
    I 22 1
    K 1
    L 2 39 39
    M 1 1 37 1
    N 4 7 1 2
    P 3
    Q
    R 34 1 4 2 16
    S 1 37 27 1 35 20
    T 1 38 5 1 39 1
    V 4 1 1
    W
    X
    Y 39
    Z
    unknown (?)
    not sequenced
    sum of seq 2 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
    oomcaa3 34 35 38 37 22 27 39 35 39 37 35 39 35 20 39
    mcaa4 R D T S I S T A Y M E L S S L
    rel. oomcaa5 85% 88% 95% 93% 55% 68% 98% 88% 98% 93% 88% 98% 88% 50% 98%
    pos occupied6 6 3 3 2 4 5 2 3 2 3 3 2 5 4 2
    Framework III CDR III
    amino acid 1 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
    A 1 2 40 37 1 6 1
    B
    C
    37 1
    D 19 40 1 7 5
    E 19 2 1
    F 2 2 1 1 1
    G 1 7 7 5
    H 1
    I 1 1 1 1
    K 1 1 1
    L 2 1 2 4 4
    M 2 2
    N 1
    P 1 1 6 4
    Q 1
    R 37 1 31 5 1
    S 1 36 1 1 1 3 3 1
    T 1 40 2 1 1 2
    V 33 1 7 1 1
    W 1 1
    X
    Y
    38 35 5 5
    Z
    1 1
    unknown (?)
    not sequenced 1 1 1 1 1 1 3 3 3
    sum of seq 2 40 40 40 40 40 40 39 39 39 39 39 39 37 37 37
    oomcaa 3 37 36 19 40 40 40 33 38 35 37 37 31 7 7 5
    mcaa4 R S D D T A V Y Y C A R D G D
    rel. oomcaa5 93% 90% 48% 100% 100% 100% 85% 97% 90% 95% 95% 79% 19% 19% 14%
    pos occupied6 4 4 3 1 1 1 5 2 4 3 3 8 10 12 18
    CDR III
    amino acid 1 98 99 100 A B C D E F G H I J K 101
    A 1 2 3 1 3 1 5
    B
    C
    3 2 1
    D 2 3 1 5 4 1 2 2 1 2 27
    E 1 1 2 1 1
    F 3 2 1 1 1 1 2 15
    G 5 9 4 7 1 3 2 2 1 1 3 1
    H 2 1 1
    I 3 1 1 1 1 1 1 1
    K 1 1 1 1 1
    L 4 3 1 2 1 1 2 1 2
    M 1 1 1 4
    N 1 1 1 1 3 1 1
    P 1 1 3 2 1
    Q 1 2 1
    R 1 3 1 1 1
    S 4 3 6 3 2 2 1 1
    T 2 1 5 1 1 1 1 1 1
    V 1 3 1 2 1 1 2 1 1
    W 2 2 1 1 1 4
    X
    Y
    4 2 3 4 3 3 2 1 2 5 6 2
    Z
    4 6 8 10 11 14 20 23 25 25 25 23 18 11 6
    unknown (?) 3
    not sequenced 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4
    sum of seq 2 37 37 37 36 36 36 36 36 36 36 36 36 36 36 36
    oomcaa 3 5 9 8 10 11 14 20 23 25 25 25 23 18 15 27
    mcaa4 G G F D
    rel. oomcaa5 14% 24% 22% 28% 31% 39% 56% 64% 69% 69% 69% 64% 50% 42% 75%
    pos occupied6 13 13 12 12 17 14 13 10 9 8 7 8 8 5 5
    Framework IV
    amino acid 1 102 103 104 105 106 107 108 109 110 111 112 113 sum
    A 340
    B
    C 79
    D 2 179
    E 1 159
    F 1 130
    G 27 26 1 450
    H 1 51
    I 7 3 113
    K 2 194
    L 12 1 204
    M 2 144
    N 1 138
    P 1 1 128
    Q 23 253
    R 1 247
    S 3 1 18 18 432
    T 21 6 16 1 390
    V 6 21 18 342
    W 29 158
    X
    Y
    11 294
    Z
    3 394
    unknown (?) 3
    not sequenced 4 11 13 13 14 19 19 19 20 20 21 22 458
    sum of seq 2 36 29 27 27 26 21 21 21 20 20 19 18
    oomcaa 3 11 29 27 23 26 21 12 21 16 18 18 18
    mcaa4 Y W G Q G T L V T V S S
    rel. oomcaa5 31% 100% 100% 85% 100% 100% 57% 100% 80% 90% 95% 100%
    pos occupied6 10 1 1 4 1 1 4 1 3 3 2 1
  • TABLE 6C
    Analysis of V heavy chain subgroup 2
    Frame work I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A 3
    B
    C
    D
    E
    1 6
    F
    G 6
    H
    I 1
    K 3 6 1
    L 6 6
    M
    N 1
    P 1 6 6
    Q 2
    R 2
    S 4
    T 6 1 2 5
    V 5 1 6
    W
    X
    Y
    Z
    3
    unknown (?)
    not sequenced 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
    sum of seq 2 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
    oomcaa 3 3 5 6 6 3 6 4 6 6 3 6 6 6 6 5
    mcaa4 Z V T L K E S G P A L V K P T
    rel. oomcaa5 50% 83% 100% 100% 50% 100% 67% 100% 100% 50% 100% 100% 100% 100% 83%
    pos occupied6 3 2 1 1 3 1 3 1 1 3 1 1 1 1 2
    Frame work I
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
    A 1
    B
    C 7
    D
    E 2
    F 3 6 1
    G 7
    H
    I
    K
    L
    6 6 2 1 6
    M
    N
    P 1
    Q 4
    R
    S
    1 6 6 6
    T 5 6 6 6 1
    V 2
    W
    X
    Y 1
    Z
    unknown (?)
    not sequenced 1 1 1 1 1 1
    sum of seq 2 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7
    oomcaa 3 4 5 6 6 6 6 7 6 3 6 7 6 6 6 6
    mcaa4 Q T L T L T C T F S G F S L S
    rel. oomcaa5 67% 83% 100% 100% 100% 100% 100% 86% 43% 86% 100% 86% 86% 86% 86%
    pos occupied6 2 2 1 1 1 1 1 2 3 2 1 2 2 2 2
    CDRI Frame work II
    amino acid1 31 A B 32 33 34 35 36 37 38 39 40 41 42 43
    A 1 1
    B
    C 2
    D 1
    E
    F
    G 4 3 3 1 7
    H
    I 1 7
    K 6
    L
    M 5
    N 2
    P 5 7
    Q 6
    R 2 1 7 1 1
    S 2 4 4 1
    T 3 1
    V 2 7
    W 7
    X
    Y
    Z
    unknown (?)
    not sequenced
    sum of seq 2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
    oomcaa 3 3 4 4 5 3 7 4 7 7 7 6 5 7 7 6
    mcaa4 T S G M G V S W I R Q P P G K
    rel. oomcaa5 43% 57% 57% 71% 43% 100% 57% 100% 100% 100% 86% 71% 100% 100% 86%
    pos occupied6 3 4 3 2 4 1 2 1 1 1 2 3 1 1 2
    Frame work II CDR II
    amino acid 1 44 45 46 47 48 49 50 51 52 A B C 53 54 55
    A 6 7
    B
    C
    D
    2 3 6
    E 7
    F 2
    G 1
    H 2 1
    I 6
    K
    L
    7 7 2 1 1
    M
    N 3
    P
    Q
    R 2
    S 2
    T
    V
    W
    7 1 4
    X 1 1 1
    Y 1 1
    Z
    6 7 7
    unknown (?)
    not sequenced
    sum of seq 2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
    oomcaa 3 6 7 7 7 7 7 2 6 2 6 7 7 4 3 6
    mcaa4 A L E W L A H I D W D D
    rel. oomcaa5 86% 100% 100% 100% 100% 100% 29% 86% 29% 86% 100% 100% 57% 43% 86%
    pos occupied6 2 1 1 1 1 1 4 2 5 2 1 1 3 3 2
    CDR II Framework III
    amino acid 1 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
    A
    B
    C
    D 5
    E 1 1
    F 1 1
    G
    H 1
    I 6
    K 1 6 4
    L 7 7
    M
    N
    P 2
    Q
    R 2 1 2 7
    S 2 6 7 4 1 5
    T 4 3 6 2
    V 1
    W 1
    X 1
    Y 3 4
    Z
    unknown (?)
    not sequenced
    sum of seq 2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
    oomcaa 3 5 6 3 4 6 4 7 7 4 4 7 7 6 6 5
    mcaa4 D K Y Y S T S L K S R L T I S
    rel.oomcaa5 71% 86% 43% 57% 86% 57% 100% 100% 57% 57% 100% 100% 86% 86% 71%
    pos occupied6 3 2 3 4 2 3 1 1 3 2 1 1 2 2 2
    Framework III
    amino acid 1 71 72 73 74 75 76 77 78 79 80 81 82 A B C
    A
    B
    C
    D
    6 1
    E
    F 1
    G
    H
    I
    2 1
    K 6 6
    L 6
    M 7 5
    N 1 5 6
    P
    Q 7
    R 1 1
    S 7 2
    T 6 5 5
    V 7 7 1
    W
    X
    Y
    Z
    1 1 1
    unknown (?)
    not sequenced
    sum of seq 2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
    oomcaa 3 6 6 6 7 6 5 7 7 7 6 5 7 5 6 5
    mcaa4 K D T S K N Q V V L T M T N M
    rel.oomcaa
    5 86% 86% 86% 100% 86% 71% 100% 100% 100% 86% 71% 100% 71% 86% 71%
    pos occupied6 2 2 2 1 2 2 1 1 1 2 2 1 3 2 3
    Framework III CDR III
    amino acid 1 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
    A 1 5 5
    B
    C 7
    D 6 7
    E
    F
    G 2
    H 1 1
    I 3
    K
    L
    M
    N
    1 1 2
    P 7 1 1
    Q 1
    R 6 1
    S 1
    T 7 7 1
    V 6 2 1 1 1
    W
    X
    Y
    7 7 2
    Z
    unknown (?)
    not sequenced 1 1 1
    sum of seq 2 7 7 7 7 7 7 7 7 7 7 7 7 6 6 6
    oomcaa 3 6 7 6 7 7 5 7 7 7 7 5 6 3 1 2
    mcaa4 D P V D T A T Y Y C A R I H N
    rel.oomcaa5 86% 100% 86% 100% 100% 71% 100% 100% 100% 100% 71% 86% 50% 17% 33%
    pos occupied6 2 1 2 1 1 2 1 1 1 1 2 2 4 6 4
    CDR III
    amino acid 1 98 99 100 A B C D E F G H I J K 101
    A 1 2 1
    B
    C
    D 6
    E 2 1
    F 3
    G 1 1 1 2 1 1 1 1
    H
    I 2
    K 1
    L 1 1 1
    M 1 2
    N 1
    P 1 1
    Q
    R 1
    S 1 1
    T 1 1
    V 1 1 1
    W 1 1 1
    X
    Y
    1 2 1 1 1 2
    Z
    2 2 3 4 4 4 6 5 3
    unknown (?)
    not sequenced 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
    sum of seq 2 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
    oomcaa 3 2 1 2 2 2 2 3 4 4 4 6 5 3 3 6
    mcaa4 I G E A F D
    rel. oomcaa5 33% 17% 33% 33% 33% 33% 50% 67% 67% 67% 100% 83% 50% 50% 100%
    pos occupied6 5 6 5 5 4 5 3 3 3 3 1 2 3 3 1
    Framework IV
    amino acid 1 102 103 104 105 106 107 108 109 110 111 112 113 sum
    A 1 35
    B
    C 16
    D 43
    E 21
    F 18
    G 6 6 55
    H 6
    I 29
    K 1 1 42
    L 1 3 78
    M 20
    N 23
    P 1 1 41
    Q 3 23
    R 2 41
    S 6 3 82
    T 6 1 5 102
    V 3 6 6 68
    W 6 29
    X 4
    Y 1 35
    Z 3
    56
    unknown (?)
    not sequenced 1 1 1 1 1 1 1 1 1 1 1 4 54
    sum of seq 2 6 6 6 6 6 6 6 6 6 6 6 3
    oomcaa 3 3 6 6 3 6 6 3 6 5 6 6 3
    mcaa4 V W G Q G T L V T V S S
    rel. oomcaa5 50% 100% 100% 50% 100% 100% 50% 100% 83% 100% 100% 100%
    pos occupied6 4 1 1 3 1 1 4 1 2 1 1 1
  • TABLE 6D
    Analysis of V heavy chain subgroup 3
    Frame work I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A 1 1 12 1 3 1
    B 1 1 1
    C
    D
    1 1 16
    E 110 9 15 166 9 8 2
    F 4
    G 181 193 174 1 202
    H 5 4
    I 9
    K 5 3 26
    L 1 5 176 43 140 1
    M 12 1
    N 1
    P 1 194
    Q 41 138 1 3 12 162
    R 6 4
    S 178 2 8
    T 1
    V 5 147 1 118 62 195
    W 1
    X
    Y
    Z
    8
    unknown (?)
    not sequenced 47 47 45 33 32 32 32 31 10 7 6 6 6 6 6
    sum of seq 2 165 165 167 179 180 180 180 181 202 205 206 206 206 206 206
    oomcaa 3 110 147 138 176 118 166 178 181 193 174 140 195 162 194 202
    mcaa4 E V Q L V E S G G G L V Q P G
    rel. oomcaa5 67% 89% 83% 98% 66% 92% 99% 100% 96% 85% 68% 95% 79% 94% 98%
    pos occupied6 5 4 7 4 5 4 3 1 2 5 3 4 7 4 4
    Frame work I
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
    A 183 192 1
    B
    C
    1 209
    D 7
    E 8 8 3 1
    F 1 1 1 201 201
    G 134 2 207 3
    H 1
    I 2 3 17 1
    K 15 4
    L 205 201 6 3
    M 1 1
    N 10 10
    P 1 2
    Q 1
    R 62 191 11
    S 206 207 4 2 209 15 174
    T 4 1 2 4 4 1 163
    V 8 7 9 1 6
    W
    X
    Y
    Z
    unknown (?)
    not sequenced 4 4 4 4 3 3 3 3 3 3 1 1 2 1 2
    sum of seq 2 208 208 208 208 209 209 209 209 209 209 211 211 210 211 210
    oomcaa3 134 206 205 191 201 207 209 183 192 209 207 201 163 201 174
    mcaa4 G S L R L S C A A S G F T F S
    rel. oomcaa5 64% 99% 99% 92% 96% 99% 100% 88% 92% 100% 98% 95% 78% 95% 83%
    pos occupied6 4 3 4 3 2 3 1 7 5 1 3 4 8 4 7
    CDRI Frame work II
    amino acid1 31 A B 32 33 34 35 36 37 38 39 40 41 42 43
    A 1 17 80 1 1 187 1
    B
    C
    1 1
    D 26 3 7 2
    E 1 10 1 1
    F 5
    G 13 31 1 2 209
    H 4 88
    I 1 1 15 12
    K 7 1 202
    L 3 3 2 3 1 2 1
    M 193
    N 35 8 3 34
    P 1 1 4 191
    Q 209 1 1
    R 7 207 7 8
    S 103 17 8 72 3 14
    T 9 15 10 4 5
    V 2 7 1 197 2
    W 30 212
    X 1
    Y 1 154 19 3
    Z
    210 210
    unknown (?)
    not sequenced 2 2 2 1 1 1
    sum of seq 2 210 210 210 210 210 212 212 212 211 211 211 212 212 212 212
    oomcaa 3 103 210 210 154 80 193 88 212 197 207 209 187 191 209 202
    mcaa4 S Y A M H W V R Q A P G K
    rel. oomcaa5 49% 100% 100% 73% 38% 91% 42% 100% 93% 98% 99% 88% 90% 99% 95%
    pos occupied6 14 1 1 9 10 4 9 1 3 3 3 9 5 4 4
    Frame work II CDR II
    amino acid 1 44 45 46 47 48 49 50 51 52 A B C 53 54 55
    A 1 77 42 1 2 14 7
    B 3 1
    C 1
    D 1 7 94 8 3
    E 198 3 2 1 2 1
    F 7 1 2 1 1 8
    G 207 33 11 10 46 4 163 85
    H 6 1
    I 3 3 191 1 1
    K 1 37 2 30 3
    L 211 5 12 1
    M 1 1
    N 13 7 9 2 13 11 1
    P 1 1 1
    Q 7 7 10
    R 1 24 1 17 5 1 2 16
    S 3 1 102 11 9 118 43 1 74 17 82
    T 3 5 4 2 13 12 3 3
    V 3 204 49 2 1 6
    W 210 1 8 6
    X 4 3
    Y 1 22 5 58 8
    Z
    14 178 178 2 1 1
    unknown (?)
    not sequenced
    sum of seq 2 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212
    oomcaa3 207 211 198 210 204 102 49 191 118 58 178 178 94 163 85
    mcaa4 G L E W V S V I S Y D G G
    rel. oomcaa5 98% 100% 93% 99% 96% 48% 23% 90% 56% 27% 84% 84% 44% 77% 40%
    pos occupied6 4 2 5 3 3 3 15 9 11 19 5 5 12 9 12
    CDR II Framework III
    amino acid 1 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
    A 9 1 2 174 33 1
    B 1 2
    C
    D
    11 17 160
    E 8 3 2 1 2
    F 1 3 2 207
    G 5 1 5 4 5 212 1
    H 1 4
    I 3 37 2 8 14 208
    K 1 61 199 8
    L 1 1 1 1 1 1
    M 8 2 1
    N 51 4 2 2
    P 1 1 6 8 18 1
    Q 3 2 2 2
    R 5 4 5 6 201
    S 48 11 4 193 2 7 211
    T 42 97 5 7 189 1
    V 2 10 2 204 1 3
    W 2
    X 4 1 1
    Y 9 151 210 1 1 1
    Z
    unknown (?)
    not sequenced
    sum of seq 2 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212
    oomcaa 3 51 97 151 210 174 160 193 204 199 212 201 207 189 208 211
    mcaa4 N T Y Y A D S V K G R F T I S
    rel. oomcaa5 24% 46% 71% 99% 82% 75% 91% 96% 94% 100% 95% 98% 89% 98% 100%
    pos occupied6 19 12 15 2 9 8 3 2 6 1 4 5 5 3 2
    Framework III
    amino acid 1 71 72 73 74 75 76 77 78 79 80 81 82 A B C
    A 57 1 8 1
    B 2
    C
    D 199 38 2 2 1 10
    E 6 4 5
    F 13
    G 1 4
    H 1 1 2 2
    I 1 2 2 3 1 1
    K 186 6 3
    L 188 209 3 1 212
    M 1 2 10 3 2 205
    N 5 170 2 188 3 181 10
    P 1
    Q 7 199
    R 211 1 1 2 8
    S 153 8 10 56 3 6 186
    T 142 1 4 2
    V 1 11 1 1
    W
    X
    2 2 4 1
    Y 194
    Z
    unknown (?)
    not sequenced 1 1
    sum of seq 2 212 212 211 211 212 212 212 212 212 212 212 212 212 212 212
    oomcaa 3 211 199 170 153 186 188 142 188 194 209 199 205 181 186 212
    mcaa4 R D N S K N T L Y L Q M N S L
    rel. oomcaa5 100% 94% 81% 73% 88% 89% 67% 89% 92% 99% 94% 97% 85% 88% 100%
    pos occupied6 2 4 4 3 8 7 6 5 5 3 6 4 11 7 1
    Framework III CDR III
    amino acid 1 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
    A 149 1 1 207 173 2 15 9 11
    B
    C 1 210 5 2 1
    D 5 15 209 2 54 7 6
    E 1 190 11 2 11
    F 1 15 1 9 6
    G 1 1 6 4 1 2 8 34 26 35
    H 1 1 3 11
    I 8 2 4 15 10
    K 30 60 4 3 5
    L 18 1 6 11 7
    M 2 1 6 1
    N 1 1 2 20 4 3
    P 9 1 3 4 29 10
    Q 1 5 3 9 2
    R 177 103 9 30 19
    S 1 1 3 9 8 11
    T 3 28 207 1 25 15 7 6 20
    V 9 187 10 1 7 7 15
    W 1 3 4 3
    X 1
    Y 211 194 12 9 8
    Z
    1 3 4
    unknown (?)
    not sequenced 1 1 1 1 1 1 1 1 7 12 13
    sum of seq 2 212 212 212 212 211 211 211 211 211 211 211 211 205 200 199
    oomcaa 3 177 149 190 209 207 207 187 211 194 210 173 103 54 30 35
    mcaa4 R A E D T A V Y Y C A R D R G
    rel. oomcaa5 83% 70% 90% 99% 98% 98% 89% 100% 92% 100% 82% 49% 26% 15% 18%
    pos occupied6 5 10 4 4 4 2 7 1 4 2 5 14 18 20 21
    CDR III
    amino acid 1 98 99 100 A B C D E F G H I J K 101
    A 7 13 7 9 6 2 3 5 5 9 13 2
    B
    C 13 5 1 2 11 3 2 1
    D 11 7 10 4 2 3 10 3 3 1 3 2 146
    E 6 3 1 13 1 1 1
    F 3 5 4 5 5 6 3 5 7 2 1 1 65 1
    G 34 17 35 17 14 23 10 5 1 5 3 2 32 6
    H 3 4 3 2 9 2 1 3 1 2 8 1
    I 6 11 4 4 3 1 3 10 3 3 2 1 2
    K 2 11 3 1
    L 26 13 4 12 8 2 6 3 10 3 2 1
    M 1 2 1 32
    N 4 6 4 3 2 2 6 2 5 2
    P 6 5 5 6 9 8 2 3 2 1 3 9
    Q 4 1 1 1 1 1 1
    R 4 10 9 7 5 5 2 3 1 1 2 4
    S 16 28 27 25 24 8 11 9 3 2 3 1 1 1
    T 6 12 9 17 17 1 2 5 1 9 3 1
    V 13 7 15 4 3 6 2 12 1 1 1 1
    W 6 5 6 7 2 4 1 6 10
    X 1 1
    Y 16 14 17 5 8 18 20 13 20 25 28 32 28
    Z
    12 21 35 54 73 87 102 110 126 135 134 120 91 71 21
    unknown (?) 3 2 1 1 3 2
    not sequenced 14 14 14 14 15 19 21 22 23 23 23 25 25 26 25
    sum of seq2 198 198 198 197 196 192 190 189 188 188 188 186 186 185 186
    oomcaa3 34 28 35 54 73 87 102 110 126 135 134 120 91 71 146
    mcaa4 G S G D
    rel. oomcaa5 17% 14% 18% 27% 37% 45% 54% 58% 67% 72% 71% 65% 49% 38% 78%
    pos occupied6 20 20 19 20 19 20 17 14 14 12 12 13 12 8 11
    Framework IV
    amino acid 1 102 103 104 105 106 107 108 109 110 111 112 113 sum
    A 1 1 2 1767
    B 1 13
    C 470
    D 2 1121
    E 1 832
    F 2 807
    G 140 130 1 2743
    H 4 179
    I 15 1 1 651
    K 13 933
    L 10 1 91 2 1881
    M 6 496
    N 1 1 844
    P 17 1 1 568
    Q 111 949
    R 8 1413
    S 7 1 118 110 3009
    T 123 27 122 1 1426
    V 34 1 1 125 119 1851
    W 158 686
    X 26
    Y 82 1598
    Z 8
    9 2 2 2 2 2 2 2 2 2 1 1 2023
    unknown (?) 12
    not sequenced 27 50 67 75 78 81 83 84 86 89 92 97 1650
    sum of seq2 184 161 144 136 133 130 128 127 125 122 119 114
    oomcaa 3 82 158 140 111 130 123 91 125 122 119 118 110
    mcaa4 Y W G Q G T L V T V S S
    rel. oomcaa5 45% 98% 97% 82% 98% 95% 71% 98% 98% 98% 99% 96%
    pos occupied6 12 3 4 6 3 6 6 2 3 3 2 4
  • TABLE 6E
    Analysis of V heavy chain subgroup 4
    Frame work I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A 19 1
    B
    C
    D
    E 32
    F
    G
    54 1 53
    H 4 2
    I
    K
    1 54
    L 7 54 53 19 1
    M
    N
    P
    33 51 1
    Q 52 50 51 20
    R 1
    S 33 52
    T 1
    V 47 1 34
    W 20
    X
    Y
    Z
    1
    unknown (?)
    not sequenced 3 3 3 3 4 4 4 3 3 4 4 3 3 4 4
    sum of seq 2 54 54 54 54 53 53 53 54 54 53 53 54 54 53 53
    oomcaa 3 52 47 50 54 51 32 33 54 33 53 53 34 54 51 52
    mcaa4 Q V Q L Q E S G P G L V K P S
    rel. oomcaa5 96% 87% 93% 100% 96% 60% 62% 100% 61% 100% 100% 63% 100% 96% 98%
    pos occupied6 3 2 2 1 2 3 2 1 4 1 1 3 1 3 2
    Frame work I
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
    A 1 1 22
    B
    C 53
    D 1
    E 44
    F 1 22
    G 2 53 53
    H 1
    I 1 1 32
    K 1
    L 53 50
    M
    N 1
    P 2 3
    Q 7
    R 1 3
    S 52 2 35 51 1 52
    T 52 53 29
    V 1 55 1 1
    W
    X
    Y
    19 1
    Z
    unknown (?)
    not sequenced 4 4 4 3 4 4 4 2 2 2 2 2 2 1 1
    sum of seq2 53 53 53 54 53 53 53 55 55 55 55 55 55 56 56
    oomcaa 3 44 52 53 52 50 53 53 29 55 35 53 53 51 32 52
    mcaa4 E T L S L T C T V S G G S I S
    rel. oomcaa5 83% 98% 100% 96% 94% 100% 100% 53% 100% 64% 96% 96% 93% 57% 93%
    pos occupied6 3 2 1 3 3 1 1 5 1 3 3 3 3 4 3
    CDRI Frame work II
    amino acid1 31 A B 32 33 34 35 36 37 38 39 40 41 42 43
    A 1 8 1
    B
    C 1
    D 4 1 1 1 1
    E 1
    F 1 1 1
    G 21 3 4 8 55
    H 2 2
    I 51
    K 54
    L 1 1
    M
    N
    1 2 2 1
    P 50 49
    Q 1 56
    R 2 1 57 3
    S 25 5 9 1 44 1 3
    T 2 1 3 1 1
    V 3
    W 1 2 56 57
    X
    Y
    48 52
    Z
    45 39
    unknown (?)
    not sequenced 1 1 1 1
    sum of seq 2 56 56 56 56 56 56 57 57 57 57 57 57 57 57 57
    oomcaa 3 25 45 39 48 52 56 44 57 51 57 56 50 49 55 54
    mcaa4 S Y Y W S W I R Q P P G K
    rel. oomcaa5 45% 80% 70% 86% 93% 100% 77% 100% 89% 100% 98% 88% 86% 96% 95%
    pos occupied6 7 6 6 7 4 1 5 1 5 1 2 5 2 3 2
    Frame work II CDR II
    amino acid 1 44 45 46 47 48 49 50 51 52 A B C 53 54 55
    A 1
    B
    C
    D
    1 1
    E 56 22
    F 1 1
    G 55 56 1 1 57
    H 24
    I 54 1 54
    K
    L
    55 2
    M
    N 21
    P 2
    Q 1 1
    R 2 9 1
    S 7 1 52
    T 8 5
    V 1 3
    W 56
    X
    Y
    1 15 32 23
    Z
    57 57 57
    unknown (?)
    not sequenced
    sum of seq 2 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57
    oomcaa 3 55 55 56 56 54 56 22 54 32 57 57 57 24 52 57
    mcaa4 G L E W I G E I Y H S G
    rel. oomcaa5 96% 96% 98% 98% 95% 98% 39% 95% 56% 100% 100% 100% 42% 91% 100%
    pos occupied6 2 2 2 2 3 2 8 2 6 1 1 1 5 2 1
    CDR II Framework III
    amino acid 1 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
    A 1 1 1
    B
    C
    D
    2 1
    E
    F 3
    G 1 1
    H 2
    I 1 1 1 1 48
    K 1 53
    L 1 55 1
    M 7
    N 2 40 53 2
    P 54 1
    Q
    R 2 3 56
    S 49 1 2 56 56 1 56
    T 1 54 1 1 1 51 1
    V 1 1 53 2
    W
    X
    Y
    11 54
    Z
    unknown (?)
    not sequenced 1 1 1 1 1 1
    sum of seq 2 57 57 57 57 56 56 56 56 57 57 57 56 56 57 57
    oomcaa 3 49 54 40 54 53 54 56 55 53 56 56 53 51 48 56
    mcaa4 S T N Y N P S L K S R V T I S
    rel. oomcaa5 86% 95% 70% 95% 95% 96% 100% 98% 93% 98% 98% 95% 91% 84% 98%
    pos occupied6 7 4 6 2 3 3 1 2 3 2 2 4 5 3 2
    Framework III
    amino acid 1 71 72 73 74 75 76 77 78 79 80 81 82 A B C
    A 1 1
    B
    C
    D
    55 1
    E 1 1
    F 1 54 1
    G 1
    H
    I 3 1 1
    K 1 51 3 46 2
    L 3 1 3 1 55 53 2
    M 2 1 1 1
    N 1 54 3 3 1
    P
    Q
    1 54 1 1
    R 2 2 2
    S 1 57 1 57 2 1 44 55
    T 52 1 4
    V 50 1 2 54
    W
    X
    Y
    Z
    unknown (?)
    not sequenced
    sum of seq 2 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57
    oomcaa 3 50 55 52 57 51 54 54 54 57 55 46 53 44 55 54
    mcaa4 V D T S K N Q F S L K L S S V
    rel. oomcaa5 88% 96% 91% 100% 89% 95% 95% 95% 100% 96% 81% 93% 77% 96% 95%
    pos occupied6 4 3 5 1 6 2 2 4 1 3 8 4 7 3 3
    Framework III CDR III
    amino acid 1 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
    A 55 57 57 56 3 3 3
    B
    C 57 1
    D 57 6 5
    E 6 1 1
    F 4 1
    G 25 9 10
    H 1
    I 3 1
    K 2 1
    L 1 2 6 7
    M 1 1 4
    N 3
    P 4 5
    Q 1
    R 1 54 4 12 2
    S 1 2 1 1 1 4 8
    T 53 55 1 1 2 1
    V 1 55 1 1 4 2 2
    W 1 2 1
    X
    Y
    57 56 1 4
    Z
    unknown (?)
    not sequenced 1 1 1
    sum of seq 2 57 57 57 57 57 57 57 57 57 57 57 57 56 56 56
    oomcaa3 53 55 57 57 55 57 55 57 56 57 56 54 25 12 10
    mcaa4 T A A D T A V Y Y C A R G R G
    rel. oomcaa5 93% 96% 100% 100% 96% 100% 96% 100% 98% 100% 98% 96% 45% 21% 18%
    pos occupied6 3 3 1 1 2 1 3 1 2 1 2 4 12 16 16
    CDR III
    amino acid 1 98 99 100 A B C D E F G H I J K 101
    A 2 5 4 2 2 4 2 1 1 1 12
    B
    C 1
    D 5 5 4 3 2 4 3 1 1 2 1 41
    E 2 1 1 3 1 2 1
    F 1 2 3 2 2 1 1 31
    G 8 10 11 4 7 7 6 1 1 1 2 1 9
    H 1 1 1 2
    I 2 4 1 3 2 3 1 1
    K 2 2 1
    L 3 5 3 2 4 1 5 3 3 1
    M 3 1 2 1 9
    N 2 1 1 5 1 1 2
    P 3 1 1 2 1 1 1 2 3 1 2 1
    Q 1 1 1 1 3 1
    R 5 5 3 2 3 1 2 2 1
    S 8 1 2 5 7 4 2 1 1 1
    T 3 4 4 3 3 1 1 1
    V 5 4 4 7 3 1 2 1
    W 2 2 4 5 1 1 2 2 1 3 2
    X
    Y
    5 3 6 4 2 3 4 8 4 8 3 5 8 2
    Z
    1 2 4 6 9 11 16 23 27 29 34 31 14 4
    unknown (?) 1 1 1 1
    not sequenced 1 1 2 3 3 6 7 8 9 9 10 11 11 11 11
    sum of seq 2 56 56 55 54 54 51 50 49 48 48 47 46 46 46 46
    oomcaa 3 8 10 11 7 9 11 16 23 27 29 34 31 14 31 41
    mcaa4 G G G V F D
    rel. oomcaa5 14% 18% 20% 13% 17% 22% 32% 47% 56% 60% 72% 67% 30% 67% 89%
    pos occupied6 16 16 16 16 18 18 13 15 13 10 9 8 5 4 4
    Framework IV
    amino acid 1 102 103 104 105 106 107 108 109 110 111 112 113 sum
    A 1 1 332
    B
    C 113
    D 210
    E 176
    F 135
    G 41 40 1 674
    H 1 1 45
    I 9 1 282
    K 3 278
    L 4 19 540
    M 9 43
    N 1 204
    P 3 2 2 281
    Q 29 334
    R 1 4 1 250
    S 1 1 36 33 986
    T 1 33 8 34 532
    V 12 36 36 488
    W 46 267
    X
    Y
    16 455
    Z 1
    466
    unknown (?) 4
    not sequenced 10 11 16 17 17 20 20 21 21 21 21 22 426
    sum of seq 2 47 46 41 40 40 37 37 36 36 36 36 35
    oomcaa 3 16 46 41 29 40 33 19 36 34 36 36 33
    mcaa4 Y W G Q G T L V T V S S
    rel. oomcaa5 34% 100% 100% 73% 100% 89% 51% 100% 94% 100% 100% 94%
    pos occupied6 8 1 1 6 1 5 4 1 3 1 1 2
  • TABLE 6F
    Analysis of V heavy chain subgroup 5
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A  1  1 89  1  1
    B
    C  1
    D  2
    E 88  1  2  4 93
    F
    G  1 92 94
    H
    I
    K 94 94
    L  1 91  2
    M  3
    N
    P
     1  1 94
    Q  3 92  1 90
    R  1  1  1  1
    S 92
    T
    V
    90 89  1 91
    W
    X
    Y
    Z
    unknown (?)
    not sequenced  5  5  5  5  4  4  4  4  2  2  2  2  2  2  2
    sum of seq 2 92 92 92 92 93 93 93 93 95 95 95 95 95 95 95
    oomcaa 3 88 90 92 91 89 90 92 92 89 93 91 94 94 94 94
    mcaa4 E V Q L V Q S G A E V K K P G
    rel. oomcaa5 96% 98% 100% 99% 96% 97% 99% 99% 94% 98% 96% 99% 99% 99% 99%
    pos occupied6  3  3  1  2  4  3  2  2  4  2  3  2  2  2  2
    Framework I
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
    A  3  2  4
    B
    C
    96  1
    D  2
    E 92  2
    F  1  3  6 97
    G 92 93
    H
    I 96  4
    K 77 89  1
    L 95
    M  1  1
    N  1  2  4
    P  1
    Q  3  1  4
    R 17  1  1  2
    S 94 94  1 90 84 10
    T  2  5 75
    V
    W
    X
    Y 90
    Z
    unknown (?)
    not sequenced  2  2  2  1  1  1  1  1  1  1  1  1
    sum of seq 2 95 95 95 96 96 96 96 96 96 96 96 96 97 97 97
    oomcaa 3 92 94 95 77 96 94 96 89 92 90 93 90 84 97 75
    mcaa4 E S L K I S C K G S G Y S F T
    rel. oomcaa5 97% 99% 100% 80% 100% 98% 100% 93% 96% 94% 97% 94% 87% 100% 77%
    pos occupied6  2  2  1  4  1  2  1  5  3  4  3  2  7  1  5
    CDRI Framework II
    amino acid1 31 A B 32 33 34 35 36 37 38 39 40 41 42 43
    A  8  1  1
    B
    C  1
    D  2  1
    E  1  3
    F  2
    G  1 72 97
    H  1  4  1
    I 93
    K  1 94
    L  1  2
    M  1  1 92
    N 14  2
    P  1 96
    Q 97
    R  1 95  1
    S 61  2  2 15
    T 16  2  1  1
    V  1 93  2
    W 93 97
    X
    Y 87
    Z
    97 97
    unknown (?)
    not sequenced
    sum of seq 2 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97
    oomcaa 3 61 97 97 87 93 93 72 97 93 95 97 92 96 97 94
    mcaa4 S Y W I G W V R Q M P G K
    rel. oomcaa5 63% 100% 100% 90% 96% 96% 74% 100% 96% 98% 100% 95% 99% 100% 97%
    pos occupied 6  8  1  1  5  4  4  5  1  4  3  1  5  2  1  2
    Framework II CDR II
    amino acid 1 44 45 46 47 48 49 50 51 52 A B C 53 54 55
    A  1  1  2  1
    B
    C
     1  1
    D 14  8 93
    E 97  2
    F  1  2
    G 96 95 69  1
    H  3  1
    I  1 75 92
    K
    L
    94  2  2  1
    M 89  1
    N
    P
     2  1 93  1
    Q  1
    R  1 14  1
    S  1  1 16 96
    T  3  1  1
    V  5  1  1  2
    W 94
    X
    Y
     3 76
    Z
    unknown (?)
    not sequenced
    sum of seq 2 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97
    oomcaa 3 96 94 97 94 89 95 75 92 76 93 97 97 69 93 96
    mcaa4 G L E W M G I I Y P G D S
    rel. oomcaa5 99% 97% 100% 97% 92% 98% 77% 95% 78% 96% 100% 100% 71% 96% 99%
    pos occupied6  2  3  1  2  4  3  7  5  6  5  1  1  6  4  2
    CDR II Framework III
    amino acid 1 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
    A  6  1
    B
    C
     1  1
    D 77  2
    E  3  2
    F  2 91  1  3
    G  1 94
    H 15
    I  4  1  1  3 88
    K  2
    L  1  4  2
    M  3
    N  2 14  2
    P 95  1  1
    Q 91 81
    R 78  3  1  1
    S  2  2 95  1 95  1  1 95
    T 85  2  1 96
    V  1 93  2
    W
    X
    Y
    12 92
    Z
    unknown (?)
    not sequenced
    sum of seq 2 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97
    oomcaa 3 77 85 78 92 95 95 95 91 91 94 81 93 96 88 95
    mcaa4 D T R Y S P S F Q G Q V T I S
    rel. oomcaa5 79% 88% 80% 95% 98% 98% 98% 94% 94% 97% 84% 96% 99% 91% 98%
    pos occupied6  6  4  5  4  3  3  3  4  4  3  3  3  2  5  2
    Framework III
    amino acid 1 71 72 73 74 75 76 77 78 79 80 81 82 A B C
    A 88  1 91
    B
    C  1
    D 97  1
    E  2  1
    F  1
    G  3  1
    H  3
    I 91
    K 93
    L 96 97
    M  1
    N  7  2  2
    P  1  1
    Q  1 93
    R  1  1  1  1  3
    S 96  1 87  2  1  1 90 91
    T  4  2 94  2  1
    V  9  2  1
    W 95
    X
    Y 94
    Z
    unknown (?)
    not sequenced
    sum of seq 2 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97
    oomcaa 3 88 97 93 96 91 87 94 91 94 96 93 95 90 91 97
    mcaa4 A D K S I S T A Y L Q W S S L
    rel. oomcaa5 91% 100% 96% 99% 94% 90% 97% 94% 97% 99% 96% 98% 93% 94% 100%
    pos occupied6  2  1  4  2  4  4  3  5  4  2  3  3  5  4  1
    Framework III CDR III
    amino acid 1 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
    A  1 96 93 92  1  1  2
    B
    C 95
    D 96  3  3
    E  1  1  1  1
    F  2  6  1
    G  4  1  9 11
    H 10  1
    I  2  9  3
    K 91  1  1  1  1
    L  2 11  2  3
    M 84  2
    N  2  1
    P  5  1  4
    Q  1  3  2
    R  3 92  7  9  2
    S 96  5  1  1  3  2
    T  1  1  1 88  1  1  1  3  2
    V  1  2  2  4  4
    W  1  2
    X
    Y
    94 89  1  6
    Z
    Unknown (?)
    not sequenced  1  2  2  2  2 52 52 52
    sum of seq 2 97 97 97 97 97 97 97 96 95 95 95 95 45 45 45
    oomcaa 3 91 96 96 96 88 93 84 94 89 95 92 92 11  9 11
    mcaa4 K A S D T A M Y Y C A R L G G
    rel. oomcaa5 94% 99% 99% 99% 91% 96% 87% 98% 94% 100% 97% 97% 24% 20% 24%
    pos occupied6  5  2  2  2  4  2  5  2  2  1  3  4 13 16 14
    CDR III
    amino acid 1 98 99 100 A B C D E F G H I J K 101
    A  3  4  3  2  1  1  4  2
    B
    C
     1  1  1  2  1
    D  3  3  1  2  1  1  2  2  1  1  2 37
    E  2  1  1  1  1
    F  3  3  2  1 26
    G 12 12  5  2  4  3 10  2  1  5
    H  2  1  1  1
    I  2  2  1  1  4  1  1  1  1
    K  1  3  1  2
    L  1  1  2  5  1  1  1
    M  1  1  1  1  1  1 10
    N  2  1  1  2  1  2
    P  3  1  2  1  1  1  1
    Q  1  1  4  2  1  2  3
    R  2  2  1  2
    S  6  4  4  5  3  5  3  2  2  1  1
    T  1  2  6  3  3  6  1  1
    V  1  1  2  1
    W  1  1  2  1  1  1
    X
    Y
     3  6  9  8  7  2  1  2  6  8  9  9 10  1
    Z
     1  1  2  8 10 16 23 30 30 31 32 30 22  7  2
    Unknown (?)  1  1  1  1
    not sequenced 52 52 52 52 52 52 52 52 52 52 52 52 52 53 52
    sum of seq 2 45 45 45 45 45 45 45 45 45 45 45 45 45 44 45
    oomcaa 3 12 12  9  8 10 16 23 30 30 31 32 30 22 26 37
    mcaa4 G G Y Y F D
    rel. oomcaa5 27% 27% 20% 18% 22% 36% 51% 67% 67% 69% 71% 67% 49% 59% 82%
    pos occupied6 18 16 15 16 15 14 11 11  9  8  4  6  6  4  5
    Framework IV
    amino acid 1 102 103 104 105 106 107 108 109 110 111 112 113 sum
    A  1 611
    B
    C 205
    D  1 458
    E  1 404
    F  2 256
    G 41 41 1065
    H 44
    I  9  2 588
    K  3 650
    L  2 25  1 549
    M  8 303
    N 64
    P  2  1  1 414
    Q 34 612
    R  3
    S  2 40 39 1545
    T  1 40  8 39 604
    V 11 40 41 594
    W 43 432
    X
    Y
    13 738
    Z
     2 635
    unknown (?)  4
    not sequenced 52 54 56 56 56 56 56 56 56 56 56 57 1678
    sum of seq 2 45 43 41 41 41 41 41 41 41 41 41 40
    oomcaa 3 13 43 41 34 41 40 25 40 39 41 40 39
    mcaa4 Y W G Q G T L V T V S S
    rel. oomcaa5 29% 100% 100% 83% 100% 98% 61% 98% 95% 100% 98% 98%
    pos occupied6 10  1  1  4  1  2  3  2  2  1  2  2
  • TABLE 6G
    Analysis of V heavy chain subgroup 6
    Framework I
    amino acid 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
    A
    B
    C
    D
    E
    F
    G 52 67
    H
    I
    K 68
    L 52 68  1
    M
    N
    P
    68 67
    Q 52 52 51 52
    R  1  1
    S 52  1 68
    T
    V
    52 66
    W
    X
    Y
    Z
    unknown (?)
    not sequenced 22 22 22 22 22 22 22 22  6  6  6  6  6  6  6
    sum of seq 2 52 52 52 52 52 52 52 52 68 68 68 68 68 68 68
    oomcaa 3 52 52 52 52 51 52 52 52 68 67 68 66 68 67 68
    mcaa4 Q V Q L Q Q S G P G L V K P S
    rel. oomcaa5 100% 100% 100% 100% 98% 100% 100% 100% 100% 99% 100% 97% 100% 99% 100%
    pos occupied6  1  1  1  1  2  1  1  1  1  2  1  3  1  2  1
    Framework I
    amino acid 1 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
    A  1 67
    B
    C 68
    D 68
    E
    F  2
    G  1 69
    H
    I 64
    K
    L
    67  1 68
    M
    N  1
    P  1
    Q 68
    R
    S 66  1  1 69 69 68
    T 68 67
    V  1  1  4 70
    W  1
    X
    Y
    Z
    unknown (?)
    not sequenced  6  6  6  6  6  5  5  5  5  5  5  5  5  4  4
    sum of seq 2 68 68 68 68 68 69 69 69 69 69 69 69 69 70 70
    oomcaa 3 68 68 67 66 68 67 68 67 64 69 69 68 69 70 68
    mcaa4 Q T L S L T C A I S G D S V S
    rel. ommcaa 5 100% 100% 99% 97% 100% 97% 99% 97% 93% 100% 100% 99% 100% 100% 97%
    pos occupied6  1  1  2  3  1  3  2  3  3  1  1  2  1  1  2
    CDRI Framework II
    amino acid1 31 A B 32 33 34 35 36 37 38 39 40 41 42 43
    A 66 67  1
    B
    C
    D
     1  1
    E
    F  1  1  1
    G  3  1  2
    H  1
    I  2  1 70
    K  3  1  1
    L  1
    M
    N
     2 66 70
    P 73
    Q 72
    R  2  1 74 73
    S 66 67  3  1 74  1 73
    T  2  1  4  1
    V  6  2
    W 74 74
    X
    Y
     1  1
    Z
    unknown (?)  1
    not sequenced
    sum of seq 2 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74
    oomcaa 3 66 66 67 66 67 74 70 74 70 74 72 74 73 73 73
    mcaa4 S N S A A W N W I R Q S P S R
    rel. ommcaa 5 89% 89% 91% 89% 91% 100% 95% 100% 95% 100% 97% 100% 99% 99% 99%
    pos occupied6  5  6  3  4  5  1  5  1  4  1  3  1  2  2  2
    Framework II CDR II
    amino acid 1 44 45 46 47 48 49 50 51 52 A B C 53 54 55
    A  1  1
    B
    C
    D
    E 74
    F  2  1  1
    G 74 74  1  1
    H  1
    I
    K  1 66
    L 74 74
    M
    N  1
    P
    Q
    R 73 72  1  1
    S  1 72
    T 73  5
    V
    W
    74 73
    X
    Y
    72 72
    Z
    74
    unknown (?)
    not sequenced
    sum of seq  2 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74
    oomcaa 3 74 74 74 74 74 74 73 73 72 72 72 74 72 66 73
    mcaa4 G L E W L G R T Y Y R S K W
    rel. ommcaa 5 100% 100% 100% 100% 100% 100% 99% 99% 97% 97% 97% 100% 97% 89% 99%
    pos occupied6  1  1  1  1  1  1  2  2  2  3  3  1  3  5  2
    CDR II Framework III
    amino acid 1 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70
    A 73  1  2
    B
    C  1
    D 68  1  2
    E  1  3  7  1
    F  7
    G  1  1  8
    H  1
    I  1 65  2 71
    K  1 67  1
    L  1  5  2  4
    M  1
    N  2 65  1  1 69
    P  1  1
    Q  2  1
    R  1  3 73
    S  2  2  1  1 73 66  1  2
    T  4 69  1
    V 58 72  4  2
    W
    X
    Y
    60  1 72
    Z
    unknown (?)
    not sequenced
    sum of seq 2 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74
    oomcaa 3 60 65 68 72 73 58 73 72 67 66 73 65 69 71 69
    mcaa4 Y N D Y A V S V K S R I T I N
    rel. ommcaa 5 81% 88% 92% 97% 99% 78% 99% 97% 91% 89% 99% 88% 93% 96% 93%
    pos occupied6  7  6  5  3  2  7  2  2  5  2  2  4  4  3  4
    Framework III
    amino acid 1 71 72 73 74 75 76 77 78 79 80 81 82 A B C
    A  6  1
    B
    C
    D
    73  3
    E  2
    F 71  1
    G
    H
     1  2  1
    I  1  1
    K 70  4
    L  1  1 74 72
    M  1  1
    N 74 63
    P 66
    Q 72 71
    R  1  1  1
    S  1 73 74  1 73
    T 71  1  2  1
    V  1  2  1 73
    W
    X
    Y
    Z
    unknown (?)
    not sequenced
    sum of seq 2 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74
    oomcaa 3 66 73 71 73 70 74 72 71 74 74 71 72 63 73 73
    mcaa4 P D T S K N Q F S L Q L N S V
    rel. oomcaa5 89% 99% 96% 99% 95% 100% 97% 96% 100% 100% 96% 97% 85% 99% 99%
    pos occupied6  4  2  4  2  3  1  3  3  1  1  3  3  7  2  2
    Framework III CDR III
    amino acid 1 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
    A  1 74 69 11  1  3
    B
    C
    73  1
    D 73 19  4  3
    E 73 10  4  2
    F  3  1  1  1  1
    G  1  1 16  4 15
    H  1
    I  2  1  2
    K  1  1  1  1
    L  1  8  4
    M  2  1
    N  1  1  3  1
    P 70 10  4
    Q  1  1  1
    R  1 69  1  7  8
    S  1  3  3  5  5  5
    T 73 74  1  1  1  4
    V 70  3  1  4  5  1
    W  1  6  8
    X
    Y
    73 70  6  4
    Z
     2  3
    unknown (?)
    not sequenced  1  1  2
    sum of seq 2 74 73 74 74 74 74 74 74 74 74 74 74 73 72 71
    oomcaa 3 73 70 73 73 74 74 70 73 70 73 69 69 19 10 15
    mcaa4 T P E D T A V Y Y C A R D P G
    rel. oomcaa5 99% 96% 99% 99% 100% 100% 95% 99% 95% 99% 93% 93% 26% 14% 21%
    pos occupied6  2  2  2  2  1  1  3  2  3  2  4  4 14 20 19
    CDR III
    amino acid 1 98 99 100 A B C D E F G H I J K 101
    A 12  4  3  2  5  8 10  1
    B
    C
     1  1  1  1
    D  7  4  3  1  6  1  1  1 62
    E  1  2  2  1  2  1
    F  1  2  3  2  1 38  4
    G 15 11  8  6  2  5  1  8  6  1 17
    H  1  1  1  1  1  1  1  1
    I  2  5  1
    K  1  1  1  1
    L  2  3  2  1  1  5  8
    M  1  5 11
    N  2  1  1  1  3  2  1  1  3
    P  5  3  5  1  1
    Q  1  1  1
    R  1  8  8  3  1  1  5  1
    S  7  6  7  3  4  2  1  1
    T  3  4  4  6  3  1  1
    V  9  4  9  5  1  1  2
    W  3  2  4  4  4
    X
    Y
     2  2  2  6  6  2  4  2  1  8  8 12 12
    Z
     7 14 23 25 33 41 47 53 54 57 56 50 28 12  4
    unknown (?)  6  1  5
    not sequenced  2  1  1  1  1  1  1  1  1  1  1  1  1  1  1
    sum of seq 2 71 72 72 72 72 72 72 72 72 72 72 72 72 72 72
    oomcaa 3 15 14 23 25 33 41 47 53 54 57 56 50 28 38 62
    mcaa4 G F D
    rel. oomcaa5 21% 19% 32% 35% 46% 57% 65% 74% 75% 79% 78% 69% 39% 53% 86%
    pos occupied6 15 17 16 16 13 13 11  8  8  4  5  7  6  6  5
    Framework IV
    amino acid 1 102 103 104 105 106 107 108 109 110 111 112 113 sum
    A  2 494
    B
    C 147
    D  1 403
    E 186
    F  2  2 150
    G 49 50 571
    H  2 18
    I  9  3  1 304
    K  1  1 293
    L  5 26 632
    M  8 31
    N 436
    P  4  6  1 387
    Q 40 539
    R  2 495
    S  4  1  1 43 46 1271
    T 45  4 45 640
    V 21  2 46 48 647
    W 65  5 398
    X
    Y
    19 518
    Z
     2 585
    unknown (?) 13
    not sequenced  5  8 23 24 23 24 25 25 28 25 28 26 580
    sum of seq 2 68 65 50 49 50 49 48 48 45 48 45 47
    oomcaa 3 21 65 49 40 50 45 26 46 45 48 43 46
    mcaa4 V W G Q G T L V T V S S
    rel. oomcaa5 31% 100% 98% 82% 100% 92% 54% 96% 100% 100% 96% 98%
    pos occupied6  9  1  2  4  1  3  7  3  1  1  2  2

    Appendix to Tables 1A-C
  • A. REFERENCES OF REARRANGED SEQUENCES REFERENCES OF REARRANGED HUMAN KAPPA SEQUENCES USED FOR ALIGNMENT
    • 1 Alescio-Zonta, L.
      Figure US20060003334A1-20060105-P00900
      Baglioni, C. (1970) Eur. J. Biochem., 15, 450-463.
    • 2 Andrews, D. W.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1981) Biochemistry, 20, 5816-5822.
    • 3 Andris, J. S., Ehrlich, P. H., Ostberg, L.
      Figure US20060003334A1-20060105-P00900
      Capra. J. D. (1992) J. Immunol., 149, 4053-4059.
    • 4 Atkinson, P. M., Lampman, G. W., Furie, B. C., Naparstek, Y., Schwartz, R. S., Stollar, B. D.
      Figure US20060003334A1-20060105-P00900
      Furie, B. (1985) J. Clin. Invest., 75, 1138-1143.
    • 5 Aucouturier, P., Bauwens, M., Khamlichi, A. A., Denoroy, L. Spinelli, S., Touchard, G., Preud'homme, J.-L.
      Figure US20060003334A1-20060105-P00900
      Cogne, M. (1993) J. Immunol., 150, 3561-3568.
    • 6 Avila, M. A., Vazques, J., Danielsson, L., Fernandez De Cossio, M. E.
      Figure US20060003334A1-20060105-P00900
      Borrebaeck, C. A. K. (1993) Gene, 127, 273-274.
    • 7 Barbas Iii, C. F., Crowe, Jr., J. E., Cababa, D., Jones, T. M., Zebedee, S. L., Murphy, B. R., Chanock, R. M.
      Figure US20060003334A1-20060105-P00900
      Burton, D. R. (1992) Proc. Natl. Acad. Sci. Usa, 89, 10164-10168.
    • 8 Barbas, C. F., Iii, et al. (1993) J-Mol-Biol., 230, 812-23.
    • 9 Bentley, D. L.
      Figure US20060003334A1-20060105-P00900
      Rabbitts, T. H. (1980) Nature, 288, 730-733.
    • 10 Bentley, D. L.
      Figure US20060003334A1-20060105-P00900
      Rabbitts, T. H. (1983) Cell, 32, 181-189.
    • 11 Bentley, D. L. (1984) Nature, 307, 77-80.
    • 12 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K.
      Figure US20060003334A1-20060105-P00900
      Teng, N. N. H. (1993) J. Immunol., 151, 5011-5021.
    • 13 Blaison, G., Kuntz, J.-L.
      Figure US20060003334A1-20060105-P00900
      Pasquali, J.-L. (1991) Eur. J. Immunol., 21, 1221-1227.
    • 14 Braun, H., Leibold, W., Barnikol, H. U.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1971) Z. Physiol. Chem., 352, 647-651; (1972) Z. Physiol. Chem., 353, 1284-1306.
    • 15 Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Kehoe, J. M. (1975) Adv. Immunology, 20, 1-40.; Andrews, D. W.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1981) Proc. Nat. Acad. Sci. Usa, 78, 3799-3803.
    • 16 Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Kehoe, J. M. (1975) Adv. Immunology, 20, 1-40.; Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1983) J. Immunol., 131, 1322-1325.
    • 17 Chastagner, P., Theze, J.
      Figure US20060003334A1-20060105-P00900
      Zouali, M. (1991) Gene, 101, 305-306.
    • 18 Chen. P. P., Robbins, D. L., Jirik, F. R., Kipps, T. J.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1987) J. Exp. Med, 166, 1900-1905.
    • 19 Chen, P. P., Robbins, D. L., Jirik, F. R., Kipps, T. J.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1987) J. Exp. Med, 166, 1900-1905; Liu, M.-F., Robbins, D. L., Crowley, J. J., Sinha, S., Kozin, F., Kipps, T. J., Carson, D. A.
      Figure US20060003334A1-20060105-P00900
      Chen. P. P. (1989) J. Immunol., 142, 688-694.
    • 20 Chersi, A.
      Figure US20060003334A1-20060105-P00900
      Natali, P. G. (1978) Immunochemistry, 15, 585-589.
    • 21 Co, M. S., Deschamps, M., Whitley, R. J.
      Figure US20060003334A1-20060105-P00900
      Queen, C. (1991) Proc. Natl. Acad. Sci. Usa, 88, 2869-2873.
    • 22 Cuisinier, A.-M., Fumoux, F., Fougereau, M.
      Figure US20060003334A1-20060105-P00900
      Tonnelle, C. (1992) Mol. Immunol., 29, 1363-1373.
    • 23 Davidson, A., Manheimer-Lory, A., Aranow, C., Peterson, R., Hannigan, N.
      Figure US20060003334A1-20060105-P00900
      Diamond, B. (1990) J. Clin. Invest., 85, 1401-1409.
    • 24 Denomme, G. A., Mahmoudi, M., Edwards, J. Y., Massicotte, H., Cairns, E.
      Figure US20060003334A1-20060105-P00900
      Bell, D. A. (1993) Hum. Antibod. Hybridomas, 4, 98-103.
    • 25 Dersimonian, H., Mcadam, K. P. W. J., Mackworth-Young, C.
      Figure US20060003334A1-20060105-P00900
      Stollar, B. D. (1989) J. Immunol., 142, 4027-4033.
    • 26 Dreyer, W. J., Gray, W. R.
      Figure US20060003334A1-20060105-P00900
      Hood, L. (1967) Cold Spring Harbor Symp. Quantitative Biol., 32, 353-367.
    • 27 Ebeling, S. B., Schutte, M. E. M.
      Figure US20060003334A1-20060105-P00900
      Logtenberg, T. (1993) Eur. J. Immunol., 23, 1405-1408.
    • 28 Eulitz, M.
      Figure US20060003334A1-20060105-P00900
      Kley, H.-P. (1977) Immunochem., 14, 289-297.
    • 29 Eulitz, M.
      Figure US20060003334A1-20060105-P00900
      Linke, R. P. (1982) Z. Physiol. Chem., 363, 1347-1358.
    • 30 Eulitz, M., Breuer, M., Eblen, A., Weiss, D. T.
      Figure US20060003334A1-20060105-P00900
      Solomon, A. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten
      Figure US20060003334A1-20060105-P00900
      P. Westermark, Kluwer Academic
    • 31 Eulitz, M., Gotze, D.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1972) Z. Physiol. Chem., 353, 487-491: Eulitz, M.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1974) Z. Physiol. Chem., 355, 842-866.
    • 32 Eulitz, M., Kley, H. P.
      Figure US20060003334A1-20060105-P00900
      Zeitler, H. J. (1979) Z. Physiol. Chem., 360, 725-734.
    • 33 Ezaki, I., Kanda, H., Sakai, K., Fukui, N., Shingu, M., Nobunaga, M.
      Figure US20060003334A1-20060105-P00900
      Watanabe, T. (1991) Arthritis And Rheumatism, 34, 343-350.
    • 34 Felgenhauer, M., Kohl, J.
      Figure US20060003334A1-20060105-P00900
      Ruker, F. (1990) Nucl. Acids Res., 18, 4927.
    • 35 Ferri, G., Stoppini, M., Iadarola, P., Bellotti, V.
      Figure US20060003334A1-20060105-P00900
      Merlini, G. (1989) Biochim. Biophys. Acta, 995, 103-108.
    • 36 Gillies, S. D., Dorai, H., Wesolowski, J., Majeau, G., Young, D., Boyd, J., Gardner, J.
      Figure US20060003334A1-20060105-P00900
      James, K. (1989) Bio/Tech., 7, 799-804.
    • 37 Goni, F.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1983) Proc. Nat. Acad. Sci. Usa, 80, 4837-4841.
    • 38 Goni, F. R., Chen, P. P., Mcginnis, D., Arjonilla, M. L., Fernandez, J., Carson, D., Solomon, A., Mendez, E.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1989) J. Immunol., 142, 3158-3163.
    • 39 Gorman, S. D., Clark, M. R., Routledge, E. G., Cobbold, S. P.
      Figure US20060003334A1-20060105-P00900
      Waldmann, H. (1991) Proc. Natl. Acad. Sci. Usa, 88, 4181-4185.
    • 40 Gottlieb, P. D., Cunningham, B. A., Rutishauser, U.
      Figure US20060003334A1-20060105-P00900
      Edelman, G. M. (1970) Biochemistry, 9, 3155-3161.
    • 41 Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M., Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., Hughes-Jones, N. C., Hoogenboom, H. R.
      Figure US20060003334A1-20060105-P00900
      Winter, G. (1993) Embo J., 12, 725-734.
    • 42 Hieter, P. A., Max, E. E., Seidman, J. G., Maizel, J. V., Jr.
      Figure US20060003334A1-20060105-P00900
      Leder, P. (1980) Cell, 22, 197-207; Klobeck, H. G, Meindl, A., Combriato, G., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1985) Nucl. Acids Res., 13, 6499-6513; Weir, L.
      Figure US20060003334A1-20060105-P00900
      Leder, P. (1986)
    • 43 Hilschmann, N.
      Figure US20060003334A1-20060105-P00900
      Craig, L. C. (1965) Proc. Nat. Acad. Sci. Usa, 53, 1403-1409; Hilschmann, N. (1967) Z. Physiol. Chem., 348, 1077-1080.
    • 44 Hilschmann, N.
      Figure US20060003334A1-20060105-P00900
      Craig, L. C. (1965) Proc. Nat. Acad. Sci. Usa, 53, 1403-1409; Hilschmann, N. (1967) Z. Physiol. Chem., 348, 1718-1722; Hilschmann, N. (1969) Naturwissenschaften, 56, 195-205.
    • 45 Hirabayashi, Y., Munakata, Y., Sasaki, T.
      Figure US20060003334A1-20060105-P00900
      Sano, H. (1992) Nucl. Acids Res., 20, 2601.
    • 46 Jaenichen, H.-R., Pech, M., Lindenmaier, W., Wildgruber, N.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1984) Nuc. Acids Res., 12, 5249-5263.
    • 47 Jirik, F. R., Sorge, J., Fong, S., Heitzmann, J. G., Curd, J. G., Chen, P. P., Goldfien, R.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1986) Proc. Nat. Acad. Sci. Usa, 83, 2195-2199.
    • 48 Kaplan, A. P.
      Figure US20060003334A1-20060105-P00900
      Metzger, H. (1969) Biochemistry, 8, 3944-3951.; Klapper, D. G.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1976) Ann. Immunol. (Inst. Pasteur), 127c, 261-271.
    • 49 Kennedy, M. A. (1991) J. Exp. Med., 173, 1033-1036.
    • 50 Kim, H. S.
      Figure US20060003334A1-20060105-P00900
      Deutsch, H. F. (1988) Immunol., 64, 573-579.
    • 51 Kipps, T. J., Tomhave, E., Chen, P. P.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1988) J. Exp. Med., 167, 840-852.
    • 52 Kipps, T. J., Tomhave, E., Chen, P. P.
      Figure US20060003334A1-20060105-P00900
      Fox, R. I. (1989) J. Immunol., 142, 4261-4268.
    • 53 Klapper, D. G.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1976) Ann. Immunol. (Inst. Pasteur), 127c, 261-271.
    • 54 Klein, U., Kuppers, R.
      Figure US20060003334A1-20060105-P00900
      Rajewsky, K. (1993) Eur. J. Immunol., 23, 3272-3277.
    • 55 Klobeck, H. G, Meindl, A., Combriato, G., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1985) Nucl. Acids Res., 13, 6499-6513.
    • 56 Klobeck, H. G., Bornkammm, G. W., Combriato, G., Mocikat, R., Pohlenz, H. D.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1985) Nucl. Acids Res., 13, 6515-6529.
    • 57 Klobeck, H. G., Combriato, G.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1984) Nuc. Acids Res., 12, 6995-7006.
    • 58 Klobeck, H. G., Solomon, A
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1984) Nature, 309, 73-76.
    • 59 Knight, G. B., Agnello, V., Bonagura, V., Barnes, J. L., Panka, D. J.
      Figure US20060003334A1-20060105-P00900
      Zhang, Q.-X. (1993) J. Exp. Med., 178, 1903-1911.
    • 60 Kohler, H., Shimizu, A., Paul, C.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1970) Science, 169, 56-59. (Kaplan, A. P.
      Figure US20060003334A1-20060105-P00900
      Metzger, H. (1969) Biochemistry, 8, 3944-3951.)
    • 61 Kratzin, H., Yang, C. Y., Krusche, J. U.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1980) Z. Physiol. Chem., 361, 1591-1598.
    • 62 Kunicki, T. J., Annis, D. S., Gorski, J.
      Figure US20060003334A1-20060105-P00900
      Nugent, D. J. (1991) J. Autoimmunity, 4, 433-446.
    • 63 Larrick, J. W., Wallace, E. F., Coloma, M. J., Bruderer, U., Lang, A. B.
      Figure US20060003334A1-20060105-P00900
      Fry, K. E. (1992) Immunological Reviews, 130, 69-85.
    • 64 Laure, C. J., Watanabe, S.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1973) Z. Physiol. Chem., 354, 1503-1504.
    • 65 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1983) J. Immunol., 131, 1322-1325.
    • 66 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1983) J. Immunol., 131, 1322-1325.
    • 67 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1983) J. Immunol., 131, 1322-1325. Pons-Estel, B., Goni, F., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1984) J. Exp. Med., 160, 893.
    • 68 Levy, S., Mendel, E., Kon, S., Avnur, Z.
      Figure US20060003334A1-20060105-P00900
      Levy, R. (1988) J. Exp. Med., 168, 475-489.
    • 69 Liepnieks, J. J., Dwulet, F. E.
      Figure US20060003334A1-20060105-P00900
      Benson, M. D. (1990) Mol. Immunol., 27, 481-485.
    • 70 Manheimer-Lory, A., Katz, J. B., Pillinger, M., Ghossein, C., Smith, A.
      Figure US20060003334A1-20060105-P00900
      Diamond, B. (1991) J. Exp. Med., 174, 1639-1652.
    • 71 Mantovani, L., Wilder, R. L.
      Figure US20060003334A1-20060105-P00900
      Casali, P. (1993) J. Immunol., 151, 473-488.
    • 72 Mariette, X., Tsapis, A.
      Figure US20060003334A1-20060105-P00900
      Brouet, J.-C. (1993) Eur. J. Immunol., 23, 846-851.
    • 73 Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J., Griffiths, A. D.
      Figure US20060003334A1-20060105-P00900
      Winter, G. (1991) J. Mol. Biol., 222, 581-597.
    • 74 Marsh, P., Mills, F.
      Figure US20060003334A1-20060105-P00900
      Gould, H. (1985) Nuc. Acids Res., 13, 6531-6544.
    • 75 Middaugh, C. R.
      Figure US20060003334A1-20060105-P00900
      Litman, G. W. (1987) J. Biol. Chem., 262, 3671-3673.
    • 76 Milstein, C.
      Figure US20060003334A1-20060105-P00900
      Deverson, E. V. (1971) Biochem. J., 123, 945-958.
    • 77 Milstein, C. (1969) Febs Letters, 2, 301-304.
    • 78 Milstein, C. (1969) Febs Letters, 2, 301-304.
    • 79 Milstein, C. P.
      Figure US20060003334A1-20060105-P00900
      Deverson, E. V. (1974) Eur. J. Biochem., 49, 377-391.
    • 80 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Hersh, E. M. (1993) Mol. Immunol., 30, 1543-1551.
    • 81 Nakatani, T., Nomura, N., Horigome, K., Ohtsuka, H.
      Figure US20060003334A1-20060105-P00900
      Noguchi, H. (1989) BioTech., 7, 805-810.
    • 82 Newkirk, M., Chen, P. P., Carson, D., Posnett, D.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1986) Mol. Immunol., 23, 239-244.
    • 83 Newkirk, M. M., Gram, H., Heinrich, G. F., Ostberg, L., Capra. J. D.
      Figure US20060003334A1-20060105-P00900
      Wasserman, R. L. (1988) J. Clin. Invest., 81, 1511-1518.
    • 84 Newkirk, M. M., Mageed, R. A., Jefferis, R., Chen, P. P.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1987) J. Exp. Med., 166, 550-564.
    • 85 Olee, B. T., Lu, E. W., Huang, D.-F., Soto-Gil, R. W., Deftos, M., Kozin, F., Carson, D. A.
      Figure US20060003334A1-20060105-P00900
      Chen, P. P. (1992) J. Exp. Med., 175, 831-842.
    • 86 Palm, W.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1973) Z. Physiol. Chem., 354, 1651-1654: (1975) Z. Physiol. Chem., 356, 167-191.
    • 87 Pascual, V., Victor, K., Lelsz, D., Spellerberg, M. B., Hamblin, T. J., Thompson, K. M., Randen, I., Natvig, J., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Stevenson, F. K. (1991) J. Immunol., 146, 4385-4391.
    • 88 Pascual, V., Victor, K., Randen, I., Thompson, K., Steinitz, M., Forre, O., Fu, S.-M., Natvig, J. B.
      Figure US20060003334A1-20060105-P00900
      Capra. J. D. (1992) Scand. J. Immunol., 36, 349-362.
    • 89 Pech, M.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1984) Nuc. Acids Res., 12, 9229-9236.
    • 90 Pech, M., Jaenichen, H.-R., Pohlenz, H.-D., Neumaier, P. S., Klobeck, H.-G.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1984) J. Mol. Biol., 176, 189-204.
    • 91 Pons-Estel, B., Goni, F., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1984) J. Exp. Med., 160, 893-904.
    • 92 Portolano, S. Mclachlan, S. M.
      Figure US20060003334A1-20060105-P00900
      Rapoport, B. (1993) J. Immunol., 151, 2839-2851.
    • 93 Portolano, S., Seto, P., Chazenbalk, G. D., Nagayama, Y., Mclachlan, S. M.
      Figure US20060003334A1-20060105-P00900
      Rapoport, B. (1991) Biochem. Biophys. Res. Commun., 179, 372-377.
    • 94 Pratt, L. F., Rassenti, L., Larrick. J., Robbins, B., Banks, P. M.
      Figure US20060003334A1-20060105-P00900
      Kipps, T. J. (1989) J. Immunol., 143, 699-705.
    • 95 Prelli, F., Tummolo, D., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1986) J. Immunol., 136, 4169-4173.
    • 96 Putnam, F. W., Whitley, E. J., Jr., Paul, C.
      Figure US20060003334A1-20060105-P00900
      Davidson, J. N. (1973) Biochemistry, 12, 3763-3780.
    • 97 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Natvig, J. B. (1993) Eur. J. Immunol., 23, 1220-1225.
    • 98 Rassenti, L. Z., Pratt, L. F., Chen, P. P., Carson, D. A.
      Figure US20060003334A1-20060105-P00900
      Kipps, T. J. (1991) J. Immunol., 147, 1060-1066.
    • 99 Reidl, L. S., Friedman, D. F., Goldman, J., Hardy, R. R., Jefferies, L. C.
      Figure US20060003334A1-20060105-P00900
      Silberstein, L. E. (1991) J. Immunol., 147, 3623-3631.
    • 100 Riechmann, L., Clark, M., Waldmann, H.
      Figure US20060003334A1-20060105-P00900
      Winter, G. (1988) Nature, 332,323-327.
    • 101 Riesen, W., Rudikoff, S., Oriol, R.
      Figure US20060003334A1-20060105-P00900
      Potter, M. (1975) Biochemistry, 14, 1052-1057; Riesen, W. F., Braun, D. G.
      Figure US20060003334A1-20060105-P00900
      Jaton, J. C. (1976) Proc. Nat. Acad. Sci. Usa, 73, 2096-2100; Riesen, W. F.
      Figure US20060003334A1-20060105-P00900
      Jaton, J. C. (1976) Biochemistry, 15, 3829.
    • 102 Rodilla Sala, E., Kratzin, D. H., Pick, A. I.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten
      Figure US20060003334A1-20060105-P00900
      P. Westermark, Kiuwer Academic
    • 103 Schiechl, H.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1971) Z. Physiol. Chem., 352, 111-115; (1972) Z. Physiol. Chem., 353, 345-370.
    • 104 Schneider, M.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1974) Z. Physiol. Chem., 355, 1164-1168.
    • 105 Shearman, C. W., Pollock, D., White, G., Hehir, K., Moore, G. P., Kanzy, E. J.
      Figure US20060003334A1-20060105-P00900
      Kurrle, R. (1991) J. Immunol., 147, 4366-4373.
    • 106 Shinoda, T. (1973) J. Biochem., 73, 433-446.
    • 107 Shinoda, T. (1975) J. Biochem., 77, 1277-1296.
    • 108 Shinoda, T., Takenawa, T.; Hoshi, A.
      Figure US20060003334A1-20060105-P00900
      Isobe, T. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten
      Figure US20060003334A1-20060105-P00900
      P. Westermark, Kluwer Academic Publishers, Dordrecht/Boston/London, Pp. 157-
    • 109 Silberstein, L. E., Litwin, S.
      Figure US20060003334A1-20060105-P00900
      Carmack, C. E. (1989) J. Exp. Med., 169, 1631-1643.
    • 110 Sims, M. J., Hassal, D. G., Brett, S., Rowan. W., Lockyer, M. J., Angel, A., Lewis, A. P., Hale, G., Waldmann, H.
      Figure US20060003334A1-20060105-P00900
      Crowe, J. S. (1993) J. Immunol., 151, 2296-2308.
    • 111 Spatz, L. A., Wong, K. K., Williams, M., Desai, R., Golier, J., Berman, J. E., Alt, F. W.
      Figure US20060003334A1-20060105-P00900
      Latov, N. (1990) J. Immunol., 144, 2821-2828.
    • 112 Stavnezer, J., Kekish, O. Batter, D., Grenier, J., Balazs, I., Henderson, E.
      Figure US20060003334A1-20060105-P00900
      Zegers, B. J. M. (1985) Nucl. Acids Res., 13, 3495-3514.
    • 113 Straubinger, B., Thiebe, R., Pech, M.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1988) Gene, 69, 209-214.
    • 114 Suter, L., Barnikol, H. U., Watanabe, S.
      Figure US20060003334A1-20060105-P00900
      Hilschmann. N. (1969) Z. Physiol. Chem., 350, 275-278; (1972) Z. Physiol. Chem., 353, 189-208.
    • 115 Tempest, P. R., Bremner, P., Lambert, M., Taylor, G., Furze, J. M., Carr, F. J.
      Figure US20060003334A1-20060105-P00900
      Harris, W. J. (1991) Bio/Tech., 9, 266-271.
    • 116 Titani, K., Shinoda, T.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1969) J. Biol. Chem., 244, 3550-3560.
    • 117 Toft, K. G., Olstad, O. K., Sletten, K.
      Figure US20060003334A1-20060105-P00900
      Westermark, P. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten
      Figure US20060003334A1-20060105-P00900
      P. Westermark, Kluwer Academic
    • 118 Van Es, J. H., Aanstoot, H., Gmelig-Meyling, F. H. J., Derksen, R. H. W. M.
      Figure US20060003334A1-20060105-P00900
      Logtenberg, T. (1992) J. Immunol., 149, 2234-2240.
    • 119 Victor, K. D., Pascual, V., Lefvert, A. K.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) Mol. Immunol., 29, 1501-1506.
    • 120 Victor, K. D., Pascual, V., Williams, C. L., Lennon, V. A.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) Eur. J. Immunol., 22, 2231-2236.
    • 121 Victor, K. D., Randen, I., Thompson, K., Forre, O., Natvig, J. B., Fu, S. M.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1991) J. Clin. Invest, 87, 1603-1613.
    • 122 Wagner, S. D.
      Figure US20060003334A1-20060105-P00900
      Luzzatto, L. (1993) Eur. J. Immunol., 23, 391-397.
    • 123 Watanabe, S.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1970) Z. Physiol. Chem., 351, 1291-1295.
    • 124 Weisbart, R. H., Wong, A. L., Noritake, D., Kacena, A., Chan, G., Ruland, C., Chin, E., Chen, I. S. Y.
      Figure US20060003334A1-20060105-P00900
      Rosenblatt, J. D. (1991) J. Immunol., 147, 2795-2801.
    • 125 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M.
      Figure US20060003334A1-20060105-P00900
      Marcus, D. M. (1992) J. Immunol., 149, 2518-2529.
    • 126 Winkler, T. H., Fehr, H.
      Figure US20060003334A1-20060105-P00900
      Kalden, J. R. (1992) Eur. J. Immunol., 22, 1719-1728.
    REFERENCES OF REARRANGED HUMAN LAMBDA SEQUENCES USED FOR ALIGNMENT
    • 1 Alexandre, D., Chuchana, P., Brockly, F., Blancher, A., Lefranc, G.
      Figure US20060003334A1-20060105-P00900
      Lefranc, M.-P. (1989) Nuc. Acids Res., 17, 3975.
    • 2 Anderson, M. L. M., Brown, L., Mckenzie, E., Kellow, J. E.
      Figure US20060003334A1-20060105-P00900
      Young, B. D. (1985) Nuc. Acids Res., 13, 2931-2941.
    • 3 Andris, J. S., Brodeur, B. R.
      Figure US20060003334A1-20060105-P00900
      Capra. J. D. (1993) Mol. Immunol., 30, 1601-1616.
    • 4 Andris, J. S., Ehrlich, P. H., Ostberg, L.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) J. Immunol., 149, 4053-4059.
    • 5 Baczko, K., Braun, D. G., Hess, M.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1970) Z. Physiol. Chem., 351, 763-767; Baczko, K., Braun, D. G.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1974) Z. Physiol. Chem., 355, 131-154.
    • 6 Berinstein, N., Levy, S.
      Figure US20060003334A1-20060105-P00900
      Levy. R. (1989) Science, 244, 337-339.
    • 7 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K.
      Figure US20060003334A1-20060105-P00900
      Teng, N. N. H. (1993) J. Immunol., 151, 5011-5021.
    • 8 Cairns, E., Kwong, P. C., Misener, V., Ip, P., Bell, D. A.
      Figure US20060003334A1-20060105-P00900
      Siminovitch, K. A. (1989) J. Immunol., 143, 685-691.
    • 9 Carroll, W. L., Yu, M., Link, M. P.
      Figure US20060003334A1-20060105-P00900
      Korsmeyer, S. J. (1989) J. Immunol., 143, 692-698.
    • 10 Chen, B. L.
      Figure US20060003334A1-20060105-P00900
      Poljak, R. J. (1974) Biochemistry, 13, 1295-1302.
    • 11 Chen, B. L., Chiu. Y. Y. H., Humphrey, R. L.
      Figure US20060003334A1-20060105-P00900
      Poljak, R. J. (1978) Biochim. Biophys. Acta, 537, 9-21.
    • 12 Combriato, G.
      Figure US20060003334A1-20060105-P00900
      Klobeck, H. G. (1991) Eur. J. Immunol., 21, 1513-1522.
    • 13 Cuisinier, A.-M., Fumoux, F., Fougereau, M.
      Figure US20060003334A1-20060105-P00900
      Tonnelle, C. (1992) Mol. Immunol., 29, 1363-1373.
    • 14 Dwulet, F. E., Strako, K.
      Figure US20060003334A1-20060105-P00900
      Benson, M. D. (1985) Scand. J. Immunol., 22, 653-660.
    • 15 Elahna, P., Livneh, A., Manheimer-Lory, A. J.
      Figure US20060003334A1-20060105-P00900
      Diamond, B. (1991) J. Immunol., 147, 2771-2776.
    • 16 Engelhard, M., Hess, M.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1974) Z. Physiol. Chem., 355, 85-88; Engelhard, M.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1975) Z. Physiol. Chem., 356, 1413-1444.
    • 17 Eulitz, M. (1974) Eur. J. Biochem., 50, 49-69.
    • 18 Eulitz, M., Breuer, M.
      Figure US20060003334A1-20060105-P00900
      Linke, R. P. (1987) Biol. Che. Hoppe-Seyler, 368, 863-870.
    • 19 Eulitz, M., Murphy, C., Weiss, D. T.
      Figure US20060003334A1-20060105-P00900
      Solomon, A. (1991) J. Immunol., 146, 3091-3096.
    • 20 Fett, J. W.
      Figure US20060003334A1-20060105-P00900
      Deutsch, H. F. (1974) Biochemistry, 13, 4102-4114.
    • 21 Fett, J. W.
      Figure US20060003334A1-20060105-P00900
      Deutsch, H. F. (1976) Immunochem., 13, 149-155.; Jabusch, J. R.
      Figure US20060003334A1-20060105-P00900
      Deutsch, H. F. (1982) Mol. Immunol., 19, 901-906.
    • 22 Furey, W. Jr., Wang, B. C. Yoo, C. S.
      Figure US20060003334A1-20060105-P00900
      Sax, M. (1983) J. Mol. Biol., 167, 661-692.
    • 23 Fykse, E.-M. Sletten, K., Husby, G.
      Figure US20060003334A1-20060105-P00900
      Cornwell, G. G., Iii (1988) Biochem. J., 256, 973-980.
    • 24 Garver, F. A.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1971) Febs Letters, 16, 128-132; (1972) Eur. J. Biochem., 26, 10-32.
    • 25 Gawinowicz, M. A., Merlini, G., Birken, S., Osserman, E. F.
      Figure US20060003334A1-20060105-P00900
      Kabat, E. A. (1991) J. Immunol., 147, 915-920.
    • 26 Ghiso, J., Solomon, A.
      Figure US20060003334A1-20060105-P00900
      Frangione. B. (1986) J. Immunol. 136, 716-719.
    • 27 Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M., Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., Hughes-Jones, N. C., Hoogenboom, H. R.
      Figure US20060003334A1-20060105-P00900
      Winter, G. (1993) Embo J., 12, 725-734.
    • 28 Guliasken, N., Idso, H., Nilsen, R., Sletten, K., Husby, G.
      Figure US20060003334A1-20060105-P00900
      Cornwell, G. G. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten
      Figure US20060003334A1-20060105-P00900
      P. Westermark, Kluwer Academic
    • 29 Harindranath, N., Goldfarb, I. S., Ikematsu, H., Burastero, S. E., Wilder, R. L., Notkins, A. L.
      Figure US20060003334A1-20060105-P00900
      Casali, P. (1991) Int. Immunol., 3, 865-875.
    • 30 Holm, E., Sletten, K.
      Figure US20060003334A1-20060105-P00900
      Husby, G. (1986) Biochem. J., 239, 545-551.
    • 31 Hughes-Jones, N. C., Bye, J. M., Beale, D.
      Figure US20060003334A1-20060105-P00900
      Coadwell, J. (1990) Biochem. J., 268, 135-140.
    • 32 Kametani, F., Yoshimura, K. Tonoike, H., Hoshi, A., Shinoda, T.
      Figure US20060003334A1-20060105-P00900
      Isobe, T. (1985) Biochem. Biophys. Res. Commun., 126, 848-852.
    • 33 Kiefer, C. R., Mcguire, B. S., Jr., Osserman, E. F.
      Figure US20060003334A1-20060105-P00900
      Garver, F. A. (1983) J. Immunol., 131, 1871-1875.
    • 34 Kiefer, C. R., Patton, H. M., Jr., Mcquire, B. S., Jr.
      Figure US20060003334A1-20060105-P00900
      Garver, F. A. (1980) J. Immunol., 124, 301-306.
    • 35 Kishimoto, T., Okajima, H., Okumoto, T.
      Figure US20060003334A1-20060105-P00900
      Taniguchi, M. (1989) Nucl. Acids Res., 17, 4385.
    • 36 Klafki, H.-W., Kratzin, H. D., Pick, A. I. Eckart, K.
      Figure US20060003334A1-20060105-P00900
      Hilschmann. N. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten
      Figure US20060003334A1-20060105-P00900
      P. Westermark, Kluwer Academic
    • 37 Kohler, H., Rudofsky, S.
      Figure US20060003334A1-20060105-P00900
      Kluskens, L. (1975) J. Immunology, 114, 415-421.
    • 38 Kojima, M., Odani, S.
      Figure US20060003334A1-20060105-P00900
      Ikenaka, T. (1980) Mol. Immunol., 17, 1407-1414.
    • 39 Komori, S., Yamasaki, N., Shigeta, M., Isojima, S.
      Figure US20060003334A1-20060105-P00900
      Watanabe, T. (1988) Clin. Exp. Immunol. 71, 508-516.
    • 40 Kratzin, H. D., Palm, W., Stangel, M., Schmidt, W. E., Friedrich, J.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1989) Biol. Chem. Hoppe-Seyler, 370, 263-272.
    • 41 Kratzin, H. D., Pick. A. I., Stangel, M.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten
      Figure US20060003334A1-20060105-P00900
      P. Westermark, Kluwer Academic Publishers, Dordrecht/Boston/London, Pp. 181-
    • 42 Langer, B., Steinmetz-Kayne, M.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1968) Z. Physiol. Chem., 349, 945-951.
    • 43 Larrick, J. W., Danielsson, L., Brenner, C. A., Wallace, E. F., Abrahamson, M., Fry, K. E.
      Figure US20060003334A1-20060105-P00900
      Borrebaeck, C. A. K. (1989) Bio/Tech., 7, 934-938.
    • 44 Levy, S., Mendel, E., Kon, S., Avnur, Z.
      Figure US20060003334A1-20060105-P00900
      Levy, R. (1988) J. Exp. Med., 168, 475-489.
    • 45 Lewis. A. P., Lemon, S. M., Barber, K. A., Murphy, P., Parry, N. R., Peakman, T. C., Sims, M. J., Worden, J.
      Figure US20060003334A1-20060105-P00900
      Crowe, J. S. (1993) J. Immunol., 151, 2829-2838.
    • 46 Liu, V. Y. S., Low, T. L. K., Infante, A.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1976) Science, 193, 1017-1020; Infante, A.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1979) J. Biol. Chem., 254, 9006-9016.
    • 47 Lopez De Castro, J. A., Chiu, Y. Y. H.
      Figure US20060003334A1-20060105-P00900
      Poljak, R. J. (1978) Biochemistry, 17, 1718-1723.
    • 48 Mantovani, L., Wilder, R. L.
      Figure US20060003334A1-20060105-P00900
      Casali, P. (1993) J. Immunol., 151, 473-488.
    • 49 Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J., Griffiths, A. D.
      Figure US20060003334A1-20060105-P00900
      Winter, G. (1991) J. Mol. Biol, 222, 581-597.
    • 50 Mihaesco, E., Roy, J.-P., Congy, N., Peran-Rivat, L.
      Figure US20060003334A1-20060105-P00900
      Mihaesco, C. (1985) Eur. J. Biochem., 150, 349-357.
    • 51 Milstein, C., Clegg, J. B.
      Figure US20060003334A1-20060105-P00900
      Jarvis, J. M. (1968) Biochem. J., 110, 631-652.
    • 52 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Hersh, E. M. (1993) Mol. Immunol., 30, 1543-1551.
    • 53 Nabeshima, Y.
      Figure US20060003334A1-20060105-P00900
      Ikenaka, T. (1979) Mol. Immunol., 16, 439-444.
    • 54 Olee, B. T., Lu, E. W., Huang, D.-F., Soto-Gil, R. W., Deftos, M., Kozin, F., Carson, D. A.
      Figure US20060003334A1-20060105-P00900
      Chen, P. P. (1992) J. Exp. Med., 175, 831-842.
    • 55 Pascual, V., Victor, K., Randen, I., Thompson, K., Steinitz, M., Forre, O., Fu, S.-M., Natvig, J. B.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) Scand. J. Immunol., 36, 349-362.
    • 56 Paul, E., Iliev, A. A., Livneh, A.
      Figure US20060003334A1-20060105-P00900
      Diamond, B. (1992) J. Immunol., 149, 3588-3595.
    • 57 Pick, A. I., Kratzin, H. D., Barnikol-Watanabe, S.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten
      Figure US20060003334A1-20060105-P00900
      P. Westermark, Kluwer Academic
    • 58 Ponstingl, H.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1969) Z. Physiol. Chem., 350, 1148-1152; (1971) Z. Physiol. Chem., 352, 859-877.
    • 59 Ponstingl, H., Hess, M.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1968) Z. Physiol. Chem., 349, 867-871; (1971) Z. Physiol. Chem., 352, 247-266.
    • 60 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Natvig, J. B. (1993) Eur. J. Immunol., 23, 1220-1225.
    • 61 Scholz, R.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1975) Z. Physiol. Chem., 356, 1333-1335.
    • 62 Settmacher, U., Jahn, S., Siegel, P., Von Baehr, R.
      Figure US20060003334A1-20060105-P00900
      Hansen, A. (1993) Mol. Immunol., 30, 953-954.
    • 63 Shinoda, T., Titani, K.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1970) J. Biol. Chem., 245, 4475-4487.
    • 64 Sletten, K., Husby, G.
      Figure US20060003334A1-20060105-P00900
      Natvig, J. B. (1974) Scand. J. Immunol., 3, 833-836.; Sletten. K., Natvig, J. B., Husby, G.
      Figure US20060003334A1-20060105-P00900
      Juul, J. (1981) Biochem. J., 195, 561-572.
    • 65 Solomon, A., Frangione, B.
      Figure US20060003334A1-20060105-P00900
      Franklin, E. C. (1982) J. Clin. Invest., 70, 453-460.; Frangione, B., Moloshok, T.
      Figure US20060003334A1-20060105-P00900
      Solomon, A. (1983) J. Immunol., 131, 2490-2493.
    • 66 Takahashi, N., Takayasu, T., Isobe, T., Shinoda, T., Okuyama, T.
      Figure US20060003334A1-20060105-P00900
      Shimizu, A. (1979) J. Biochem., 86, 1523-1535.
    • 67 Takahashi, N., Takayasu, T., Shinoda, T., Ito, S., Okuyama, T.
      Figure US20060003334A1-20060105-P00900
      Shimizu, A. (1980) Biomed. Res., 1, 321-333.
    • 68 Takahashi, Y., Takahashi, N., Tetaert, D.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1983) Proc. Nat. Acad. Sci. Usa. 80, 3686-3690.
    • 69 Takayasu, T., Takahashi, N., Shinoda, T., Okuyama, T.
      Figure US20060003334A1-20060105-P00900
      Tomioka, H. (1980) J. Biochem., 89, 421-436.
    • 70 Titani, K., Wikler, M., Shinoda, T.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1970) J. Biol. Chem., 245, 2171-2176.
    • 71 Toft, K. G., Sletten, K.
      Figure US20060003334A1-20060105-P00900
      Husby, G. (1985) Biol. Chem. Hoppe-Seyler, 366, 617-625.
    • 72 Tonoike. H., Kametani, F., Hoshi, A., Shinoda, T.
      Figure US20060003334A1-20060105-P00900
      Isobe, T. (1985) Biochem. Biophys. Res. Commun., 126, 1228-1234.
    • 73 Tonoike, H., Kametani, F., Hoshi, A., Shinoda, T.
      Figure US20060003334A1-20060105-P00900
      Isobe, T. (1985) Febs Letters, 185, 139-141.
    • 74 Tsujimoto, Y.
      Figure US20060003334A1-20060105-P00900
      Croce, C. M. (1984) Nucl. Acids Res., 12, 8407-8414.
    • 75 Tsunetsugu-Yokota, Y., Minekawa, T., Shigemoto, K., Shirasawa, T.
      Figure US20060003334A1-20060105-P00900
      Takemori, T. (1992) Mol. Immunol., 29, 723-728.
    • 76 Tveteraas, T., Sletten, K.
      Figure US20060003334A1-20060105-P00900
      Westermark, P. (1985) Biochem. J., 232, 183-190.
    • 77 Vasicek, T. J.
      Figure US20060003334A1-20060105-P00900
      Leder, P. (1990) J. Exp. Med., 172, 609-620.
    • 78 Victor, K. D., Randen, I., Thompson, K., Forre, O., Natvig, J. B., Fu, S. M.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1991) J. Clin. Invest., 87, 1603-1613.
    • 79 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M.
      Figure US20060003334A1-20060105-P00900
      Marcus, D. M. (1992) J. Immunol., 149, 2518-2529.
    • 80 Wikier, M.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1970) J. Biol. Chem., 245, 4488-4507.
    • 81 Winkler, T. H., Fehr, H.
      Figure US20060003334A1-20060105-P00900
      Kalden, J. R. (1992) Eur. J. Immunol., 22, 1719-1728.
    • 82 Yago, K., Zenita, K. Ohwaki, I., Harada, Y., Nozawa, S., Tsukazaki, K., Iwamori, M., Endo, N., Yasuda, N., Okuma, M.
      Figure US20060003334A1-20060105-P00900
      Kannagi, R. (1993) Mol. Immunol., 30, 1481-1489.
    • 83 Yamasaki, N., Komori, S.
      Figure US20060003334A1-20060105-P00900
      Watanabe, T. (1987) Mol. Immunol., 24, 981-985.
    • 84 Zhu, D., Kim, H. S.
      Figure US20060003334A1-20060105-P00900
      Deutsch, H. F. (1983) Mol. Immunol., 20, 1107-1116.
    • 85 Zhu, D., Zhang, H., Zhu, N.
      Figure US20060003334A1-20060105-P00900
      Luo, X. (1986) Scientia Sinica, 29, 746-755.
    REFERENCES OF REARRANGED HUMAN HEAVY CHAIN SEQUENCES USED FOR ALIGNMENT
    • 1 Adderson, E. E., Azmi, F. H., Wilson, P. M., Shackelford, P. G.
      Figure US20060003334A1-20060105-P00900
      Carroll, W. L. (1993) J. Immunol., 151, 800-809.
    • 2 Adderson, E. E., Shackelford, P. G., Quinn, A.
      Figure US20060003334A1-20060105-P00900
      Carroll, W. L. (1991) J. Immunol., 147, 1667-1674.
    • 3 Akahori, Y., Kurosawa, Y., Kamachi, Y., Torii, S.
      Figure US20060003334A1-20060105-P00900
      Matsuoka, H. (1990) J. Clin. Invest., 85, 1722-1727.
    • 4 Andris, J. S., Brodeur, B. R.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1993) Mol. Immunol., 30, 1601-1616.
    • 5 Andris, J. S., Ehrlich, P. H., Ostberg, L.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) J. Immunol., 149, 4053-4059.
    • 6 Andris, J. S., Johnson, S., Zolla-Pazner, S.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1991) Proc. Natl. Acad. Sci. Usa, 88, 7783-7787.
    • 7 Anker, R., Conley, M. E.
      Figure US20060003334A1-20060105-P00900
      Pollok, B. A. (1989) J. Exp. Med., 169, 2109-2119.
    • 8 Atkinson, P. M., Lampman, G. W., Furie, B. C., Naparstek, Y., Schwartz, R. S., Stollar, B. D.
      Figure US20060003334A1-20060105-P00900
      Furie, B. (1985) J. Clin. Invest., 75, 1138-1143.; Lampman, G. W., Furie, B., Schwartz, R. S., Stollar, B. D.
      Figure US20060003334A1-20060105-P00900
      Furie, B. C. (1989)
    • 9 Avila, M. A., Vazques, J., Danielsson, L., Fernandez De Cossio, M. E.
      Figure US20060003334A1-20060105-P00900
      Borrebaeck, C. A. K. (1993) Gene, 127, 273-274.
    • 10 Bakkus, M. H. C., Heirman, C., Van Riet, I., Van Camp, B.
      Figure US20060003334A1-20060105-P00900
      Thielemans, K. (1992) Blood, 80, 2326-2335.
    • 11 Barbas Iii, C. F., Crowe, Jr. J. E., Cababa. D., Jones, T. M., Zebedee, S. L., Murphy, B. R., Chanock, R. M.
      Figure US20060003334A1-20060105-P00900
      Burton. D. R. (1992) Proc. Natl. Acad. Sci. Usa, 89, 10164-10168.
    • 12 Barbas, C. F., Iii, Collet, T. A., Amberg, W., Roben, P., Binley, J. M., Hoekstra, D., Cababa, D., Jones, T. M., Williamson, R. A., Pilkington, G. R., Haigwood, N. L., Cabezas, E., Satterthwait, A. C., Sanz, I.
      Figure US20060003334A1-20060105-P00900
      Burton, D. R. (1993) J. Mol. Biol., 230, 812-823.
    • 13 Berman, J. E., Humphries, C. G., Barth, J., Alt. F. W.
      Figure US20060003334A1-20060105-P00900
      Tucker, P. W. (1991) J. Exp. Med., 173, 1529-1535.
    • 14 Berman, J. E., Mellis, S. J., Pollock, R., Smith, C. L., Suh, H., Heinke, B., Kowal, C., Surti, U., Chess, L., Cantor, C. R
      Figure US20060003334A1-20060105-P00900
      Alt, F. W. (1988) Embo J., 7, 727-738.
    • 15 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K.
      Figure US20060003334A1-20060105-P00900
      Teng, N. N. H. (1993) J. Immunol., 151, 5011-5021.
    • 16 Bird, J., Galili, N., Link, M., Stites, D.
      Figure US20060003334A1-20060105-P00900
      Sklar, J. (1988) J. Exp. Med., 168, 229-245.
    • 17 Cai, J., Humphries, C., Richardson, A.
      Figure US20060003334A1-20060105-P00900
      Tucker, P. W. (1992) J. Exp. Med., 176, 1073-1081.
    • 18 Cairns, E., Kwong, P. C., Misener, V., Ip, P., Bell, D. A.
      Figure US20060003334A1-20060105-P00900
      Siminovitch, K. A. (1989) J. Immunol., 143, 685-691.
    • 19 Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Hopper, J. E. (1976) Immunochemistry, 13, 995-999; Hopper, J. E., Noyes, C., Heinrikson, R.
      Figure US20060003334A1-20060105-P00900
      Kessel, J. W. (1976) J. Immunol., 116, 743-746.
    • 20 Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Kehoe, J. M. (1974) Proc. Nat. Acad. Sci. Usa, 71, 845-848.
    • 21 Carroll, W. L., Yu, M., Link, M. P.
      Figure US20060003334A1-20060105-P00900
      Korsmeyer, S. J. (1989) J. Immunol., 143, 692-698.
    • 22 Chen, P. P., Liu, M.-F., Glass, C. A., Sinha, S., Kipps, T. J.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1989) Arthritis
      Figure US20060003334A1-20060105-P00900
      Rheumatism, 32, 72-76; Kipps, T. J., Tomhave, E., Pratt, L. F., Duffy, S., Chen, P. P.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1989) Proc. Natl. Acad. Sci. Usa, 86, 5913-5917.
    • 23 Chiu, Y. Y. H., Lopez De Castro, J. A.
      Figure US20060003334A1-20060105-P00900
      Poljak, R. J. (1979) Biochemistry, 18, 553-560.
    • 24 Cleary, M. L. Meeker, T. C., Levy, S., Lee, E., Trela, M., Sklar, J.
      Figure US20060003334A1-20060105-P00900
      Levy, R. (1986) Cell, 44, 97-106.
    • 25 Cuisinier, A.-M., Fumoux, F., Fougereau, M.
      Figure US20060003334A1-20060105-P00900
      Tonnelle, C. (1992) Mol. Immunol., 29, 1363-1373.
    • 26 Cuisinier, A.-M., Gauthier, L., Boubli, L., Fougereau, M.
      Figure US20060003334A1-20060105-P00900
      Tonnelle, C. (1993) Eur. J. Immunol., 23, 110-118.
    • 27 Cunningham, B. A., Gottiieb, P. D., Pflumm, M. N.
      Figure US20060003334A1-20060105-P00900
      Edelman, G. M. (1971) Progress In Immunology (B. Amos, Ed.), Academic Press, N.Y., Pp. 3-24.
    • 28 Cunningham, B. A., Rutishauser, U., Gall, W. E., Gottlieb, P. D., Waxdal, M. J.
      Figure US20060003334A1-20060105-P00900
      Edelman, G. M. (1970) Biochemistry, 9, 3161-3170.
    • 29 Deane, M.
      Figure US20060003334A1-20060105-P00900
      Norton, J. D. (1990) Eur. J. Immunol., 20, 2209-2217.
    • 30 Deane, M.
      Figure US20060003334A1-20060105-P00900
      Norton, J. D. (1991) Leukemia, 5, 646-650.
    • 31 Dersimonian, H., Schwartz, R. S., Barrett, K. J.
      Figure US20060003334A1-20060105-P00900
      Stollar, B. D. (1987) J. Immunol., 139, 2496-2501.
    • 32 Dersimonian, H., Schwartz, R. S., Barrett, K. J.
      Figure US20060003334A1-20060105-P00900
      Stollar, B. D. (1987) J. Immunol., 139, 2496-2501; Chen, P. P., Liu, M.-F., Sinha, S.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1988) Arth. Rheum., 31, 1429-1431.
    • 33 Desai, R., Spatz, L., Matsuda, T., Ilyas. A. A., Berman, J. E., Alt, F. W., Kabat, E. A.
      Figure US20060003334A1-20060105-P00900
      Latov, N. (1990) J. Neuroimmunol., 26, 35-41.
    • 34 Ezaki, I., Kanda, H., Sakai, K., Fukui, N., Shingu, M., Nobunaga, M.
      Figure US20060003334A1-20060105-P00900
      Watanabe, T. (1991) Arthritis And Rheumatism, 34, 343-350.
    • 35 Felgenhauer, M., Kohl, J.
      Figure US20060003334A1-20060105-P00900
      Ruker, F. (1990) Nucl. Acids Res. 18, 4927.
    • 36 Florent, G., Lehman, D.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1974) Biochemistry, 13, 2482-2498.
    • 37 Friedlander, R. M., Nussenzweig, M. C.
      Figure US20060003334A1-20060105-P00900
      Leder, P. (1990) Nucl. Acids Res., 18, 4278.
    • 38 Gawinowicz, M. A., Merlini, G., Birken, S., Osserman, E. F.
      Figure US20060003334A1-20060105-P00900
      Kabat, E. A. (1991) J. Immunol., 147, 915-920.
    • 39 Gillies, S. D., Dorai, H., Wesolowski, J., Majeau, G., Young, D., Boyd, J., Gardner, J.
      Figure US20060003334A1-20060105-P00900
      James, K. (1989) Bio/Tech., 7, 799-804.
    • 40 Goni, F.
      Figure US20060003334A1-20060105-P00900
      Frangione, B. (1983) Proc. Nat. Acad. Sci. Usa, 80, 4837-4841.
    • 41 Gorman, S. D., Clark, M. R., Routledge, E. G., Cobbold, S. P.
      Figure US20060003334A1-20060105-P00900
      Waldmann, H. (1991) Proc. Natl. Acad. Sci. Usa, 88, 4181-4185.
    • 42 Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M., Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., Hughes-Jones, N. C., Hoogenboom, H. R.
      Figure US20060003334A1-20060105-P00900
      Winter, G. (1993) Embo J. 12, 725-734.
    • 43 Grillot-Courvalin, C., Brouet, J.-C., Piller, F., Rassenti, L. Z., Labaume, S., Silverman, G. J., Silberstein, L.
      Figure US20060003334A1-20060105-P00900
      Kipps, T. J. (1992) Eur. J. Immunol., 22, 1781-1788.
    • 44 Guillaume, T., Rubinstein, D. B., Young, F., Tucker, L., Logtenberg, T., Schwartz, R. S.
      Figure US20060003334A1-20060105-P00900
      Barrett, K. L. (1990) J. Immunol., 145, 1934-1945; Young, F., Tucker, L., Rubinstein, D., Guillaume, T., Andre-Schwartz, J., Barrett, K. J., Schwartz, R. S.
      Figure US20060003334A1-20060105-P00900
      Logtenberg, T. (1990)
    • 45 Harindranath, N., Goldfarb, I. S., Ikematsu, H., Burastero, S. E., Wilder, R. L., Notkins, A. L.
      Figure US20060003334A1-20060105-P00900
      Casali, P. (1991) Int. Immunol., 3, 865-875.
    • 46 Hillson, J. L., Oppliger, I. R., Sasso, E. H., Milner, E. C. B.
      Figure US20060003334A1-20060105-P00900
      Wener, M. H. (1992) J. Immunol., 149, 3741-3752.
    • 47 Hirabayashi. Y., Munakata, Y., Sasaki, T.
      Figure US20060003334A1-20060105-P00900
      Sano, H. (1992) Nucl. Acids Res., 20, 2601.
    • 48 Hoch, S.
      Figure US20060003334A1-20060105-P00900
      Schwaber, J. (1987) J. Immunol., 139, 1689-1693.
    • 49 Huang, C., Stewart, A. K., Schwartz, R. S.
      Figure US20060003334A1-20060105-P00900
      Stollar, B. D. (1992) J. Clin. Invest., 89, 1331-1343.
    • 50 Hughes-Jones, N. C., Bye, J. M., Beale, D.
      Figure US20060003334A1-20060105-P00900
      Coadwell, J. (1990) Biochem. J., 268, 135-140.
    • 51 Ikematsu, H., Harindranath, N., Ueki, Y., Notkins, A. L.
      Figure US20060003334A1-20060105-P00900
      Casali, P. (1993) J. Immunol., 150, 1325-1337.
    • 52 Ikematsu, H., Kasaian, M. T., Schettino, E. W.
      Figure US20060003334A1-20060105-P00900
      Casali, P. (1993) J. Immunol., 151, 3604-3616.
    • 53 Kelly, P. J., Pascual, V., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Lipsky, P. E. (1992) J. Immunol., 148, 1294-1301.
    • 54 Kipps, T. J.
      Figure US20060003334A1-20060105-P00900
      Duffy, S. F. (1991) J. Clin. Invest., 87, 2087-2096.
    • 55 Kipps, T. J., Tomhave, E., Pratt, L. F., Duffy, S., Chen, P. P.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1989) Proc. Natl. Acad. Sci. Usa, 86, 5913-5917.
    • 56 Kishimoto, T., Okajima, H., Okumoto, T.
      Figure US20060003334A1-20060105-P00900
      Taniguchi, M. (1989) Nucl. Acids Res., 17, 4385.
    • 57 Knight, G. B., Agnello, V., Bonagura, V., Barnes, J. L., Panka, D. J.
      Figure US20060003334A1-20060105-P00900
      Zhang, Q.-X (1993) J. Exp. Med., 178, 1903-1911.
    • 58 Kohler, H., Shimizu, A., Paul, C., Moore, V.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1970) Nature, 227, 1318-1320; Florent, G., Lehman, D.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1974) Biochemistry, 13, 2482-2498
    • 59 Komori, S., Yamasaki, N., Shigeta, M., Isojima, S.
      Figure US20060003334A1-20060105-P00900
      Watanabe, T. (1988) Clin. Exp. Immunol., 71, 508-516.
    • 60 Kon, S., Levy, S.
      Figure US20060003334A1-20060105-P00900
      Levy, R. (1987) Proc. Natl. Acad. Sci. Usa, 84, 5053-5057.
    • 61 Kratzin, H., Altevogt, P., Ruban, E., Kortt, A., Staroscik, K.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1975) Z. Physiol. Chem., 356, 1337-1342; Kratzin, H., Altevogt, P., Kortt, A., Ruban, E.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1978) Z. Physiol. Chem., 359, 1717-1745.
    • 62 Kudo, A. Ishihara. T. Nishimura, Y.
      Figure US20060003334A1-20060105-P00900
      Watanabe, T. (1985) Gene, 33, 181-189.
    • 63 Kunicki, T. J., Annis, D. S., Gorski, J.
      Figure US20060003334A1-20060105-P00900
      Nugent. D. J. (1991) J. Autoimmunity, 4, 433-446.
    • 64 Larrick, J. W., Wallace, E. F., Coloma, M. J., Bruderer, U., Lang, A. B.
      Figure US20060003334A1-20060105-P00900
      Fry, K. E. (1992) Immunological Reviews, 130, 69-85.
    • 65 Lehman, D. W.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1980) Proc. Nat. Acad. Sci. Usa, 77, 3239-3243.
    • 66 Lewis, A. P., Lemon, S. M., Barber, K. A., Murphy, P., Parry, N. R., Peakman, T. C., Sims, M. J., Worden, J.
      Figure US20060003334A1-20060105-P00900
      Crowe, J. S. (1993) J. Immunol., 151, 2829-2838.
    • 67 Liu, V. Y. S., Low, T. L. K., Infante, A.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1976) Science, 193, 1017-1020.
    • 68 Logtenberg, T., Young, F. M., Van Es, J. H., Gmelig-Meyling, F. H. J., Berman, J. E.
      Figure US20060003334A1-20060105-P00900
      Alt, F. W. (1989) J. Autoimmunity, 2, 203-213.
    • 69 Logtenberg, T., Young, F. M., Van Es, J. H., Gmelig-Meyling, F. H. J.
      Figure US20060003334A1-20060105-P00900
      Alt, F. W. (1989) J. Exp. Med., 170, 1347-1355.
    • 70 Manheimer-Lory, A., Katz, J. B., Pillinger, M., Ghossein, C., Smith, A.
      Figure US20060003334A1-20060105-P00900
      Diamond, B. (1991) J. Exp. Med., 174, 1639-1652.
    • 71 Mantovani, L., Wilder, R. L.
      Figure US20060003334A1-20060105-P00900
      Casali, P. (1993) J. Immunol., 151, 473-488.
    • 72 Mariette, X., Tsapis, A.
      Figure US20060003334A1-20060105-P00900
      Brouet, J.-C. (1993) Eur. J. Immunol., 23, 846-851.
    • 73 Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J., Griffiths, A. D.
      Figure US20060003334A1-20060105-P00900
      Winter, G. (1991) J. Mol. Biol., 222, 581-597.
    • 74 Meeker, T. C., Grimaldi, J., O'rourke, R., Loeb, J. Juliusson, G.
      Figure US20060003334A1-20060105-P00900
      Einhorn, S. (1988) J. Immol., 141, 3994-3998.
    • 75 Milili, M., Fougereau. M., Guglielmi, P.
      Figure US20060003334A1-20060105-P00900
      Schiff, C. (1991) Mol. Immunol., 28, 753-761.
    • 76 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Hersh, E. M. (1993) Mol. Immunol., 30, 1543-1551.
    • 77 Mortari, F., Wang, J.-Y.
      Figure US20060003334A1-20060105-P00900
      Schroeder, Jr., H. W. (1993) J. Immunol., 150, 1348-1357.
    • 78 Newkirk, M. M., Gram, H., Heinrich, G. F., Ostberg, L., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Wasserman, R. L. (1988) J. Clin. Invest, 81, 1511-1518.
    • 79 Newkirk, M. M., Mageed, R. A., Jefferis, R., Chen, P. P.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1987) J. Exp. Med., 166, 550-564.
    • 80 Nickerson, K. G., Berman, J., Glickman, E., Chess, L.
      Figure US20060003334A1-20060105-P00900
      Alt, F. W. (1989) J. Exp. Med., 169, 1391-1403.
    • 81 Olee, B. T., Lu, E. W., Huang, D.-F., Soto-Gil, R. W., Deftos, M., Kozin, F., Carson, D. A.
      Figure US20060003334A1-20060105-P00900
      Chen, P. P. (1992) J. Exp. Med., 175, 831-842.
    • 82 Pascual, V., Randen, I., Thompson, K., Sioud, M. Forre, O., Natvig, J.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1990) J. Clin. Invest., 86, 1320-1328.
    • 83 Pascual, V., Randen, I., Thompson, K., Sioud, M. Forre, O., Natvig, J.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1990) J. Clin. Invest., 86, 1320-1328; Randen, I., Brown, D., Thompson, K. M., Hughes-Jones, N., Pascual, V., Victor, K., Capra, J. D., Forre, O.
      Figure US20060003334A1-20060105-P00900
      Natvig, J. B. (1992)
    • 84 Pascual, V., Victor, K., Lelsz, D., Spellerberg, M. B., Hamblin, T. J., Thompson, K. M., Randen, I., Natvig. J., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Stevenson, F. K. (1991) J. Immunol., 146, 4385-4391.
    • 85 Pascual, V., Victor, K., Randen, I., Thompson, K., Steinitz, M., Forre, O., Fu, S.-M., Natvig, J. B.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) Scand. J. Immunol., 36, 349-362.
    • 86 Pascual, V., Victor, K., Spellerberg, M., Hamblin, T. J., Stevenson, F. K.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) J. Immunol., 149, 2337-2344.
    • 87 Ponstingl, H., Schwarz, J., Reichel, W.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1970) Z. Physiol. Chem., 351, 1591-1594.; Ponstingl, H.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1976) Z. Physiol. Chem., 357, 1571-1604.
    • 88 Portolano, S., Mclachlan, S. M.
      Figure US20060003334A1-20060105-P00900
      Rapoport, B. (1993) J. Immunol., 151, 2839-2851.
    • 89 Portolano, S., Seto, P., Chazenbalk, G. D., Nagayama, Y., Mclachlan, S. M.
      Figure US20060003334A1-20060105-P00900
      Rapoport, B. (1991) Biochem. Biophys. Res. Commun., 179,372-377.
    • 90 Pratt, L. F., Szubin, R., Carson, D. A.
      Figure US20060003334A1-20060105-P00900
      Kipps, T. J. (1991) J. Immunol., 147, 2041-2046.
    • 91 Press, E. M.
      Figure US20060003334A1-20060105-P00900
      Hogg, N. M. (1970) Biochem. J., 117, 641-660.
    • 92 Putnam, F. W., Shimizu, A., Paul., C., Shinoda, T.
      Figure US20060003334A1-20060105-P00900
      Kohler, H. (1971) Ann. N.Y. Acad. Sci. 190, 83-103.
    • 93 Putnam, F. W., Takahashi, N., Tetaert, D., Debuire, B.
      Figure US20060003334A1-20060105-P00900
      Lin, L. C. (1981) Proc. Nat. Acad. Sci. Usa; 78, 6168-6172.; Takahashi, N., Tetaert, D., Debuire, B., Lin, L.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1982) Proc. Nat. Acad. Sci. Usa, 79, 2850-2854.
    • 94 Raaphorst, F. M., Timmers, E., Kenter, M. J. H., Van Tol, M. J. D., Vossen, J. M.
      Figure US20060003334A1-20060105-P00900
      Schuurman, R. K. B. (1992) Eur. J. Immunol., 22, 247-251.
    • 95 Rabbitts, T. H., Bentley, D. L., Dunnick, W., Forster, A., Matthyssens, G.
      Figure US20060003334A1-20060105-P00900
      Milstein, C. (1980) Cold Spring Harb. Symp. Quanti. Biol., 45, 867-878; Matthyssens, G.
      Figure US20060003334A1-20060105-P00900
      Rabbitts, T. H. (1980) Proc. Nat. Acad. Sci. Usa, 77, 6561-6565.
    • 96 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O., Capra, J. D.
      Figure US20060003334A1-20060105-P00900
      Natvig, J. B. (1993) Eur. J. Immunol., 23, 1220-1225.
    • 97 Rassenti, L. Z.
      Figure US20060003334A1-20060105-P00900
      Kipps, T. J. (1993) J. Exp. Med., 177, 1039-1046.
    • 98 Reidi, L. S., Friedman, D. F., Goldman, J., Hardy, R. R., Jefferies, L. C.
      Figure US20060003334A1-20060105-P00900
      Silberstein, L. E. (1991) J. Immunol., 147, 3623-3631.
    • 99 Roudier, J., Silverman, G. J., Chen, P. P., Carson, D. A.
      Figure US20060003334A1-20060105-P00900
      Kipps, T. J. (1990) J. Immunol., 144, 1526-1530.
    • 100 Sanz, I., Casali, P., Thomas, J. W., Notkins, A. L.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1989) J. Immunol., 142, 4054-4061.
    • 101 Sanz. I., Dang. H., Takei, M., Talal, N.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1989) J. Immunol., 142, 883-887.
    • 102 Schmidt, W. E., Jung, H-.D., Palm, W.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1983) Z. Physiol. Chem., 364, 713-747.
    • 103 Schroeder, H. W., Jr.
      Figure US20060003334A1-20060105-P00900
      Wang, J. Y. (1990) Proc. Natl. Acad. Sci. Usa, 87, 6146-6150.
    • 104 Schroeder, H. W., Jr., Hillson, J. L.
      Figure US20060003334A1-20060105-P00900
      Perlmutter, R. M. (1987) Science, 238, 791-793.
    • 105 Schroeder, H. W., Jr., Hillson, J. L.
      Figure US20060003334A1-20060105-P00900
      Perlmutter, R. M. (1987) Science, 238, 791-793; Chen, P. P., Liu, M.-F., Glass, C. A., Sinha, S., Kipps, T. J.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1989) Arthritis
      Figure US20060003334A1-20060105-P00900
      Rheumatism, 32, 72-76.
    • 106 Schroeder, H. W., Jr., Hillson, J. L.
      Figure US20060003334A1-20060105-P00900
      Perlmutter, R. M. (1987) Science, 238, 791-793; Chen, P. P., Liu, M.-F., Sinha, S.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1988) Arth. Rheum., 31, 1429-1431.
    • 107 Schutte, M. E., Ebeling, S. B., Akkermans, K. E, Gmelig-Meyling, F. H.
      Figure US20060003334A1-20060105-P00900
      Logtenberg, T. (1991) Eur. J. Immunol., 21, 1115-1121.
    • 108 Schutte, M. E., Ebeling, S. B., Akkermans, K. E., Gmelig-Meyling, F. H. J.
      Figure US20060003334A1-20060105-P00900
      Logtenberg, T. (1991) Eur. J. Immunol., 21, 1115-1121.
    • 109 Settmacher, U., Jahn, S., Siegel, P., Von Baehr, R.
      Figure US20060003334A1-20060105-P00900
      Hansen, A. (1993) Mol. Immunol., 30, 953-954.
    • 110 Shen, A., Humphries, C., Tucker, P.
      Figure US20060003334A1-20060105-P00900
      Blattner, F. (1987) Proc. Natl. Acad. Sci. Usa, 84, 8563-8567.
    • 111 Shimizu, A., Nussenzweig, M. C., Mizuta, T.-R., Leder, P.
      Figure US20060003334A1-20060105-P00900
      Honjo, T. (1989) Proc. Natl. Acad. Sci. Usa, 86, 8020-8023.
    • 112 Shin, E. K., Matsuda, F., Fujikura, J., Akamizu, T., Sugawa, H., Mori, T.
      Figure US20060003334A1-20060105-P00900
      Honjo, T. (1993) Eur. J. Immunol., 23, 2365-2367.
    • 113 Silberstein, L. E., Litwin, S.
      Figure US20060003334A1-20060105-P00900
      Carmack, C. E. (1989) J. Exp. Med. 169, 1631-1643.
    • 114 Singal, D. P., Frame, B., Joseph, S., Blajchman, M. A.
      Figure US20060003334A1-20060105-P00900
      Leber, B. F. (1993) Immunogenet., 38, 242.
    • 115 Spatz, L. A., Wong, K. K., Williams, M., Desai, R., Golier, J., Berman, J. E., Alt, F. W.
      Figure US20060003334A1-20060105-P00900
      Latov, N. (1990) J. Immunol., 144, 2821-2828.
    • 116 Steiner, L. A., Garcia-Pardo, A.
      Figure US20060003334A1-20060105-P00900
      Margolies, M. N. (1979) Biochemistry, 18, 4068-4080.
    • 117 Stewart, A. K., Huang, C., Stollar, B. D.
      Figure US20060003334A1-20060105-P00900
      Schwartz, R. S. (1993) J. Exp. Med., 177, 409-418.
    • 118 Thomas, J. W. (1993) J. Immunol., 150, 1375-1382.
    • 119 Torano, A.
      Figure US20060003334A1-20060105-P00900
      Putnam, F. W. (1978) Proc. Nat. Acad. Sci. Usa, 75, 966-969.
    • 120 Van Der Heijden, R. W. J., Bunschoten, H., Pascual, V., Uytdehaag, F. G. C. M., Osterhaus, A. D. M. E.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1990) J. Immunol., 144, 2835-2839.
    • 121 Van Der Stoep, N., Van Der Linden, J.
      Figure US20060003334A1-20060105-P00900
      Logtenberg, T. (1993) J. Exp. Med., 177, 99-107.
    • 122 Van Es, J. H., Gmelig-Meyling, F. H. J.
      Figure US20060003334A1-20060105-P00900
      Logtenberg, T. (1992) Eur. J. Immunol., 22, 2761-2764.
    • 123 Varade, W. S., Marin, E., Kittelberger, A. M.
      Figure US20060003334A1-20060105-P00900
      Insel, R. A. (1993) J. Immunol., 150, 4985-4995.
    • 124 Victor, K. D., Pascual, V., Lefvert, A. K.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) Mol. Immunol., 29, 1501-1506.
    • 125 Victor, K. D., Pascual, V., Williams, C. L., Lennon, V. A.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1992) Eur. J. Immunol., 22, 2231-2236.
    • 126 Watanabe, S., Barnikol, H. U., Horn, J., Bertram, J.
      Figure US20060003334A1-20060105-P00900
      Hilschmann, N. (1973) Z. Physiol. Chem., 354, 1505-1509.
    • 127 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M.
      Figure US20060003334A1-20060105-P00900
      Marcus, D. M. (1992) J. Immunol., 149, 2518-2529.
    • 128 White, M. B., Word, C. J., Humphries, C. G., Blattner, F. R.
      Figure US20060003334A1-20060105-P00900
      Tucker, P. W. (1990) Mol. Cell. Biol., 10, 3690-3699.
    • 129 Winkler, T. H., Fehr, H.
      Figure US20060003334A1-20060105-P00900
      Kalden, J. R. (1992) Eur. J. Immunol., 22, 1719-1728.
    • 130 Yago, K., Zenita, K., Ohwaki, I., Harada, Y., Nozawa, S., Tsukazaki, K., Iwamori, M., Endo, N., Yasuda, N., Okuma, M.
      Figure US20060003334A1-20060105-P00900
      Kannagi, R. (1993) Mol. Immunol., 30, 1481-1489.
    • 131 Zelenetz, A. D., Chen, T. T.
      Figure US20060003334A1-20060105-P00900
      Levy, R. (1992) J. Exp. Med., 176, 1137-1148.
    B. REFERENCES OF GERMLINE SEQUENCES REFERENCES OF HUMAN GERMLINE KAPPA SEQUENCES
    • 1 Cox, J. P. L, Tomlinson, I. M.
      Figure US20060003334A1-20060105-P00900
      Winter, G. (1994) Eur. J. Immunol., 24, 827-836.
    • 2 Huber, C., Et Al. (1993) Eur. J. Immunol., 23, 2868.
    • 3 Klobeck, H. G., Bornkammm, G. W., Combriato, G., Mocikat, R., Pohlenz, H. D.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1985) Nucl. Acids Res., 13, 6515-6529.
    • 4 Lautner-Rieske, A., Huber, C., Meindl, A., Pargent, W., Schable, K. F., Thiebe, R., Zocher, I.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1992) Eur. J. Immunol. 22, 1023.
    • 5 Lorenz, W., Schäble, K. F., Thiebe, R., Stavnezer, J.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1988) Mol. Immunol., 25, 479.
    • 6 Pargent, W., Meindl, A., Thiebe, R., Mitzel, S.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1991) Eur. J. Immunol., 21, 1821-1827.
    • 7 Pech, M.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1984) Nuc. Acids Res., 12, 9229-9236.
    • 8 Pech, M., Jaenichen, H.-R., Pohlenz, H.-D., Neumaier, P. S., Klobeck, H.-G.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1984) J. Mol. Biol., 176, 189-204.
    • 9 Scott, M. G., Crimmins, D. L., Mccourt, D. W., Chung, G., Schable, K. F., Thiebe, R., Quenzel, E.-M., Zachau, H. G.
      Figure US20060003334A1-20060105-P00900
      Nahm, M. H. (1991) J. Immunol., 147, 4007-4013.
    • 10 Stavnezer, J., Kekish, O., Batter, D., Grenier, J., Balazs, I., Henderson, E.
      Figure US20060003334A1-20060105-P00900
      Zegers, B. J. M. (1985) Nucl. Acids Res., 13, 3495-3514.
    • 11 Straubinger, B., Huber, E., Lorenz, W., Osterholzer, E., Pargent, W., Pech, M., Pohlenz, H.-D., Zimmer, F.-J.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1988) J. Mol. Biol., 199, 23-34.
    • 12 Straubinger, B., Thiebe, R., Huber, C., Osterholzer, E.
      Figure US20060003334A1-20060105-P00900
      Zachau, H. G. (1988) Biol. Chem. Hoppe-Seyer, 369, 601-607.
    REFERENCES OF HUMAN GERMLINE LAMBDA SEQUENCES 1 Williams, S. C. Winter, G. (1993) Eur. J. Immunol., 23, 1456-1461.
    • 2 Siminovitch, K. A., Misener, V., Kwong, P. C., Song, Q.-L.
      Figure US20060003334A1-20060105-P00900
      Chen, P. P. (1989) J. Clin. Invest., 84, 1675-1678.
    • 3 Brockly, F., Alexandre, D., Chuchana, P., Huck, S., Lefranc, G.
      Figure US20060003334A1-20060105-P00900
      Lefranc, M.-P. (1989) Nuc. Acids. Res., 17, 3976.
    • 4 Daley, M. D., Peng, H.-Q., Misener, V., Liu, X.-Y., Chen, P. P.
      Figure US20060003334A1-20060105-P00900
      Siminovitch, K. A. (1992) Mol. Immunol., 29, 1515-1518.
    • 5 Deftos, M., Soto-Gil, R., Quan, M., Olee, T.
      Figure US20060003334A1-20060105-P00900
      Chen, P. P. (1994) Scand. J. Immunol., 39, 95.
    • 6 Stiernholm, N. B. J., Kuzniar, B.
      Figure US20060003334A1-20060105-P00900
      Berinstein, N. L. (1994) J. Immunol., 152, 4969-4975.
    • 7 Combriato, G.
      Figure US20060003334A1-20060105-P00900
      Klobeck, H. G. (1991) Eur. J. Immunol., 21, 1513-1522.
    • 8 Anderson, M. L. M., Szajnert, M. F., Kaplan, J. C., Mccoll, L.
      Figure US20060003334A1-20060105-P00900
      Young, B. D. (1984) Nuc. Acids Res., 12, 6647-6661.
    REFERENCES OF HUMAN GERMLINE HEAVY CHAIN SEQUENCES
    • 1 Adderson, E. E. Azmi, F. H., Wilson, P. M., Shackelford, P. G.
      Figure US20060003334A1-20060105-P00900
      Carroll, W. L. (1993) J. Immunol., 151, 800-809.
    • 2 Andris, J. S. Brodeur, B. R.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1993) Mol. Immunol., 30, 1601-1616.
    • 3 Berman, J. E., Mellis, S. J., Pollock, R., Smith, C. L, Suh, H., Heinke, B., Kowal, C., Surti, U., Chess, L., Cantor, C. R
      Figure US20060003334A1-20060105-P00900
      Alt, F. W. (1988) Embo J., 7, 727-738.
    • 4 Buluwela, L.
      Figure US20060003334A1-20060105-P00900
      Rabbitts, T. H. (1988) Eur. J. Immunol., 18, 1843-1845.; Buluwela, L., Albertson, D. G., Sherrington, P., Rabbitts, P. H., Spurr, N.
      Figure US20060003334A1-20060105-P00900
      Rabbitts, T. H. (1988) Embo J., 7, 2003-2010.
    • 5 Chen, P. P., Liu, M.-F., Sinha, S.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1988) Arth. Rheum., 31, 1429-1431.
    • 6 Chen, P. P., Liu, M.-F., Glass, C. A., Sinha, S., Kipps, T. J.
      Figure US20060003334A1-20060105-P00900
      Carson, D. A. (1989) Arthritis
      Figure US20060003334A1-20060105-P00900
      Rheumatism, 32, 72-76.
    • 7 Cook, G. P. et al. (1994) Nature Genetics 7, 162-168.
    • 8 Haino, M. et al., (1994). J. Biol. Chem. 269, 2619-2626
    • 9 Humphries, C. G., Shen, A., Kuziel, W. A., Capra, J. D., Blattner, F. R.
      Figure US20060003334A1-20060105-P00900
      Tucker, P. W. (1988) Nature, 331, 446-449.
    • 10 Kodaira, M., Kinashi, T., Umemura, I., Matsuda, F., Noma, T., Ono, Y.
      Figure US20060003334A1-20060105-P00900
      Honjo, T. (1986) J. Mol. Biol., 190, 529-541.
    • 11 Lee, K. H., Matsuda, F., Kinashi, T., Kodaira, M.
      Figure US20060003334A1-20060105-P00900
      Honjo, T. (1987) J. Mol. Biol., 195, 761-768.
    • 12 Matsuda, F., Lee, K. H., Nakai, S., Sato, T., Kodaira, M., Zong, S. Q., Ohno, H., Fukuhara, S.
      Figure US20060003334A1-20060105-P00900
      Honjo, T. (1988) Embo J., 7, 1047-1051.
    • 13 Matsuda, F., Shin, E. K, Hirabayashi, Y., Nagaoka, H., Yoshida, M. C., Zong, S. Q.
      Figure US20060003334A1-20060105-P00900
      Honjo, T. (1990) Embo J., 9, 2501-2506.
    • 14 Matsuda, F., Shin, E. K., Nagaoka, H., Matsumura, R., Haino, M., Fukita, Y., Taka-Ishi, S., Imai, T., Riley, J. H., Anand, R. Et, Al. (1993) Nature Genet. 3, 88-94
    • 15 Nagaoka, H., Ozawa, K., Matsuda, F., Hayashida, H., Matsumura, R., Haino, M., Shin, E. K., Fukita, Y., Imai, T., Anand, R., Yokoyama, K., Eki, T., Soeda, E.
      Figure US20060003334A1-20060105-P00900
      Honjo, T. (1993). (Temporal)
    • 16 Rechavi, G., Bienz, B., Ram, D., Ben-Neriah, Y., Cohen, J. B., Zakut, R.
      Figure US20060003334A1-20060105-P00900
      Givol. D. (1982) Proc. Nat. Acad. Sci. Usa, 79, 4405-4409.
    • 17 Sanz, I., Kelly, P., Williams, C., Scholl, S., Tucker, P.
      Figure US20060003334A1-20060105-P00900
      Capra, J. D. (1989) Embo J., 8, 3741-3748.
    • 18 Shin, E. K., Matsuda, F., Fujikura, J., Akamizu, T., Sugawa, H., Mori, T.
      Figure US20060003334A1-20060105-P00900
      Honjo, T. (1993) Eur. J. Immunol., 23, 2365-2367.
    • 19 Tomlinson, Im., Walter, G., Marks, Jd., Liewelyn, Mb.
      Figure US20060003334A1-20060105-P00900
      Winter. G. (1992) J. Mol. Biol. 227, 776-798.
    • 20 Van Der Maarel, S., Van Dijk, K. W., Alexander, C. M., Sasso, E. H., Bull, A.
      Figure US20060003334A1-20060105-P00900
      Milner, E. C. B. (1993) J. Immunol., 150, 2858-2868.
    • 21 Van Dijk, K. W., Mortari, F., Kirkham, P. M., Schroeder, Jr., H. W.
      Figure US20060003334A1-20060105-P00900
      Milner, E. C. B. (1993) Eur. J. Immunol. 23, 832-839.
    • 22 Van Es, J. H., Aanstoot, H., Gmelig-Meyling, F. H. J., Derksen, R. H. W. M.
      Figure US20060003334A1-20060105-P00900
      Logtenberg, T. (1992) J. Immunol., 149, 2234-2240.
    • 23 Weng, N.-P., Snyder, J. G., Yu-Lee, L.-Y.
      Figure US20060003334A1-20060105-P00900
      Marcus, D. M. (1992) Eur. J. Immunol., 22, 1075-1082.
    • 24 Winkler, T. H., Fehr, H.
      Figure US20060003334A1-20060105-P00900
      Kalden, J. R. (1992) Eur. J. Immunol., 22, 1719-1728.
    • 25 Olee, T., Yang, P. M., Siminovitch, K. A., Olsen, N. J., Hillson, J. L., Wu, J., Kozin, F., Carson, D. A.
      Figure US20060003334A1-20060105-P00900
      Chen, P. P. (1991) J. Clin. Invest 88, 193-203.
    • 26 Chen, P. P.
      Figure US20060003334A1-20060105-P00900
      Yang, P. M. (1990) Scand. J. Immunol. 31, 593-599.
    • 27 Tomlinson, M., Walter, G., Cook
      Figure US20060003334A1-20060105-P00900
      Winter, G. (Unpublished)

Claims (27)

1-55. (canceled)
56. A method of preparing a library of nucleic acids, wherein each nucleic acid encodes an immunoglobulin variable domain comprising consensus framework sequences, comprising:
(a) identifying a plurality of immunoglobulin variable domain amino acid sequences, each comprising four consensus framework regions interspaced by three complementary determining regions CDR1, CDR2, and CDR3, wherein said consensus framework regions have been identified by the following steps:
(i) aligning three or more known human immunoglobulin sequences;
(ii) identifying the conserved framework regions of said known human immunoglobulin sequences;
(iii) comparing the amino acids at each corresponding position of said conserved framework regions; and
(iv) deducing consensus framework regions from said comparing in step (a)(iii); and
(b) synthesizing a plurality of nucleic acids encoding said plurality of immunoglobulin variable domain amino acid sequences provided in step (a), wherein each of said nucleic acids comprises DNA cleavage sites at the boundary between each consensus framework region and complementary determining region, and wherein each of said cleavage sites is unique within said nucleic acid but common to all nucleic acid sequences of said library at corresponding positions.
57. The method according to claim 56, wherein said known human immunoglobulin sequences in step (a)(i) are human Vκ immunoglobulin sequences.
58. The method according to claim 56, wherein said known human immunoglobulin sequences in step (a)(i) are human Vλ immunoglobulin sequences.
59. The method according to claim 56, wherein said known human immunoglobulin sequences in step (a)(i) are human VH immunoglobulin sequences.
60. The method according to claim 57, wherein said nucleic acids synthesized in step (b) are selected from the group consisting of Vκ1 (SEQ ID NO:42), Vκ2 (SEQ ID NO: 44), Vκ3 (SEQ ID NO: 46), and Vκ4 (SEQ ID NO: 48).
61. The method according to claim 58, wherein said nucleic acids synthesized in step (b) are selected from the group consisting of Vλ1 (SEQ ID NO:50), Vλ2 (SEQ ID NO: 52), and Vλ3 (SEQ ID NO: 54).
62. The method according to claim 59, wherein said nucleic acids synthesized in step (b) are selected from the group consisting of VH1A (SEQ ID NO:56), VH1B (SEQ ID NO: 58), VH2 (SEQ ID NO: 60), VH3 (SEQ ID NO: 62), VH4 (SEQ ID NO: 64), VH5 (SEQ ID NO: 66), and VH6 (SEQ ID NO: 68).
63. The method according to claim 56, further comprising inserting said nucleic acids into an expression vector.
64. The method according to claim 63. The method according to claim 83, wherein said nucleic acids encoding said immunoglobulin variable domain amino acid sequences comprise codons that are frequently used in said host cell.
65. The method according to claim 64, wherein said host cell is E. coli.
66. The method according to claim 65, wherein said expression vector is a phagemid vector.
67. The method according to claim 56, wherein said CDR1 is selected from the group consisting of VH CDR1 germline sequences.
68. The method according to claim 67, wherein said CDR1 is selected from the group consisting of VH1-12-1, VH1-13-16, VH2-31-10, VH3-13-8, VH4-11-7, CH5-12-1, and VH6-35-1.
69. The method according to claim 56, wherein said CDR1 is selected from the group consisting of Vλ CDR1 germline sequences.
70. The method according to claim 69, wherein said CDR1 is selected from the group consisting of VHUMLV86, DPL11, and DPL23.
71. The method according to claim 56, wherein said CDR1 is selected from the group consisting of Vκ CDR1 germline sequences.
72. The method according to claim 71, wherein said CDR1 is selected from the group consisting of Vκ1-14, Vκ2-6, Vκ33-1, and Vκ4-1.
73. The method according to claim 56, wherein said CDR2 is selected from the group consisting of VH CDR2 germline sequences.
74. The method according to claim 73, wherein said CDR2 is selected from the group consisting of VH1-12-1, VH1-13-6, VH2-31-3, VH3-13-8, VH4-11-8, VH4-31-17, VH5-12-1, and VH6-35-1.
75. The method according to claim 56, wherein said CDR2 is selected from the group consisting of Vλ CDR2 germline sequences.
76. The method according to claim 75, wherein said CDR2 is selected from the group consisting of DPL5, DPL12, and HUMLV318.
77. The method according to claim 56, wherein said CDR2 is selected from the group consisting of Vκ CDR2 germline sequences.
78. The method according to claim 77, wherein said CDR2 is selected from the group consisting of Vκ1-2, Vκ2-6, Vκ3-4, and Vκ4-1.
79. The method according to claim 56, wherein said CDR3 is selected from random amino acid sequences.
80. The method according to claim 56 wherein said CDR3 is an amino acid sequence selected from Vκ CDR3 sequences comprising the amino acid sequence N1-Gln-N-3-N4-N-5-N6-N-7-N8-Thr, wherein:
N1 is an amino acid selected from the group consisting of Phe, His, Leu, Met, and Gln;
N3 is an amino acid other than Cys or Pro;
N4 is an amino acid selected from the group consisting of Asp, Gly, Asn, Ser, and Phe;
N5 is an amino acid selected from the group consisting of Asp, Gly, Asn, and Ser;
N6 is an amino acid other than Cys;
N7 is Pro or Ser; and
N8 is an amino acid other than Cys.
81. The method according to claim 56 wherein said CDR3 is an amino acid sequence selected from Vλ CDR3 sequences comprising the amino acid sequence Gln-Ser-N-3-Asp-N-5-N6-N-7-N8-N-9-N10, wherein:
N1 is an amino acid selected from the group consisting of Arg, Trp, or Phe;
N3 is an amino acid other than Cys or Pro;
N5 is an amino acid other then Cys or Trp;
N6 is an amino acid other than Cys or Trp;
N7 is an amino acid other than Cys or Trp;
N8 is an amino acid other than Cys or Trp or N8 is absent;
N9 is an amino acid other than Cys or Trp or N9 is absent; and
N10 is an amino acid other than Cys.
US10/834,397 1995-08-18 2004-04-29 Protein (poly)peptides libraries Abandoned US20060003334A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/834,397 US20060003334A1 (en) 1995-08-18 2004-04-29 Protein (poly)peptides libraries
US11/642,593 US8513164B2 (en) 1995-08-18 2006-12-21 Protein (poly)peptides libraries

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP95113021 1995-08-18
EP95113021.0 1995-08-18
PCT/EP1996/003647 WO1997008320A1 (en) 1995-08-18 1996-08-19 Protein/(poly)peptide libraries
US09/490,324 US6828422B1 (en) 1995-08-18 2000-01-24 Protein/(poly)peptide libraries
US10/834,397 US20060003334A1 (en) 1995-08-18 2004-04-29 Protein (poly)peptides libraries

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/490,324 Division US6828422B1 (en) 1995-08-18 2000-01-24 Protein/(poly)peptide libraries

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/642,593 Division US8513164B2 (en) 1995-08-18 2006-12-21 Protein (poly)peptides libraries

Publications (1)

Publication Number Publication Date
US20060003334A1 true US20060003334A1 (en) 2006-01-05

Family

ID=8219537

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/025,769 Expired - Lifetime US6300064B1 (en) 1995-08-18 1998-02-18 Protein/(poly)peptide libraries
US10/834,397 Abandoned US20060003334A1 (en) 1995-08-18 2004-04-29 Protein (poly)peptides libraries
US11/642,593 Expired - Fee Related US8513164B2 (en) 1995-08-18 2006-12-21 Protein (poly)peptides libraries

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/025,769 Expired - Lifetime US6300064B1 (en) 1995-08-18 1998-02-18 Protein/(poly)peptide libraries

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/642,593 Expired - Fee Related US8513164B2 (en) 1995-08-18 2006-12-21 Protein (poly)peptides libraries

Country Status (11)

Country Link
US (3) US6300064B1 (en)
EP (1) EP0859841B1 (en)
JP (3) JP4436457B2 (en)
AT (1) ATE219517T1 (en)
AU (1) AU725609C (en)
CA (1) CA2229043C (en)
DE (1) DE69621940T2 (en)
DK (2) DK1143006T3 (en)
ES (1) ES2176484T3 (en)
PT (1) PT859841E (en)
WO (1) WO1997008320A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232333A1 (en) * 2000-04-17 2003-12-18 Dyax Corp. Novel methods of constructing librabries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel librabries
US20060166252A1 (en) * 2000-04-17 2006-07-27 Ladner Robert C Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US20060246515A1 (en) * 2002-08-12 2006-11-02 Li Zhu High throughput generation and affinity maturation of humanized antibody
US20060257937A1 (en) * 2000-12-18 2006-11-16 Dyax Corp., A Delaware Corporation Focused libraries of genetic packages
WO2007117657A2 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20090075378A1 (en) * 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
US20090181855A1 (en) * 2007-09-14 2009-07-16 Adimab, Inc. Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
US20100056386A1 (en) * 2007-09-14 2010-03-04 Adimab, Inc. Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
US20110082054A1 (en) * 2009-09-14 2011-04-07 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
US20110118147A1 (en) * 2008-03-13 2011-05-19 Ladner Robert C Libraries of genetic packages comprising novel hc cdr3 designs
US20110172125A1 (en) * 2008-04-24 2011-07-14 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US9354228B2 (en) 2010-07-16 2016-05-31 Adimab, Llc Antibody libraries
CN109689684A (en) * 2016-07-06 2019-04-26 细胞基因公司 Antibody and application thereof with low immunogenicity

Families Citing this family (581)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
CA2184584C (en) 1994-03-08 2003-04-08 Jing-Shan Hu Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DE69621940T2 (en) * 1995-08-18 2003-01-16 Morphosys Ag PROTEIN - / (POLY) PEPTIDE LIBRARIES
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
US6141769A (en) 1996-05-16 2000-10-31 Resilience Corporation Triple modular redundant computer system and associated method
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9701425D0 (en) * 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2010213725A (en) * 1998-01-20 2010-09-30 Univ Illinois Yeast cell surface display of protein and uses thereof
CA2323787A1 (en) * 1998-03-13 1999-09-16 Wayne Marasco Humanized antibody and uses thereof
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
JP2002530080A (en) * 1998-11-19 2002-09-17 インサイト・ファーマスーティカルズ・インコーポレイテッド Immunoglobulin / Superfamily / Protein
US6787638B1 (en) * 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
CA2358684C (en) 1999-01-15 2013-07-16 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
NZ515686A (en) 1999-06-01 2005-01-28 Biogen Inc A blocking monoclonal antibody to integrin VLA-1 and its use for the treatment of inflammatory disorders such as arthritis
US20090233806A1 (en) * 1999-07-06 2009-09-17 Carr Francis J Protein isolation and analysis
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US7351540B1 (en) * 2000-03-17 2008-04-01 Merck Patent Gmbh Protein isolation and analysis
JP2001275682A (en) * 2000-03-31 2001-10-09 Kankyo Meneki Gijutsu Kenkyusho:Kk Gene encoding antimalathion monoclonal antibody
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
CA2403425C (en) 2000-04-11 2013-08-27 Genentech, Inc. Multivalent antibodies and uses therefor
AU2005200250B2 (en) * 2000-05-08 2007-10-25 Celldex Therapeutics, Inc. Human monoclonal antibodies to dendritic cells
US20040019187A1 (en) * 2000-05-12 2004-01-29 Zoltan Nagy Immunomodulatory human mhc class II antigens-binding polypeptides
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
MXPA02012867A (en) 2000-06-29 2003-09-05 Abbott Lab Dual specificity antibodies and methods of making and using.
DE60136816D1 (en) 2000-07-27 2009-01-15 Genentech Inc SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7051028B2 (en) * 2000-11-15 2006-05-23 Ndsu-Research Foundation Concurrency control in high performance database systems
US7858559B2 (en) 2000-11-17 2010-12-28 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP1341902A2 (en) 2000-12-08 2003-09-10 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
AU2011223997B2 (en) * 2000-12-18 2013-09-19 Dyax Corp. Focused Libraries of Genetic Packages
ES2347532T3 (en) * 2001-04-13 2010-11-02 Biogen Idec Ma Inc. ANTIBODIES AGAINST VLA-1.
CA2444632A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20040010376A1 (en) * 2001-04-17 2004-01-15 Peizhi Luo Generation and selection of protein library in silico
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
EP1390741B1 (en) * 2001-04-17 2012-10-31 Abmaxis, Inc. Structure-based construction of human antibody library
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
WO2003007979A1 (en) * 2001-07-18 2003-01-30 Board Of Regents, The University Of Texas System An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CA2456121A1 (en) 2001-08-03 2003-02-20 Medical Research Council Intracellular antibodies
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
DK1440083T3 (en) 2001-10-25 2013-03-25 Medical Res Council MOLECULES
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
US7115716B2 (en) * 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
MXPA04004658A (en) * 2001-11-19 2004-08-13 Applied Molecular Evolution Tumor specific monoclonal antibodies.
EP1461428B1 (en) 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Method for producing hybrid antibodies
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EA011853B1 (en) 2002-03-13 2009-06-30 Байоджен Айдек Ма Инк. ANTI- αβANTIBODIES
CN103536916B (en) 2002-04-09 2016-08-17 比奥根Ma公司 For the method treating TWEAK associated conditions
NZ536412A (en) 2002-05-22 2008-10-31 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2003239544A1 (en) * 2002-05-24 2003-12-12 Tularik Inc. Amplification and overexpression of oncogenes
US20030232387A1 (en) * 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2004015063A2 (en) * 2002-08-07 2004-02-19 Tularik Inc. Amplification and overexpression of oncogenes
GB0226729D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
AU2004239065B2 (en) 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040248189A1 (en) * 2003-06-05 2004-12-09 Grzegorz Bulaj Method of making a library of phylogenetically related sequences
JP4667383B2 (en) 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Aglycosyl anti-CD154 (CD40 ligand) antibody and use thereof
CA2528529A1 (en) * 2003-06-20 2004-12-29 Amgen Inc. Gene amplification and overexpression in cancer
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
DE10346627A1 (en) * 2003-10-08 2005-05-19 Weiss, Stefan, PD Dr. Single-chain antibodies against the 37 kDa / 67 kDa laminin receptor as tools for the diagnosis and treatment of prion diseases and cancer, their production and use
ES2405848T3 (en) * 2003-12-23 2013-06-04 Biokit S.A. Compositions and methods for detection of pathogenic infection
HUE025369T2 (en) 2004-02-06 2016-02-29 Morphosys Ag Anti-CD38 human antibodies and uses therefor
SI2511297T1 (en) 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US7311906B2 (en) 2004-04-30 2007-12-25 Brigham Young University Anti-viral activity of an anti-thymidine kinase monoclonal antibody
CA2504920C (en) 2004-05-14 2014-04-01 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof
US7837998B2 (en) 2004-05-21 2010-11-23 Nathaniel Lallatin Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
US8551486B2 (en) 2004-05-21 2013-10-08 Savoy Pharmaceuticals, Inc. Monoclonal antibodies to human thymidine kinase to treat cancer
WO2005118642A2 (en) 2004-06-01 2005-12-15 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
WO2006004663A2 (en) * 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
EP2322554A1 (en) 2004-06-30 2011-05-18 Domantis Limited Composition comprising an anti-TNF-alpha domain antibody for the treatment of rheumatoid arthritis
EP1781680B8 (en) * 2004-07-06 2016-05-18 Bioren, LLC Universal antibody libraries
KR20070047327A (en) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. Anti-cd154 antibodies
US7728118B2 (en) 2004-09-17 2010-06-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
RU2401842C2 (en) 2004-10-08 2010-10-20 Домантис Лимитед Antagonists and method of using said antagonists
EP3540062B1 (en) * 2004-11-16 2021-05-12 Humanigen, Inc. Immunoglobulin variable region cassette exchange
JP5185624B2 (en) 2004-12-02 2013-04-17 ドマンティス リミテッド Bispecific antibodies targeting serum albumin and GLP-1 or PYY
AR052051A1 (en) 2004-12-15 2007-02-28 Neuralab Ltd AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
AU2006226192A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
UA99897C2 (en) 2005-05-10 2012-10-25 Инсайт Корпорейшн Modulators of indoleamine 2,3-dioxygenase and methods of using the same
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MX339015B (en) 2005-05-27 2016-05-09 Biogen Ma Inc Tweak binding antibodies.
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
UA99701C2 (en) 2005-07-01 2012-09-25 Медарекс, Инк. Human monoclonal antibody that specifically binds to programmed death ligand 1 (pd-l1)
CN102875681A (en) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 Anti-alpha v beta 6 antibodies and uses thereof
JP2009510002A (en) 2005-09-30 2009-03-12 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Binding domains of proteins of the repulsion-inducing molecule (RGM) protein family, and functional fragments thereof, and uses thereof
CN103554259B (en) 2005-10-12 2016-05-18 莫佛塞斯公司 Specificity is for generation and the qualification of the derivative treatment of the complete people HuCAL GOLD-antibody of people CD38
AR058140A1 (en) * 2005-10-24 2008-01-23 Wyeth Corp PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS
AU2006311661B2 (en) 2005-11-07 2011-05-26 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
CA2628552A1 (en) 2005-11-09 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Identification and characterization of function-blocking anti-ed-b-fibronectin antibodies
PL1954718T3 (en) 2005-11-30 2015-04-30 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007064972A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
JP2009517069A (en) 2005-12-01 2009-04-30 ドマンティス リミテッド Competitive domain antibody format that binds to interleukin 1 receptor type 1
CN101454344A (en) 2005-12-01 2009-06-10 杜门蒂斯有限公司 Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
SI1960428T1 (en) 2005-12-12 2011-10-28 Hoffmann La Roche Antibodies against amyloid beta with glycosylation in the variable region
US8273688B2 (en) 2005-12-20 2012-09-25 Morphosys Ag Collection of HCDR3 regions and uses therefor
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
ES2539830T3 (en) 2006-01-20 2015-07-06 Cell Signaling Technology, Inc. ROS mutant and translocation kinase in human non-small cell lung carcinoma
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
WO2007087673A1 (en) 2006-02-01 2007-08-09 Arana Therapeutics Limited Domain antibody construct
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
WO2007109243A2 (en) * 2006-03-20 2007-09-27 Duramed Pharmaceuticals, Inc. Methods for comparing the immunogenicity of products and uses thereof
CA2648846A1 (en) 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
HUE035732T2 (en) 2006-04-14 2018-05-28 Cell Signaling Technology Inc Gene defects and mutant ALK kinase in human solid tumors
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
DK2013236T3 (en) 2006-04-28 2015-09-21 Delenex Therapeutics Ag ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK
EP1918302A3 (en) * 2006-05-18 2009-11-18 AvantGen, Inc. Methods for the identification and the isolation of epitope specific antibodies
CN105381459A (en) * 2006-05-25 2016-03-09 比奥根Ma公司 Methods of treating stroke
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
CN101563105B (en) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 Compositions and methods for inhibiting smad4-deficient cancers
CA2664698C (en) 2006-09-28 2016-06-07 The Macfarlane Burnet Institute For Medical Research And Public Health Limited A method and kit for evaluating cd4 t-cell numbers
AU2007303572A1 (en) 2006-10-02 2008-04-10 Sea Lane Biotechnologies, Llc Design and construction of diverse synthetic peptide and polypeptide libraries
US7744890B2 (en) * 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
MX2009004519A (en) * 2006-11-03 2009-05-12 Wyeth Corp Glycolysis-inhibiting substances in cell culture.
ES2397637T3 (en) 2006-11-10 2013-03-08 Massachusetts Institute Of Technology PAK inhibitors for use in the treatment of neurodevelopmental disorders
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab Dual-specific il-1a/ il-1b antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2134855A4 (en) 2007-03-12 2011-01-05 Dana Farber Cancer Inst Inc Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
SI2125894T1 (en) 2007-03-22 2019-05-31 Biogen Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
AU2008259590A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
DK2158315T3 (en) 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
BRPI0814645A2 (en) 2007-07-25 2015-01-27 Alexion Pharma Inc METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE.
JP5889529B2 (en) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー Treatment of amyloidogenic diseases
EP2199390B1 (en) 2007-08-30 2016-12-21 Daiichi Sankyo Company, Limited Anti-epha2 antibody
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9096855B2 (en) 2007-10-18 2015-08-04 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
JP2011504236A (en) * 2007-11-20 2011-02-03 スリーエム イノベイティブ プロパティズ カンパニー Method for analyzing bacterial samples using a polymer sensor containing diacetylene
HUE027358T2 (en) * 2007-11-26 2016-09-28 Bayer Ip Gmbh Anti-mesothelin antibodies and uses therefor
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
EP2080770A1 (en) 2008-01-21 2009-07-22 MorphoSys AG Proteinaceous binding molecules comprising purification tags
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
ES2524266T3 (en) 2008-07-08 2014-12-04 Incyte Corporation 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
JP5560270B2 (en) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド NOTCH binding agents and antagonists and methods of use thereof
HUE029982T2 (en) 2008-07-18 2017-04-28 Bristol Myers Squibb Co Compositions monovalent for cd28 binding and methods of use
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
KR101732056B1 (en) * 2008-07-25 2017-05-02 인스티튜트 포 리서치 인 바이오메드슨 Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010016806A1 (en) 2008-08-08 2010-02-11 Agency For Science, Technology And Research (A*Star) Vhz for diagnosis and treatment of cancers
EA026110B1 (en) 2008-08-14 2017-03-31 Сефалон Острэйлиа Пти Лтд. Anti-il-12/il-23 antibodies
EP2344180A2 (en) 2008-09-23 2011-07-20 Wyeth LLC Methods for predicting production of activating signals by cross-linked binding proteins
US9347043B2 (en) * 2008-10-22 2016-05-24 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
CN104740631B (en) 2008-10-29 2019-04-16 阿布林克斯公司 The preparation of single domain antigen-binding molecule
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
DK2894165T3 (en) 2008-11-10 2023-03-20 Alexion Pharma Inc Methods and compositions for treating complement-related disorders
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
EP2364326B1 (en) 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
SI2376121T2 (en) 2008-12-22 2021-11-30 The University Of Melbourne Osteoarthritis treatment
CA2747206C (en) 2008-12-22 2018-04-24 The University Of Melbourne Pain treatment
TWI480050B (en) 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd Anti-mst1r antibodies and uses thereof
EP2881402B1 (en) 2009-02-12 2017-05-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
JP2012518398A (en) 2009-02-24 2012-08-16 グラクソ グループ リミテッド Antigen binding construct
MX2011007049A (en) 2009-02-24 2011-08-03 Esbatech Alcon Biomed Res Unit Methods for identifying immunobinders of cell-surface antigens.
WO2010097394A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2406386B1 (en) * 2009-03-10 2019-01-23 DSM IP Assets B.V. Method for improving the yield of a polypeptide
UY32560A (en) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag IMMUNOCONJUGADOS OF ANTIMESOTELINA AND USES OF THE SAME
MX349056B (en) 2009-04-29 2017-07-06 Janssen Biotech Inc Toll-like receptor 3 antagonists.
EP2799453B1 (en) 2009-04-29 2019-04-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ERG2 monoclonal antibodies and their therapeutic use
CA2762837C (en) 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
AU2010252939B2 (en) 2009-05-29 2014-06-26 Morphosys Ag A collection and methods for its use
SG176947A1 (en) 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
SG177583A1 (en) 2009-07-09 2012-02-28 Hoffmann La Roche In vivo tumor vasculature imaging
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
TWI483736B (en) 2009-10-23 2015-05-11 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
NZ600470A (en) 2009-12-09 2015-02-27 Bayer Pharma AG Anti-c4.4a antibodies and uses thereof
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
KR101961495B1 (en) 2009-12-23 2019-03-22 아비펩 피티와이 리미티트 Immuno-conjugates and methods for producing them 2
WO2011082345A2 (en) 2009-12-30 2011-07-07 Brigham Young University Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
CN102958534B (en) 2010-01-13 2014-11-05 昂考梅德药品有限公司 Notch1 binding agents and methods of use thereof
EP2354159A1 (en) 2010-02-05 2011-08-10 RWTH Aachen CCL17 inhibitors for use in T helper cell-driven diseases
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
US10393754B2 (en) 2010-02-17 2019-08-27 Cedars-Sinai Medical Center Methods of diagnosing and treating heart failure
TWI672318B (en) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 Folate receptor 1 antibodies and immunoconjugates and uses thereof
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
EP2544719B1 (en) 2010-03-12 2019-07-03 Debiopharm International S.A. Cd37-binding molecules and immunoconjugates thereof
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
ES2552954T3 (en) 2010-04-30 2015-12-03 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for the use of antibodies
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
EP2593476A2 (en) 2010-07-16 2013-05-22 Ablynx N.V. Modified single domain antigen binding molecules and uses thereof
NZ604415A (en) 2010-07-20 2014-10-31 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
AU2011293127B2 (en) 2010-08-27 2016-05-12 Abbvie Stemcentrx Llc Notum protein modulators and methods of use
SG10201506959SA (en) 2010-09-03 2015-10-29 Stemcentrx Inc Novel modulators and methods of use
ES2719624T3 (en) 2010-09-23 2019-07-11 Prec Biologics Inc Peptidomimetics of colon and pancreas cancer
AR083495A1 (en) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit STABLE AND SOLUBLE ANTIBODIES
PL2640742T3 (en) * 2010-11-19 2019-01-31 Morphosys Ag A collection of antibody sequences its use
KR20130121886A (en) 2010-11-24 2013-11-06 글락소 그룹 리미티드 Multispecific antigen binding proteins targeting hgf
RU2592672C9 (en) 2010-12-08 2016-11-27 СтемСентРкс, Инк. Novel modulators and methods for use thereof
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
JP2014506448A (en) 2011-01-19 2014-03-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Binding proteins for inhibitors of clotting factors
EP3263125A3 (en) 2011-02-02 2018-03-14 Emory University Antagonism of the vip signaling pathway
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
WO2012138694A2 (en) 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
TWI636793B (en) 2011-04-21 2018-10-01 西雅圖遺傳學公司 New binder-drug conjugates (adcs) and use thereof
JP6038121B2 (en) 2011-04-21 2016-12-07 ガーバン インスティテュート オブ メディカル リサーチ Modified variable domain molecules and methods for their production and use B
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US20140213459A1 (en) 2011-05-27 2014-07-31 Roland Beckmann Antibodies with improved folding stability
EP2726506A1 (en) 2011-05-27 2014-05-07 Dutalys Removal of monomeric targets
SI2726510T1 (en) 2011-05-27 2023-06-30 F. Hoffmann - La Roche Ag Dual targeting
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
DK2718326T3 (en) 2011-06-13 2020-10-26 Csl Ltd ANTIBODIES TO G-CSFR AND USES THEREOF
EP2535352B1 (en) 2011-06-16 2015-08-12 Universitätsklinikum Freiburg Pharmaceutical compound with antibodies against catalase and superoxide dismutase for tumour treatment
CN106167526A (en) 2011-07-15 2016-11-30 昂考梅德药品有限公司 RSPO bonding agent and its application
JP2014520873A (en) 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン Use of c-Fms antagonists
PL3418300T3 (en) 2011-07-18 2021-05-04 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EA201490623A1 (en) 2011-09-12 2016-01-29 Янссен Байотек Инк. Antagonists of toll-like receptor 3 for the treatment of metabolic and cardiovascular diseases
MX2014003313A (en) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Bispecific binding molecules for 5t4 and cd3.
PL3485903T3 (en) 2011-09-23 2023-06-12 Mereo Biopharma 5, Inc. Vegf/dll4 binding agents and uses thereof
BR122020013379B1 (en) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES AGAINST TL1A AND THEIR USES
RU2631931C2 (en) 2011-10-07 2017-09-28 Байсикл Терапьютикс Лимитед Modulation of structured proteins specificity
HUE037087T2 (en) 2011-10-19 2018-08-28 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
BR112014009925B1 (en) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE BUILDERS AND THEIR USES
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
DK2797957T3 (en) 2011-11-23 2019-09-23 Medimmune Llc BINDING MOLECULES SPECIFIC TO HER3 AND APPLICATIONS THEREOF
AR088941A1 (en) 2011-11-23 2014-07-16 Bayer Ip Gmbh ANTI-FGFR2 ANTIBODIES AND THEIR USES
SG11201403085PA (en) 2011-12-14 2014-10-30 Seattle Genetics Inc Fgfr antibody drug conjugates (adcs) and the use thereof
MX352772B (en) 2012-01-27 2017-12-07 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration.
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
PL2817338T3 (en) 2012-02-24 2017-12-29 Abbvie Stemcentrx Llc Dll3 modulators and methods of use
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
US9708388B2 (en) 2012-04-11 2017-07-18 Hoffmann-La Roche Inc. Antibody light chains
WO2013158859A1 (en) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
ES2698950T3 (en) 2012-05-10 2019-02-06 Bayer Pharma AG Antibodies capable of binding Coagulation Factor XI and / or its activated form, Factor XIa, and uses thereof
CA2875980A1 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
WO2014003830A1 (en) 2012-06-25 2014-01-03 Emory University Particle-nucleic acid conjugates and therapeutic uses related thereto
CN104755498B (en) 2012-08-31 2019-06-18 伊缪诺金公司 For detecting the diagnostic assay and kit of folacin receptor 1
SG11201502989XA (en) 2012-11-05 2015-05-28 Genzyme Corp Compositions and methods for treating proteinopathies
LT2928923T (en) 2012-12-10 2020-02-25 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
AU2014213009B2 (en) 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
WO2014121325A1 (en) 2013-02-07 2014-08-14 Csl Limited Il-11r binding proteins and uses thereof
RU2019109456A (en) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи NEW ANTIBODY CONJUGATES AND THEIR APPLICATIONS
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
EA201890895A1 (en) 2013-03-15 2019-02-28 Зинджения, Инк. MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION
WO2014151680A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
CN112870368A (en) 2013-03-27 2021-06-01 西达-赛奈医疗中心 Reduction and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
BR112015027313A2 (en) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anti-cd38 antibodies and attenuated interferon alfa-2b fusions
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US20160237160A1 (en) 2013-06-14 2016-08-18 Bayer Pharma Aktiengesellschaft Anti-tweakr antibodies and uses thereof
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
WO2015011660A1 (en) 2013-07-23 2015-01-29 Biocon Limited Methods for controlling fucosylation levels in proteins
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
WO2015031541A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
EP4215209A1 (en) 2013-09-02 2023-07-26 The University of Melbourne A method of treatment
KR102357635B1 (en) 2013-10-02 2022-01-28 메디뮨 엘엘씨 Neutralizing anti-influenza a antibodies and uses thereof
US20150132323A1 (en) 2013-10-08 2015-05-14 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
US9803008B2 (en) 2013-11-28 2017-10-31 Csl Limited Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B)
US9309314B2 (en) 2013-12-03 2016-04-12 Agency For Science, Technology And Research (A*Star) Polypeptides, nucleic acids and uses thereof
EP3080161B1 (en) 2013-12-09 2021-03-24 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
KR102466794B1 (en) 2013-12-18 2022-11-11 씨에스엘 리미티드 Method of treating wounds
DK3086814T3 (en) 2013-12-23 2020-09-14 Bayer Pharma AG BINDER CONJUGATES (ADCS) WITH KSP INHIBITORS
CA2936488C (en) 2014-01-14 2022-05-03 The Medical College Of Wisconsin, Inc. Targeting clptm1l for treatment and prevention of cancer
SG11201606898TA (en) 2014-02-21 2016-09-29 Stemcentrx Inc Anti-dll3 antibodies and drug conjugates for use in melanoma
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
DK3126384T3 (en) 2014-04-01 2021-01-18 Adimab Llc MULTISPECIFIC ANTIBODY ANALOGS INCLUDING A COMMON LIGHT CHAIN, AND METHODS FOR THEIR PREPARATION AND USE
MA50678A (en) 2014-04-08 2020-08-05 Boston Pharmaceuticals Inc IL-21 SPECIFIC BINDING MOLECULES AND THEIR USES
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
JP2017518737A (en) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Anti-pSYK antibody molecules and their use for SYK targeted therapeutics
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
US9903868B2 (en) 2014-05-16 2018-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the detection and quantitation of biomarkers
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
CN113563462A (en) 2014-07-15 2021-10-29 免疫医疗有限责任公司 Neutralizing anti-influenza b antibodies and uses thereof
US20170275373A1 (en) 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
MX2017001401A (en) 2014-07-31 2017-08-07 Amgen Res (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs.
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
WO2016061617A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
EP3209697A4 (en) 2014-10-23 2018-05-30 La Trobe University Fn14-binding proteins and uses thereof
WO2016065409A1 (en) 2014-10-29 2016-05-06 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
HUE054339T2 (en) 2014-11-10 2021-08-30 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
EP4242329A3 (en) 2014-12-08 2023-10-25 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
US10485880B2 (en) 2014-12-15 2019-11-26 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
EP3253793A4 (en) 2015-02-02 2018-11-14 i2 Pharmaceuticals, Inc. Anti-surrogate light chain antibodies
EP3253801B1 (en) 2015-02-02 2020-03-04 Georg Bauer Single domain-vhh fragments bind to and inhibit catalase, respectively superoxide dismutase, for use in the therapy of tumors
WO2016150899A2 (en) 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
CN108064236B (en) 2015-03-31 2021-12-10 免疫医疗有限公司 Novel forms of IL33, mutant forms of IL33, antibodies, assays and methods of use thereof
CA2982131A1 (en) 2015-04-10 2016-10-13 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
JP6907124B2 (en) 2015-04-17 2021-07-21 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Bispecific antibody construct against CDH3 and CD3
EP3736287A1 (en) 2015-05-11 2020-11-11 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
US10900975B2 (en) 2015-05-12 2021-01-26 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods of epitope binning and antibody profiling
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
DK3303384T3 (en) 2015-06-01 2021-10-18 Medimmune Llc NEUTRALIZING ANTI-INFLUENZA BINDING MOLECULES AND USES THEREOF
US10711064B2 (en) 2015-06-04 2020-07-14 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
CN114917361A (en) 2015-06-22 2022-08-19 拜耳医药股份有限公司 Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups
US20180318438A1 (en) 2015-06-23 2018-11-08 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
EP3313522A1 (en) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
CR20170562A (en) 2015-06-24 2018-02-01 Hoffmann La Roche TRANSFERRINE ANTI-RECEIVER ANTIBODIES WITH DESIGNATED AFFINITY.
HUE053619T2 (en) 2015-06-29 2021-07-28 Immunogen Inc Anti-cd123 antibodies and conjugates and derivatives thereof
TWI793062B (en) 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Antibody constructs for dll3 and cd3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究(慕尼黑)公司 Antibody constructs for cd70 and cd3
JO3792B1 (en) 2015-07-31 2021-01-31 Amgen Res Munich Gmbh Antibody constructs for flt3 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Antibody constructs for msln and cd3
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
EP3569244A1 (en) 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CA2997801A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CA3000779A1 (en) 2015-10-05 2017-04-13 Morphosys Ag Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
ITUB20155272A1 (en) 2015-11-02 2017-05-02 Scuola Normale Superiore Intracellular antibody
EP3374398B1 (en) 2015-11-10 2020-03-18 MedImmune, LLC Binding molecules specific for asct2 and uses thereof
EP3402513A4 (en) 2016-01-13 2019-10-23 Medlmmune, LLC Method of treating influenza a
HRP20220081T1 (en) 2016-02-03 2022-04-15 Amgen Research (Munich) Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
ES2935419T3 (en) 2016-02-03 2023-03-06 Amgen Res Munich Gmbh Bispecific antibody constructs for PSMA and CD3 that bind to T cells
JP6987072B2 (en) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド Activin type 2 receptor binding protein and its use
BR112018067951A2 (en) 2016-03-10 2019-02-05 Viela Bio Inc ilt7-binding molecules and methods of using these
BR112018068461A2 (en) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugate, pharmaceutical composition, methods for preparing a conjugate and for alleviating a symptom of a cancer.
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
US11685714B2 (en) 2016-03-24 2023-06-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
PT3436461T (en) 2016-03-28 2024-01-23 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
JP7022707B2 (en) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Specific antibody-drug-conjugate (ADC) including KSP inhibitor and anti-CD123 antibody
EP3490677A4 (en) 2016-07-07 2020-05-13 Berg LLC Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
EP3487880A1 (en) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5 (grp78) antibodies and uses thereof
CN109689090B (en) 2016-08-05 2023-12-26 免疫医疗有限责任公司 anti-O2 antibodies and uses thereof
CN106279414A (en) * 2016-08-31 2017-01-04 天津医科大学总医院 Humanized's anti-amylin antibody and preparation method thereof
WO2018041740A1 (en) 2016-09-01 2018-03-08 Bayer Pharma Aktiengesellschaft Non-covalent display system using fimgt/dsf
CA3032251A1 (en) 2016-09-01 2018-03-08 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
US11453726B2 (en) 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
MX2019003703A (en) 2016-09-30 2020-08-13 Janssen Biotech Inc Safe and effective method of treating psoriasis with anti-il23 specific antibody.
WO2018075408A1 (en) 2016-10-17 2018-04-26 Alexion Pharmaceuticals, Inc. Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
JP7160484B2 (en) 2016-10-19 2022-10-25 メディミューン,エルエルシー ANTI-O1 ANTIBODY AND USES THEREOF
US10322174B2 (en) 2016-10-26 2019-06-18 Cedars-Sinai Medical Center Neutralizing anti-TL1A monoclonal antibodies
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
KR20190080949A (en) 2016-11-23 2019-07-08 바이오버라티브 테라퓨틱스 인크. A bispecific antibody that binds to coagulation factor IX and coagulation factor X
WO2018102594A1 (en) 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
CA3043624A1 (en) 2016-12-16 2018-06-21 Merck Patent Gmbh Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
KR102583006B1 (en) 2016-12-21 2023-09-27 바이엘 파마 악티엔게젤샤프트 Antibody drug conjugates (adcs) having enzymatically cleavable groups
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
CN110312533B (en) 2016-12-21 2023-11-03 拜耳公司 Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
AU2018214451B2 (en) 2017-02-06 2022-02-03 Meat & Livestock Australia Limited Immunostimulating compositions and uses therefore
EP3600453A1 (en) 2017-03-30 2020-02-05 Duke University Radiolabeled biomolecules and their use
CA3058290A1 (en) 2017-04-18 2018-10-25 Universite Libre De Bruxelles Biomarkers and targets for proliferative diseases
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
KR20190141243A (en) 2017-05-05 2019-12-23 암젠 인크 Pharmaceutical compositions comprising bispecific antibody constructs for improved storage and administration
EP3401328A1 (en) 2017-05-10 2018-11-14 Bayer Pharma Aktiengesellschaft One step antibody humanization by golden gate based germline framework region shuffling
EP3403649A1 (en) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
EP3406253A1 (en) 2017-05-24 2018-11-28 Bayer Aktiengesellschaft Inhibitors and antagonists of human pycr1
AU2018280683A1 (en) 2017-06-05 2019-10-17 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
MA49565A (en) 2017-07-11 2020-05-20 Compass Therapeutics Llc AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND THEIR USES
KR20230066126A (en) 2017-07-27 2023-05-12 알렉시온 파마슈티칼스, 인코포레이티드 High concentration anti-c5 antibody formulations
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-cd200 therapy
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Use of activators and stimulators of sgc comprising a beta2 subunit
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
PL3717011T3 (en) 2017-11-29 2023-03-27 Csl Limited Method of treating or preventing ischemia-reperfusion injury
JP7344206B2 (en) 2017-12-11 2023-09-13 アムジェン インコーポレイテッド Continuous manufacturing process for bispecific antibody products
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US20210087267A1 (en) 2017-12-20 2021-03-25 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
JP2021512142A (en) 2018-01-25 2021-05-13 エイシーエム バイオラブズ プライベート リミテッド Polymersomes containing solubilized encapsulating antigens, and how to make and use them
JP2021512103A (en) 2018-01-31 2021-05-13 バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft Antibody drug conjugate (ADCS) containing a NAPPT inhibitor
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019160976A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
CA3092470A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
SG11202008186RA (en) 2018-03-07 2020-09-29 Forschungsverbund Berlin Ev Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
BR112020018480B1 (en) 2018-03-14 2022-09-27 Surface Oncology, Inc USES OF ANTIBODIES THAT BIND CD39 IN THE TREATMENT OF CANCER
MA52094A (en) 2018-03-22 2021-01-27 Adimab Llc ANTI-IL-27 ANTIBODIES AND THEIR USES
WO2019180204A1 (en) 2018-03-23 2019-09-26 Université Libre de Bruxelles Wnt signaling agonist molecules
EP4253958A3 (en) 2018-03-26 2023-12-06 Glycanostics s.r.o. Means and methods for glycoprofiling of a protein
WO2019190877A1 (en) 2018-03-26 2019-10-03 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement c3 convertase
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
WO2019209952A2 (en) 2018-04-23 2019-10-31 Emory University Vip antagonists and uses in treating cancer
MA52366A (en) 2018-04-25 2021-03-03 Prometheus Biosciences Inc OPTIMIZED ANTI-TL1A ANTIBODIES
MA52940A (en) 2018-05-18 2021-04-28 Incyte Corp FUSION PYRIMIDINE DERIVATIVES USED AS A2A / A2B INHIBITORS
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
US20200109195A1 (en) 2018-05-21 2020-04-09 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
KR102115300B1 (en) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 Antibody library and Screening Method of Antibody by Using the Same
EP3801613A1 (en) 2018-06-04 2021-04-14 Bayer Aktiengesellschaft Inhibitors of shp2
CN112601553A (en) 2018-06-18 2021-04-02 拜耳股份有限公司 Binder-drug conjugates against CXCR5 with enzymatically cleavable linkers and improved activity profile
MX2020014158A (en) 2018-06-20 2021-04-12 Incyte Corp Anti-pd-1 antibodies and uses thereof.
TW202016144A (en) 2018-06-21 2020-05-01 日商第一三共股份有限公司 Compositions including cd3 antigen binding fragments and uses thereof
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
WO2020006408A1 (en) 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor
KR20210029221A (en) 2018-07-05 2021-03-15 바이엘 악티엔게젤샤프트 Method for producing freeze-dried pellets containing anti-coagulation factor XIa (FXIa) antibodies
EP3824295A4 (en) 2018-07-18 2022-04-27 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
US20210301017A1 (en) 2018-07-30 2021-09-30 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
AU2019314999A1 (en) 2018-08-03 2021-02-11 Amgen Inc. Antibody constructs for CLDN18.2 and CD3
EP3833442A2 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antibodies that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
EP3833443A1 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigen binding agents that bind cd277 and uses thereof
CA3109732A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
CN112996539A (en) 2018-09-12 2021-06-18 Acm生物实验室私人有限公司 Polymersomes comprising covalently bound antigens, methods of making and uses thereof
KR20230148273A (en) 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody
CN112789058A (en) 2018-10-11 2021-05-11 安进公司 Downstream processing of bispecific antibody constructs
WO2020102387A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
JP2022507836A (en) 2018-11-20 2022-01-18 タケダ ワクチン,インコーポレイテッド New anti-Zika virus antibody and its use
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
KR20210111792A (en) 2018-12-28 2021-09-13 스팍스 테라퓨틱스 인크. Binding molecules specific for claudin 18.2, compositions and methods thereof for treating cancer and other diseases
EP3911679A1 (en) 2019-01-16 2021-11-24 Compass Therapeutics LLC Formulations of antibodies that bind human cd137 and uses thereof
CA3126778A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
MA54870A (en) 2019-01-29 2021-12-08 Incyte Corp PYRAZOLOPYRIDINES AND TRIAZOLOPYRIDINES USED AS A2A/A2B INHIBITORS
EP3917571A4 (en) 2019-01-31 2022-10-12 Agency For Science, Technology And Research Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
IL285719B (en) 2019-02-18 2022-07-01 Atb Therapeutics Method of producing a binder-toxin fusion protein in a plant cell or a whole plant
EP3938384A4 (en) 2019-03-14 2022-12-28 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
WO2020201195A2 (en) 2019-04-04 2020-10-08 Bayer Aktiengesellschaft Agonists of adiponectin
AU2020271402A1 (en) 2019-04-09 2021-10-07 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Protein binders for iRhom2
CN114127312A (en) 2019-04-30 2022-03-01 拉利玛生物医药公司 Markers of ataxin sensitivity for determining the efficacy of ataxin replacement therapy
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
US20220259547A1 (en) 2019-06-13 2022-08-18 Amgeng Inc. Automated biomass-based perfusion control in the manufacturing of biologics
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
EP4007602A1 (en) 2019-08-01 2022-06-08 Incyte Corporation A dosing regimen for an ido inhibitor
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
BR112022002351A2 (en) 2019-09-16 2022-07-19 Surface Oncology Inc ANTI-CD39 ANTIBODY COMPOSITIONS AND METHODS
US20210115127A1 (en) 2019-09-25 2021-04-22 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
AU2020360849A1 (en) 2019-09-30 2022-04-14 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Protein binders to iRhom2 epitopes
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
JP2022553324A (en) 2019-10-24 2022-12-22 プロメテウス バイオサイエンシーズ,インク. Humanized antibodies against TNF-like ligand 1A (TL1A) and uses thereof
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP4069301A1 (en) 2019-12-04 2022-10-12 Bayer Aktiengesellschaft Inhibitors of shp2
EP4077392A1 (en) 2019-12-20 2022-10-26 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2021123173A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
TW202135824A (en) 2020-01-03 2021-10-01 美商英塞特公司 Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
CN114929278A (en) 2020-01-06 2022-08-19 瓦西尼斯公司 anti-CCR 8 antibodies and uses thereof
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
TW202140027A (en) 2020-03-06 2021-11-01 美商英塞特公司 Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
TW202200615A (en) 2020-03-12 2022-01-01 美商安進公司 Method for treatment and prophylaxis of crs in patients
BR112022018111A2 (en) 2020-03-19 2022-10-25 Amgen Inc ANTIBODIES AGAINST MUCIN 17 AND USES THEREOF
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20220017636A1 (en) 2020-05-19 2022-01-20 Amgen Inc. Mageb2 binding constructs
CA3183693A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
IL300701A (en) 2020-08-17 2023-04-01 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
WO2022047359A1 (en) 2020-08-31 2022-03-03 Berg Llc Protein biomarkers for pancreatic cancer
KR20230084497A (en) 2020-09-11 2023-06-13 메디뮨 리미티드 Therapeutic B7-H4 binding molecules
JP2023542301A (en) 2020-09-12 2023-10-06 メディミューン リミテッド Scoring method for anti-B7H4 antibody drug conjugate therapy
CA3194792A1 (en) 2020-09-15 2022-03-24 Bayer Aktiengesellschaft Novel anti-a2ap antibodies and uses thereof
CN116368154A (en) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 Trispecific binding agents
AR124017A1 (en) 2020-11-06 2023-02-01 Amgen Res Munich Gmbh POLYPEPTIDES WITH ENHANCED CLIPPING PROFILE
EP4240768A2 (en) 2020-11-06 2023-09-13 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
AU2021375733A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs binding to cd3
KR20230098334A (en) 2020-11-06 2023-07-03 암젠 리서치 (뮌헨) 게엠베하 Polypeptide constructs that selectively bind to CLDN6 and CD3
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
JP2023551519A (en) 2020-11-30 2023-12-08 インサイト・コーポレイション Combination therapy of anti-CD19 antibody and parsaclisib
TW202241441A (en) 2020-12-29 2022-11-01 美商英塞特公司 Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
CA3204731A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Anti-dll3 antibody-drug conjugate
AU2022225064A1 (en) 2021-02-26 2023-08-10 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
KR20230150319A (en) 2021-03-01 2023-10-30 사이롬 게임베하 Humanized antibody against iRhom2
KR20230156764A (en) 2021-03-12 2023-11-14 얀센 바이오테크 인코포레이티드 Method for treating psoriatic arthritis patients with inadequate response to TNF therapy by anti-IL23 specific antibody
AU2022233792A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2022195028A2 (en) 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules
WO2022207652A1 (en) 2021-03-29 2022-10-06 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
BR112023018061A2 (en) 2021-03-30 2023-10-03 Bayer Ag ANTI-SEMA3A ANTIBODIES AND USES THEREOF
WO2022216798A1 (en) 2021-04-06 2022-10-13 Berg Llc Protein markers for the prognosis of breast cancer progression
IL307530A (en) 2021-04-06 2023-12-01 Bpgbio Inc Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
IL307531A (en) 2021-04-06 2023-12-01 Bpgbio Inc Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
WO2022216795A1 (en) * 2021-04-09 2022-10-13 Abterra Biosciences, Inc. Method for antibody identification from protein mixtures
BR112023021224A2 (en) 2021-04-12 2024-01-16 Acm Biolabs Pte Ltd POLYMEROSOMES COMPRISING SOLUBLE ENCAPSULATED POLYNUCLEOTIDE AND IONIZABLE LIPID, AS WELL AS METHODS OF PRODUCTION AND USES THEREOF
EP4326335A1 (en) 2021-04-23 2024-02-28 Forschungsverbund Berlin E.V. Thiol-conjugation with unsaturated phosphorus(v) compounds
EP4334358A1 (en) 2021-05-06 2024-03-13 Amgen Research (Munich) GmbH Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
KR20240005809A (en) 2021-05-07 2024-01-12 서피스 온콜로지, 엘엘씨 Anti-IL-27 antibodies and uses thereof
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
AU2022340907A1 (en) 2021-09-02 2024-03-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
US20230190805A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Methods of identifying metastatic lesions in a patient and treating thereof
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023078968A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023083919A1 (en) 2021-11-09 2023-05-19 Tubulis Gmbh Conjugates comprising a phosphorus (v) and a camptothecin moiety
US20230330258A1 (en) 2021-11-09 2023-10-19 Tubulis Gmbh Conjugates comprising a phosphorus (v) and a drug moiety
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
US20230357392A1 (en) 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy
TW202348252A (en) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 Combination therapies for treatment of cancer with therapeutic binding molecules
WO2023156634A1 (en) 2022-02-17 2023-08-24 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
US20230357851A1 (en) 2022-04-06 2023-11-09 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring frataxin-replacement therapy
TW202346368A (en) 2022-05-12 2023-12-01 德商安美基研究(慕尼黑)公司 Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2023240201A1 (en) 2022-06-08 2023-12-14 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024033362A1 (en) 2022-08-08 2024-02-15 Atb Therapeutics Humanized antibodies against cd79b
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395750A (en) * 1981-02-03 1983-07-26 W. C. Heraeus Gmbh Operating room light
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
US5476786A (en) * 1987-05-21 1995-12-19 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5482858A (en) * 1987-05-21 1996-01-09 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5580717A (en) * 1990-05-01 1996-12-03 Affymax Technologies N.V. Recombinant library screening methods
US5693761A (en) * 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5693493A (en) * 1985-11-01 1997-12-02 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5840479A (en) * 1990-02-01 1998-11-24 Behring Diagnostics Gmbh Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5969108A (en) * 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US5977322A (en) * 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US6096551A (en) * 1992-01-27 2000-08-01 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US6248516B1 (en) * 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6303313B1 (en) * 1990-01-11 2001-10-16 Stratagene Method for generating libraries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69229477T2 (en) * 1991-09-23 1999-12-09 Cambridge Antibody Tech Methods for the production of humanized antibodies
DK0616640T3 (en) * 1991-12-02 2004-12-20 Medical Res Council Preparation of anti-self antibodies from repertoires of antibody segments and presented in phage
WO1995011998A1 (en) * 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE69621940T2 (en) 1995-08-18 2003-01-16 Morphosys Ag PROTEIN - / (POLY) PEPTIDE LIBRARIES
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395750A (en) * 1981-02-03 1983-07-26 W. C. Heraeus Gmbh Operating room light
US5693493A (en) * 1985-11-01 1997-12-02 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5482858A (en) * 1987-05-21 1996-01-09 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5476786A (en) * 1987-05-21 1995-12-19 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6248516B1 (en) * 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
US5693761A (en) * 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6303313B1 (en) * 1990-01-11 2001-10-16 Stratagene Method for generating libraries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5840479A (en) * 1990-02-01 1998-11-24 Behring Diagnostics Gmbh Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")
US5580717A (en) * 1990-05-01 1996-12-03 Affymax Technologies N.V. Recombinant library screening methods
US5969108A (en) * 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6096551A (en) * 1992-01-27 2000-08-01 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5977322A (en) * 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Anderson et al,Vaccine, 1994, 12, 8, 736-740. *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683028B2 (en) 2000-04-17 2017-06-20 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US10829541B2 (en) 2000-04-17 2020-11-10 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20060166252A1 (en) * 2000-04-17 2006-07-27 Ladner Robert C Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US20030232333A1 (en) * 2000-04-17 2003-12-18 Dyax Corp. Novel methods of constructing librabries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel librabries
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US9382535B2 (en) 2000-04-17 2016-07-05 Dyax Corp. Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US8901045B2 (en) 2000-04-17 2014-12-02 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20090162835A9 (en) * 2000-04-17 2009-06-25 Dyax Corp. Novel methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US10604753B2 (en) 2000-12-18 2020-03-31 Dyax Corp. Focused libraries of genetic packages
US9617536B2 (en) 2000-12-18 2017-04-11 Dyax Corp. Focused libraries of genetic packages
US8895475B2 (en) 2000-12-18 2014-11-25 Robert Charles Ladner Focused libraries of genetic packages
US8399384B2 (en) 2000-12-18 2013-03-19 Dyax Corp. Focused libraries of genetic packages
US20060257937A1 (en) * 2000-12-18 2006-11-16 Dyax Corp., A Delaware Corporation Focused libraries of genetic packages
US9803190B2 (en) 2000-12-18 2017-10-31 Dyax Corp. Focused libraries of genetic packages
US8466091B2 (en) 2000-12-18 2013-06-18 Dyax Corp. Focused libraries of genetic packages
US20060246515A1 (en) * 2002-08-12 2006-11-02 Li Zhu High throughput generation and affinity maturation of humanized antibody
US9464286B2 (en) 2002-08-12 2016-10-11 Adimab, Llc High throughput generation and affinity maturation of humanized antibody
US10329555B2 (en) 2002-08-12 2019-06-25 Adimab, Llc High throughput generation and affinity maturation of humanized antibody
WO2007117657A2 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20100061974A1 (en) * 2006-04-07 2010-03-11 Quadros Edward V Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US8603950B2 (en) 2007-02-20 2013-12-10 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US8685897B2 (en) 2007-02-20 2014-04-01 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US9637556B2 (en) 2007-02-20 2017-05-02 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US20090093024A1 (en) * 2007-02-20 2009-04-09 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US20090075378A1 (en) * 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
US9260533B2 (en) 2007-02-20 2016-02-16 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US20110183855A1 (en) * 2007-02-20 2011-07-28 Anaptysbio, Inc. Somatic hypermutation systems
US10196635B2 (en) 2007-09-14 2019-02-05 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US10189894B2 (en) 2007-09-14 2019-01-29 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US11008383B2 (en) 2007-09-14 2021-05-18 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US11008568B2 (en) 2007-09-14 2021-05-18 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20090181855A1 (en) * 2007-09-14 2009-07-16 Adimab, Inc. Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
US20100056386A1 (en) * 2007-09-14 2010-03-04 Adimab, Inc. Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
US10718066B2 (en) 2008-03-13 2020-07-21 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
US20110118147A1 (en) * 2008-03-13 2011-05-19 Ladner Robert C Libraries of genetic packages comprising novel hc cdr3 designs
US11926926B2 (en) 2008-03-13 2024-03-12 Takeda Pharmaceutical Company Limited Libraries of genetic packages comprising novel HC CDR3 designs
US20110172125A1 (en) * 2008-04-24 2011-07-14 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
US11598024B2 (en) 2008-04-24 2023-03-07 Takeda Pharmaceutical Company Limited Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
US10683342B2 (en) 2008-04-24 2020-06-16 Dyax Corp. Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
US9388510B2 (en) 2008-04-24 2016-07-12 Dyax Corp. Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
US20110082054A1 (en) * 2009-09-14 2011-04-07 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
US10889811B2 (en) 2010-07-16 2021-01-12 Adimab, Llc Antibody libraries
US10138478B2 (en) 2010-07-16 2018-11-27 Adimab, Llc Antibody libraries
US9354228B2 (en) 2010-07-16 2016-05-31 Adimab, Llc Antibody libraries
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US9834612B2 (en) 2011-07-22 2017-12-05 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US11427632B2 (en) 2016-07-06 2022-08-30 Celgene Corporation Antibodies with low immunogenicity and uses thereof
CN109689684A (en) * 2016-07-06 2019-04-26 细胞基因公司 Antibody and application thereof with low immunogenicity

Also Published As

Publication number Publication date
WO1997008320A1 (en) 1997-03-06
EP0859841B1 (en) 2002-06-19
JP2010246549A (en) 2010-11-04
DK1143006T3 (en) 2008-07-14
AU6874596A (en) 1997-03-19
PT859841E (en) 2002-11-29
EP0859841A1 (en) 1998-08-26
CA2229043A1 (en) 1997-03-06
JP2010029198A (en) 2010-02-12
JP5362650B2 (en) 2013-12-11
US8513164B2 (en) 2013-08-20
DK0859841T3 (en) 2002-09-09
US6300064B1 (en) 2001-10-09
DE69621940D1 (en) 2002-07-25
AU725609B2 (en) 2000-10-12
ATE219517T1 (en) 2002-07-15
JP2001519643A (en) 2001-10-23
JP4436457B2 (en) 2010-03-24
JP4629787B2 (en) 2011-02-09
ES2176484T3 (en) 2002-12-01
CA2229043C (en) 2016-06-07
AU725609C (en) 2002-01-03
US20080026948A1 (en) 2008-01-31
DE69621940T2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
US8513164B2 (en) Protein (poly)peptides libraries
US7264963B1 (en) Protein(poly)peptide libraries
Knappik et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
CA2119930C (en) Production of chimeric antibodies - a combinatorial approach
US7195866B2 (en) Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US8257705B2 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
EP2281078B1 (en) Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
de Haard et al. Creating and engineering human antibodies for immunotherapy
AU2002249854A1 (en) Focused libraries of genetic packages
WO2002061071A2 (en) Focused libraries of genetic packages
JP2011074078A (en) Adapter-directed display system
EP1143006B1 (en) Vectors/DNA-sequences from human combinatorial antibody libraries
AU764097B2 (en) Protein/(poly)peptide libraries
Kim et al. An approach for preventing recombination-deletion of the 40–50 anti-digoxin antibody VH gene from the phage display vector pComb3
Hoogenboom et al. Building antibodies from their genes
Little et al. Recombinant Antibodies: Construction and Production
Roberts The cloning, characterisation and engineering of an IGF-I-BINDING single chain Fv
Amersdorfer et al. " 1 f) Phage Display
Amersdorfer et al. Phage Display
Sblattero The Development of a Single Vector Recombination System to Make Large Phage Antibody Libraries
Binda Bypassing immunization in an attempt to develop beta 1 specific monoclonal human antibodies from semi-synthetic repertoires

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION